{"DataElement":{"publicId":"3211626","version":"1","preferredName":"Diagnosis Type","preferredDefinition":"The process of identifying a disease by the signs and symptoms._Something distinguishable as an identifiable class based on common qualities.:The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._The process of identifying a disease by the signs and symptoms","longName":"PRETEXT_STAGING","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3210666","version":"1","preferredName":"Diagnosis Type Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms._Something distinguishable as an identifiable class based on common qualities.:The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"2442484v1.0:3210625v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2442484","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"09046428-50E1-6C1D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-01-04","modifiedBy":"ONEDATA","dateModified":"2006-01-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3210625","version":"1","preferredName":"Type Diagnosis","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.:The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"C25284:C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52D73D-9A82-B185-E040-BB89AD4360AB","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52DFE0-7BE7-4182-E040-BB89AD43757F","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"5/05/14 CDE released per Ian Fore as part of Draft Model content review. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3210689","version":"1","preferredName":"DiagnosisType","preferredDefinition":"The process of identifying a disease by the signs and symptoms","longName":"3210689v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"java.lang.String","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Aspartylglycosaminuria","valueDescription":"Aspartylglycosaminuria","ValueMeaning":{"publicId":"3028421","version":"1","preferredName":"Aspartylglycosaminuria","longName":"3028421","preferredDefinition":"A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspartylglycosaminuria","conceptCode":"C61273","definition":"A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FD46-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FD04AFB-E5E8-E28A-E040-BB89AD4358EA","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-03-31","modifiedBy":"ONEDATA","dateModified":"2011-03-31","deletedIndicator":"No"},{"value":"Congenital Pure Red Cell Aplasia","valueDescription":"Congenital Pure Red Cell Aplasia","ValueMeaning":{"publicId":"3199134","version":"1","preferredName":"Congenital Pure Red Cell Aplasia","longName":"3199134","preferredDefinition":"An inherited condition characterized by aplasia of the erythroid series only. The white cells and platelets are not affected. Patients develop anemia usually in infancy.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Pure Red Cell Aplasia","conceptCode":"C61236","definition":"An inherited condition characterized by aplasia of the erythroid series only. The white cells and platelets are not affected. Patients develop anemia usually in infancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DAC64CD-9F51-0F86-E040-BB89AD436AC4","latestVersionIndicator":"Yes","beginDate":"2011-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-03-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"04/13/2011 - Updated with current NCIt name for VM.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FD04AFB-E5FC-E28A-E040-BB89AD4358EA","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-03-31","modifiedBy":"ONEDATA","dateModified":"2011-03-31","deletedIndicator":"No"},{"value":"Fucosidosis","valueDescription":"Fucosidosis","ValueMeaning":{"publicId":"3028419","version":"1","preferredName":"Fucosidosis","longName":"3028419","preferredDefinition":"An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fucosidosis","conceptCode":"C61274","definition":"An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FCFE-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-90A6-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Gaucher Disease","valueDescription":"Gaucher Disease","ValueMeaning":{"publicId":"3028418","version":"1","preferredName":"Gaucher Disease","longName":"3028418","preferredDefinition":"An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gaucher Disease","conceptCode":"C61268","definition":"An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FCDB-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-90BA-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Hunter Syndrome","valueDescription":"Hunter Syndrome","ValueMeaning":{"publicId":"3028417","version":"1","preferredName":"Hunter Syndrome","longName":"3028417","preferredDefinition":"An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides.  It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hunter Syndrome","conceptCode":"C61260","definition":"An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides.  It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FCB8-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-90CE-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Hurler Syndrome","valueDescription":"Hurler Syndrome","ValueMeaning":{"publicId":"3028416","version":"1","preferredName":"Hurler Syndrome","longName":"3028416","preferredDefinition":"An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hurler Syndrome","conceptCode":"C61261","definition":"An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC95-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-90E2-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Lesch-Nyhan Syndrome","valueDescription":"Lesch-Nyhan Syndrome","ValueMeaning":{"publicId":"3028414","version":"1","preferredName":"Lesch-Nyhan Syndrome","longName":"3028414","preferredDefinition":"An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lesch-Nyhan Syndrome","conceptCode":"C61255","definition":"An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC4F-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-90F6-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Maroteaux-Lamy Syndrome","valueDescription":"Maroteaux-Lamy Syndrome","ValueMeaning":{"publicId":"3028412","version":"1","preferredName":"Maroteaux-Lamy Syndrome","longName":"3028412","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maroteaux-Lamy Syndrome","conceptCode":"C61264","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC07-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-910A-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Mucolipidosis","valueDescription":"Mucolipidosis","ValueMeaning":{"publicId":"3028415","version":"1","preferredName":"Mucolipidosis","longName":"3028415","preferredDefinition":"A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucolipidosis","conceptCode":"C61267","definition":"A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC72-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-911E-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Nesidioblastosis","valueDescription":"Nesidioblastosis","ValueMeaning":{"publicId":"3192960","version":"1","preferredName":"Nesidioblastosis","longName":"3192960","preferredDefinition":"A sporadic or inherited disorder characterized by the focal or diffuse proliferation of Langerhans cells in the pancreas. It results in hyperinsulinemia and hypoglycemia.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nesidioblastosis","conceptCode":"C4375","definition":"A sporadic or inherited disorder characterized by the focal or diffuse proliferation of the cells of the islets of Langerhans in the pancreas. It results in hyperinsulinemia and hypoglycemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9CE5E606-44F3-3056-E040-BB89AD430EB6","latestVersionIndicator":"Yes","beginDate":"2011-02-22","endDate":null,"createdBy":"SORENSENS","dateCreated":"2011-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-9128-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Niemann-Pick Disease","valueDescription":"Niemann-Pick Disease","ValueMeaning":{"publicId":"3028411","version":"1","preferredName":"Niemann-Pick Disease","longName":"3028411","preferredDefinition":"An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Niemann-Pick Disease","conceptCode":"C61269","definition":"An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FBBC-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-913C-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Renal Disorder","valueDescription":"Renal Disorder","ValueMeaning":{"publicId":"2975595","version":"1","preferredName":"Renal Disorder","longName":"2975595","preferredDefinition":"A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kidney Disorder","conceptCode":"C3149","definition":"A neoplastic or non-neoplastic condition affecting the kidney. Representative examples of non-neoplastic conditions include glomerulonephritis and nephrotic syndrome. Representative examples of neoplastic conditions include benign processes (e.g., renal lipoma and renal fibroma) and malignant processes (e.g., renal cell carcinoma and renal lymphoma).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C084539-0EDE-6AD0-E040-BB89AD43189B","latestVersionIndicator":"Yes","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-9150-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Trisomy 18","valueDescription":"Trisomy 18","ValueMeaning":{"publicId":"3192961","version":"1","preferredName":"Trisomy 18","longName":"3192961","preferredDefinition":"A chromosomal abnormality consisting of the presence of a third copy of chromosome 18 in somatic cells.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trisomy 18","conceptCode":"C36626","definition":"A chromosomal abnormality consisting of the presence of a third copy of chromosome 18 in somatic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9CE5E606-4529-3056-E040-BB89AD430EB6","latestVersionIndicator":"Yes","beginDate":"2011-02-22","endDate":null,"createdBy":"SORENSENS","dateCreated":"2011-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-915A-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Wolman Disease","valueDescription":"Wolman Disease","ValueMeaning":{"publicId":"3028409","version":"1","preferredName":"Wolman Disease","longName":"3028409","preferredDefinition":"A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wolman Disease","conceptCode":"C61271","definition":"A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FAFB-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9FDE8F97-916E-385A-E040-BB89AD432C87","beginDate":null,"endDate":null,"createdBy":"CURTIST","dateCreated":"2011-04-01","modifiedBy":"ONEDATA","dateModified":"2011-04-01","deletedIndicator":"No"},{"value":"Autosomal Recessive Polycystic Kidney Disease","valueDescription":"Autosomal Recessive Polycystic Kidney Disease","ValueMeaning":{"publicId":"3210895","version":"1","preferredName":"Autosomal Recessive Polycystic Kidney Disease","longName":"3210895","preferredDefinition":"Polycystic kidney disease inherited in an autosomal recessive pattern. Patients present with progressive renal failure early in life. The autosomal recessive trait is associated with abnormalities of chromosome 6.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autosomal Recessive Polycystic Kidney Disease","conceptCode":"C84579","definition":"Polycystic kidney disease inherited in an autosomal recessive pattern. Patients present with progressive renal failure early in life. The autosomal recessive trait is associated with abnormalities of chromosome 6.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B0EA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B100-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Babesiosis","valueDescription":"Babesiosis","ValueMeaning":{"publicId":"3210896","version":"1","preferredName":"Babesiosis","longName":"3210896","preferredDefinition":"A parasitic infection caused by Babesia. It is transmitted by ticks and infects the red blood cells. Signs and symptoms include fever, fatigue and hemolytic anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Babesiosis","conceptCode":"C84581","definition":"A parasitic infection caused by Babesia. It is transmitted by ticks and infects the red blood cells. Signs and symptoms include fever, fatigue and hemolytic anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B10C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B122-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Balantidiasis","valueDescription":"Balantidiasis","ValueMeaning":{"publicId":"3210897","version":"1","preferredName":"Balantidiasis","longName":"3210897","preferredDefinition":"A parasitic protozoal infection caused by Balantidium coli that involves the large intestinal mucosa. Signs and symptoms include nausea, vomiting, diarrhea, abdominal pain, fever, headache and weight loss.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Balantidiasis","conceptCode":"C84583","definition":"A parasitic protozoal infection caused by Balantidium coli that involves the large intestinal mucosa. Signs and symptoms include nausea, vomiting, diarrhea, abdominal pain, fever, headache and weight loss.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B12E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B144-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Balkan Endemic Nephropathy","valueDescription":"Balkan Endemic Nephropathy","ValueMeaning":{"publicId":"3210898","version":"1","preferredName":"Balkan Endemic Nephropathy","longName":"3210898","preferredDefinition":"A chronic tubulointerstitial nephropathy that affects people in certain rural areas along the Danube river in the Balkans. It leads to end-stage renal disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Balkan Endemic Nephropathy","conceptCode":"C84584","definition":"A chronic tubulointerstitial nephropathy that affects people in certain rural areas along the Danube river in the Balkans. It leads to end-stage renal disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B150-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B166-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Barth Syndrome","valueDescription":"Barth Syndrome","ValueMeaning":{"publicId":"3210899","version":"1","preferredName":"Barth Syndrome","longName":"3210899","preferredDefinition":"A rare X-linked syndrome caused by mutations in TAZ1 gene. Signs and symptoms include cardiomyopathy, neutropenia, muscle weakness and atrophy, growth delay, cardiolipin deficiency and 3-methylglutaconic aciduria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Barth Syndrome","conceptCode":"C84585","definition":"A rare X-linked syndrome caused by mutations in TAZ1 gene. Signs and symptoms include cardiomyopathy, neutropenia, muscle weakness and atrophy, growth delay, cardiolipin deficiency and 3-methylglutaconic aciduria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B172-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B188-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bartonella Infection","valueDescription":"Bartonella Infection","ValueMeaning":{"publicId":"3210900","version":"1","preferredName":"Bartonella Infection","longName":"3210900","preferredDefinition":"A gram-negative bacterial infection caused by Bartonella bacilliformis. It is transmitted by ticks, flies and mosquitoes. Signs and symptoms include fever, headache, muscle pain, enlargement of the lymph nodes and anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bartonella Infection","conceptCode":"C84586","definition":"A gram-negative bacterial infection caused by bacteria of the genus Bartonella. It is transmitted by ticks, flies and mosquitoes. Signs and symptoms include fever, headache, muscle pain, enlargement of the lymph nodes and anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B194-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B1AA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bartter Syndrome","valueDescription":"Bartter Syndrome","ValueMeaning":{"publicId":"3210901","version":"1","preferredName":"Bartter Syndrome","longName":"3210901","preferredDefinition":"A rare inherited syndrome characterized by juxtaglomerular cell hyperplasia, hyperaldosteronism, hypokalemia, and alkalosis. Patients have high levels of plasma renin concentration which is not associated with hypertension.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bartter Syndrome","conceptCode":"C34412","definition":"A rare inherited syndrome characterized by juxtaglomerular cell hyperplasia, hyperaldosteronism, hypokalemia, and alkalosis. Patients have high levels of plasma renin concentration which is not associated with hypertension.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B1B6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B1CC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nevoid Basal Cell Carcinoma Syndrome","valueDescription":"Nevoid Basal Cell Carcinoma Syndrome","ValueMeaning":{"publicId":"3210902","version":"1","preferredName":"Nevoid Basal Cell Carcinoma Syndrome","longName":"3210902","preferredDefinition":"An autosomal dominant genetic syndrome caused by abnormalities in the PTCH gene.  It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida).  Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nevoid Basal Cell Carcinoma Syndrome","conceptCode":"C2892","definition":"An autosomal dominant genetic syndrome caused by abnormalities in the PTCH and SUFU gene. It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida). Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B1D8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B1EE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Becker's Muscular Dystrophy","valueDescription":"Becker's Muscular Dystrophy","ValueMeaning":{"publicId":"3210903","version":"1","preferredName":"Becker's Muscular Dystrophy","longName":"3210903","preferredDefinition":"An X-linked inherited disorder characterized by slowly progressing weakness in the muscles of the legs and pelvis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Becker's Muscular Dystrophy","conceptCode":"C84587","definition":"An X-linked inherited disorder characterized by slowly progressing weakness in the muscles of the legs and pelvis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B1FA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B210-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Beckwith-Wiedemann Syndrome","valueDescription":"Beckwith-Wiedemann Syndrome","ValueMeaning":{"publicId":"2967368","version":"1","preferredName":"Beckwith-Wiedemann Syndrome","longName":"2967368","preferredDefinition":"A genetic syndrome caused by abnormalities in chromosome 11.  It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia.  Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, Rhabdomyosarcoma) and adrenal cortex carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beckwith-Wiedemann Syndrome","conceptCode":"C34415","definition":"A genetic syndrome caused by abnormalities in chromosome 11. It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia. Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, rhabdomyosarcoma) and adrenal cortex carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AB32307-57DC-1A4F-E040-BB89AD43618C","latestVersionIndicator":"Yes","beginDate":"2009-12-14","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-14","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B222-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Behcet Syndrome","valueDescription":"Behcet Syndrome","ValueMeaning":{"publicId":"2593579","version":"1","preferredName":"Behcet Syndrome","longName":"2593579","preferredDefinition":"Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS, THROMBOPHLEBITIS, gastrointestinal ulcerations, RETINAL VASCULITIS, and OPTIC ATROPHY may occur as well.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Behcet Syndrome","conceptCode":"C34416","definition":"A rare chronic inflammatory disorder of unknown etiology. It is characterized by the development of ulcers in the mouth and genital region and uveitis. Other signs and symptoms include arthritis, deep vein thrombosis and superficial thrombophlebitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C01CF8-E883-093C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B22C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Benign Fibrous Histiocytoma","valueDescription":"Benign Fibrous Histiocytoma","ValueMeaning":{"publicId":"3210904","version":"1","preferredName":"Benign Fibrous Histiocytoma","longName":"3210904","preferredDefinition":"A benign neoplasm composed of fibroblastic spindle cells in a whorled storiform pattern.  It is characterized by the presence of foam cells, inflammatory cells, hemosiderin deposition and stromal hemorrhage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibrous Histiocytoma","conceptCode":"C3739","definition":"A benign neoplasm composed of fibroblastic spindle cells in a whorled storiform pattern.  It is characterized by the presence of foam cells, inflammatory cells, hemosiderin deposition and stromal hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B238-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B24E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Benign Migratory Glossitis","valueDescription":"Benign Migratory Glossitis","ValueMeaning":{"publicId":"3210905","version":"1","preferredName":"Benign Migratory Glossitis","longName":"3210905","preferredDefinition":"A benign condition characterized by the development of irregular patches in the surface of the tongue resulting in a map-like appearance. The patches migrate from day to day and usually resolve without treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Migratory Glossitis","conceptCode":"C84588","definition":"A benign condition characterized by the development of irregular patches in the surface of the tongue resulting in a map-like appearance. The patches migrate from day to day and usually resolve without treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B25A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B270-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Benign Mucous Membrane Pemphigoid","valueDescription":"Benign Mucous Membrane Pemphigoid","ValueMeaning":{"publicId":"3210906","version":"1","preferredName":"Benign Mucous Membrane Pemphigoid","longName":"3210906","preferredDefinition":"A chronic autoimmune disorder characterized by the development of blisters and ulcers in mucous membranes. It affects most often the gums, eyelids and genital mucosa sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Mucous Membrane Pemphigoid","conceptCode":"C34907","definition":"A chronic autoimmune disorder characterized by the development of blisters and ulcers in mucous membranes. It affects most often the gums, eyelids and genital mucosa sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B27C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B292-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Benign Neonatal Epilepsy","valueDescription":"Benign Neonatal Epilepsy","ValueMeaning":{"publicId":"3210907","version":"1","preferredName":"Benign Neonatal Epilepsy","longName":"3210907","preferredDefinition":"An inherited or sporadic disorder characterized by epileptic seizures in the first four to six weeks of life. The seizures tend to subside after the fifteenth week of life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Neonatal Epilepsy","conceptCode":"C84593","definition":"An inherited or sporadic disorder characterized by epileptic seizures in the first four to six weeks of life. The seizures tend to subside after the fifteenth week of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B29E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B2B4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Berardinelli-Seip Congenital Lipodystrophy","valueDescription":"Berardinelli-Seip Congenital Lipodystrophy","ValueMeaning":{"publicId":"3210908","version":"1","preferredName":"Berardinelli-Seip Congenital Lipodystrophy","longName":"3210908","preferredDefinition":"A genetic disorder caused by mutations in the AGPAT2 and BSCL2 genes. It is characterized by lipoatrophy in the trunk, face, and extremities, hypertriglyceridemia, muscle hypertrophy, cardiomyopathy and hepatomegaly. Patients develop insulin resistance, leading to diabetes mellitus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Berardinelli-Seip Congenital Lipodystrophy","conceptCode":"C84594","definition":"A genetic disorder caused by mutations in the AGPAT2 and BSCL2 genes. It is characterized by lipoatrophy in the trunk, face, and extremities, hypertriglyceridemia, muscle hypertrophy, cardiomyopathy and hepatomegaly. Patients develop insulin resistance, leading to diabetes mellitus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B2C0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B2D6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bernard-Soulier Syndrome","valueDescription":"Bernard-Soulier Syndrome","ValueMeaning":{"publicId":"3210909","version":"1","preferredName":"Bernard-Soulier Syndrome","longName":"3210909","preferredDefinition":"A rare, autosomal recessive bleeding disorder characterized by deficiency or absence of the Ib/IX/V complex on the surface of platelets. It results in thrombocytopenia, prolonged bleeding time and the presence of giant platelets.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bernard-Soulier Syndrome","conceptCode":"C84595","definition":"A rare, autosomal recessive bleeding disorder characterized by deficiency or absence of the Ib/IX/V complex on the surface of platelets. It results in thrombocytopenia, prolonged bleeding time and the presence of giant platelets.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B2E2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B2F8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Beta-Mannosidosis","valueDescription":"Beta-Mannosidosis","ValueMeaning":{"publicId":"3210910","version":"1","preferredName":"Beta-Mannosidosis","longName":"3210910","preferredDefinition":"An autosomal recessive lysosomal storage disease characterized by a deficient activity of the enzyme beta-mannosidase. It is caused by mutations in the MANBA gene. Common features of this disorder are mental retardation, developmental delays and recurrent respiratory infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beta-Mannosidosis","conceptCode":"C84596","definition":"An autosomal recessive lysosomal storage disease characterized by a deficient activity of the enzyme beta-mannosidase. It is caused by mutations in the MANBA gene. Common features of this disorder are mental retardation, developmental delays and recurrent respiratory infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B304-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B31A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Beta-Methylcrotonylglycinuria","valueDescription":"Beta-Methylcrotonylglycinuria","ValueMeaning":{"publicId":"3210911","version":"1","preferredName":"Beta-Methylcrotonylglycinuria","longName":"3210911","preferredDefinition":"A very rare metabolic disorder characterized by an inborn error in the leucine degradation pathway. Patients excrete large amounts of beta-methyl-crotonylglycine in the urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beta-Methylcrotonylglycinuria","conceptCode":"C84597","definition":"A very rare metabolic disorder characterized by an inborn error in the leucine degradation pathway. Patients excrete large amounts of beta-methyl-crotonylglycine in the urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B326-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B33C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Biliary Cirrhosis","valueDescription":"Biliary Cirrhosis","ValueMeaning":{"publicId":"3210912","version":"1","preferredName":"Biliary Cirrhosis","longName":"3210912","preferredDefinition":"Cirrhosis of the liver caused either by destruction of the intrahepatic bile ducts (primary biliary cirrhosis) or blockage of the extrahepatic bile ducts (secondary biliary cirrhosis).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biliary Cirrhosis","conceptCode":"C51225","definition":"Cirrhosis of the liver caused either by destruction of the intrahepatic bile ducts (primary biliary cirrhosis) or blockage of the extrahepatic bile ducts (secondary biliary cirrhosis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B348-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B35E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Biotinidase Deficiency","valueDescription":"Biotinidase Deficiency","ValueMeaning":{"publicId":"3210913","version":"1","preferredName":"Biotinidase Deficiency","longName":"3210913","preferredDefinition":"A genetic disorder caused by mutations in the BTD gene. It is characterized by reduced or absent activity of the enzyme biotinidase which is responsible for the recycling of the vitamin biotin. Signs and symptoms appear in childhood and include seizures, hypotonia and developmental delays. If left untreated, it leads to vision and hearing loss, infections, alopecia and ataxia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biotinidase Deficiency","conceptCode":"C84598","definition":"A genetic disorder caused by mutations in the BTD gene. It is characterized by reduced or absent activity of the enzyme biotinidase which is responsible for the recycling of the vitamin biotin. Signs and symptoms appear in childhood and include seizures, hypotonia and developmental delays. If left untreated, it leads to vision and hearing loss, infections, alopecia and ataxia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B36A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B380-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bladder Neoplasm","valueDescription":"Bladder Neoplasm","ValueMeaning":{"publicId":"3210914","version":"1","preferredName":"Bladder Neoplasm","longName":"3210914","preferredDefinition":"A benign or malignant, primary or metastatic neoplasm of the bladder. - 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Neoplasm","conceptCode":"C2901","definition":"A benign or malignant, primary or metastatic neoplasm of the bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B38C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B3A2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Blastomycosis","valueDescription":"Blastomycosis","ValueMeaning":{"publicId":"3210915","version":"1","preferredName":"Blastomycosis","longName":"3210915","preferredDefinition":"A fungal infection caused by inhalation of spores of Blastomyces dermatitidis. It presents with flu-like symptoms including fever, chills, cough, pleuritic chest pain and myalgias. It may lead to a chronic granulomatous pulmonary infection and disseminate to other anatomic sites including skin, nervous system and bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blastomycosis","conceptCode":"C34428","definition":"A fungal infection caused by inhalation of spores of Blastomyces dermatitidis. It presents with flu-like symptoms including fever, chills, cough, pleuritic chest pain and myalgias. It may lead to a chronic granulomatous pulmonary infection and disseminate to other anatomic sites including skin, nervous system and bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B3AE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B3C4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bloom Syndrome","valueDescription":"Bloom Syndrome","ValueMeaning":{"publicId":"2730287","version":"1","preferredName":"Bloom Syndrome","longName":"2730287","preferredDefinition":"Bloom syndrome is an autosomal recessive disorder associated with mutations in BLM gene encoding protein that belongs to the family of DNA helicases. It is characterized by predisposition to cancer, immunodeficiency, high sensitivity to UV and genomic instability of somatic cells. (Oncogene 2001 Dec 13;20(57):8276-80)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bloom Syndrome","conceptCode":"C2903","definition":"Bloom syndrome is an autosomal recessive disorder associated with mutations in BLM gene encoding protein that belongs to the family of DNA helicases. It is characterized by predisposition to cancer, immunodeficiency, high sensitivity to UV and genomic instability of somatic cells. (Oncogene 2001 Dec 13;20(57):8276-80)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"468669DD-2FE6-4A98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B3D6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bone Necrosis","valueDescription":"Bone Necrosis","ValueMeaning":{"publicId":"2944089","version":"1","preferredName":"Bone Necrosis","longName":"2944089","preferredDefinition":"Death of bone tissue due to traumatic or nontraumatic causes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Necrosis","conceptCode":"C34880","definition":"Death of bone tissue due to traumatic or nontraumatic causes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742DD56B-154D-A7E6-E040-BB89AD43063D","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B3E8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bone Paget Disease","valueDescription":"Bone Paget Disease","ValueMeaning":{"publicId":"3210916","version":"1","preferredName":"Bone Paget Disease","longName":"3210916","preferredDefinition":"Paget's Disease is a disease of bone that initially results in the excessive resorption of bone (by osteoclasts) followed by the replacement of normal bone marrow with vascular and fibrous tissue. (On-line Medical Dictionary)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Paget Disease","conceptCode":"C3292","definition":"A disease of bone that initially results in the excessive resorption of bone (by osteoclasts) followed by the replacement of normal bone marrow with vascular and fibrous tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B3F4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B40A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Botulism","valueDescription":"Botulism","ValueMeaning":{"publicId":"3210917","version":"1","preferredName":"Botulism","longName":"3210917","preferredDefinition":"A serious bacterial infection caused by botulinum toxin which is produced by Clostridium botulinum. Patients are infected usually by ingestion of contaminated food or wound contamination. It leads to muscle paralysis which may result in respiratory failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Botulism","conceptCode":"C84599","definition":"A serious bacterial infection caused by botulinum toxin which is produced by Clostridium botulinum. Patients are infected usually by ingestion of contaminated food or wound contamination. It leads to muscle paralysis which may result in respiratory failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B416-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B42C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Brachial Plexopathy","valueDescription":"Brachial Plexopathy","ValueMeaning":{"publicId":"2566121","version":"1","preferredName":"Brachial Plexopathy","longName":"2566121","preferredDefinition":"A brachial plexus disorder characterized by regional paresthesia, pain and muscle weakness, and limited movement in the arm or hand.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brachial Plexopathy","conceptCode":"C27194","definition":"A brachial plexus disorder characterized by regional paresthesia, pain and muscle weakness, and limited movement in the arm or hand.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CF56-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-07-23","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-07-23","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B43E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Brachial Plexus Neuritis","valueDescription":"Brachial Plexus Neuritis","ValueMeaning":{"publicId":"3210918","version":"1","preferredName":"Brachial Plexus Neuritis","longName":"3210918","preferredDefinition":"An inflammatory process affecting the brachial plexus. It results in severe pain in the upper extremity and shoulder, upper arm weakness and loss of sensation in the upper arm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brachial Plexus Neuritis","conceptCode":"C84600","definition":"An inflammatory process affecting the brachial plexus. It results in severe pain in the upper extremity and shoulder, upper arm weakness and loss of sensation in the upper arm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B44A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B460-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Brain Iron Accumulation Type I Syndrome","valueDescription":"Brain Iron Accumulation Type I Syndrome","ValueMeaning":{"publicId":"3210919","version":"1","preferredName":"Brain Iron Accumulation Type I Syndrome","longName":"3210919","preferredDefinition":"A rare neuroaxonal dystrophy, histologically characterized by axonal spheroids, iron deposition, lewy body (LB)-like intraneuronal inclusions and neurofibrillary tangles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brain Iron Accumulation Type I Syndrome","conceptCode":"C8967","definition":"A rare neuroaxonal dystrophy, histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions and neurofibrillary tangles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B46C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B482-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Brown-Sequard Syndrome","valueDescription":"Brown-Sequard Syndrome","ValueMeaning":{"publicId":"3210920","version":"1","preferredName":"Brown-Sequard Syndrome","longName":"3210920","preferredDefinition":"A disorder caused by a spinal injury leading to an incomplete spinal lesion. Patients develop paralysis, ataxia and loss of sensation. Causes include spinal cord tumors, spinal traumas, ischemia, and inflammatory processes affecting the spine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brown-Sequard Syndrome","conceptCode":"C84601","definition":"A disorder caused by a spinal injury leading to an incomplete spinal lesion. Patients develop paralysis, ataxia and loss of sensation. Causes include spinal cord tumors, spinal traumas, ischemia, and inflammatory processes affecting the spine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B48E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B4A4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Brucellosis","valueDescription":"Brucellosis","ValueMeaning":{"publicId":"3210921","version":"1","preferredName":"Brucellosis","longName":"3210921","preferredDefinition":"A gram negative bacterial infection caused by bacteria of the genus Brucella. Humans are infected by ingesting unpasteurized milk or meat from infected animals. Signs and symptoms include fevers, sweating, weakness, headache, muscle pain, arthritis and anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brucellosis","conceptCode":"C84602","definition":"A gram negative bacterial infection caused by bacteria of the genus Brucella. Humans are infected by ingesting unpasteurized milk or meat from infected animals. Signs and symptoms include fevers, sweating, weakness, headache, muscle pain, arthritis and anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B4B0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B4C6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Brugada Syndrome","valueDescription":"Brugada Syndrome","ValueMeaning":{"publicId":"3210922","version":"1","preferredName":"Brugada Syndrome","longName":"3210922","preferredDefinition":"A condition characterized by a pattern of right bundle branch block (RBBB) and ST-segment elevation within electrocardiogram (ECG) leads V1-V3. This pattern emerges as a result of a defect in ion channel genes, resulting in abnormal electrophysiological activity in the right ventricle and a propensity to malignant tachyarrhythmias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brugada Syndrome Ventricular Arrhythmia by ECG Finding","conceptCode":"C71059","definition":"An electrocardiographic finding of a pattern of right bundle branch block and ST-segment elevation within electrocardiogram leads V1-V3. This pattern emerges as a result of a defect in ion channel genes, resulting in atypical electrophysiological activity in the right ventricle and a propensity for malignant tachyarrhythmias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B4D2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B4E8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bundle Branch Block","valueDescription":"Bundle Branch Block","ValueMeaning":{"publicId":"3210923","version":"1","preferredName":"Bundle Branch Block","longName":"3210923","preferredDefinition":"An electrocardiographic finding defined by prolongation of the QRS complex. It is caused by damage of one of the bundle branches, resulting in the delay or obstruction of the conduction of electrical impulses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bundle Branch Block by ECG Finding","conceptCode":"C84603","definition":"An electrocardiographic finding of a prolongation of the QRS complex. It is caused by damage to one of the bundle branches, resulting in impaired transmission of cardiac electrical impulses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B4F4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B50A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Burkitt Lymphoma","valueDescription":"Burkitt Lymphoma","ValueMeaning":{"publicId":"2568284","version":"1","preferredName":"Burkitt Lymphoma","longName":"2568284","preferredDefinition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt's lymphoma, Burkitt's lymphoma with plasmacytoid differentiation, and atypical Burkitt's/Burkitt's-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Lymphoma","conceptCode":"C2912","definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7C9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":"04/13/2011 - tc - Updated with current NCIt name and definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B51C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Burning Mouth Syndrome","valueDescription":"Burning Mouth Syndrome","ValueMeaning":{"publicId":"2945852","version":"1","preferredName":"Burning Mouth Syndrome","longName":"2945852","preferredDefinition":"A condition characterized by a burning or tingling sensation on the lips, tongue, or entire mouth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burning Mouth Syndrome","conceptCode":"C62545","definition":"A condition characterized by a burning or tingling sensation on the lips, tongue, or entire mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74597246-16AC-6D19-E040-BB89AD431E08","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B52E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Buruli Ulcer","valueDescription":"Buruli Ulcer","ValueMeaning":{"publicId":"3210924","version":"1","preferredName":"Buruli Ulcer","longName":"3210924","preferredDefinition":"A cutaneous infection caused by Mycobacterium ulcerans. It presents with painless nodular swelling of the skin, leading to the formation of necrotizing ulcers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Buruli Ulcer","conceptCode":"C84604","definition":"A cutaneous infection caused by Mycobacterium ulcerans. It presents with painless nodular swelling of the skin, leading to the formation of necrotizing ulcers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B53A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B550-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Byssinosis","valueDescription":"Byssinosis","ValueMeaning":{"publicId":"3210925","version":"1","preferredName":"Byssinosis","longName":"3210925","preferredDefinition":"An occupational lung disorder caused by exposure to cotton dust. It occurs more commonly in workers in the textile industry. Signs and symptoms include chest tightness, cough and wheezing. The symptoms tend to get worse at the beginning of the week and subside by the end of the week.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Byssinosis","conceptCode":"C84605","definition":"An occupational lung disorder caused by exposure to cotton dust. It occurs more commonly in workers in the textile industry. Signs and symptoms include chest tightness, cough and wheezing. The symptoms tend to get worse at the beginning of the week and subside by the end of the week.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B55C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B572-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"CADASIL Syndrome","valueDescription":"CADASIL Syndrome","ValueMeaning":{"publicId":"3210926","version":"1","preferredName":"CADASIL Syndrome","longName":"3210926","preferredDefinition":"A hereditary cerebrovascular disorder caused by mutations in the Notch 3 gene. It is characterized by alterations of the muscular wall of the small vessels in the brain, resulting in transient ischemic attacks. It may lead to cognitive problems and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CADASIL Syndrome","conceptCode":"C84606","definition":"A hereditary cerebrovascular disorder caused by mutations in the Notch 3 gene. It is characterized by alterations of the muscular wall of the small vessels in the brain, resulting in transient ischemic attacks. It may lead to cognitive problems and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B57E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B594-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Calciphylaxis","valueDescription":"Calciphylaxis","ValueMeaning":{"publicId":"3210927","version":"1","preferredName":"Calciphylaxis","longName":"3210927","preferredDefinition":"A rare syndrome characterized by vascular calcification and skin necrosis. It seen in patients with end stage renal disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calciphylaxis","conceptCode":"C84607","definition":"A rare syndrome characterized by vascular calcification and skin necrosis. It seen in patients with end stage renal disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B5A0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B5B6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Campomelic Dysplasia","valueDescription":"Campomelic Dysplasia","ValueMeaning":{"publicId":"3210928","version":"1","preferredName":"Campomelic Dysplasia","longName":"3210928","preferredDefinition":"A genetic congenital disorder characterized by bowing and angulation of the long bones. It may be associated with other skeletal and extraskeletal defects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Campomelic Dysplasia","conceptCode":"C84609","definition":"A genetic congenital disorder characterized by bowing and angulation of the long bones. It may be associated with other skeletal and extraskeletal defects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B5C2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B5D8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Camurati-Engelmann Syndrome","valueDescription":"Camurati-Engelmann Syndrome","ValueMeaning":{"publicId":"3210929","version":"1","preferredName":"Camurati-Engelmann Syndrome","longName":"3210929","preferredDefinition":"An autosomal dominant skeletal disorder caused by mutations in the TGFB1 gene. It is characterized by thickening of the bones, particularly the long bones of the extremities. It is associated with muscle weakness and tiredness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Camurati-Engelmann Syndrome","conceptCode":"C84610","definition":"An autosomal dominant skeletal disorder caused by mutations in the TGFB1 gene. It is characterized by thickening of the bones, particularly the long bones of the extremities. It is associated with muscle weakness and tiredness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B5E4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B5FA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Canavan Disease","valueDescription":"Canavan Disease","ValueMeaning":{"publicId":"3210930","version":"1","preferredName":"Canavan Disease","longName":"3210930","preferredDefinition":"A disorder that belongs in the group of leukodystrophies. It is caused by mutations in the ASPA gene which is responsible for the production of the enzyme aspartoacylase. It is characterized by spongy degeneration of the white matter of the brain. Signs and symptoms appear in infancy and include mental retardation, loss of motor skills, abnormal muscle tone, feeding difficulties and a very large head.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Canavan Disease","conceptCode":"C84611","definition":"A disorder that belongs in the group of leukodystrophies. It is caused by mutations in the ASPA gene which is responsible for the production of the enzyme aspartoacylase. It is characterized by spongy degeneration of the white matter of the brain. Signs and symptoms appear in infancy and include mental retardation, loss of motor skills, abnormal muscle tone, feeding difficulties and a very large head.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B606-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B61C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Capillary Leak Syndrome","valueDescription":"Capillary Leak Syndrome","ValueMeaning":{"publicId":"2780142","version":"1","preferredName":"Capillary Leak Syndrome","longName":"2780142","preferredDefinition":"A syndrome characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capillary Leak Syndrome","conceptCode":"C62578","definition":"A syndrome characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56172F89-7756-66E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B62E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Carbamoyl-Phosphate Synthetase I Deficiency","valueDescription":"Carbamoyl-Phosphate Synthetase I Deficiency","ValueMeaning":{"publicId":"3210931","version":"1","preferredName":"Carbamoyl-Phosphate Synthetase I Deficiency","longName":"3210931","preferredDefinition":"A congenital disorder caused by mutations in the CPS1 gene. It is characterized by accumulation of ammonia in the blood. Signs and symptoms appear in infancy and include lethargy, seizures, developmental delay and mental disability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carbamoyl-Phosphate Synthetase I Deficiency","conceptCode":"C84612","definition":"A congenital disorder caused by mutations in the CPS1 gene. It is characterized by accumulation of ammonia in the blood. Signs and symptoms appear in infancy and include lethargy, seizures, developmental delay and mental disability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B63A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B650-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Carbohydrate-Deficient Glycoprotein Syndrome","valueDescription":"Carbohydrate-Deficient Glycoprotein Syndrome","ValueMeaning":{"publicId":"3210932","version":"1","preferredName":"Carbohydrate-Deficient Glycoprotein Syndrome","longName":"3210932","preferredDefinition":"An autosomal recessive disorder of carbohydrate metabolism. It is characterized by psychomotor retardation, growth retardation, ataxia, seizures, hepatomegaly with steatosis and hypothyroidism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carbohydrate-Deficient Glycoprotein Syndrome","conceptCode":"C84615","definition":"An genetically heterogeneous group of autosomal recessive disorders of carbohydrate metabolism characterized by psychomotor retardation, growth retardation, ataxia, seizures, hepatomegaly with steatosis and hypothyroidism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B65C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B672-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cardiofaciocutaneous Syndrome","valueDescription":"Cardiofaciocutaneous Syndrome","ValueMeaning":{"publicId":"3210933","version":"1","preferredName":"Cardiofaciocutaneous Syndrome","longName":"3210933","preferredDefinition":"A rare genetic syndrome most often caused by BRAF gene mutations. It is characterized by a distinctive facial appearance (high forehead, short nose, and widely spaced eyes), sparse and brittle hair, skin disorders, heart malformations, mental retardation and developmental delay.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cardiofaciocutaneous Syndrome","conceptCode":"C84617","definition":"A rare genetic syndrome most often caused by BRAF gene mutations. It is characterized by a distinctive facial appearance (high forehead, short nose, and widely spaced eyes), sparse and brittle hair, skin disorders, heart malformations, mental retardation and developmental delay.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B67E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B694-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Carney Syndrome","valueDescription":"Carney Syndrome","ValueMeaning":{"publicId":"3210934","version":"1","preferredName":"Carney Syndrome","longName":"3210934","preferredDefinition":"An autosomal dominant disorder most often caused by mutations in the PRKAR1A gene. It is characterized by the presence of myxomas in the heart and skin, skin hyperpigmentation, increased endocrine activity and schwannomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carney Complex","conceptCode":"C4705","definition":"An autosomal dominant disorder most often caused by mutations in the PRKAR1A gene. It is characterized by the presence of myxomas in the heart and skin, skin hyperpigmentation, increased endocrine activity and melanotic schwannomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B6A0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B6B6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Caroli Disease","valueDescription":"Caroli Disease","ValueMeaning":{"publicId":"3210935","version":"1","preferredName":"Caroli Disease","longName":"3210935","preferredDefinition":"A rare congenital disorder characterized by cystic dilatation of the intrahepatic bile ducts. It is associated with cholangitis and the formation of stones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Caroli Disease","conceptCode":"C84619","definition":"A rare congenital disorder characterized by cystic dilatation of the intrahepatic bile ducts. It is associated with cholangitis and the formation of stones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B6C2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B6D8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cataplexy","valueDescription":"Cataplexy","ValueMeaning":{"publicId":"3210936","version":"1","preferredName":"Cataplexy","longName":"3210936","preferredDefinition":"A rare disorder characterized by sudden and transient episodes of loss of muscle tone. It often follows an experience of intense emotions. It is seen in patients with narcolepsy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cataplexy","conceptCode":"C84618","definition":"A rare disorder characterized by sudden and transient episodes of loss of muscle tone. It often follows an experience of intense emotions. It is seen in patients with narcolepsy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B6E4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B6FA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cat-Scratch Disease","valueDescription":"Cat-Scratch Disease","ValueMeaning":{"publicId":"3210937","version":"1","preferredName":"Cat-Scratch Disease","longName":"3210937","preferredDefinition":"A bacterial infection caused by Bartonella henselae. It is transmitted to humans from a scratch, bite, or lick from a cat. A blister or a bump appears on the skin following the scratch or bite. Subsequently, there is lymph node enlargement around the scratch or bite site. The lymph node enlargement most often occurs under the arm or the neck. Some patients experience fever, fatigue, headaches or sore throat as well.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cat-Scratch Disease","conceptCode":"C84620","definition":"A bacterial infection caused by Bartonella henselae. It is transmitted to humans from a scratch, bite, or lick from a cat. A blister or a bump appears on the skin following the scratch or bite. Subsequently, there is lymph node enlargement around the scratch or bite site. The lymph node enlargement most often occurs under the arm or the neck. Some patients experience fever, fatigue, headaches or sore throat as well.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B706-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B71C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cavernous Hemangioma","valueDescription":"Cavernous Hemangioma","ValueMeaning":{"publicId":"3210938","version":"1","preferredName":"Cavernous Hemangioma","longName":"3210938","preferredDefinition":"A hemangioma characterized by the presence of cavernous vascular spaces.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cavernous Hemangioma","conceptCode":"C3086","definition":"A hemangioma characterized by the presence of cavernous vascular spaces.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B728-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B73E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Necrotizing Enterocolitis","valueDescription":"Necrotizing Enterocolitis","ValueMeaning":{"publicId":"3211285","version":"1","preferredName":"Necrotizing Enterocolitis","longName":"3211285","preferredDefinition":"A serious, life-threatening disorder characterized by necrotic changes affecting portions of the small and large intestine. It is usually seen in neonates, particularly premature infants. Signs and symptoms include abdominal distention and tenderness, intestinal bleeding and ileus. It may lead to cardiovascular collapse and shock.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Necrotizing Enterocolitis","conceptCode":"C84915","definition":"A fulminating disease of neonates in which there is extensive mucosal ulceration, pseudomembrane formation, submucosal hemorrhage, and necrosis usually of the right colon, cecum, terminal ileum, and appendix, possibly due to perinatal intestinal ischemia and bacterial invasion. Progression can lead to necrosis, perforation and/or scarring of the intestinal tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E857-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E86D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Necrotizing Fasciitis","valueDescription":"Necrotizing Fasciitis","ValueMeaning":{"publicId":"3211286","version":"1","preferredName":"Necrotizing Fasciitis","longName":"3211286","preferredDefinition":"Infection of the deep skin and subcutaneous tissues and necrosis of the fascia. It is caused by bacteria including group A streptococcus, Staphylococcus aureus and Clostridium perfringens. It may develop following trauma and invasive procedures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Necrotizing Fasciitis","conceptCode":"C84916","definition":"Infection of the deep skin and subcutaneous tissues and necrosis of the fascia. It is caused by bacteria including group A streptococcus, Staphylococcus aureus and Clostridium perfringens. It may develop following trauma and invasive procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E879-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E88F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Necrotizing Ulcerative Gingivitis","valueDescription":"Necrotizing Ulcerative Gingivitis","ValueMeaning":{"publicId":"3211287","version":"1","preferredName":"Necrotizing Ulcerative Gingivitis","longName":"3211287","preferredDefinition":"A bacterial infectious process affecting the gums. It is characterized by the development of necrotic, ulcerated, and painful lesions with creation of pseudomembranes extending along the gingival margins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Necrotizing Ulcerative Gingivitis","conceptCode":"C34637","definition":"A bacterial infectious process affecting the gums. It is characterized by the development of necrotic, ulcerated, and painful lesions with creation of pseudomembranes extending along the gingival margins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E89B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E8B1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nelson Syndrome","valueDescription":"Nelson Syndrome","ValueMeaning":{"publicId":"3211288","version":"1","preferredName":"Nelson Syndrome","longName":"3211288","preferredDefinition":"A syndrome that develops following bilateral adrenalectomy for Cushing syndrome. The signs and symptoms result from the presence of an adenocorticotropin-secreting pituitary gland adenoma, and include enlargement of the sella turcica and pressure on the adjacent structures, and skin hyperpigmentation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nelson Syndrome","conceptCode":"C84917","definition":"A syndrome that develops following bilateral adrenalectomy for Cushing syndrome. The signs and symptoms result from the presence of an adenocorticotropin-secreting pituitary gland adenoma, and include enlargement of the sella turcica and pressure on the adjacent structures, and skin hyperpigmentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E8BD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E8D3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neonatal Respiratory Distress Syndrome","valueDescription":"Neonatal Respiratory Distress Syndrome","ValueMeaning":{"publicId":"3211289","version":"1","preferredName":"Neonatal Respiratory Distress Syndrome","longName":"3211289","preferredDefinition":"A condition of the newborn marked by dyspnea with cyanosis, most frequently occurring in premature infants, children of diabetic mothers and infants delivered by cesarean section, and sometimes with no predisposing cause.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Respiratory Distress Syndrome","conceptCode":"C27560","definition":"A condition beginning in the first day of life that results from inadequate surfactant production, causing increased work of breathing and impaired gas exchange.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E8DF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E8F5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neoplasm of the Diffuse Neuroendocrine System","valueDescription":"Neoplasm of the Diffuse Neuroendocrine System","ValueMeaning":{"publicId":"3211290","version":"1","preferredName":"Neoplasm of the Diffuse Neuroendocrine System","longName":"3211290","preferredDefinition":"A tumor made up of cells with APUD properties. - 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm of the Diffuse Neuroendocrine System","conceptCode":"C2879","definition":"A tumor made up of cells with APUD properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E901-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E917-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nephrocalcinosis","valueDescription":"Nephrocalcinosis","ValueMeaning":{"publicId":"3211291","version":"1","preferredName":"Nephrocalcinosis","longName":"3211291","preferredDefinition":"Deposition of calcium in the renal parenchyma, resulting from high levels of calcium in the blood and/or urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nephrocalcinosis","conceptCode":"C84918","definition":"Deposition of calcium in the renal parenchyma, resulting from high levels of calcium in the blood and/or urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E923-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E939-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nephrogenic Diabetes Insipidus","valueDescription":"Nephrogenic Diabetes Insipidus","ValueMeaning":{"publicId":"3211292","version":"1","preferredName":"Nephrogenic Diabetes Insipidus","longName":"3211292","preferredDefinition":"Diabetes insipidus caused by insensitivity of the kidneys to antidiuretic hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nephrogenic Diabetes Insipidus","conceptCode":"C84919","definition":"Diabetes insipidus caused by insensitivity of the kidneys to antidiuretic hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E945-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E95B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nephrogenic Fibrosing Dermopathy","valueDescription":"Nephrogenic Fibrosing Dermopathy","ValueMeaning":{"publicId":"3211293","version":"1","preferredName":"Nephrogenic Fibrosing Dermopathy","longName":"3211293","preferredDefinition":"A rare disorder characterized by fibrosis of the skin and internal organs. It occurs in patients with renal failure who had imaging studies performed using gadolinium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nephrogenic Fibrosing Dermopathy","conceptCode":"C84920","definition":"A rare disorder characterized by fibrosis of the skin and internal organs. It occurs in patients with renal failure who had imaging studies performed using gadolinium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E967-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E97D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Netherton Syndrome","valueDescription":"Netherton Syndrome","ValueMeaning":{"publicId":"3211294","version":"1","preferredName":"Netherton Syndrome","longName":"3211294","preferredDefinition":"A rare autosomal recessive form of ichthyosis caused by mutations in the SPINK5 gene. Patients have spiky and fragile hair.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Netherton Syndrome","conceptCode":"C84922","definition":"A rare autosomal recessive form of ichthyosis caused by mutations in the SPINK5 gene. Patients have spiky and fragile hair.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E989-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E99F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neural Tube Defect","valueDescription":"Neural Tube Defect","ValueMeaning":{"publicId":"3211295","version":"1","preferredName":"Neural Tube Defect","longName":"3211295","preferredDefinition":"A congenital defect characterized by failure of the neural tube to close completely; this results in the presence of openings in the brain or spinal cord. Examples of neural tube defects include encephalocele and spina bifida.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neural Tube Defect","conceptCode":"C84923","definition":"A congenital defect characterized by failure of the neural tube to close completely; this results in the presence of openings in the brain or spinal cord. Examples of neural tube defects include encephalocele and spina bifida.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E9AB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E9C1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neuroacanthocytosis","valueDescription":"Neuroacanthocytosis","ValueMeaning":{"publicId":"3211296","version":"1","preferredName":"Neuroacanthocytosis","longName":"3211296","preferredDefinition":"A group of neurologic disorders associated with acanthocytosis on the peripheral blood smear. The neurologic disorders include movement disorders, ataxia, cognitive disturbances, personality changes, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroacanthocytosis","conceptCode":"C84926","definition":"A group of neurologic disorders associated with acanthocytosis on the peripheral blood smear. The neurologic disorders include movement disorders, ataxia, cognitive disturbances, personality changes, and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E9CD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E9E3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neurocysticercosis","valueDescription":"Neurocysticercosis","ValueMeaning":{"publicId":"3211297","version":"1","preferredName":"Neurocysticercosis","longName":"3211297","preferredDefinition":"A parasitic infection with tapeworms of the genus Taenia affecting the brain. It is manifested with seizures and headaches.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurocysticercosis","conceptCode":"C84932","definition":"A parasitic infection with tapeworms of the genus Taenia affecting the brain. It is manifested with seizures and headaches.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E9EF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EA05-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neuroendocrine Neoplasm","valueDescription":"Neuroendocrine Neoplasm","ValueMeaning":{"publicId":"3211298","version":"1","preferredName":"Neuroendocrine Neoplasm","longName":"3211298","preferredDefinition":"A benign or malignant neoplasm composed of cells of neuroendocrine origin.  Representative examples include paraganglioma, carcinoid tumor, and neuroendocrine carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroendocrine Neoplasm","conceptCode":"C3809","definition":"An epithelial neoplasm with neuroendocrine differentiation. This category includes neuroendocrine tumors, neuroendocrine carcinomas, and paragangliomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EA11-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EA27-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neurofibroma","valueDescription":"Neurofibroma","ValueMeaning":{"publicId":"2838641","version":"1","preferredName":"Neurofibroma","longName":"2838641","preferredDefinition":"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurofibroma","conceptCode":"C3272","definition":"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5A84-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EA39-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neurofibromatosis","valueDescription":"Neurofibromatosis","ValueMeaning":{"publicId":"2967364","version":"1","preferredName":"Neurofibromatosis","longName":"2967364","preferredDefinition":"A group of disorders characterized by an autosomal dominant pattern of inheritance with high rates of spontaneous mutation and multiple neurofibromas or neurilemmomas. NEUROFIBROMATOSIS 1 (generalized neurofibromatosis) accounts for approximately 95% of cases, although multiple additional subtypes (e.g., NEUROFIBROMATOSIS 2, neurofibromatosis 3, etc.) have been described. (From Neurochirurgie 1998 Nov;44(4):267-72)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurofibromatosis","conceptCode":"C6727","definition":"An autosomal dominant hereditary neoplastic syndrome. Two distinct clinicopathological entities are recognized: neurofibromatosis type 1 and neurofibromatosis type 2. Neurofibromatosis type 1 is associated with the presence of cafe-au-lait cutaneous lesions, multiple neurofibromas, malignant peripheral nerve sheath tumors, optic nerve gliomas, and bone lesions. Neurofibromatosis type 2 is associated with the presence of schwannomas, meningiomas, and gliomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AB32307-5790-1A4F-E040-BB89AD43618C","latestVersionIndicator":"Yes","beginDate":"2009-12-14","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EA43-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neurofibromatosis Type 1","valueDescription":"Neurofibromatosis Type 1","ValueMeaning":{"publicId":"2962080","version":"1","preferredName":"Neurofibromatosis Type 1","longName":"2962080","preferredDefinition":"Type 1 (peripheral) neurofibromatosis (von Recklinghausen's disease), is the most common type of neurofibromatosis.  It is characterized clinically by cutaneous and subcutaneous tumors with patches of hyperpigmentation. The hyperpigmented skin areas, are present from birth and found anywhere on the body surface.  They can vary markedly in size and color.  The dark brown areas are called cafe-au-lait spots. The multiple cutaneous and subcutaneous tumors are nerve sheath neoplasms, called neurofibromas.  They can develop anywhere along the peripheral nerve fibers. Neurofibromas can become quite large, causing a major disfigurement, eroding bone, and compressing various peripheral nerve structures.  Type 1 neurofibromatosis has dominant inheritance, with a gene locus on the proximal long arm of chromosome 17.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurofibromatosis Type 1","conceptCode":"C3273","definition":"The most common type of neurofibromatosis.  It is characterized clinically by cutaneous and subcutaneous tumors with patches of hyperpigmentation. The hyperpigmented skin areas, are present from birth and found anywhere on the body surface.  They can vary markedly in size and color.  The dark brown areas are called cafe-au-lait spots. The multiple cutaneous and subcutaneous tumors are nerve sheath tumors, called neurofibromas.  They can develop anywhere along the peripheral nerve fibers. Neurofibromas can become quite large, causing a major disfigurement, eroding bone, and compressing various peripheral nerve structures.  Type 1 neurofibromatosis has dominant inheritance, with a gene locus on the proximal long arm of chromosome 17.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78BA0E7A-4A8D-2225-E040-BB89AD436E34","latestVersionIndicator":"Yes","beginDate":"2009-11-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-19","modifiedBy":"GDEEN","dateModified":"2023-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EA55-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neurofibromatosis Type 2","valueDescription":"Neurofibromatosis Type 2","ValueMeaning":{"publicId":"2962078","version":"1","preferredName":"Neurofibromatosis Type 2","longName":"2962078","preferredDefinition":"An autosomal dominant disorder caused by mutations in the NF2 tumor suppressor gene.  It is characterized by the development of peripheral and central nervous system tumors including acoustic schwannomas, neurofibromas, gliomas, and meningiomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurofibromatosis Type 2","conceptCode":"C3274","definition":"An autosomal dominant disorder caused by mutations in the NF2 tumor suppressor gene.  It is characterized by the development of peripheral and central nervous system tumors including acoustic schwannomas, neurofibromas, gliomas, and meningiomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78BA0E7A-4A67-2225-E040-BB89AD436E34","latestVersionIndicator":"Yes","beginDate":"2009-11-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-19","modifiedBy":"GDEEN","dateModified":"2023-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EA67-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neurogenic Diabetes Insipidus","valueDescription":"Neurogenic Diabetes Insipidus","ValueMeaning":{"publicId":"3211299","version":"1","preferredName":"Neurogenic Diabetes Insipidus","longName":"3211299","preferredDefinition":"Diabetes insipidus caused by decreased secretion of antidiuretic hormone from the pituitary gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurogenic Diabetes Insipidus","conceptCode":"C84933","definition":"Diabetes insipidus caused by decreased secretion of antidiuretic hormone from the pituitary gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EA73-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EA89-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neuromyelitis Optica","valueDescription":"Neuromyelitis Optica","ValueMeaning":{"publicId":"3211300","version":"1","preferredName":"Neuromyelitis Optica","longName":"3211300","preferredDefinition":"An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuromyelitis Optica","conceptCode":"C84934","definition":"An autoimmune inflammatory syndrome characterized by optic neuritis and myelitis. Signs and symptoms include loss of vision, weakness and paralysis of the extremities, and loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EA95-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EAAB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neuronal Ceroid Lipofuscinosis","valueDescription":"Neuronal Ceroid Lipofuscinosis","ValueMeaning":{"publicId":"3211301","version":"1","preferredName":"Neuronal Ceroid Lipofuscinosis","longName":"3211301","preferredDefinition":"A group of mostly autosomal recessive inherited neurodegenerative disorders characterized by accumulation of lipofuscin in the neuronal cells and in other tissues including liver, spleen, kidneys, and myocardium. Signs and symptoms include motor disturbances and cognitive decline.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuronal Ceroid Lipofuscinosis","conceptCode":"C61257","definition":"A group of mostly autosomal recessive inherited neurodegenerative disorders characterized by accumulation of lipofuscin in the neuronal cells and in other tissues including liver, spleen, kidneys, and myocardium. Signs and symptoms include motor disturbances and cognitive decline.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EAB7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EACD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neurosyphilis","valueDescription":"Neurosyphilis","ValueMeaning":{"publicId":"3211302","version":"1","preferredName":"Neurosyphilis","longName":"3211302","preferredDefinition":"Infection of the brain or spinal cord by Treponema pallidum. It occurs many years following the original infection which remained untreated. Signs and symptoms include abnormal gait, blindness, depression, paralysis, seizures and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurosyphilis","conceptCode":"C84935","definition":"Infection of the brain or spinal cord by Treponema pallidum. It occurs many years following the original infection which remained untreated. Signs and symptoms include abnormal gait, blindness, depression, paralysis, seizures and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EAD9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EAEF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neurotoxicity Syndrome","valueDescription":"Neurotoxicity","ValueMeaning":{"publicId":"3211303","version":"1","preferredName":"Neurotoxicity","longName":"3211303","preferredDefinition":"A group of neurologic disorders caused by damage to the nervous system following exposure to pharmacologic, biologic, and chemical agents. Examples of neurotoxins include chemotherapy agents, radiation treatment, heavy metals, pesticides, and food additives.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurotoxicity Syndrome","conceptCode":"C27961","definition":"A group of neurologic disorders caused by damage to the nervous system following exposure to pharmacologic, biologic, and chemical agents. Examples of neurotoxins include chemotherapy agents, radiation treatment, heavy metals, pesticides, and food additives.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EAFB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EB11-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Niemann-Pick Disease, Type C","valueDescription":"Niemann-Pick Disease, Type C","ValueMeaning":{"publicId":"3211304","version":"1","preferredName":"Niemann-Pick Disease, Type C","longName":"3211304","preferredDefinition":"An autosomal recessive inherited lysosomal storage disease caused by mutations in the NPC1 and NPC2 genes. It is characterized by progressive neurologic deterioration manifested with ataxia, dementia, seizures, and dystonia. Other signs and symptoms include hepatosplenomegaly, jaundice, and respiratory failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Niemann-Pick Disease, Type C","conceptCode":"C85214","definition":"An autosomal recessive inherited lysosomal storage disease caused by mutations in the NPC1 and NPC2 genes. It is characterized by progressive neurologic deterioration manifested with ataxia, dementia, seizures, and dystonia. Other signs and symptoms include hepatosplenomegaly, jaundice, and respiratory failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EB27-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EB3D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Night Blindness","valueDescription":"Night Blindness","ValueMeaning":{"publicId":"2945771","version":"1","preferredName":"Night Blindness","longName":"2945771","preferredDefinition":"An inability to see clearly in dim light; due to a deficiency of vitamin A or to a retinal disorder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Night Blindness","conceptCode":"C34850","definition":"Inability to see clearly in dim light.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7458E815-90F7-DD76-E040-BB89AD43104A","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EB4F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nijmegen Breakage Syndrome","valueDescription":"Nijmegen Breakage Syndrome","ValueMeaning":{"publicId":"3211305","version":"1","preferredName":"Nijmegen Breakage Syndrome","longName":"3211305","preferredDefinition":"A disorder, wherein unstable chromosomes have a tendency to break and become rearranged, characterized by microcephaly, stunted growth, subnormal mental development, cafe-au-lait spots, and immunodeficiency. The syndrome is named after the University of Nijmegen in the Netherlands. (JABL99)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nijmegen Breakage Syndrome","conceptCode":"C4692","definition":"A disorder, wherein unstable chromosomes have a tendency to break and become rearranged, characterized by microcephaly, stunted growth, subnormal mental development, cafe-au-lait spots, and immunodeficiency. The syndrome is named after the University of Nijmegen in the Netherlands. (JABL99)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EB5B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EB71-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Noma","valueDescription":"Gangrenous Stomatitis","ValueMeaning":{"publicId":"3211306","version":"1","preferredName":"Gangrenous Stomatitis","longName":"3211306","preferredDefinition":"Gangrene of the mucous membranes of the mouth leading to ulcers and destruction of the soft tissues of the face and bones. It usually occurs in malnourished children in areas of poor sanitation and immunocompromised patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gangrenous Stomatitis","conceptCode":"C34852","definition":"Gangrene of the mucous membranes of the mouth leading to ulcers and destruction of the soft tissues of the face and bones. It usually occurs in malnourished children in areas of poor sanitation and immunocompromised patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EB7D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EB93-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Non-Small Cell Lung Carcinoma","valueDescription":"Non-Small Cell Lung Carcinoma","ValueMeaning":{"publicId":"2581628","version":"1","preferredName":"Non-Small Cell Lung Carcinoma","longName":"2581628","preferredDefinition":"A group of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.  Non-small cell lung carcinomas have a poor response to conventional chemotherapy.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Non-Small Cell Carcinoma","conceptCode":"C2926","definition":"A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0BE9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-07","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-07","modifiedBy":"ONEDATA","dateModified":"2006-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EBA5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Non-Trisomic Autosomal Aneuploidy","valueDescription":"Non-Trisomic Autosomal Aneuploidy","ValueMeaning":{"publicId":"3211307","version":"1","preferredName":"Non-Trisomic Autosomal Aneuploidy","longName":"3211307","preferredDefinition":"Autosomal aneuploidy not associated with trisomy. It results in developmental malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Trisomic Autosomal Aneuploidy","conceptCode":"C84561","definition":"Autosomal aneuploidy not associated with trisomy. It results in developmental malformations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EBB1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EBC7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Noonan Syndrome","valueDescription":"Noonan Syndrome","ValueMeaning":{"publicId":"3211308","version":"1","preferredName":"Noonan Syndrome","longName":"3211308","preferredDefinition":"A genetic syndrome caused by mutations in the PTPN11 gene (over 50% of the cases) or less frequently mutations in the SOS1, RAF1, or KRAS genes.  It is characterized by short stature, webbed neck, hypertelorism, low-set ears, deafness, and thrombocytopenia or abnormal platelet function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Noonan Syndrome","conceptCode":"C34854","definition":"A genetic syndrome caused by mutations in the PTPN11 gene (over 50% of the cases) or less frequently mutations in the SOS1, RAF1, or KRAS genes. It is characterized by short stature, webbed neck, hypertelorism, low-set ears, deafness, and thrombocytopenia or abnormal platelet function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EBD3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EBE9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ochronosis","valueDescription":"Ochronosis","ValueMeaning":{"publicId":"3211309","version":"1","preferredName":"Ochronosis","longName":"3211309","preferredDefinition":"A disorder characterized by bluish-black discoloration of the cartilaginous tissues due to accumulation of homogentisic acid. It is associated with alkaptonuria. Signs and symptoms include dark urine, skin pigmentation, and arthritis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ochronosis","conceptCode":"C84938","definition":"A disorder characterized by bluish-black discoloration of the cartilaginous tissues due to accumulation of homogentisic acid. It is associated with alkaptonuria. Signs and symptoms include dark urine, skin pigmentation, and arthritis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EBF5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EC0B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ocular Cicatricial Pemphigoid","valueDescription":"Ocular Cicatricial Pemphigoid","ValueMeaning":{"publicId":"3211310","version":"1","preferredName":"Ocular Cicatricial Pemphigoid","longName":"3211310","preferredDefinition":"A chronic autoimmune disorder that belongs to the mucous membrane pemphigoid disorders. It is characterized by bilateral scarring and opacification of the conjunctivae. It presents with pain and burning sensation in the eyes and photophobia. It leads to blindness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ocular Cicatricial Pemphigoid","conceptCode":"C84939","definition":"A chronic autoimmune disorder that belongs to the mucous membrane pemphigoid disorders. It is characterized by bilateral scarring and opacification of the conjunctivae. It presents with pain and burning sensation in the eyes and photophobia. It leads to blindness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EC17-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EC2D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Oculocerebrorenal Syndrome","valueDescription":"Oculocerebrorenal Syndrome","ValueMeaning":{"publicId":"3211311","version":"1","preferredName":"Oculocerebrorenal Syndrome","longName":"3211311","preferredDefinition":"An X-linked inherited multisystem metabolic disorder caused by mutations in the OCRL1 gene. The main manifestations of this disorder result from involvement of the eyes, nervous system and kidneys. Signs and symptoms include congenital cataracts, infantile glaucoma, intellectual disability, hypotonia, aminoaciduria and renal tubular dysfunction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oculocerebrorenal Syndrome","conceptCode":"C84940","definition":"An X-linked inherited multisystem metabolic disorder caused by mutations in the OCRL1 gene. The main manifestations of this disorder result from involvement of the eyes, nervous system and kidneys. Signs and symptoms include congenital cataracts, infantile glaucoma, intellectual disability, hypotonia, aminoaciduria and renal tubular dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EC39-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EC4F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Oculocutaneous Albinism","valueDescription":"Oculocutaneous Albinism","ValueMeaning":{"publicId":"3211312","version":"1","preferredName":"Oculocutaneous Albinism","longName":"3211312","preferredDefinition":"An autosomal recessive inherited disorder caused by mutations of the OCA2, SLC45A2, TYR and TYRP1 genes. It is characterized by hypopigmentation of the skin, hair, and eyes, resulting in very fair skin, white colored hair, and reduced pigmentation in the iris and retina. Individuals may have vision disturbances and photophobia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oculocutaneous Albinism","conceptCode":"C84941","definition":"An autosomal recessive inherited disorder caused by mutations of the OCA2, SLC45A2, TYR and TYRP1 genes. It is characterized by hypopigmentation of the skin, hair, and eyes, resulting in very fair skin, white colored hair, and reduced pigmentation in the iris and retina. Individuals may have vision disturbances and photophobia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EC5B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EC71-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Oculopharyngeal Muscular Dystrophy","valueDescription":"Oculopharyngeal Muscular Dystrophy","ValueMeaning":{"publicId":"3211313","version":"1","preferredName":"Oculopharyngeal Muscular Dystrophy","longName":"3211313","preferredDefinition":"An autosomal dominant inherited disorder caused by mutations in the PABPN1 gene. It is characterized by late-onset eyelid ptosis and dysphagia. Patients have a positive family history involving at least two generations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oculopharyngeal Muscular Dystrophy","conceptCode":"C84942","definition":"An autosomal dominant disorder caused by mutations in the PABPN1 gene, encoding polyadenylate-binding protein 2. The condition is characterized by progressive ptosis, dysphagia and weakness of the muscles of the face, neck, and extraocular muscles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EC7D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EC93-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Oligodendroglioma","valueDescription":"Oligodendroglioma","ValueMeaning":{"publicId":"2838655","version":"1","preferredName":"Oligodendroglioma","longName":"2838655","preferredDefinition":"A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligodendroglioma","conceptCode":"C3288","definition":"A well-differentiated (WHO grade 2), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A770F5-59CD-03F5-E040-BB89AD435AD2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EC9D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Olivopontocerebellar Atrophy","valueDescription":"Olivopontocerebellar Atrophy","ValueMeaning":{"publicId":"3211314","version":"1","preferredName":"Olivopontocerebellar Atrophy","longName":"3211314","preferredDefinition":"A group of sporadic and inherited neurodegenerative disorders affecting the cerebellum, pons, and inferior olives.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Olivopontocerebellar Atrophy","conceptCode":"C84947","definition":"A group of sporadic and inherited neurodegenerative disorders affecting the cerebellum, pons, and inferior olives.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ECA9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ECBF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Opsoclonus Myoclonus Syndrome","valueDescription":"Opsoclonus Myoclonus Syndrome","ValueMeaning":{"publicId":"3211315","version":"1","preferredName":"Opsoclonus Myoclonus Syndrome","longName":"3211315","preferredDefinition":"A combination of opsoclonus (involuntary conjugate eye movements of large amplitude) and myoclonic jerks. This can be a paraneoplastic syndrome (a result of brain metastasis) or post-infectious (viral encephalitis).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Opsoclonus Myoclonus Syndrome","conceptCode":"C4686","definition":"A combination of opsoclonus (involuntary conjugate eye movements of large amplitude) and myoclonic jerks. This can be a paraneoplastic syndrome (a result of brain metastasis) or post-infectious (viral encephalitis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ECCB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ECE1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Optic Atrophy","valueDescription":"Optic Atrophy","ValueMeaning":{"publicId":"3211316","version":"1","preferredName":"Optic Atrophy","longName":"3211316","preferredDefinition":"A disorder characterized by loss of optic nerve fibers. It may be inherited or acquired. Acquired causes include ischemia, optic nerve neuropathy, glaucoma, trauma, radiation, brain tumors, and multiple sclerosis. It leads to vision disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Optic Atrophy","conceptCode":"C34863","definition":"A disorder characterized by loss of optic nerve fibers. It may be inherited or acquired. Acquired causes include ischemia, optic nerve neuropathy, glaucoma, trauma, radiation, brain tumors, and multiple sclerosis. It leads to vision disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ECED-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ED03-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Optic Neuritis","valueDescription":"Optic Neuritis","ValueMeaning":{"publicId":"3211317","version":"1","preferredName":"Optic Neuritis","longName":"3211317","preferredDefinition":"A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Optic Neuritis","conceptCode":"C84950","definition":"A disorder characterized by inflammation of the optic nerve. Causes include autoimmune disorders, infections, toxins, drugs, and multiple sclerosis. It may manifest with acute loss of vision and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ED0F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ED25-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Organoid Nevus","valueDescription":"Organoid Nevus","ValueMeaning":{"publicId":"3211318","version":"1","preferredName":"Organoid Nevus","longName":"3211318","preferredDefinition":"A hamartomatous skin lesion containing sebaceous glands. It is usually located in the scalp.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Organoid Nevus","conceptCode":"C4678","definition":"A hamartomatous skin lesion containing sebaceous glands. It is usually located in the scalp.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ED31-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ED47-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ornithine Carbamoyltransferase Deficiency Disease","valueDescription":"Ornithine Carbamoyltransferase Deficiency Disease","ValueMeaning":{"publicId":"3211319","version":"1","preferredName":"Ornithine Carbamoyltransferase Deficiency Disease","longName":"3211319","preferredDefinition":"An X-linked urea cycle metabolic disorder characterized by deficiency of ornithine carbamoyltransferase, resulting in the accumulation of amino acids and ammonia in the serum. Signs and symptoms include seizures, delayed growth, behavioral changes, ataxia, lethargy, and coma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ornithine Carbamoyltransferase Deficiency Disease","conceptCode":"C84957","definition":"An X-linked urea cycle metabolic disorder characterized by deficiency of ornithine carbamoyltransferase, resulting in the accumulation of amino acids and ammonia in the serum. Signs and symptoms include seizures, delayed growth, behavioral changes, ataxia, lethargy, and coma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ED53-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ED69-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ornithine Transcarbamylase Deficiency","valueDescription":"Ornithine Transcarbamylase Deficiency","ValueMeaning":{"publicId":"3211320","version":"1","preferredName":"Ornithine Transcarbamylase Deficiency","longName":"3211320","preferredDefinition":"An X-linked urea cycle metabolic disorder characterized by deficiency of ornithine transcarbamylase, resulting in the accumulation of ammonia in the serum. Symptoms include vomiting, lethargy, and coma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ornithine Transcarbamylase Deficiency","conceptCode":"C84960","definition":"An X-linked urea cycle metabolic disorder characterized by deficiency of ornithine transcarbamylase, resulting in the accumulation of ammonia in the serum. Symptoms include vomiting, lethargy, and coma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ED75-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ED8B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Orofaciodigital Syndrome Type 1","valueDescription":"Orofaciodigital Syndrome Type 1","ValueMeaning":{"publicId":"3211321","version":"1","preferredName":"Orofaciodigital Syndrome Type 1","longName":"3211321","preferredDefinition":"An X-linked inherited syndrome caused by mutations in the OFD1 gene mapped to chromosome Xp22.2.  It is characterized by malformations of the face, oral cavity, and fingers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orofaciodigital Syndrome Type 1","conceptCode":"C75481","definition":"An X-linked inherited syndrome caused by mutations in the OFD1 gene mapped to chromosome Xp22.2.  It is characterized by malformations of the face, oral cavity, and fingers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ED97-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EDAD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Orthostatic Hypotension","valueDescription":"Orthostatic Hypotension","ValueMeaning":{"publicId":"3211322","version":"1","preferredName":"Orthostatic Hypotension","longName":"3211322","preferredDefinition":"Sudden fall of the blood pressure of at least 20/10 mm Hg when a person stands up.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orthostatic Hypotension","conceptCode":"C84970","definition":"Sudden fall of the blood pressure of at least 20/10 mm Hg when a person stands up.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EDB9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EDCF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Orthostatic Intolerance","valueDescription":"Orthostatic Intolerance","ValueMeaning":{"publicId":"3211323","version":"1","preferredName":"Orthostatic Intolerance","longName":"3211323","preferredDefinition":"A condition characterized by development of symptoms while standing. It is an autonomic nervous system disorder and the symptoms are relieved once the person sits back down. Symptoms include heart palpitations, sweating, anxiety, lightheadedness, hyperpnea, anxiety, and blurred vision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orthostatic Intolerance","conceptCode":"C84973","definition":"A condition characterized by development of symptoms while standing. It is an autonomic nervous system disorder and the symptoms are relieved once the person sits back down. Symptoms include heart palpitations, sweating, anxiety, lightheadedness, hyperpnea, anxiety, and blurred vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EDDB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EDF1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ossification of Posterior Longitudinal Ligament","valueDescription":"Ossification of Posterior Longitudinal Ligament","ValueMeaning":{"publicId":"3211324","version":"1","preferredName":"Ossification of Posterior Longitudinal Ligament","longName":"3211324","preferredDefinition":"A disorder characterized by benign depositions of calcium in the posterior longitudinal ligament. Signs and symptoms result from the compression of nerve roots and include motor and sensory disturbances in the lower and upper extremities, and pain in the neck and arms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ossification of Posterior Longitudinal Ligament","conceptCode":"C84975","definition":"A disorder characterized by benign depositions of calcium in the posterior longitudinal ligament. Signs and symptoms result from the compression of nerve roots and include motor and sensory disturbances in the lower and upper extremities, and pain in the neck and arms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EDFD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EE13-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Osteochondrodysplasia","valueDescription":"Osteochondrodysplasia","ValueMeaning":{"publicId":"3211325","version":"1","preferredName":"Osteochondrodysplasia","longName":"3211325","preferredDefinition":"A term referring to disorders characterized by abnormalities in the development of bones and cartilage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteochondrodysplasia","conceptCode":"C84978","definition":"A term referring to disorders characterized by abnormalities in the development of bones and cartilage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EE1F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EE35-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Osteogenesis Imperfecta","valueDescription":"Osteogenesis Imperfecta","ValueMeaning":{"publicId":"3211326","version":"1","preferredName":"Osteogenesis Imperfecta","longName":"3211326","preferredDefinition":"A group of usually autosomal dominant inherited disorders characterized by defective synthesis of collagen type I resulting in defective collagen formation. It is characterized by brittle and easily fractured bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteogenesis Imperfecta","conceptCode":"C26837","definition":"A group of usually autosomal dominant inherited disorders characterized by defective synthesis of collagen type I resulting in defective collagen formation. It is characterized by brittle and easily fractured bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EE41-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EE57-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Central Core Disease","valueDescription":"Central Core Disease","ValueMeaning":{"publicId":"3210939","version":"1","preferredName":"Central Core Disease","longName":"3210939","preferredDefinition":"An autosomal dominant congenital disorder affecting the skeletal muscles. Microscopically, it is characterized by disorganized areas, which are called cores, seen usually in the center of the muscle fibers. Clinically it presents as mild to severe muscle weakness.  It may be associated with skeletal abnormalities including scoliosis, joint deformities, and hip dislocation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Core Disease","conceptCode":"C83010","definition":"An autosomal dominant congenital disorder affecting the skeletal muscles. Microscopically, it is characterized by disorganized areas, which are called cores, seen usually in the center of the muscle fibers. Clinically it presents as mild to severe muscle weakness. It may be associated with skeletal abnormalities including scoliosis, joint deformities, and hip dislocation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B74A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B760-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Osteomalacia","valueDescription":"Osteomalacia","ValueMeaning":{"publicId":"3211327","version":"1","preferredName":"Osteomalacia","longName":"3211327","preferredDefinition":"A metabolic bone disease that results from either a deficiency in vitamin D, or an abnormality in the metabolism of vitamin D, or a deficiency of calcium in the diet.  The most common symptoms are bone pain and muscle weakness.  When it occurs in children it is commonly referred to as rickets. (Diagnostic Surgical Pathology, 3rd ed.) --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteomalacia","conceptCode":"C26838","definition":"A metabolic bone disease that results from either a deficiency in vitamin D, or an abnormality in the metabolism of vitamin D, or a deficiency of calcium in the diet.  The most common symptoms are bone pain and muscle weakness.  When it occurs in children it is commonly referred to as rickets. (Diagnostic Surgical Pathology, 3rd ed.) --2003","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EE63-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EE79-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acute Lymphoblastic Leukemia","valueDescription":"ALL","ValueMeaning":{"publicId":"2573071","version":"1","preferredName":"ALL","longName":"2573071","preferredDefinition":"A leukemia with an acute onset, characterized by the presence of lymphoblasts or Burkitt cells in the bone marrow and the peripheral blood.  It includes the precursor B lymphoblastic leukemia, precursor T lymphoblastic leukemia, and Burkitt's leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA7C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"KUMMEROA","dateModified":"2022-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8E78-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2581275","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"2581275","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8E82-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Adenocarcinoma","valueDescription":"Adenocarcinoma","ValueMeaning":{"publicId":"2567203","version":"1","preferredName":"Adenocarcinoma","longName":"2567203","preferredDefinition":"A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D390-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8E8C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Appendix Carcinoma","valueDescription":"Appendix Carcinoma","ValueMeaning":{"publicId":"3210690","version":"1","preferredName":"Appendix Carcinoma","longName":"3210690","preferredDefinition":"A malignant epithelial neoplasm arising from the appendix.  The vast majority of the cases are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Appendix Carcinoma","conceptCode":"C9330","definition":"A malignant epithelial neoplasm arising from the appendix.  The vast majority of the cases are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8E98-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8EAE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Skin Basal Cell Carcinoma","valueDescription":"Skin Basal Cell Carcinoma","ValueMeaning":{"publicId":"2961462","version":"1","preferredName":"Skin Basal Cell Carcinoma","longName":"2961462","preferredDefinition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like.. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Basal Cell Carcinoma","conceptCode":"C2921","definition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AB07DC-B5C7-F05E-E040-BB89AD43180B","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8EC0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bladder Carcinoma","valueDescription":"Bladder Carcinoma","ValueMeaning":{"publicId":"3210691","version":"1","preferredName":"Bladder Carcinoma","longName":"3210691","preferredDefinition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Carcinoma","conceptCode":"C4912","definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8ECC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8EE2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Breast Carcinoma","valueDescription":"Breast Carcinoma","ValueMeaning":{"publicId":"2581276","version":"1","preferredName":"Breast Carcinoma","longName":"2581276","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A89-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8EEC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bronchogenic Carcinoma","valueDescription":"Bronchogenic Carcinoma","ValueMeaning":{"publicId":"3210692","version":"1","preferredName":"Bronchogenic Carcinoma","longName":"3210692","preferredDefinition":"A lung carcinoma arising from the bronchial epithelium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bronchogenic Carcinoma","conceptCode":"C35875","definition":"A lung carcinoma arising from the bronchial epithelium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8EF8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8F0E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Carcinoma","valueDescription":"Carcinoma","ValueMeaning":{"publicId":"2935533","version":"1","preferredName":"Carcinoma","longName":"2935533","preferredDefinition":"A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71F88553-C4BB-17CC-E040-BB89AD43398B","latestVersionIndicator":"Yes","beginDate":"2009-08-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8F18-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Carcinoma In Situ","valueDescription":"Carcinoma in Situ","ValueMeaning":{"publicId":"2567176","version":"1","preferredName":"Carcinoma in Situ","longName":"2567176","preferredDefinition":"A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma In Situ","conceptCode":"C2917","definition":"A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D375-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8F2A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cervical Carcinoma","valueDescription":"Cervical Carcinoma","ValueMeaning":{"publicId":"3125029","version":"1","preferredName":"Cervical Carcinoma","longName":"3125029","preferredDefinition":"Cervical carcinoma may arise from either the exocervical squamous epithelium or the endocervical glandular epithelium.  The major histologic types of cervical carcinoma are: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma and undifferentiated carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Carcinoma","conceptCode":"C9039","definition":"A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are squamous cell carcinoma and adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C8C84BA-75CF-B840-E040-BB89AD4308AA","latestVersionIndicator":"Yes","beginDate":"2010-07-29","endDate":null,"createdBy":"WHITES","dateCreated":"2010-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8F3C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Childhood Acute Lymphoblastic Leukemia","valueDescription":"Childhood Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3210693","version":"1","preferredName":"Childhood Acute Lymphoblastic Leukemia","longName":"3210693","preferredDefinition":"An acute lymphoblastic leukemia occurring during childhood.  The majority of cases are B-acute lymphoblastic leukemias. Approximately 15% of the cases are T-acute lymphoblastic leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Acute Lymphoblastic Leukemia","conceptCode":"C3168","definition":"An acute lymphoblastic leukemia occurring during childhood.  The majority of cases are B-acute lymphoblastic leukemias. Approximately 15% of the cases are T-acute lymphoblastic leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8F48-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8F5E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Childhood Brain Germinoma","valueDescription":"Childhood Brain Germinoma","ValueMeaning":{"publicId":"3210694","version":"1","preferredName":"Childhood Brain Germinoma","longName":"3210694","preferredDefinition":"A germinoma arising from the brain during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Brain Germinoma","conceptCode":"C6207","definition":"A germinoma arising from the brain during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8F6A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8F80-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Childhood Brain Neoplasm","valueDescription":"Childhood Brain Neoplasm","ValueMeaning":{"publicId":"3210695","version":"1","preferredName":"Childhood Brain Neoplasm","longName":"3210695","preferredDefinition":"An abnormal growth of the cells that comprise the tissues of the brain in a person less than twenty one years old. This term does not specify whether the growth is benign or malignant nor does it specify location.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Brain Neoplasm","conceptCode":"C7703","definition":"A benign or malignant, primary or metastatic neoplasm of the brain occurring in children.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8F8C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8FA2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Childhood Rhabdomyosarcoma","valueDescription":"Childhood Rhabdomyosarcoma","ValueMeaning":{"publicId":"3210696","version":"1","preferredName":"Childhood Rhabdomyosarcoma","longName":"3210696","preferredDefinition":"An aggressive malignant mesenchymal neoplasm arising from skeletal muscle in children.  Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomical sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Rhabdomyosarcoma","conceptCode":"C7705","definition":"An aggressive malignant mesenchymal neoplasm arising from skeletal muscle in children.  Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8FAE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8FC4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cholangiocarcinoma","valueDescription":"Cholangiocarcinoma","ValueMeaning":{"publicId":"3165468","version":"1","preferredName":"Cholangiocarcinoma","longName":"3165468","preferredDefinition":"An malignant tumor composed of cells resembling those of bile ducts. Cholangiocarcinoma is a relatively rare tumor in most populations. It can arise from any portion of the intrahepatic bile duct epithelium or the hepatic ducts. Grossly, the lesions are nodular, grayish-white firm and solid. Microscopically, the vast majority of cholangiocarcinomas are adenocarcinomas showing tubular and/or papillary structures. Early detection of cholangiocarcinomas is difficult, and the overall prognosis after resection is poor (adapted from WHO, 2000).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cholangiocarcinoma","conceptCode":"C4436","definition":"A carcinoma that arises from the intrahepatic bile ducts, the hepatic ducts, or the common bile duct distal to the insertion of the cystic duct. The vast majority of tumors are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96D7AA2D-09B1-EB1F-E040-BB89AD436E93","latestVersionIndicator":"Yes","beginDate":"2010-12-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2010-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8FCE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chronic Lymphocytic Leukemia","valueDescription":"CLL","ValueMeaning":{"publicId":"2590865","version":"1","preferredName":"CLL","longName":"2590865","preferredDefinition":"The most common type of chronic lymphoid leukemia, and comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  The clinical course is indolent, but this type of leukemia is not considered to be curable with available therapy. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2843C971-29AB-37A6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8FE0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","valueDescription":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","ValueMeaning":{"publicId":"2558495","version":"1","preferredName":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","longName":"2558495","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B18C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-8FF2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Clear Cell Sarcoma of the Kidney","valueDescription":"Clear Cell Sarcoma of the Kidney","ValueMeaning":{"publicId":"3210697","version":"1","preferredName":"Clear Cell Sarcoma of the Kidney","longName":"3210697","preferredDefinition":"A rare pediatric sarcoma affecting the kidney. It is characterized by the presence of epithelioid or spindle cells forming cords or nests, separated by fibrovascular septa. This type of sarcoma frequently metastasizes to the bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell Sarcoma of the Kidney","conceptCode":"C4264","definition":"A rare pediatric sarcoma affecting the kidney. It is characterized by the presence of epithelioid or spindle cells forming cords or nests, separated by fibrovascular septa. It metastasizes to lung, bone, brain and soft tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8FFE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9014-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Colorectal Carcinoma","valueDescription":"Colorectal Carcinoma","ValueMeaning":{"publicId":"2672910","version":"1","preferredName":"Colorectal Carcinoma","longName":"2672910","preferredDefinition":"A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colorectal Carcinoma","conceptCode":"C2955","definition":"A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37D5FE1C-A72F-09FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9026-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Osteopoikilosis","valueDescription":"Osteopoikilosis","ValueMeaning":{"publicId":"3211328","version":"1","preferredName":"Osteopoikilosis","longName":"3211328","preferredDefinition":"A rare autosomal dominant inherited disorder characterized by the presence of small areas of increased density throughout the bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteopoikilosis","conceptCode":"C84985","definition":"A rare autosomal dominant inherited disorder characterized by the presence of small areas of increased density throughout the bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EE85-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EE9B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pachyonychia Congenita","valueDescription":"Pachyonychia Congenita","ValueMeaning":{"publicId":"3211329","version":"1","preferredName":"Pachyonychia Congenita","longName":"3211329","preferredDefinition":"A rare genetic disorder caused by mutations in the KRT6A, KRT6B, KRT616, and KRT17 genes. It is characterized by hypertrophy and abnormalities in the shape of the fingernails and toe nails.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pachyonychia Congenita","conceptCode":"C84986","definition":"A rare genetic disorder caused by mutations in the KRT6A, KRT6B, KRT16, and KRT17 genes. It is characterized by hypertrophy and abnormalities in the shape of the fingernails and toe nails.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EEA7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EEBD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Paget Disease","valueDescription":"Paget Disease","ValueMeaning":{"publicId":"2566821","version":"1","preferredName":"Paget Disease","longName":"2566821","preferredDefinition":"A malignant neoplasm composed of large cells with large nuclei, prominent nucleoli, and abundant pale cytoplasm (Paget cells).  Paget's cell neoplasms include Paget's disease of the nipple and extramammary Paget's disease which may affect the vulva, penis, anus, skin and scrotum. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paget Disease","conceptCode":"C7073","definition":"A malignant neoplasm composed of large cells with large nuclei, prominent nucleoli, and abundant pale cytoplasm (Paget cells).  Paget cell neoplasms include Paget disease of the nipple and extramammary Paget disease which may affect the vulva, penis, anus, skin and scrotum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D212-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-08-18","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":"04/13/2011 - tc - Updated with current NCIt name and definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EECF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Paget Disease of the Breast","valueDescription":"Ductal carcinoma in situ involving nipple skin (Paget disease)","ValueMeaning":{"publicId":"3211330","version":"1","preferredName":"Ductal carcinoma in situ involving nipple skin (Paget disease)","longName":"3211330","preferredDefinition":"A malignant neoplasm in which there is infiltration of the skin overlying the breast by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (Paget cells). It is almost always associated with an intraductal or invasive ductal carcinoma of the breast. The clinical features include focal skin reddening, and eczema. Retraction of the nipple may sometimes occur.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Paget Disease","conceptCode":"C47857","definition":"A malignant neoplasm in which there is infiltration of the skin overlying the breast by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (Paget cells). It is almost always associated with an intraductal or invasive ductal carcinoma of the breast. The clinical features include focal skin reddening, and eczema. Retraction of the nipple may sometimes occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EEDB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EEF1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pagetoid Reticulosis","valueDescription":"Pagetoid Reticulosis","ValueMeaning":{"publicId":"3211331","version":"1","preferredName":"Pagetoid Reticulosis","longName":"3211331","preferredDefinition":"A variant of mycosis fungoides, characterized by an exclusively intraepidermal atypical (cerebriform) lymphocytic infiltrate.  Patients present with a localized psoriasiform or hyperkeratotic patch or plaque, usually in the extremities.  Extracutaneous dissemination of the disease has never been reported.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pagetoid Reticulosis","conceptCode":"C35794","definition":"A variant of mycosis fungoides, characterized by an exclusively intraepidermal atypical (cerebriform) lymphocytic infiltrate.  Patients present with a localized psoriasiform or hyperkeratotic patch or plaque, usually in the extremities.  Extracutaneous dissemination of the disease has never been reported.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EEFD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EF13-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pallister-Hall Syndrome","valueDescription":"Pallister-Hall Syndrome","ValueMeaning":{"publicId":"3211332","version":"1","preferredName":"Pallister-Hall Syndrome","longName":"3211332","preferredDefinition":"A very rare autosomal dominant inherited disorder caused by mutations in the GLI3 gene. It is characterized by a spectrum of abnormalities which include polydactyly, cutaneous syndactyly, bifid epiglottis, hypothalamic hamartoma, and laryngotracheal cleft.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pallister-Hall Syndrome","conceptCode":"C84987","definition":"A very rare autosomal dominant inherited disorder caused by mutations in the GLI3 gene. It is characterized by a spectrum of abnormalities which include polydactyly, cutaneous syndactyly, bifid epiglottis, hypothalamic hamartoma, and laryngotracheal cleft.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EF1F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EF35-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Palmar Fibromatosis","valueDescription":"Palmar Fibromatosis","ValueMeaning":{"publicId":"3211333","version":"1","preferredName":"Palmar Fibromatosis","longName":"3211333","preferredDefinition":"A superficial fibromatosis arising from the soft tissue of the palm. It is characterized by the presence of spindle-shaped fibroblasts, and an infiltrative growth pattern. It predominantly affects adult males.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palmar Fibromatosis","conceptCode":"C3469","definition":"A superficial fibromatosis arising from the soft tissue of the palm. It is characterized by the presence of spindle-shaped fibroblasts, and an infiltrative growth pattern. It predominantly affects adult males.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EF41-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EF57-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Palmoplantar Keratoderma","valueDescription":"Palmoplantar Keratoderma","ValueMeaning":{"publicId":"3211334","version":"1","preferredName":"Palmoplantar Keratoderma","longName":"3211334","preferredDefinition":"A group of autosomal dominant, autosomal recessive, X-linked inherited or acquired disorders characterized by the thickening of the palms and soles due to hyperkeratosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palmoplantar Keratoderma","conceptCode":"C34748","definition":"A group of autosomal dominant, autosomal recessive, X-linked inherited or acquired disorders characterized by the thickening of the palms and soles due to hyperkeratosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EF63-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EF79-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pancreatic Insulin Producing Tumor","valueDescription":"Pancreatic Insulin Producing Neuroendocrine Tumor","ValueMeaning":{"publicId":"3211335","version":"1","preferredName":"Pancreatic Insulin Producing Neuroendocrine Tumor","longName":"3211335","preferredDefinition":"A usually benign, well circumscribed neoplasm arising from the beta cells of the pancreas.  Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Insulin-Producing Neuroendocrine Tumor","conceptCode":"C3140","definition":"An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas.  It may or may not be associated with inappropriate secretion of insulin and an associated clinical syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EF85-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EF9B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pancreatic Endocrine Carcinoma","valueDescription":"Pancreatic Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"3211336","version":"1","preferredName":"Pancreatic Neuroendocrine Carcinoma","longName":"3211336","preferredDefinition":"A malignant endocrine neoplasm arising from the islets of Langerhans.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Neuroendocrine Carcinoma","conceptCode":"C3770","definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EFA7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EFBD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pantothenate Kinase-Associated Neurodegeneration","valueDescription":"Pantothenate Kinase-Associated Neurodegeneration","ValueMeaning":{"publicId":"3211337","version":"1","preferredName":"Pantothenate Kinase-Associated Neurodegeneration","longName":"3211337","preferredDefinition":"A rare autosomal recessive inherited disorder caused by mutations in the PANK2 gene. It is characterized by abnormal accumulation of iron in the basal ganglia. Signs and symptoms include progressive motor disturbances, muscle spasm and rigidity, dysarthria, mental deterioration, and behavioral changes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pantothenate Kinase-Associated Neurodegeneration","conceptCode":"C84988","definition":"A rare autosomal recessive inherited disorder caused by mutations in the PANK2 gene. It is characterized by abnormal accumulation of iron in the basal ganglia. Signs and symptoms include progressive motor disturbances, muscle spasm and rigidity, dysarthria, mental deterioration, and behavioral changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EFC9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-EFDF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Panuveitis","valueDescription":"Panuveitis","ValueMeaning":{"publicId":"3211338","version":"1","preferredName":"Panuveitis","longName":"3211338","preferredDefinition":"A disorder characterized by inflammation of the entire uvea which includes the iris, ciliary body, and choroid. Causes include systemic infections, sarcoidosis, and cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panuveitis","conceptCode":"C84989","definition":"A disorder characterized by inflammation of the entire uvea which includes the iris, ciliary body, and choroid. Causes include systemic infections, sarcoidosis, and cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-EFEB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F001-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Papillary Cystadenocarcinoma","valueDescription":"Papillary Cystadenocarcinoma","ValueMeaning":{"publicId":"3211339","version":"1","preferredName":"Papillary Cystadenocarcinoma","longName":"3211339","preferredDefinition":"A malignant cystic serous or mucinous epithelial neoplasm characterized by the presence of malignant glandular epithelial cells forming papillary structures. Stromal invasion is present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Cystadenocarcinoma","conceptCode":"C3777","definition":"A malignant cystic serous or mucinous epithelial neoplasm characterized by the presence of malignant glandular epithelial cells forming papillary structures. Stromal invasion is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F00D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F023-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Papilledema","valueDescription":"Papilledema","ValueMeaning":{"publicId":"2946002","version":"1","preferredName":"Papilledema","longName":"2946002","preferredDefinition":"Swelling around the optic disc, usually due to increased intracranial pressure or pressure on the optic nerve by a tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papilledema","conceptCode":"C3307","definition":"Swelling around the optic disc, usually due to increased intracranial pressure or pressure on the optic nerve by a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746944AF-41D0-DCDB-E040-BB89AD437B02","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F02D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Papillon-Lefevre Syndrome","valueDescription":"Papillon-Lefevre Syndrome","ValueMeaning":{"publicId":"3211340","version":"1","preferredName":"Papillon-Lefevre Syndrome","longName":"3211340","preferredDefinition":"A rare autosomal recessive inherited disorder caused by mutations in the cathepsin C gene. It is manifested with periodontitis resulting in the premature loss of teeth and palmoplantar keratoderma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillon-Lefevre Syndrome","conceptCode":"C84992","definition":"A rare autosomal recessive inherited disorder caused by mutations in the cathepsin C gene. It is manifested with periodontitis resulting in the premature loss of teeth and palmoplantar keratoderma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F039-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F04F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Paracoccidioidomycosis","valueDescription":"Paracoccidioidomycosis","ValueMeaning":{"publicId":"3211341","version":"1","preferredName":"Paracoccidioidomycosis","longName":"3211341","preferredDefinition":"A systemic fungal infection caused by Paracoccidioides brasiliensis that is most often seen in immunocompromised patients. It affects the mucous membranes, lymph nodes, lungs and bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paracoccidioidomycosis","conceptCode":"C34891","definition":"A systemic fungal infection caused by Paracoccidioides brasiliensis that is most often seen in immunocompromised patients. It affects the mucous membranes, lymph nodes, lungs and bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F05B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F071-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Paraganglioma","valueDescription":"Paraganglioma","ValueMeaning":{"publicId":"3211342","version":"1","preferredName":"Paraganglioma","longName":"3211342","preferredDefinition":"A benign or malignant neoplasm arising from paraganglia located along the sympathetic or parasympathetic nerves.  Infrequently, it may arise outside the usual distribution of the sympathetic and parasympathetic paraganglia.  Tumors arising from the adrenal gland medulla are called pheochromocytomas.  Morphologically, paragangliomas usually display a nesting (Zellballen) growth pattern.  There are no reliable morphologic criteria to distinguish between benign and malignant paragangliomas.  The only definitive indicator of malignancy is the presence of regional or distant metastases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paraganglioma","conceptCode":"C3308","definition":"A neoplasm arising from paraganglia located along the sympathetic or parasympathetic nerves.  Infrequently, it may arise outside the usual distribution of the sympathetic and parasympathetic paraganglia.  Tumors arising from the adrenal gland medulla are called pheochromocytomas.  Morphologically, paragangliomas usually display a nesting (Zellballen) growth pattern.  There are no reliable morphologic criteria to distinguish between benign and malignant paragangliomas.  The only definitive indicator of malignancy is the presence of regional or distant metastases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F07D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F093-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Paragonimiasis","valueDescription":"Paragonimiasis","ValueMeaning":{"publicId":"3211343","version":"1","preferredName":"Paragonimiasis","longName":"3211343","preferredDefinition":"A parasitic infection caused by trematodes of the Paragonimus genus. Humans are infected from ingestion of raw or undercooked food. It results in chronic lung infection and eosinophilia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paragonimiasis","conceptCode":"C84995","definition":"A parasitic infection caused by trematodes of the Paragonimus genus. Humans are infected from ingestion of raw or undercooked food. It results in chronic lung infection and eosinophilia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F09F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F0B5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Paraneoplastic Cerebellar Degeneration","valueDescription":"Paraneoplastic Cerebellar Degeneration","ValueMeaning":{"publicId":"3211344","version":"1","preferredName":"Paraneoplastic Cerebellar Degeneration","longName":"3211344","preferredDefinition":"A rare, immune-mediated disorder characterized by cerebellar degeneration due to the presence of an often undetected malignancy (usually carcinoma or lymphoma) in an anatomic site other than the cerebellum. Signs and symptoms include progressive ataxia, dysarthria, and nystagmus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paraneoplastic Cerebellar Degeneration","conceptCode":"C4685","definition":"A rare, immune-mediated disorder characterized by cerebellar degeneration due to the presence of an often undetected malignancy (usually carcinoma or lymphoma) in an anatomic site other than the cerebellum. Signs and symptoms include progressive ataxia, dysarthria, and nystagmus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F0C1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F0D7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Paraplegia","valueDescription":"Paraplegia","ValueMeaning":{"publicId":"3211345","version":"1","preferredName":"Paraplegia","longName":"3211345","preferredDefinition":"Complete paralysis of the lower half of the body including both legs, often caused by damage to the spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paraplegia","conceptCode":"C50687","definition":"Complete paralysis of the lower half of the body including both legs, often caused by damage to the spinal cord.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F0E3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F0F9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Parapsoriasis","valueDescription":"Parapsoriasis","ValueMeaning":{"publicId":"3211346","version":"1","preferredName":"Parapsoriasis","longName":"3211346","preferredDefinition":"An inflammatory skin disorder of unknown etiology characterized by papules and plaques or scaly patches resembling psoriasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Parapsoriasis","conceptCode":"C3312","definition":"An inflammatory skin disorder of unknown etiology characterized by papules and plaques or scaly patches resembling psoriasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F105-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F11B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Parkinson's Disease","valueDescription":"Parkinson's Disease","ValueMeaning":{"publicId":"2751450","version":"1","preferredName":"Parkinson's Disease","longName":"2751450","preferredDefinition":"progressive, degenerative disorder of the nervous system characterized by tremors, rigidity, bradykinesia, postural instability, and gait abnormalities; caused by a loss of neurons and a decrease of dopamine in the basal ganglia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Parkinson Disease","conceptCode":"C26845","definition":"A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DCDBBEC-81A7-741C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-05-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F125-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Paroxysmal Nocturnal Hemoglobinuria","valueDescription":"Paroxysmal Nocturnal Hemoglobinuria","ValueMeaning":{"publicId":"2593267","version":"1","preferredName":"Paroxysmal Nocturnal Hemoglobinuria","longName":"2593267","preferredDefinition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paroxysmal Nocturnal Hemoglobinuria","conceptCode":"C61233","definition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2880CCB0-13F1-07E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F12F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pars Planitis","valueDescription":"Pars Planitis","ValueMeaning":{"publicId":"3211347","version":"1","preferredName":"Pars Planitis","longName":"3211347","preferredDefinition":"An inflammatory disorder of the cilliary body in the uvea that affects healthy, younger individuals who are often asymptomatic. It has a long clinical course with relapses and remissions. Symptoms include mildly decreased vision and floaters. It may be associated with autoimmune disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pars Planitis","conceptCode":"C34903","definition":"An inflammatory disorder of the cilliary body in the uvea that affects healthy, younger individuals who are often asymptomatic. It has a long clinical course with relapses and remissions. Symptoms include mildly decreased vision and floaters. It may be associated with autoimmune disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F13B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F151-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pelger-Huet Anomaly","valueDescription":"Pelger-Huet Anomaly","ValueMeaning":{"publicId":"3211348","version":"1","preferredName":"Pelger-Huet Anomaly","longName":"3211348","preferredDefinition":"An autosomal dominant inherited condition caused by mutations in the lamin B receptor gene. It is characterized by defects in the neutrophil lobulation, resulting in the presence of dumbbell-shaped neutrophils with bilobed nuclei in the peripheral blood smear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pelger-Huet Anomaly","conceptCode":"C85002","definition":"An autosomal dominant inherited condition caused by mutations in the lamin B receptor gene. It is characterized by defects in the neutrophil lobulation, resulting in the presence of dumbbell-shaped neutrophils with bilobed nuclei in the peripheral blood smear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F15D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F173-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pelizaeus-Merzbacher Disease","valueDescription":"Pelizaeus-Merzbacher Disease","ValueMeaning":{"publicId":"3211349","version":"1","preferredName":"Pelizaeus-Merzbacher Disease","longName":"3211349","preferredDefinition":"An X-linked inherited disorder caused by mutations in the PLP1 gene on chromosome X.  The signs and symptoms are the result of defective myelination of the central nervous system and include nystagmus, hypotonia, tremor, ataxia, spastic quadriparesis, and diffuse leukoencephalopathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pelizaeus-Merzbacher Disease","conceptCode":"C75487","definition":"An X-linked inherited disorder caused by mutations in the PLP1 gene on chromosome X.  The signs and symptoms are the result of defective myelination of the central nervous system and include nystagmus, hypotonia, tremor, ataxia, spastic quadriparesis, and diffuse leukoencephalopathy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F17F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F195-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pemphigoid Gestationis","valueDescription":"Pemphigoid Gestationis","ValueMeaning":{"publicId":"3211350","version":"1","preferredName":"Pemphigoid Gestationis","longName":"3211350","preferredDefinition":"A rare autoimmune bullous dermatitis that develops during pregnancy, most often during the second and third trimesters.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pemphigoid Gestationis","conceptCode":"C85003","definition":"An autoimmune bullous dermatitis that develops during pregnancy, most often during the second and third trimesters.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F1A1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F1B7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pemphigus","valueDescription":"Pemphigus","ValueMeaning":{"publicId":"3211351","version":"1","preferredName":"Pemphigus","longName":"3211351","preferredDefinition":"An autoimmune blistering skin disorder. Morphologically it is characterized by acantholysis and intraepidermal blister formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pemphigus","conceptCode":"C34909","definition":"A blistering skin disorder. Morphologically it is characterized by acantholysis and intraepidermal blister formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F1C3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F1D9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Condyloma Acuminatum","valueDescription":"Condyloma Acuminatum","ValueMeaning":{"publicId":"3210698","version":"1","preferredName":"Condyloma Acuminatum","longName":"3210698","preferredDefinition":"A sexually transmitted papillary growth caused by the human papilloma virus. It usually arises in the skin and mucous membranes of the perianal region and external genitalia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Condyloma Acuminatum","conceptCode":"C2960","definition":"A sexually transmitted papillary growth caused by the human papillomavirus. It usually arises in the skin and mucous membranes of the perianal region and external genitalia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9032-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9048-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Esophageal Carcinoma","valueDescription":"Esophageal Carcinoma","ValueMeaning":{"publicId":"3210699","version":"1","preferredName":"Esophageal Carcinoma","longName":"3210699","preferredDefinition":"A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophageal Carcinoma","conceptCode":"C3513","definition":"A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9054-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-906A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ewing Sarcoma","valueDescription":"Ewing Sarcoma","ValueMeaning":{"publicId":"2593150","version":"1","preferredName":"Ewing Sarcoma","longName":"2593150","preferredDefinition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ewing Sarcoma","conceptCode":"C4817","definition":"A small round cell tumor that lacks morphologic, immunohistochemical, and electron microscopic evidence of neuroectodermal differentiation. It represents one of the two ends of the spectrum called Ewing sarcoma/peripheral neuroectodermal tumor. It affects mostly males under age 20, and it can occur in soft tissue or bone. Pain and the presence of a mass are the most common clinical symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6E8E-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9074-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fallopian Tube Carcinoma","valueDescription":"Fallopian Tube Carcinoma","ValueMeaning":{"publicId":"3210700","version":"1","preferredName":"Fallopian Tube Carcinoma","longName":"3210700","preferredDefinition":"A carcinoma arising from the fallopian tube which is attached to the uterine corpus (uterine body). Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fallopian Tube Carcinoma","conceptCode":"C3867","definition":"A carcinoma arising from the fallopian tube. Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9080-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9096-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gallbladder Carcinoma","valueDescription":"Gallbladder Carcinoma","ValueMeaning":{"publicId":"3210701","version":"1","preferredName":"Gallbladder Carcinoma","longName":"3210701","preferredDefinition":"A malignant tumor arising from the epithelium of the gallbladder. It is associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, most gallbladder carcinomas are adenocarcinomas; squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gallbladder Carcinoma","conceptCode":"C3844","definition":"A malignant tumor arising from the epithelium of the gallbladder. It is usually associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, most gallbladder carcinomas are adenocarcinomas; squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-90A2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-90B8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gastric Carcinoma","valueDescription":"Gastric Carcinoma","ValueMeaning":{"publicId":"3125028","version":"1","preferredName":"Gastric Carcinoma","longName":"3125028","preferredDefinition":"A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Carcinoma","conceptCode":"C4911","definition":"A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C8C84BA-75AC-B840-E040-BB89AD4308AA","latestVersionIndicator":"Yes","beginDate":"2010-07-29","endDate":null,"createdBy":"WHITES","dateCreated":"2010-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-90CA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glioblastoma","valueDescription":"Glioblastoma","ValueMeaning":{"publicId":"2578734","version":"1","preferredName":"Glioblastoma","longName":"2578734","preferredDefinition":"A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-009B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"ONEDATA","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-90D4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Head and Neck Carcinoma","valueDescription":"Head and Neck Carcinoma","ValueMeaning":{"publicId":"3210702","version":"1","preferredName":"Head and Neck Carcinoma","longName":"3210702","preferredDefinition":"A carcinoma of any tissue within the head and neck region.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Head and Neck Carcinoma","conceptCode":"C35850","definition":"A carcinoma that arises from the head and neck region.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-90E0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-90F6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hepatoblastoma","valueDescription":"Stratum 5: Hepatoblastoma","ValueMeaning":{"publicId":"3210703","version":"1","preferredName":"Stratum 5: Hepatoblastoma","longName":"3210703","preferredDefinition":"A malignant liver neoplasm that occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Grossly, hepatoblastoma is solid, well circumscribed, and more often solitary than multiple. Microscopically, most of the tumors are composed exclusively of immature hepatocytic elements. About a fourth of hepatoblastomas contain a stromal component that may be undifferentiated or develop into bone or cartilage. The treatment of choice for hepatoblastoma is surgical excision with adjuvant therapy. Liver transplantation is being increasingly used as well.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatoblastoma","conceptCode":"C3728","definition":"A malignant embryonal neoplasm that arises from the liver. It occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Microscopically,  it consists of either epithelial or epithelial and mesenchymal components.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9102-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9118-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hepatocellular Carcinoma","valueDescription":"Hepatocellular Carcinoma","ValueMeaning":{"publicId":"2573454","version":"1","preferredName":"Hepatocellular Carcinoma","longName":"2573454","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBFB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CHILLIJ","dateModified":"2007-03-27","changeDescription":"03/27/2007 - Updated with NCI Thesaurus definition (abbreviated version.)","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9122-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"High Grade Cervical Squamous Intraepithelial Neoplasia","valueDescription":"High Grade Cervical Squamous Intraepithelial Neoplasia","ValueMeaning":{"publicId":"3210704","version":"1","preferredName":"High Grade Cervical Squamous Intraepithelial Neoplasia","longName":"3210704","preferredDefinition":"Moderate or severe dysplasia of the cervical squamous epithelium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade Cervical Squamous Intraepithelial Neoplasia","conceptCode":"C40197","definition":"A precancerous neoplastic process that affects the cervical squamous epithelium. It is usually associated with human papillomavirus infection. It is classified as cervical squamous intraepithelial neoplasia 2 when there is nuclear atypia in both the upper and lower epithelial layers, mitotic figures are confined to the basal two-thirds of the epithelium, and maturation is present in the upper half of the epithelium. It is classified as cervical squamous intraepithelial neoplasia 3 when there is nuclear atypia and mitotic figures throughout the entire thickness of the epithelium, and maturation is absent or confined to the upper third of the epithelium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-912E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9144-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hodgkin Lymphoma","valueDescription":"Hodgkin's Lymphoma","ValueMeaning":{"publicId":"2581278","version":"1","preferredName":"Hodgkin's Lymphoma","longName":"2581278","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells.  There are two distinct subtypes: nodular lymphocyte predominant Hodgkin's lymphoma and classical Hodgkin's lymphoma.  Hodgkin's lymphoma has a bimodal age distribution, and involves primarily lymph nodes.  Current therapy for Hodgkin's lymphoma has resulted in an excellent outcome and cure for the majority of patients. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-04-26","modifiedBy":"LEATHERJ","dateModified":"2008-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-914E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Kaposi Sarcoma","valueDescription":"Kaposi sarcoma","ValueMeaning":{"publicId":"2568842","version":"1","preferredName":"Kaposi sarcoma","longName":"2568842","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9F7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"UMLLOADER_COPPAPRD","dateModified":"2009-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9160-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Leiomyoma","valueDescription":"Leiomyoma","ValueMeaning":{"publicId":"3210705","version":"1","preferredName":"Leiomyoma","longName":"3210705","preferredDefinition":"A well-circumscribed benign smooth muscle neoplasm characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leiomyoma","conceptCode":"C3157","definition":"A well-circumscribed benign smooth muscle neoplasm characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-916C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9182-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Leukemia","valueDescription":"Leukemia","ValueMeaning":{"publicId":"2567354","version":"1","preferredName":"Leukemia","longName":"2567354","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D427-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-18","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-18","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-918C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Liposarcoma","valueDescription":"Liposarcoma","ValueMeaning":{"publicId":"2579805","version":"1","preferredName":"Liposarcoma","longName":"2579805","preferredDefinition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Representative morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid/round cell liposarcoma.  The metastatic potential is higher in less differentiated tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposarcoma","conceptCode":"C3194","definition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma.  The metastatic potential is higher in less differentiated tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04CA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9196-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Liver and Intrahepatic Biliary Tract Carcinoma","valueDescription":"Liver and Intrahepatic Biliary Tract Carcinoma","ValueMeaning":{"publicId":"3210706","version":"1","preferredName":"Liver and Intrahepatic Biliary Tract Carcinoma","longName":"3210706","preferredDefinition":"A carcinoma arising from the liver or intrahepatic bile duct.  The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liver and Intrahepatic Bile Duct Carcinoma","conceptCode":"C7927","definition":"A carcinoma that arises from the hepatocytes or intrahepatic bile ducts.  The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-91A2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-91B8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lobular Breast Carcinoma In Situ","valueDescription":"Lobular Breast Carcinoma In Situ","ValueMeaning":{"publicId":"2581227","version":"1","preferredName":"Lobular Breast Carcinoma In Situ","longName":"2581227","preferredDefinition":"Lobular carcinoma in situ is characterized by a proliferation of monomorphic cells completely filling the lumina. The overall lobular architecture is preserved. LCIS is frequently multifocal (90% in some series) and bilateral. LCIS seldom becomes invasive, however there is an increased risk of infiltrating ductal adenocarcinoma.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Lobular Carcinoma In Situ","conceptCode":"C4018","definition":"A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A58-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-91C2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lung Carcinoma","valueDescription":"Lung Carcinoma","ValueMeaning":{"publicId":"2581279","version":"1","preferredName":"Lung Carcinoma","longName":"2581279","preferredDefinition":"A carcinoma originating in the lung.  Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas.  Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas.  Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Carcinoma","conceptCode":"C4878","definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-91CC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lymphoma","valueDescription":"Lymphoma","ValueMeaning":{"publicId":"2567355","version":"1","preferredName":"Lymphoma","longName":"2567355","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D428-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-18","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-18","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-91D6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Bone Neoplasm","valueDescription":"Malignant Bone Neoplasm","ValueMeaning":{"publicId":"3210707","version":"1","preferredName":"Malignant Bone Neoplasm","longName":"3210707","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the bones.  Representative examples of primary malignant bone neoplasms include osteosarcoma, chondrosarcoma, and Ewing sarcoma.  Primary malignant bone neoplasms most often affect children and adolescents.  Representative examples of metastatic malignant neoplasms to the bones include carcinomas arising from other anatomic sites and lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Bone Neoplasm","conceptCode":"C4016","definition":"A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-91E2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-91F8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Brain Neoplasm","valueDescription":"Malignant Brain Neoplasm","ValueMeaning":{"publicId":"3210708","version":"1","preferredName":"Malignant Brain Neoplasm","longName":"3210708","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Brain Neoplasm","conceptCode":"C3568","definition":"A primary or metastatic malignant neoplasm affecting the brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9204-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-921A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Eye Neoplasm","valueDescription":"Malignant Eye Neoplasm","ValueMeaning":{"publicId":"3210709","version":"1","preferredName":"Malignant Eye Neoplasm","longName":"3210709","preferredDefinition":"A primary or metastatic tumor involving the structures of the eye (conjunctiva, cornea, uvea, retina), the lacrimal gland, and the orbit.  Representative examples are melanoma, carcinoma, lymphoma, and retinoblastoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Eye Neoplasm","conceptCode":"C4767","definition":"A primary or metastatic malignant neoplasm involving the structures of the eye (conjunctiva, cornea, uvea, retina), the lacrimal system, and the eyelid. Representative examples include melanoma, carcinoma, lymphoma, and retinoblastoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9226-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-923C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Ovarian Neoplasm","valueDescription":"Malignant Ovarian Neoplasm","ValueMeaning":{"publicId":"3210710","version":"1","preferredName":"Malignant Ovarian Neoplasm","longName":"3210710","preferredDefinition":"A primary or metastatic malignant tumor involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Ovarian Neoplasm","conceptCode":"C7431","definition":"A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9248-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-925E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Pineal Region Neoplasm","valueDescription":"Malignant Pineal Region Neoplasm","ValueMeaning":{"publicId":"3210711","version":"1","preferredName":"Malignant Pineal Region Neoplasm","longName":"3210711","preferredDefinition":"Abnormal malignant growth of the cells that comprise the pineal parenchyma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Pineal Region Neoplasm","conceptCode":"C3573","definition":"A malignant neoplasm that affects the pineal region.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-926A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9280-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Skin Neoplasm","valueDescription":"Malignant Skin Neoplasm","ValueMeaning":{"publicId":"3210712","version":"1","preferredName":"Malignant Skin Neoplasm","longName":"3210712","preferredDefinition":"A primary or metastatic tumor involving the skin. Primary malignant skin tumors most often are carcinomas (either basal cell or squamous cell carcinomas that arise from cells in the epidermis) or melanomas that arise from pigment-containing skin melanocytes. Metastatic tumors to the skin include carcinomas and lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Skin Neoplasm","conceptCode":"C2920","definition":"A primary or metastatic malignant neoplasm involving the skin. Primary malignant skin neoplasms most often are carcinomas (either basal cell or squamous cell carcinomas) or melanomas. Metastatic malignant neoplasms to the skin include carcinomas and lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-928C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-92A2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Splenic Neoplasm","valueDescription":"Malignant Splenic Neoplasm","ValueMeaning":{"publicId":"3210713","version":"1","preferredName":"Malignant Splenic Neoplasm","longName":"3210713","preferredDefinition":"A malignant neoplasm affecting the spleen. Representative examples include leukemias, lymphomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Splenic Neoplasm","conceptCode":"C3539","definition":"A malignant neoplasm affecting the spleen. Representative examples include leukemias, lymphomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-92AE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-92C4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Uterine Neoplasm","valueDescription":"Malignant Uterine Neoplasm","ValueMeaning":{"publicId":"3210714","version":"1","preferredName":"Malignant Uterine Neoplasm","longName":"3210714","preferredDefinition":"Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Uterine Neoplasm","conceptCode":"C3552","definition":"Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-92D0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-92E6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Melanoma","valueDescription":"Melanoma","ValueMeaning":{"publicId":"2561514","version":"1","preferredName":"Melanoma","longName":"2561514","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD57-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-05","modifiedBy":"COOPERM","dateModified":"2018-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-92F0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mesothelioma","valueDescription":"Mesothelioma","ValueMeaning":{"publicId":"3210715","version":"1","preferredName":"Mesothelioma","longName":"3210715","preferredDefinition":"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesothelioma","conceptCode":"C3234","definition":"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-92FC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9312-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Monoclonal Gammopathy of Undetermined Significance","valueDescription":"Monoclonal Gammopathy of Undetermined Significance","ValueMeaning":{"publicId":"2838621","version":"1","preferredName":"Monoclonal Gammopathy of Undetermined Significance","longName":"2838621","preferredDefinition":"A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Gammopathy of Undetermined Significance","conceptCode":"C3996","definition":"A condition in which an abnormal amount of a single immunoglobulin is present in the serum. This category includes IgM monoclonal gammopathy of undetermined significance and non-IgM monoclonal gammopathy of undetermined significance. Up to 25% of cases of monoclonal gammopathy of undetermined significance  progress to a B-cell malignancy or myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B0A2-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9324-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Myelodysplastic Syndrome","valueDescription":"Myelodysplastic Syndrome","ValueMeaning":{"publicId":"2570433","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"2570433","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E02E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9336-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neuroblastoma","valueDescription":"Neuroblastoma","ValueMeaning":{"publicId":"2573075","version":"1","preferredName":"Neuroblastoma","longName":"2573075","preferredDefinition":"Neuroblastoma is a specific type of neuroblastic tumor which is characterized by the presense of neuroblastic cells forming groups or nests separated by delicate stromal septa without prominent Schwannian stroma. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroblastoma","conceptCode":"C3270","definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA80-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9340-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neuroendocrine Carcinoma","valueDescription":"Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2559503","version":"1","preferredName":"Neuroendocrine Carcinoma","longName":"2559503","preferredDefinition":"A malignant neuroendocrine tumor composed of cells containing secretory granules that stain positive for NSE and chromogranin.  Tumor cells are often round and form clusters or trabecular sheets.  Representative examples are carcinoid tumor, small cell carcinoma, and Merkel cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroendocrine Carcinoma","conceptCode":"C3773","definition":"A usually aggressive carcinoma composed of malignant cells exhibiting neuroendocrine differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B57C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9352-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Merkel Cell Carcinoma","valueDescription":"Merkel Cell Carcinoma","ValueMeaning":{"publicId":"3210716","version":"1","preferredName":"Merkel Cell Carcinoma","longName":"3210716","preferredDefinition":"A rare malignant cutaneous tumor seen in elderly patients.  Its usual location is on the head, neck and extremities.  The tumor is composed of small round cells with scanty cytoplasm arranged in a trabecular pattern, or in ill-defined nodules or in a diffuse pattern.  The tumor cells contain cytoplasmic membrane-bound dense core granules resembling neurosecretory granules.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Merkel Cell Carcinoma","conceptCode":"C9231","definition":"A rare aggressive neuroendocrine carcinoma that usually arises from the skin. Rarely, it arises from extracutaneous sites, including the oral cavity, salivary glands, breast, vulva, and vaginal wall. The tumor is composed of small round cells with scanty cytoplasm. Merkel cell polyomavirus is implicated in the majority of cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-935E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9374-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neuroglial Tumor","valueDescription":"Neuroglial Tumor","ValueMeaning":{"publicId":"3210717","version":"1","preferredName":"Neuroglial Tumor","longName":"3210717","preferredDefinition":"A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells).  Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas.  Tumors that arise from oligodendrocytes are called oligodendroglial tumors.  Tumors that arise from ependymal cells are called ependymomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioma","conceptCode":"C3059","definition":"A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9380-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9396-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Non-Hodgkin Lymphoma","valueDescription":"Non-Hodgkin lymphoma","ValueMeaning":{"publicId":"2568326","version":"1","preferredName":"Non-Hodgkin lymphoma","longName":"2568326","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7F3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-02","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-93A8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Oral Neoplasm","valueDescription":"Oral Neoplasm","ValueMeaning":{"publicId":"3210718","version":"1","preferredName":"Oral Neoplasm","longName":"3210718","preferredDefinition":"A benign or malignant tumor involving the oral cavity and/or the lips.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Neoplasm","conceptCode":"C8989","definition":"A benign or malignant neoplasm involving the oral cavity and/or the lips.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-93B4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-93CA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Osteosarcoma","valueDescription":"Osteosarcoma","ValueMeaning":{"publicId":"3179363","version":"1","preferredName":"Osteosarcoma","longName":"3179363","preferredDefinition":"A usually aggressive malignant bone-forming mesenchymal tumor, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteosarcoma","conceptCode":"C9145","definition":"A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-8659-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"REEVESD","dateModified":"2014-07-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-93DC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pancreatic Carcinoma","valueDescription":"Pancreatic Carcinoma","ValueMeaning":{"publicId":"2672905","version":"1","preferredName":"Pancreatic Carcinoma","longName":"2672905","preferredDefinition":"A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Carcinoma","conceptCode":"C3850","definition":"A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37D5FE1C-A62B-09FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-16","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-93EE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Parathyroid Gland Carcinoma","valueDescription":"Parathyroid Gland Carcinoma","ValueMeaning":{"publicId":"3210719","version":"1","preferredName":"Parathyroid Gland Carcinoma","longName":"3210719","preferredDefinition":"A malignant tumor arising from the parenchymal cells of the parathyroid gland. It is associated with the symptoms of primary hyperparathyroidism, resulting from the excessive production of parathyroid hormone. Morphologically, the differential diagnosis from parathyroid gland adenoma may be difficult. A definitive diagnosis of carcinoma is made only in the presence of capsular invasion, vascular invasion, and/or perineural invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Parathyroid Gland Carcinoma","conceptCode":"C4906","definition":"A malignant tumor arising from the parenchymal cells of the parathyroid gland. It is associated with the symptoms of primary hyperparathyroidism, resulting from the excessive production of parathyroid hormone. Morphologically, the differential diagnosis from parathyroid gland adenoma may be difficult. A definitive diagnosis of carcinoma is made only in the presence of capsular invasion, vascular invasion, and/or perineural invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-93FA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9410-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Peripheral Nervous System Neoplasm","valueDescription":"Peripheral Nervous System Neoplasm","ValueMeaning":{"publicId":"3210720","version":"1","preferredName":"Peripheral Nervous System Neoplasm","longName":"3210720","preferredDefinition":"A benign or malignant neoplasm arising from a peripheral nerve or the perineural sheaths.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral Nervous System Neoplasm","conceptCode":"C3321","definition":"A benign or malignant neoplasm arising from a peripheral nerve or the perineural sheaths.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-941C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9432-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Adrenal Gland Pheochromocytoma","valueDescription":"Adrenal Gland Pheochromocytoma","ValueMeaning":{"publicId":"3210721","version":"1","preferredName":"Adrenal Gland Pheochromocytoma","longName":"3210721","preferredDefinition":"A benign or malignant neuroendocrine neoplasm of the sympathetic nervous system that secretes catecholamines.  It arises from the chromaffin cells of the adrenal medulla.  Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenal Gland Pheochromocytoma","conceptCode":"C3326","definition":"A neuroendocrine neoplasm of the sympathetic nervous system that arises from the chromaffin cells of the adrenal medulla and secretes catecholamines. Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-943E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9454-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pituitary Gland Neoplasm","valueDescription":"Pituitary Gland Neoplasm","ValueMeaning":{"publicId":"3210722","version":"1","preferredName":"Pituitary Gland Neoplasm","longName":"3210722","preferredDefinition":"A benign or malignant neoplasm affecting the pituitary gland. The vast majority are adenomas arising from the anterior lobe of the pituitary gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pituitary Gland Neoplasm","conceptCode":"C3330","definition":"A benign or malignant neoplasm affecting the pituitary gland. The vast majority are pituitary neuroendocrine tumors (formerly pituitary adenomas).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9460-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9476-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Plasma Cell Leukemia","valueDescription":"Plasma Cell Leukemia","ValueMeaning":{"publicId":"3210723","version":"1","preferredName":"Plasma Cell Leukemia","longName":"3210723","preferredDefinition":"An aggressive plasma cell neoplasm with usually short survival. It is characterized by the presence of neoplastic plasma cells in the peripheral blood. The peripheral blood plasma cells comprise more than 20% of the peripheral blood white cells. It may be the initial presentation of a plasma cell neoplasm or manifest as a terminal complication of plasma cell myeloma. Lymphadenopathy and organomegaly are frequent clinical signs, whereas bone pain and osteolytic lesions are less frequently present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell Leukemia","conceptCode":"C3180","definition":"An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9482-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9498-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Plasma Cell Myeloma","valueDescription":"Plasma Cell Myeloma","ValueMeaning":{"publicId":"2559811","version":"1","preferredName":"Plasma Cell Myeloma","longName":"2559811","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-94AA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Plasmacytoma","valueDescription":"Plasmacytoma","ValueMeaning":{"publicId":"3210724","version":"1","preferredName":"Plasmacytoma","longName":"3210724","preferredDefinition":"A malignant (clonal) proliferation of plasma cells that are cytologically and immunophenotypically identical to those of plasma cell myeloma, but manifest a localized osseous or extraosseous growth pattern. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasmacytoma","conceptCode":"C9349","definition":"A malignant neoplasm characterized by the presence of a monoclonal population of plasma cells forming a tumor mass.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-94B6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-94CC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lymphoblastic Lymphoma","valueDescription":"Lymphoblastic Lymphoma","ValueMeaning":{"publicId":"3210725","version":"1","preferredName":"Lymphoblastic Lymphoma","longName":"3210725","preferredDefinition":"A lymphoma composed of immature small to medium-sized precursor lymphoid cells (lymphoblasts). It includes the B- and T-cell lymphoblastic lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoblastic Lymphoma","conceptCode":"C9360","definition":"A lymphoma composed of immature small to medium-sized precursor lymphoid cells (lymphoblasts). It includes the B- and T-cell lymphoblastic lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-94D8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-94EE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Prostate Neoplasm","valueDescription":"Prostate Neoplasm","ValueMeaning":{"publicId":"2593176","version":"1","preferredName":"Prostate Neoplasm","longName":"2593176","preferredDefinition":"A benign or malignant tumor involving the prostate gland. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Neoplasm","conceptCode":"C3343","definition":"A benign, borderline, or malignant neoplasm that affects the prostate gland.  Representative examples include benign prostate phyllodes tumor, prostatic intraepithelial neoplasia, prostate carcinoma, and prostate sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-6618-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-94F8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Renal Neoplasm","valueDescription":"Renal Neoplasm","ValueMeaning":{"publicId":"3210726","version":"1","preferredName":"Renal Neoplasm","longName":"3210726","preferredDefinition":"A benign or malignant neoplasm affecting the kidney. Representative examples of benign renal neoplasms include fibroma, lipoma, oncocytoma, and juxtaglomerular cell tumor. Representative examples of malignant renal neoplasms include renal cell carcinoma, renal pelvis carcinoma, Wilms tumor, rhabdoid tumor, sarcoma, and lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kidney Neoplasm","conceptCode":"C3150","definition":"A benign or malignant neoplasm affecting the kidney. Representative examples of benign renal neoplasms include fibroma, lipoma, oncocytoma, and juxtaglomerular cell tumor. Representative examples of malignant renal neoplasms include renal cell carcinoma, renal pelvis carcinoma, Wilms tumor, rhabdoid tumor, sarcoma, and lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9504-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-951A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Rhabdoid Tumor of the Kidney","valueDescription":"Rhabdoid Tumor of the Kidney","ValueMeaning":{"publicId":"3210727","version":"1","preferredName":"Rhabdoid Tumor of the Kidney","longName":"3210727","preferredDefinition":"A rhabdoid tumor that arises from the kidney.  It occurs in children and it is associated with abnormalities of chromosome 22. It is characterized by the presence of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rhabdoid Tumor of the Kidney","conceptCode":"C8715","definition":"A rhabdoid tumor that arises from the kidney.  It occurs in children and it is associated with abnormalities of chromosome 22. It is characterized by the presence of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9526-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-953C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sarcoma","valueDescription":"Sarcoma","ValueMeaning":{"publicId":"2574579","version":"1","preferredName":"Sarcoma","longName":"2574579","preferredDefinition":"A usually aggressive malignant mesenchymal cell tumor most commonly arising from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels.  Sarcomas occur in both children and adults.  The prognosis depends largely on the degree of differentiation (grade) of the tumor.  Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma","conceptCode":"C9118","definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F060-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-04-26","modifiedBy":"REEVESD","dateModified":"2006-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9546-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Penile Fibromatosis","valueDescription":"Penile Fibromatosis","ValueMeaning":{"publicId":"3211352","version":"1","preferredName":"Penile Fibromatosis","longName":"3211352","preferredDefinition":"Fibromatosis arising from the soft tissues of the penis. It is characterized by the presence of spindle-shaped fibroblasts, and an infiltrative growth pattern.  It causes the penis to bend when it becomes erect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penile Fibromatosis","conceptCode":"C3316","definition":"Fibromatosis arising from the soft tissues of the penis. It is characterized by the presence of spindle-shaped fibroblasts, and an infiltrative growth pattern.  It causes the penis to bend when it becomes erect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F1E5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F1FB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Perineural Cyst","valueDescription":"Perineural Cyst","ValueMeaning":{"publicId":"3211353","version":"1","preferredName":"Perineural Cyst","longName":"3211353","preferredDefinition":"Cyst of the nerve roots filled with cerebrospinal fluid, usually located in the sacral area of the spine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perineural Cyst","conceptCode":"C4797","definition":"Cyst of the nerve roots filled with cerebrospinal fluid, usually located in the sacral area of the spine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F207-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F21D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Peritoneal Panniculitis","valueDescription":"Peritoneal Panniculitis","ValueMeaning":{"publicId":"3211354","version":"1","preferredName":"Peritoneal Panniculitis","longName":"3211354","preferredDefinition":"A disorder characterized by chronic inflammation and fibrosis of the adipose tissues in the peritoneal cavity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peritoneal Panniculitis","conceptCode":"C85004","definition":"A disorder characterized by chronic inflammation and fibrosis of the adipose tissues in the peritoneal cavity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F229-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F23F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Peroxisomal Disorder","valueDescription":"Peroxisomal Disorder","ValueMeaning":{"publicId":"3211355","version":"1","preferredName":"Peroxisomal Disorder","longName":"3211355","preferredDefinition":"A group of congenital disorders of lipid metabolism, caused by loss of the normal peroxisomes. Signs and symptoms include developmental delays, mental retardation, facial abnormalities, hepatomegaly, and hypotonia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peroxisomal Disorder","conceptCode":"C85005","definition":"A group of congenital disorders of lipid metabolism, caused by loss of the normal peroxisomes. Signs and symptoms include developmental delays, mental retardation, facial abnormalities, hepatomegaly, and hypotonia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F24B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F261-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Persistent Fetal Circulation Syndrome","valueDescription":"Persistent Fetal Circulation Syndrome","ValueMeaning":{"publicId":"3211356","version":"1","preferredName":"Persistent Fetal Circulation Syndrome","longName":"3211356","preferredDefinition":"A cardiopulmonary syndrome characterized by hypoxemia due to increased pulmonary vascular resistance and subsequent right-to-left shunting of the blood through the foramen ovale and ductus arteriosus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Persistent Fetal Circulation","conceptCode":"C85006","definition":"A cardiopulmonary disorder characterized by systemic arterial hypoxemia secondary to pulmonary hypertension and extrapulmonary right to left shunting across the foramen ovale and ductus arteriosus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F26D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F283-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Perthes Disease","valueDescription":"Perthes Disease","ValueMeaning":{"publicId":"3211357","version":"1","preferredName":"Perthes Disease","longName":"3211357","preferredDefinition":"A very rare disorder of unknown etiology affecting children. It is characterized by avascular necrosis of the femoral head.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perthes Disease","conceptCode":"C34766","definition":"A very rare disorder of unknown etiology affecting children. It is characterized by avascular necrosis of the femoral head.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F28F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F2A5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Petit Mal Epilepsy","valueDescription":"Petit Mal Epilepsy","ValueMeaning":{"publicId":"3211358","version":"1","preferredName":"Petit Mal Epilepsy","longName":"3211358","preferredDefinition":"Epilepsy characterized by very brief episodes of sudden cessation of activity, usually associated with eye blinking. There is no loss of the muscle tone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Absence Epilepsy","conceptCode":"C3023","definition":"Epilepsy characterized by very brief episodes of sudden cessation of activity, usually associated with eye blinking. There is no loss of the muscle tone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F2B1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F2C7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Peutz-Jeghers Syndrome","valueDescription":"Peutz-Jeghers Syndrome","ValueMeaning":{"publicId":"3211359","version":"1","preferredName":"Peutz-Jeghers Syndrome","longName":"3211359","preferredDefinition":"An inherited condition characterized by generalized hamartomatous multiple polyposis of the intestinal tract. Transmitted in an autosomal dominant fashion, Peutz-Jeghers syndrome consistently involves the jejunum and is associated with melanin spots of the lips, buccal mucosa, and fingers. This syndrome is associated with abnormalities of chromosome 19. Also known as Jeghers-Peutz syndrome and Peutz's syndrome. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peutz-Jeghers Syndrome","conceptCode":"C3324","definition":"An inherited condition characterized by generalized hamartomatous multiple polyposis of the intestinal tract. Transmitted in an autosomal dominant fashion, Peutz-Jeghers syndrome consistently involves the jejunum and is associated with melanin spots of the lips, buccal mucosa, and fingers. This syndrome is associated with abnormalities of chromosome 19. Also known as Jeghers-Peutz syndrome and Peutz's syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F2D3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F2E9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Phenylketonuria","valueDescription":"Phenylketonuria","ValueMeaning":{"publicId":"3211360","version":"1","preferredName":"Phenylketonuria","longName":"3211360","preferredDefinition":"A disorder characterized by the body's inability to break down and utilize the essential amino acid phenylalanine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenylketonuria","conceptCode":"C81315","definition":"An autonomic recessive genetic disorder characterized by the body's inability to metabolize and utilize the amino acid phenylalanine, resulting in mental retardation, behavioral and movement problems, seizures, and developmental delays.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F2F5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F30B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pick's Disease","valueDescription":"Pick's Disease","ValueMeaning":{"publicId":"3211361","version":"1","preferredName":"Pick's Disease","longName":"3211361","preferredDefinition":"A rare neurodegenerative disorder leading to dementia. It is characterized by frontotemporal lobar degeneration with accumulation of tau proteins which form Pick bodies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pick's Disease","conceptCode":"C85008","definition":"A rare neurodegenerative disorder leading to dementia. It is characterized by frontotemporal lobar degeneration with accumulation of tau proteins which form Pick bodies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F317-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F32D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Piebaldism","valueDescription":"Piebaldism","ValueMeaning":{"publicId":"3211362","version":"1","preferredName":"Piebaldism","longName":"3211362","preferredDefinition":"A rare, autosomal dominant disorder caused usually by mutations in the KIT gene. It is characterized by abnormalities in the development of melanocytes. It presents with multiple symmetrical hypopigmented or depigmented patches of skin and a midline patch of white hair.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piebaldism","conceptCode":"C85009","definition":"A rare, autosomal dominant disorder caused usually by mutations in the KIT gene. It is characterized by abnormalities in the development of melanocytes. It presents with multiple symmetrical hypopigmented or depigmented patches of skin and a midline patch of white hair.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F339-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F34F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pierre Robin Syndrome","valueDescription":"Pierre Robin Syndrome","ValueMeaning":{"publicId":"3211363","version":"1","preferredName":"Pierre Robin Syndrome","longName":"3211363","preferredDefinition":"A rare congenital malformation characterized by micrognathia, posterior retraction of the tongue, and cleft palate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pierre Robin Syndrome","conceptCode":"C85010","definition":"A rare congenital malformation characterized by micrognathia, posterior retraction of the tongue, and cleft palate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F35B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F371-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pilomatricoma","valueDescription":"Pilomatricoma","ValueMeaning":{"publicId":"3211364","version":"1","preferredName":"Pilomatricoma","longName":"3211364","preferredDefinition":"A benign adnexal neoplasm arising from hair-bearing skin surfaces, usually the head and neck and upper extremities. It usually presents as a solitary, slow-growing nodular mass. Morphologically, it displays differentiation towards the matrix and inner sheath of the normal hair follicle and the hair cortex. Complete surgical excision is usually curative. Occasionally, it may recur.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pilomatricoma","conceptCode":"C7368","definition":"A benign adnexal neoplasm arising from hair-bearing skin surfaces, usually the head and neck and upper extremities. It usually presents as a solitary, slow-growing nodular mass. Morphologically, it displays differentiation towards the matrix and inner sheath of the normal hair follicle and the hair cortex. Complete surgical excision is usually curative. Occasionally, it may recur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F37D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F393-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pineal Region Neoplasm","valueDescription":"Pineal Region Neoplasm","ValueMeaning":{"publicId":"3211365","version":"1","preferredName":"Pineal Region Neoplasm","longName":"3211365","preferredDefinition":"Neoplasms that are located in the pineal gland.  These neoplasms arise either from pineal parenchymal cells (pineocytes), as do pineocytomas and the more aggressive pineoblastomas, or from other cell types, as do pineal astrocytic tumors (notably pilocytic astrocytomas) and germ cell tumors.  Clinical symptoms include neuro-ophthalmologic dysfunction, changes in mental status, dysfunction of the brain stem, and hypothalamic-based endocrine abnormalities. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineal Region Neoplasm","conceptCode":"C3328","definition":"A benign or malignant neoplasm that affects the pineal region.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F39F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F3B5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pinta","valueDescription":"Pinta","ValueMeaning":{"publicId":"3211366","version":"1","preferredName":"Pinta","longName":"3211366","preferredDefinition":"An endemic bacterial infection caused by Treponema carateum. It is manifested with chronic cutaneous lesions. The early lesions consist of papules and erythematous plaques. The late lesions consist of hypochromic, achromic, hyperpigmented and atrophic lesions. The late skin lesions may cause destruction of bones and cartilage and produce disfiguring changes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pinta","conceptCode":"C85011","definition":"An endemic bacterial infection caused by Treponema carateum. It is manifested with chronic cutaneous lesions. The early lesions consist of papules and erythematous plaques. The late lesions consist of hypochromic, achromic, hyperpigmented and atrophic lesions. The late skin lesions may cause destruction of bones and cartilage and produce disfiguring changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F3C1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F3D7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Piriformis Muscle Syndrome","valueDescription":"Piriformis Muscle Syndrome","ValueMeaning":{"publicId":"3211367","version":"1","preferredName":"Piriformis Muscle Syndrome","longName":"3211367","preferredDefinition":"A condition referring to irritation or compression of the proximal sciatic nerve, secondary to contraction of the piriformis muscle. It results in pain in the hip or the back of the leg mimicking disk-related sciatica.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piriformis Muscle Syndrome","conceptCode":"C85012","definition":"A condition referring to irritation or compression of the proximal sciatic nerve, secondary to contraction of the piriformis muscle. It results in pain in the hip or the back of the leg mimicking disk-related sciatica.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F3E3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F3F9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pityriasis Lichenoides","valueDescription":"Pityriasis Lichenoides","ValueMeaning":{"publicId":"3211368","version":"1","preferredName":"Pityriasis Lichenoides","longName":"3211368","preferredDefinition":"A rare cutaneous disorder of unknown etiology that can present either as an acute condition, with multiple papular lesions which become vesicular and necrotic (pityriasis lichenoides et varioliformis acuta) or chronic, with small, scaling papules (pityriasis lichenoides chronica).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pityriasis Lichenoides","conceptCode":"C85013","definition":"A rare cutaneous disorder of unknown etiology that can present either as an acute condition, with multiple papular lesions which become vesicular and necrotic (pityriasis lichenoides et varioliformis acuta) or chronic, with small, scaling papules (pityriasis lichenoides chronica).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F405-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F41B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pityriasis Rubra Pilaris","valueDescription":"Pityriasis Rubra Pilaris","ValueMeaning":{"publicId":"3211369","version":"1","preferredName":"Pityriasis Rubra Pilaris","longName":"3211369","preferredDefinition":"A rare cutaneous disorder of unknown etiology characterized by the presence of reddish-orange scaly plaques, palmoplantar keratoderma, keratotic follicular papules, and confluent erythematous areas with areas of normal skin between the lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pityriasis Rubra Pilaris","conceptCode":"C85014","definition":"A rare cutaneous disorder of unknown etiology characterized by the presence of reddish-orange scaly plaques, palmoplantar keratoderma, keratotic follicular papules, and confluent erythematous areas with areas of normal skin between the lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F427-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F43D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Plague","valueDescription":"Plague","ValueMeaning":{"publicId":"3211370","version":"1","preferredName":"Plague","longName":"3211370","preferredDefinition":"A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plague","conceptCode":"C85015","definition":"A Gram-negative bacterial infection caused by Yersinia pestis. It is usually transmitted to humans from bites of infected rodent fleas. It is manifested as a bubonic, septicemic, or pneumonic plague. In bubonic plague, the lymph nodes adjacent to the site of the skin bite are infected and enlarged. In septicemic plague, the infection spreads directly through the bloodstream. In pneumonic plague, the infection spreads to the lungs either following bubonic plague, or by inhalation of infective droplets. If untreated, it may lead to death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F449-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F45F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Plummer-Vinson Syndrome","valueDescription":"Plummer-Vinson Syndrome","ValueMeaning":{"publicId":"3211371","version":"1","preferredName":"Plummer-Vinson Syndrome","longName":"3211371","preferredDefinition":"A syndrome characterized by dysphagia, upper esophageal webs, iron deficiency anemia, and glossitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plummer-Vinson Syndrome","conceptCode":"C85016","definition":"A syndrome characterized by dysphagia, upper esophageal webs, iron deficiency anemia, and glossitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F46B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F481-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pneumoconiosis","valueDescription":"Pneumoconiosis","ValueMeaning":{"publicId":"2559819","version":"1","preferredName":"Pneumoconiosis","longName":"2559819","preferredDefinition":"An occupational lung disorder caused by inhalation of dust particles. It is characterized by bilateral interstitial lung infiltrates. Representative examples include asbestosis, silicosis, anthracosis, and talc pneumoconiosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pneumoconiosis","conceptCode":"C26861","definition":"An occupational lung disorder caused by inhalation of dust particles. It is characterized by bilateral interstitial lung infiltrates. Representative examples include asbestosis, silicosis, anthracosis, and talc pneumoconiosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6B8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F48B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"POEMS Syndrome","valueDescription":"POEMS Syndrome","ValueMeaning":{"publicId":"3211372","version":"1","preferredName":"POEMS Syndrome","longName":"3211372","preferredDefinition":"A syndrome characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.  It is often associated with osteosclerotic myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"POEMS Syndrome","conceptCode":"C80303","definition":"A syndrome characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. It is associated with plasma cell dyscrasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F497-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F4AD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Poland Syndrome","valueDescription":"Poland Syndrome","ValueMeaning":{"publicId":"3211373","version":"1","preferredName":"Poland Syndrome","longName":"3211373","preferredDefinition":"A rare developmental disorder characterized by underdevelopment or absence of the pectoralis muscle in one side of the chest, usually associated with ipsilateral cutaneous syndactyly, and ipsilateral breast and nipple hypoplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Poland Syndrome","conceptCode":"C85017","definition":"A rare developmental disorder characterized by underdevelopment or absence of the pectoralis muscle in one side of the chest, usually associated with ipsilateral cutaneous syndactyly, and ipsilateral breast and nipple hypoplasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F4B9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F4CF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Polymyalgia Rheumatica","valueDescription":"Polymyalgia Rheumatica","ValueMeaning":{"publicId":"3211374","version":"1","preferredName":"Polymyalgia Rheumatica","longName":"3211374","preferredDefinition":"A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymyalgia Rheumatica","conceptCode":"C85018","definition":"A syndrome characterized by pain, stiffness, and tenderness of the proximal muscle groups including the shoulder, pelvic girdle and the neck. There is no muscle atrophy and muscle biopsies do not reveal pathologic changes. Additional signs and symptoms include low grade fever, fatigue and depression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F4DB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F4F1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Polymyositis","valueDescription":"Polymyositis","ValueMeaning":{"publicId":"2585215","version":"1","preferredName":"Polymyositis","longName":"2585215","preferredDefinition":"Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY, NERVOUS SYSTEM); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymyositis","conceptCode":"C26925","definition":"An idiopathic inflammatory disorder affecting the muscles. It presents with symmetrical proximal muscle weakness and elevated skeletal muscle enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2687D788-9C0F-74B4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-01-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F4FB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Polyostotic Fibrous Dysplasia","valueDescription":"Polyostotic Fibrous Dysplasia","ValueMeaning":{"publicId":"3211375","version":"1","preferredName":"Polyostotic Fibrous Dysplasia","longName":"3211375","preferredDefinition":"A genetic syndrome caused by mutations in the GNAS1 gene. It is characterized by deformities and fractures of the bones, endocrine abnormalities including early puberty, and skin hyperpigmentation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyostotic Fibrous Dysplasia","conceptCode":"C34610","definition":"Fibrous dysplasia affecting more than one bone. When it is associated with caf-au-lait skin pigmentation and endocrine disorders, it is known as McCune-Albright syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F507-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F51D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Porokeratosis","valueDescription":"Porokeratosis","ValueMeaning":{"publicId":"3211376","version":"1","preferredName":"Porokeratosis","longName":"3211376","preferredDefinition":"A clonal proliferation of abnormal keratinocytes characterized by the development of localized or multiple atrophic skin patches surrounded by an annular keratotic ring called cornoid lamella.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Porokeratosis","conceptCode":"C85019","definition":"A clonal proliferation of abnormal keratinocytes characterized by the development of localized or multiple atrophic skin patches surrounded by an annular keratotic ring called cornoid lamella.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F529-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F53F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Postural Orthostatic Tachycardia Syndrome","valueDescription":"Postural Orthostatic Tachycardia Syndrome","ValueMeaning":{"publicId":"3211377","version":"1","preferredName":"Postural Orthostatic Tachycardia Syndrome","longName":"3211377","preferredDefinition":"A syndrome characterized by orthostatic intolerance resulting in tachycardia, often accompanied by a decrease in the blood pressure. It occurs when individuals change from the supine position to an upright position. Other signs and symptoms include lightheadedness, fainting, fatigue and muscle weakness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Postural Orthostatic Tachycardia Syndrome","conceptCode":"C85020","definition":"A syndrome characterized by orthostatic intolerance resulting in tachycardia, often accompanied by a decrease in the blood pressure. It occurs when individuals change from the supine position to an upright position. Other signs and symptoms include lightheadedness, fainting, fatigue and muscle weakness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F54B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F561-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Prader-Willi Syndrome","valueDescription":"Prader-Willi Syndrome","ValueMeaning":{"publicId":"3211378","version":"1","preferredName":"Prader-Willi Syndrome","longName":"3211378","preferredDefinition":"A genetic syndrome caused by deletions or disruptions of chromosome 15.  It is characterized by reduced fetal activity, mental retardation, hypotonia, short stature, and hypogonadism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prader-Willi Syndrome","conceptCode":"C75463","definition":"A genetic syndrome caused by deletions or disruptions of chromosome 15. It is characterized by reduced fetal activity, mental retardation, hypotonia, short stature, and hypogonadism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F56D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F583-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Precocious Puberty","valueDescription":"Precocious Puberty","ValueMeaning":{"publicId":"2946087","version":"1","preferredName":"Precocious Puberty","longName":"2946087","preferredDefinition":"Unusually early sexual maturity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Precocious Puberty","conceptCode":"C79704","definition":"Unusually early sexual maturity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746AE5AE-6708-370C-E040-BB89AD4351E3","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F595-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Preeclampsia","valueDescription":"Preeclampsia","ValueMeaning":{"publicId":"3211379","version":"1","preferredName":"Preeclampsia","longName":"3211379","preferredDefinition":"A pregnancy-related disorder characterized by an increase in the blood pressure after the twentieth week of gestation, and by the presence of proteinuria. It may appear up to six weeks post-partum. It may lead to eclampsia with development of tonic-clonic seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Preeclampsia","conceptCode":"C85021","definition":"A systolic blood pressure of 140 mmHg or higher, or a diastolic blood pressure of 90 mmHg or higher on two occasions at least 4 hours apart (or greater than or equal to 160/110 mmHg within a short interval) after 20 weeks of gestation in a woman with previously normal blood pressure. It may present with proteinuria but if not, it may be associated with thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary edema, or new-onset cerebral or visual disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F5A1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F5B7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pre-Excitation Syndrome","valueDescription":"Pre-Excitation Syndrome","ValueMeaning":{"publicId":"3211380","version":"1","preferredName":"Pre-Excitation Syndrome","longName":"3211380","preferredDefinition":"A syndrome characterized by premature contractions of the ventricles due to the presence of an accessory conductive pathway between the atria and the ventricles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pre-Excitation Syndrome","conceptCode":"C34940","definition":"An electrocardiographic finding characterized by a premature activation of the whole or some part of the ventricle. The PR interval is usually shortened and delta waves are frequently present. (CDISC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F5C3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F5D9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pregnancy Associated Hypertension","valueDescription":"Pregnancy Associated Hypertension","ValueMeaning":{"publicId":"3211381","version":"1","preferredName":"Pregnancy Associated Hypertension","longName":"3211381","preferredDefinition":"The most common complication of pregnancy. It may appear as chronic hypertension or preeclampsia. It may cause brain hemorrhage, pulmonary edema, abruptio placentae, gestational diabetes mellitus, renal failure, premature delivery and fetal growth abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gestational Hypertension","conceptCode":"C4371","definition":"A blood pressure elevation after 20 weeks of gestation in the absence of either proteinuria or systemic findings like thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary edema or the new-onset of cerebral or visual disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F5E5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F5FB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Priapism","valueDescription":"Priapism","ValueMeaning":{"publicId":"3211382","version":"1","preferredName":"Priapism","longName":"3211382","preferredDefinition":"Persistent and usually painful erection that lasts for at least four hours, in the absence of physical or psychological stimulation. It may be caused by hematologic disorders including sickle cell disease and leukemia, spinal cord injuries, and medications.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Priapism","conceptCode":"C85022","definition":"Persistent and usually painful erection that lasts for at least four hours in the absence of physical or psychological stimulation, which can be caused by hematologic disorders, including sickle cell disease and leukemia, spinal cord injuries, and medications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F607-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F61D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Primary Effusion Lymphoma","valueDescription":"Primary Effusion Lymphoma","ValueMeaning":{"publicId":"2559886","version":"1","preferredName":"Primary Effusion Lymphoma","longName":"2559886","preferredDefinition":"An aggressive non-Hodgkin B-cell lymphoma composed of large cells, presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV) [HHV-8/KSHV]. It mostly occurs in the setting of immunodeficiency; most cases have been reported in HIV positive patients. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. The prognosis is extremely unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Effusion Lymphoma","conceptCode":"C6915","definition":"A large B-cell lymphoma usually presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Rare HHV8-positive lymphomas indistinguishable from primary effusion lymphomas (PEL) present as solid tumor masses, and have been termed extracavitary PEL. The prognosis is extremely unfavorable. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6FB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F62F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Primary Hyperparathyroidism","valueDescription":"Primary Hyperparathyroidism","ValueMeaning":{"publicId":"3211383","version":"1","preferredName":"Primary Hyperparathyroidism","longName":"3211383","preferredDefinition":"Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Hyperparathyroidism","conceptCode":"C48280","definition":"Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F63B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F651-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Primary Hypertrophic Osteoarthropathy","valueDescription":"Primary Hypertrophic Osteoarthropathy","ValueMeaning":{"publicId":"3211384","version":"1","preferredName":"Primary Hypertrophic Osteoarthropathy","longName":"3211384","preferredDefinition":"A rare disorder of unknown etiology characterized by hypertrophy of the bones of the distal extremities, periostosis of the tubular bones, digital clubbing, and skin changes including coarse facial features, acne, and hyperhydrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Hypertrophic Osteoarthropathy","conceptCode":"C85023","definition":"A rare disorder characterized by hypertrophy of the bones of the distal extremities, periostosis of the tubular bones, digital clubbing, and skin changes including coarse facial features, acne, and hyperhydrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F65D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F673-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Primary Progressive Aphasia","valueDescription":"Primary Progressive Aphasia","ValueMeaning":{"publicId":"3211385","version":"1","preferredName":"Primary Progressive Aphasia","longName":"3211385","preferredDefinition":"A rare neurologic progressive disorder characterized by impairment of the language and speech abilities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Progressive Aphasia","conceptCode":"C85024","definition":"A rare neurologic progressive disorder characterized by impairment of the language and speech abilities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F67F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F695-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Primary Progressive Nonfluent Aphasia","valueDescription":"Primary Progressive Nonfluent Aphasia","ValueMeaning":{"publicId":"3211386","version":"1","preferredName":"Primary Progressive Nonfluent Aphasia","longName":"3211386","preferredDefinition":"A rare neurologic progressive disorder characterized by impairment of the production of speech.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Progressive Nonfluent Aphasia","conceptCode":"C85025","definition":"A rare neurologic progressive disorder characterized by impairment of the production of speech.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F6A1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F6B7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Progeria","valueDescription":"Progeria","ValueMeaning":{"publicId":"3211387","version":"1","preferredName":"Progeria","longName":"3211387","preferredDefinition":"A very rare genetic disorder caused by mutations in the LMNA gene. It is characterized by premature aging. Signs and symptoms include failure to thrive, limited growth, alopecia, wrinkled skin, small face, development of atherosclerosis, and heart disease. There is no cure for this condition. Individuals do not usually survive beyond their early twenties. Death usually occurs as a result of complications from atherosclerosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progeria","conceptCode":"C34951","definition":"A very rare genetic disorder caused by mutations in the LMNA gene. It is characterized by premature aging. Signs and symptoms include failure to thrive, limited growth, alopecia, wrinkled skin, small face, development of atherosclerosis, and heart disease. There is no cure for this condition. Individuals do not usually survive beyond their early twenties. Death usually occurs as a result of complications from atherosclerosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F6C3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F6D9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Progressive Bulbar Palsy","valueDescription":"Progressive Bulbar Palsy","ValueMeaning":{"publicId":"3211388","version":"1","preferredName":"Progressive Bulbar Palsy","longName":"3211388","preferredDefinition":"A progressive motor neuron disorder affecting the muscles which are innervated by cranial nerves of the lower brain stem. Signs and symptoms include difficulties in chewing and swallowing, dysarthria, and weakness of the facial muscles and tongue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Bulbar Palsy","conceptCode":"C85026","definition":"A progressive motor neuron disorder affecting the muscles which are innervated by cranial nerves of the lower brain stem. Signs and symptoms include difficulties in chewing and swallowing, dysarthria, and weakness of the facial muscles and tongue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F6E5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F6FB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Progressive Multifocal Leukoencephalopathy","valueDescription":"Progressive Multifocal Leukoencephalopathy","ValueMeaning":{"publicId":"2934606","version":"1","preferredName":"Progressive Multifocal Leukoencephalopathy","longName":"2934606","preferredDefinition":"A progressive demyelination within the central nervous system associated with reactivation of a latent JC virus infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Multifocal Leukoencephalopathy","conceptCode":"C26815","definition":"A progressive demyelination within the central nervous system associated with reactivation of a latent JC virus infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71855E80-BADD-E674-E040-BB89AD437920","latestVersionIndicator":"Yes","beginDate":"2009-08-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F705-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Progressive Muscular Atrophy","valueDescription":"Progressive Muscular Atrophy","ValueMeaning":{"publicId":"3211389","version":"1","preferredName":"Progressive Muscular Atrophy","longName":"3211389","preferredDefinition":"A rare, milder form of amyotrophic lateral sclerosis. It is characterized by a slowly progressive clinical course. Signs and symptoms include muscle weakness, atrophy, and fasciculation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Muscular Atrophy","conceptCode":"C85027","definition":"A rare, milder form of amyotrophic lateral sclerosis. It is characterized by a slowly progressive clinical course. Signs and symptoms include muscle weakness, atrophy, and fasciculation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F711-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F727-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Progressive Myoclonus Epilepsy","valueDescription":"Progressive Myoclonus Epilepsy","ValueMeaning":{"publicId":"3211390","version":"1","preferredName":"Progressive Myoclonus Epilepsy","longName":"3211390","preferredDefinition":"A rare group of disorders characterized by the development of myoclonic and tonic-clonic epileptic seizures associated with progressive degeneration of the nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Myoclonus Epilepsy","conceptCode":"C7636","definition":"A rare group of disorders characterized by the development of myoclonic and tonic-clonic epileptic seizures associated with progressive degeneration of the nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F733-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F749-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Progressive Supranuclear Palsy","valueDescription":"Progressive Supranuclear Palsy","ValueMeaning":{"publicId":"3211391","version":"1","preferredName":"Progressive Supranuclear Palsy","longName":"3211391","preferredDefinition":"A rare neurodegenerative disorder characterized by gait and balance difficulties and loss of coordination of eye movements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Supranuclear Palsy","conceptCode":"C85028","definition":"A rare neurodegenerative disorder characterized by gait and balance difficulties and loss of coordination of eye movements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F755-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F76B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Prolidase Deficiency","valueDescription":"Prolidase Deficiency","ValueMeaning":{"publicId":"3211392","version":"1","preferredName":"Prolidase Deficiency","longName":"3211392","preferredDefinition":"A rare autosomal recessive inherited inborn error of metabolism caused by mutations in the PEPD gene. Signs and symptoms include facial abnormalities, mental retardation, skin ulcers, susceptibility to infections, and skeletal abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prolidase Deficiency","conceptCode":"C85029","definition":"A rare autosomal recessive inherited inborn error of metabolism caused by mutations in the PEPD gene. Signs and symptoms include facial abnormalities, mental retardation, skin ulcers, susceptibility to infections, and skeletal abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F777-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F78D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Propionic Acidemia","valueDescription":"Propionic Acidemia","ValueMeaning":{"publicId":"3211393","version":"1","preferredName":"Propionic Acidemia","longName":"3211393","preferredDefinition":"A rare autosomal inherited organic acid disorder caused by mutations in the PCCA and PCCB genes. It results in the accumulation of harmful organic acids in the blood and urine. Signs and symptoms appear in infancy and include vomiting, poor feeding, loss of appetite, hypotonia, and lethargy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propionic Acidemia","conceptCode":"C85030","definition":"A rare autosomal inherited organic acid disorder caused by mutations in the PCCA and PCCB genes. It results in the accumulation of harmful organic acids in the blood and urine. Signs and symptoms appear in infancy and include vomiting, poor feeding, loss of appetite, hypotonia, and lethargy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F799-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F7AF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Prosopagnosia","valueDescription":"Prosopagnosia","ValueMeaning":{"publicId":"3211394","version":"1","preferredName":"Prosopagnosia","longName":"3211394","preferredDefinition":"Impaired ability to recognize other human faces in the absence of a vision disorder. It may be a congenital disorder or the result of brain injury.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prosopagnosia","conceptCode":"C85031","definition":"Impaired ability to recognize other human faces in the absence of a vision disorder. It may be a congenital disorder or the result of brain injury.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F7BB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F7D1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Proteus Syndrome","valueDescription":"Proteus Syndrome","ValueMeaning":{"publicId":"3211395","version":"1","preferredName":"Proteus Syndrome","longName":"3211395","preferredDefinition":"A very rare congenital disorder characterized by the development of multiple cutaneous and subcutaneous lesions including lipomas, nevi, and vascular malformations, associated with partial gigantism or digital overgrowth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Proteus Syndrome","conceptCode":"C85032","definition":"A very rare congenital disorder characterized by the development of multiple cutaneous and subcutaneous lesions including lipomas, nevi, and vascular malformations, associated with partial gigantism or digital overgrowth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F7DD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F7F3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Prune Belly Syndrome","valueDescription":"Prune Belly Syndrome","ValueMeaning":{"publicId":"3211396","version":"1","preferredName":"Prune Belly Syndrome","longName":"3211396","preferredDefinition":"A rare congenital syndrome occurring almost exclusively in males. It is characterized by partial or complete lack of the abdominal wall muscles, enlarged bladder, dilated ureters, hydronephrosis, and undescended testes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prune Belly Syndrome","conceptCode":"C85033","definition":"A rare congenital syndrome occurring almost exclusively in males. It is characterized by partial or complete lack of the abdominal wall muscles, enlarged bladder, dilated ureters, hydronephrosis, and undescended testes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F7FF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F815-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pseudohypoaldosteronism","valueDescription":"Pseudohypoaldosteronism","ValueMeaning":{"publicId":"3211397","version":"1","preferredName":"Pseudohypoaldosteronism","longName":"3211397","preferredDefinition":"An inherited or acquired disorder of electrolyte metabolism, characterized by the inability of the renal tubules to respond to aldosterone. It is manifested by hyperkalemic metabolic acidosis, urinary salt wasting, normal or increased aldosterone secretion and normal glomerular filtration rate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pseudohypoaldosteronism","conceptCode":"C85034","definition":"An inherited or acquired disorder of electrolyte metabolism, characterized by the inability of the renal tubules to respond to aldosterone. It is manifested by hyperkalemic metabolic acidosis, urinary salt wasting, normal or increased aldosterone secretion and normal glomerular filtration rate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F821-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F837-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pseudomyxoma Peritonei","valueDescription":"Pseudomyxoma Peritonei","ValueMeaning":{"publicId":"3211398","version":"1","preferredName":"Pseudomyxoma Peritonei","longName":"3211398","preferredDefinition":"A well differentiated mucinous adenocarcinoma of the peritoneum.  The vast majority of cases represent tumor spread from a primary well differentiated mucinous adenocarcinoma of the appendix.  Cases of pseudomyxoma peritonei associated with mucinous adenocarcinomas of the gallbladder, stomach, colon, rectum, pancreas, lung, breast, and fallopian tubes have also been reported.  In the past, the ovary has been considered as a common primary site associated with pseudomyxoma peritonei.  However, there is recent evidence based on immunohistochemistry and molecular genetic analysis suggesting that most cases of pseudomyxoma peritonei probably represent metastasis from an appendiceal and not ovarian primary. --2005","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pseudomyxoma Peritonei","conceptCode":"C3345","definition":"A usually well differentiated mucinous adenocarcinoma of the peritoneum.  The majority of cases represent tumor spread from a primary low grade mucinous neoplasm of the appendix.  Cases of pseudomyxoma peritonei associated with mucinous adenocarcinomas of the gallbladder, stomach, colon, rectum, pancreas, lung, breast, and fallopian tubes have also been reported.  In the past, the ovary has been considered as a common primary site associated with pseudomyxoma peritonei.  However, there is recent evidence based on immunohistochemistry and molecular genetic analysis suggesting that most cases of pseudomyxoma peritonei probably represent metastasis from an appendiceal and not ovarian primary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F843-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F859-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Small Intestinal Carcinoma","valueDescription":"Small Intestinal Carcinoma","ValueMeaning":{"publicId":"3210728","version":"1","preferredName":"Small Intestinal Carcinoma","longName":"3210728","preferredDefinition":"A carcinoma arising from the small intestine. The vast majority are adenocarcinomas. The remaining cases are adenosquamous, squamous, or undifferentiated carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Intestinal Carcinoma","conceptCode":"C7724","definition":"A carcinoma arising from the small intestine. The vast majority are adenocarcinomas. The remaining cases are adenosquamous, squamous, or undifferentiated carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9552-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9568-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Smoldering Myeloma","valueDescription":"Smoldering Myeloma","ValueMeaning":{"publicId":"3210729","version":"1","preferredName":"Smoldering Myeloma","longName":"3210729","preferredDefinition":"A plasma cell myeloma lacking clinical manifestations and organ impairment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Smoldering Multiple Myeloma","conceptCode":"C7149","definition":"Multiple myeloma lacking clinical manifestations and organ impairment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9574-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-958A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Squamous Cell Carcinoma","valueDescription":"Squamous Cell Carcinoma","ValueMeaning":{"publicId":"2567412","version":"1","preferredName":"Squamous Cell Carcinoma","longName":"2567412","preferredDefinition":"A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Squamous Cell Carcinoma","conceptCode":"C2929","definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D461-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9594-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Stromal Neoplasm","valueDescription":"Stromal Neoplasm","ValueMeaning":{"publicId":"3210730","version":"1","preferredName":"Stromal Neoplasm","longName":"3210730","preferredDefinition":"A benign or malignant neoplasm composed of mesenchymal stromal cells.  Representative examples include gastrointestinal stromal tumor, endometrial stromal sarcoma, and prostate stromal sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stromal Neoplasm","conceptCode":"C6781","definition":"A benign or malignant mesenchymal neoplasm composed of stromal cells.  Representative examples include gastrointestinal stromal tumor, endometrial stromal sarcoma, and prostate stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-95A0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-95B6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thyroid Gland Carcinoma","valueDescription":"Thyroid Gland Carcinoma","ValueMeaning":{"publicId":"2581280","version":"1","preferredName":"Thyroid Gland Carcinoma","longName":"2581280","preferredDefinition":"A carcinoma arising from the thyroid gland.  It is usually an adenocarcinoma and includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Carcinoma","conceptCode":"C4815","definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-95C0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Uterine Corpus Cancer","valueDescription":"Uterine Corpus Cancer","ValueMeaning":{"publicId":"3210731","version":"1","preferredName":"Uterine Corpus Cancer","longName":"3210731","preferredDefinition":"A malignant neoplasm arising from the uterine corpus. This category includes endometrial carcinoma and carcinosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Corpus Cancer","conceptCode":"C61574","definition":"A malignant neoplasm arising from the uterine corpus. This category includes endometrial carcinoma and carcinosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-95CC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-95E2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Vaginal Carcinoma","valueDescription":"Vaginal Carcinoma","ValueMeaning":{"publicId":"3125025","version":"1","preferredName":"Vaginal Carcinoma","longName":"3125025","preferredDefinition":"A carcinoma arising from the vaginal epithelium. The majority of vaginal carcinomas are squamous cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaginal Carcinoma","conceptCode":"C3917","definition":"A carcinoma arising from the vaginal epithelium. The majority of vaginal carcinomas are squamous cell carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C8C84BA-753B-B840-E040-BB89AD4308AA","latestVersionIndicator":"Yes","beginDate":"2010-07-29","endDate":null,"createdBy":"WHITES","dateCreated":"2010-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-95F4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Vulvar Carcinoma","valueDescription":"Vulvar Carcinoma","ValueMeaning":{"publicId":"3210732","version":"1","preferredName":"Vulvar Carcinoma","longName":"3210732","preferredDefinition":"A carcinoma arising from the vulva.  It usually affects elderly women but has been observed in premenopausal women as well.  The most frequently seen histologic type is squamous cell carcinoma. The most common site of involvement is the labia majora.  In many cases, the development of vulvar cancer is preceded by condyloma or squamous dysplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vulvar Carcinoma","conceptCode":"C4866","definition":"A carcinoma arising from the vulva.  It usually affects elderly women but has been observed in premenopausal women as well.  The most frequently seen histologic type is squamous cell carcinoma. The most common site of involvement is the labia majora.  In many cases, the development of vulvar cancer is preceded by condyloma or squamous dysplasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9600-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9616-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wilms Tumor","valueDescription":"Wilms Tumor","ValueMeaning":{"publicId":"2593188","version":"1","preferredName":"Wilms Tumor","longName":"2593188","preferredDefinition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wilms Tumor","conceptCode":"C3267","definition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-66BA-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9620-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acute Respiratory Distress Syndrome","valueDescription":"Adult respiratory distress syndrome","ValueMeaning":{"publicId":"2562613","version":"1","preferredName":"Adult respiratory distress syndrome","longName":"2562613","preferredDefinition":"A disorder characterized by progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult respiratory distress syndrome","conceptCode":"E13299","definition":"A disorder characterized by progressive and life-threatening pulmonary distress in the absence of an underlying pulmonary condition, usually following major trauma or surgery.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C1A2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"HARTLEYG","dateModified":"2016-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9632-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alpha-1 Antitrypsin Deficiency","valueDescription":"Alpha-1 Antitrypsin Deficiency","ValueMeaning":{"publicId":"3171840","version":"1","preferredName":"Alpha-1 Antitrypsin Deficiency","longName":"3171840","preferredDefinition":"A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-1 Antitrypsin Deficiency","conceptCode":"C84397","definition":"A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DDA7EA-0146-07E7-E040-BB89AD4351C6","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"WHITES","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-963C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Anemia","valueDescription":"Anemia","ValueMeaning":{"publicId":"2568585","version":"1","preferredName":"Anemia","longName":"2568585","preferredDefinition":"A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anemia","conceptCode":"C2869","definition":"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8F6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-25","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9646-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Aneurysm","valueDescription":"Aneurysm","ValueMeaning":{"publicId":"3210733","version":"1","preferredName":"Aneurysm","longName":"3210733","preferredDefinition":"Bulging or ballooning in an area of an artery secondary to arterial wall weakening.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aneurysm","conceptCode":"C26693","definition":"Bulging or ballooning in an area of an artery secondary to arterial wall weakening.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9652-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9668-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Antiphospholipid Syndrome","valueDescription":"antiphospholipid syndrome","ValueMeaning":{"publicId":"2579893","version":"1","preferredName":"antiphospholipid syndrome","longName":"2579893","preferredDefinition":" A syndrome associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses, marked by the presence of antibodies directed against phospholipids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiphospholipid Syndrome","conceptCode":"C61283","definition":"A disorder caused by the presence of autoantibodies directed against phospholipids, causing a hypercoaguable state, which may result in blood clots, stroke, heart attack, and in women, significant pregnancy-related complications, including miscarriage and still birth. The syndrome is often associated with other autoimmune disorders, most commonly lupus erythematosus, and infections, including syphilis and Lyme disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0522-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"CURTIST","dateModified":"2011-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9672-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Aplastic Anemia","valueDescription":"Aplastic Anemia","ValueMeaning":{"publicId":"2593270","version":"1","preferredName":"Aplastic Anemia","longName":"2593270","preferredDefinition":"A condition in which the bone marrow is unable to produce blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aplastic Anemia","conceptCode":"C2870","definition":"Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2880D74E-659D-0A0D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9684-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Arrhythmia","valueDescription":"Arrhythmia","ValueMeaning":{"publicId":"2573555","version":"1","preferredName":"Arrhythmia","longName":"2573555","preferredDefinition":"Arrhythmia; an abnormal rate of muscle contractions in the heart.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arrhythmia","conceptCode":"C2881","definition":"Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC60-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"REEVESD","dateModified":"2006-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-968E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Asbestos-Related Lung Disorder","valueDescription":"Asbestos-Related Lung Disorder","ValueMeaning":{"publicId":"3210734","version":"1","preferredName":"Asbestos-Related Lung Disorder","longName":"3210734","preferredDefinition":"A disorder affecting the lungs due to asbestos exposure. Examples include asbestosis and lung carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asbestos-Related Lung Disorder","conceptCode":"C84472","definition":"A disorder affecting the lungs due to asbestos exposure. Examples include asbestosis and lung carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-969A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-96B0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Asthma","valueDescription":"Asthma","ValueMeaning":{"publicId":"2975594","version":"1","preferredName":"Asthma","longName":"2975594","preferredDefinition":"A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asthma","conceptCode":"C28397","definition":"A chronic respiratory disease manifested as difficulty breathing due to the narrowing of bronchial passageways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C08420A-B206-2A47-E040-BB89AD433D97","latestVersionIndicator":"Yes","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-96BA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Atherosclerosis","valueDescription":"Atherosclerosis","ValueMeaning":{"publicId":"3210735","version":"1","preferredName":"Atherosclerosis","longName":"3210735","preferredDefinition":"Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atherosclerosis","conceptCode":"C35768","definition":"Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-96C6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-96DC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Atrial Fibrillation","valueDescription":"Atrial Fibrillation: C50466","ValueMeaning":{"publicId":"2580236","version":"1","preferredName":"Atrial Fibrillation: C50466","longName":"2580236","preferredDefinition":"A supraventricular arrhythmia characterized by uncoordinated atrial myocardium activation due to multiple reentry circuits with consequent deterioration of atrial mechanical function. Instead of intermittently contracting, the atria quiver continuously in a chaotic pattern, causing a totally irregular, often tachycardia ventricular rate. On the ECG it is described by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape, and timing, associated with an irregular, frequently rapid ventricular response when atrioventricular conduction is intact.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atrial Fibrillation","conceptCode":"C50466","definition":"A disorder characterized by an electrocardiographic finding of a supraventricular arrhythmia characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape and timing and are accompanied by an irregular ventricular response. (CDISC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0679-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-07-13","modifiedBy":"ONEDATA","dateModified":"2006-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-96E6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Atrial Septal Defect","valueDescription":"Atrial Septal Defect","ValueMeaning":{"publicId":"3210736","version":"1","preferredName":"Atrial Septal Defect","longName":"3210736","preferredDefinition":"A congenital disorder characterized by the presence of a defect (opening) in the septum that separates the two atria of the heart. The atrial septal opening that is present in the fetus and  normally closes within weeks or months after birth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atrial Septal Defect","conceptCode":"C84473","definition":"The presence of a defect (opening) in the septum that separates the two atria of the heart. It can be congenital or acquired.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-96F2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9708-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bronchiectasis","valueDescription":"Bronchiectasis","ValueMeaning":{"publicId":"3210737","version":"1","preferredName":"Bronchiectasis","longName":"3210737","preferredDefinition":"Segmental, irreversible dilation of the bronchial tree resulting in the accumulation of secretions which leads to obstruction. The most common cause is bacterial infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bronchiectasis","conceptCode":"C84475","definition":"Segmental, irreversible dilation of the bronchial tree resulting in the accumulation of secretions which leads to obstruction. The most common cause is bacterial infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9714-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-972A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bronchitis","valueDescription":"Bronchitis","ValueMeaning":{"publicId":"2944459","version":"1","preferredName":"Bronchitis","longName":"2944459","preferredDefinition":"An acute or chronic inflammatory process affecting the bronchi.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bronchitis","conceptCode":"C2911","definition":"An acute or chronic inflammatory process affecting the bronchi.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74331C4B-D5AB-D41C-E040-BB89AD435AA5","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9734-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cardiac Arrest","valueDescription":"Cardiac Arrest","ValueMeaning":{"publicId":"2944038","version":"1","preferredName":"Cardiac Arrest","longName":"2944038","preferredDefinition":"Sudden cessation of the pumping function of the heart, with disappearance of arterial blood pressure, connoting either ventricular fibrillation or ventricular standstill.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cardiac Arrest","conceptCode":"C50479","definition":"The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Cardiac arrest may be reversed by CPR, and/or defibrillation, cardioversion or cardiac pacing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742DD56B-145B-A7E6-E040-BB89AD43063D","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9746-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cardiogenic Shock","valueDescription":"Cardiogenic Shock","ValueMeaning":{"publicId":"3210738","version":"1","preferredName":"Cardiogenic Shock","longName":"3210738","preferredDefinition":"Shock resulting from primary failure of the heart in its pumping function, as in myocardial infarction, severe cardiomyopathy, or mechanical obstruction or compression of the heart.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cardiogenic Shock","conceptCode":"C50482","definition":"Shock resulting from primary failure of the heart in its pumping function, as in myocardial infarction, severe cardiomyopathy, or mechanical obstruction or compression of the heart.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9752-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9768-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cardiomyopathy","valueDescription":"Cardiomyopathy","ValueMeaning":{"publicId":"2585212","version":"1","preferredName":"Cardiomyopathy","longName":"2585212","preferredDefinition":"A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cardiomyopathy","conceptCode":"C34830","definition":"A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2687D788-9B74-74B4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-01-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9772-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Carotid Artery Disorder","valueDescription":"Carotid Artery Disorder","ValueMeaning":{"publicId":"3210739","version":"1","preferredName":"Carotid Artery Disorder","longName":"3210739","preferredDefinition":"A non-neoplastic or neoplastic disorder affecting the carotid artery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carotid Artery Disorder","conceptCode":"C84476","definition":"A non-neoplastic or neoplastic disorder affecting the carotid artery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-977E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9794-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chronic Obstructive Pulmonary Disease","valueDescription":"Chronic Obstructive Airways Disease","ValueMeaning":{"publicId":"2573574","version":"1","preferredName":"Chronic Obstructive Airways Disease","longName":"2573574","preferredDefinition":"A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Obstructive Pulmonary Disease","conceptCode":"C3199","definition":"A chronic and progressive lung disorder characterized by the loss of elasticity of the bronchial tree and the air sacs, destruction of the air sacs wall, thickening of the bronchial wall, and mucous accumulation in the bronchial tree. The pathologic changes result in the disruption of the air flow in the bronchial airways. Signs and symptoms include shortness of breath, wheezing, productive cough, and chest tightness. The two main types of chronic obstructive pulmonary disease are chronic obstructive bronchitis and emphysema.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC73-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CZECHS","dateModified":"2008-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-97A6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Congenital Coronary Artery Abnormality","valueDescription":"Congenital Coronary Artery Abnormality","ValueMeaning":{"publicId":"3210740","version":"1","preferredName":"Congenital Coronary Artery Abnormality","longName":"3210740","preferredDefinition":"A congenital condition referring to defects of the course and structure of the coronary arteries.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Coronary Artery Abnormality","conceptCode":"C84477","definition":"A congenital condition referring to defects of the course and structure of the coronary arteries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-97B2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-97C8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Congenital Septal Defect","valueDescription":"Congenital Septal Defect","ValueMeaning":{"publicId":"3210741","version":"1","preferredName":"Congenital Septal Defect","longName":"3210741","preferredDefinition":"A congenital disorder characterized by the presence of an abnormal communication between the atria or the ventricles of the heart due to defects in the cardiac septum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Septal Defect","conceptCode":"C84482","definition":"A congenital disorder characterized by the presence of an abnormal communication between the atria or the ventricles of the heart due to defects in the cardiac septum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-97D4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-97EA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Coronary Artery Disease","valueDescription":"Coronary Disease","ValueMeaning":{"publicId":"2760269","version":"1","preferredName":"Coronary Disease","longName":"2760269","preferredDefinition":"An imbalance between myocardial functional requirements and the capacity of the coronary vessels to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coronary Artery Disease","conceptCode":"C26732","definition":"Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FF5CBC6-3CA7-1060-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-97F4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Coronary Microvascular Disease","valueDescription":"Coronary Microvascular Disease","ValueMeaning":{"publicId":"3210742","version":"1","preferredName":"Coronary Microvascular Disease","longName":"3210742","preferredDefinition":"A disorder affecting the smallest coronary arteries. Causes include atherosclerosis and arterial spasm. Chest pain is a frequently observed symptom.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coronary Microvascular Disease","conceptCode":"C84478","definition":"A disorder affecting the smallest coronary arteries. Causes include atherosclerosis and arterial spasm. Chest pain is a frequently observed symptom.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9800-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9816-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cough","valueDescription":"Cough","ValueMeaning":{"publicId":"2562655","version":"1","preferredName":"Cough","longName":"2562655","preferredDefinition":"A sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs, and usually accompanied by a distinctive sound.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cough","conceptCode":"C37935","definition":"A sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs, and usually accompanied by a distinctive sound.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C1CC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9820-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cystic Fibrosis","valueDescription":"Cystic Fibrosis","ValueMeaning":{"publicId":"3210743","version":"1","preferredName":"Cystic Fibrosis","longName":"3210743","preferredDefinition":"A congenital metabolic disorder affecting the exocrine glands, inherited as an autosomal trait. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production which causes obstruction of passageways (including pancreatic and bile ducts, intestines, and bronchi). The sweat sodium and chloride content are increased. Symptoms usually appear in childhood and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cystic Fibrosis","conceptCode":"C2975","definition":"A congenital, autosomal, metabolic disorder affecting the exocrine glands. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production that causes obstruction of passageways, including pancreatic and bile ducts, intestines, and bronchi. Symptoms usually appear in childhood, and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather secondary to increased sodium and chloride concentration in sweat.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-982C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9842-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Deep Vein Thrombosis","valueDescription":"Deep Vein Thrombosis","ValueMeaning":{"publicId":"3156055","version":"1","preferredName":"Deep Vein Thrombosis","longName":"3156055","preferredDefinition":"A blood clot (thrombus) in a deep vein in the thigh or leg.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deep Vein Thrombosis","conceptCode":"C49343","definition":"A blood clot in a deep vein, predominantly in the lower extremity, but may include the pelvis or upper extremity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"943EB81A-F2FF-AEDF-E040-BB89AD431BBC","latestVersionIndicator":"Yes","beginDate":"2010-11-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9854-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Endocarditis","valueDescription":"Endocarditis","ValueMeaning":{"publicId":"3210744","version":"1","preferredName":"Endocarditis","longName":"3210744","preferredDefinition":"Inflammation of the endocardium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endocarditis","conceptCode":"C34582","definition":"Inflammation of the endocardium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9860-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9876-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Excessive Blood Clotting","valueDescription":"Excessive Blood Clotting","ValueMeaning":{"publicId":"3210745","version":"1","preferredName":"Excessive Blood Clotting","longName":"3210745","preferredDefinition":"A condition characterized by an abnormally high level of thrombi. Causes include thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, bone marrow disorders, and antiphospholipid antibody syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thrombophilia","conceptCode":"C84479","definition":"A condition characterized by an abnormally high level of thrombi. Causes include thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, bone marrow disorders, and antiphospholipid antibody syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9882-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9898-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fanconi Anemia","valueDescription":"Fanconi anemia","ValueMeaning":{"publicId":"2579909","version":"1","preferredName":"Fanconi anemia","longName":"2579909","preferredDefinition":"A rare and often fatal inherited disease in which the bone marrow fails to produce red blood cells, white blood cells, platelets, or a combination of these cells. The disease may transform into myelodysplastic syndrome or leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fanconi Anemia","conceptCode":"C62505","definition":"An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0532-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-98A2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Heart Block","valueDescription":"Heart Block","ValueMeaning":{"publicId":"3210746","version":"1","preferredName":"Heart Block","longName":"3210746","preferredDefinition":"An impairment of transmission of the cardiac electrical impulse along the fibers normally responsible impulse propagation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heart Block by ECG Finding","conceptCode":"C34665","definition":"An electrocardiographic finding of blocked cardiac electrical impulses along the fibers normally responsible for impulse conduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-98AE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-98C4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Heart Failure","valueDescription":"Heart Failure","ValueMeaning":{"publicId":"2718360","version":"1","preferredName":"Heart Failure","longName":"2718360","preferredDefinition":"Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements or the ability to do so only at an elevated filling pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heart Failure","conceptCode":"C50577","definition":"Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements. Clinical symptoms of heart failure include: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42D5D049-038F-6FD0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-98CE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Heart Murmur","valueDescription":"Heart Murmur","ValueMeaning":{"publicId":"3210747","version":"1","preferredName":"Heart Murmur","longName":"3210747","preferredDefinition":"A periodic humming or blowing sound heard on auscultation of the heart that can indicate the presence of cardiac disease; murmurs are the result of vibrations caused by the turbulent flow of blood in the heart or great vessels. Murmurs are characterized according to the area of generation (mitral, aortic, tricuspid, or pulmonary) and according to the period of the cycle (systolic or diastolic).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heart Murmur","conceptCode":"C84480","definition":"A periodic humming or blowing sound heard on auscultation of the heart that can indicate the presence of cardiac disease; murmurs are the result of vibrations caused by the turbulent flow of blood in the heart or great vessels. Murmurs are characterized according to the area of generation (mitral, aortic, tricuspid, or pulmonary) and according to the period of the cycle (systolic or diastolic).","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-98DA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-98F0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemochromatosis","valueDescription":"Hemochromatosis","ValueMeaning":{"publicId":"3171844","version":"1","preferredName":"Hemochromatosis","longName":"3171844","preferredDefinition":"An inherited metabolic disorder characterized by iron accumulation in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Hemochromatosis","conceptCode":"C84481","definition":"An inherited metabolic disorder characterized by iron accumulation in the tissues.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DDA7EA-0192-07E7-E040-BB89AD4351C6","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"WHITES","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-98FA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemolytic Anemia","valueDescription":"Hemolytic Anemia","ValueMeaning":{"publicId":"2579904","version":"1","preferredName":"Hemolytic Anemia","longName":"2579904","preferredDefinition":"Anemia resulting from the premature destruction of the peripheral blood red cells. It may be congenital or it may be caused by infections, medications, or malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemolytic Anemia","conceptCode":"C34376","definition":"Anemia resulting from the premature destruction of the peripheral blood red cells. It may be congenital or it may be caused by infections, medications, or malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-052D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9904-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemophilia","valueDescription":"Hemophilia","ValueMeaning":{"publicId":"2580124","version":"1","preferredName":"Hemophilia","longName":"2580124","preferredDefinition":"Group of hereditary disorders in which affected individuals fail to make enough of certain proteins needed to form blood clots.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemophilia","conceptCode":"C3093","definition":"A deficiency or abnormality of a blood coagulation factor characterized by the tendency to hemorrhage. Hemophilia is typically a hereditary disorder but, rarely, may be acquired. Inherited coagulation factor-deficient hemophilias include hemophilia A or classic hemophilia (hereditary factor VIII deficiency) hemophilia B or Christmas disease (hereditary factor IX deficiency), and hemophilia C (hereditary factor XI deficiency). Factor VIII inhibitors may occur spontaneously as autoantibodies, resulting in acquired hemophilia known as acquired factor VIII deficiency. Approximately 10% of patients with acquired hemophilia have an underlying malignancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0609-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-04-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-04-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-990E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hypercholesterolemia","valueDescription":"Hypercholesterolemia","ValueMeaning":{"publicId":"2751387","version":"1","preferredName":"Hypercholesterolemia","longName":"2751387","preferredDefinition":"Hypercholesterolemia; the presence of an abnormal amount of cholesterol in the cells and plasma of the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypercholesterolemia","conceptCode":"C37967","definition":"A laboratory test result indicating an increased amount of cholesterol in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DC907AE-08A4-716C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-05-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9918-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hypertension","valueDescription":"Hypertension","ValueMeaning":{"publicId":"2558888","version":"1","preferredName":"Hypertension","longName":"2558888","preferredDefinition":"Pathological increase in blood pressure; a repeatedly elevated blood pressure exceeding 140 over 90 mmHg.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypertension","conceptCode":"C3117","definition":"Blood pressure that is abnormally high.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B315-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9922-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hypotension","valueDescription":"Hypotension","ValueMeaning":{"publicId":"2562556","version":"1","preferredName":"Hypotension","longName":"2562556","preferredDefinition":"Abnormally low blood pressure seen in shock but not necessarily indicative of it. (Dorland, 28th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypotension","conceptCode":"C3128","definition":"Blood pressure that is abnormally low.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C169-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-04","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-10-04","modifiedBy":"ZHANGW","dateModified":"2008-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-992C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Idiopathic Pulmonary Fibrosis","valueDescription":"Idiopathic Pulmonary Fibrosis","ValueMeaning":{"publicId":"3210748","version":"1","preferredName":"Idiopathic Pulmonary Fibrosis","longName":"3210748","preferredDefinition":"Chronic and progressive fibrosis of the lung parenchyma of unknown cause.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idiopathic Pulmonary Fibrosis","conceptCode":"C35716","definition":"Chronic and progressive fibrosis of the lung parenchyma of unknown cause.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9938-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-994E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Idiopathic Thrombocytopenic Purpura","valueDescription":"Idiopathic Thrombocytopenic Purpura","ValueMeaning":{"publicId":"2579903","version":"1","preferredName":"Idiopathic Thrombocytopenic Purpura","longName":"2579903","preferredDefinition":"Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Immune Thrombocytopenia","conceptCode":"C3446","definition":"Acquired thrombocytopenia of unknown cause, characterized by immune-mediated destruction of normal platelets. It affects both children and adults. It manifests with petechiae, purpura, and overt bleeding. Based upon the duration of the disease, it is classified as newly diagnosed (from diagnosis until 3 months), persistent (3-12 months), and chronic (lasting for more than 12 months).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-052C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9958-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Insomnia","valueDescription":"Insomnia","ValueMeaning":{"publicId":"2563609","version":"1","preferredName":"Insomnia","longName":"2563609","preferredDefinition":"A sleep disorder characterized by difficulty in falling asleep and/or remaining asleep.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insomnia","conceptCode":"C28286","definition":"A sleep disorder characterized by difficulty in falling asleep and/or remaining asleep.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C586-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9962-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Iron-Deficiency Anemia","valueDescription":"Iron-Deficiency Anemia","ValueMeaning":{"publicId":"3210749","version":"1","preferredName":"Iron-Deficiency Anemia","longName":"3210749","preferredDefinition":"Anemia caused by low iron intake, inefficient iron absorption in the gastrointestinal tract, or chronic blood loss.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iron-Deficiency Anemia","conceptCode":"C84484","definition":"Anemia caused by low iron intake, inefficient iron absorption in the gastrointestinal tract, or chronic blood loss.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-996E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9984-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Kawasaki Disease","valueDescription":"Kawasaki Disease","ValueMeaning":{"publicId":"3210750","version":"1","preferredName":"Kawasaki Disease","longName":"3210750","preferredDefinition":"A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kawasaki Disease","conceptCode":"C34825","definition":"A vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9990-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-99A6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Central Nervous System Cavernous Hemangioma","valueDescription":"Central Nervous System Cavernous Hemangioma","ValueMeaning":{"publicId":"3210940","version":"1","preferredName":"Central Nervous System Cavernous Hemangioma","longName":"3210940","preferredDefinition":"A cavernous hemangioma arising from the central nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Cavernous Hemangioma","conceptCode":"C84621","definition":"A cavernous hemangioma arising from the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B76C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B782-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Central Nervous System Vasculitis","valueDescription":"Central Nervous System Vasculitis","ValueMeaning":{"publicId":"3210941","version":"1","preferredName":"Central Nervous System Vasculitis","longName":"3210941","preferredDefinition":"Vasculitis affecting the blood vessels of the brain and/or spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Vasculitis","conceptCode":"C84622","definition":"Vasculitis affecting the blood vessels of the brain and/or spinal cord.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B78E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B7A4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Central Pontine Myelinolysis","valueDescription":"Central Pontine Myelinolysis","ValueMeaning":{"publicId":"3210942","version":"1","preferredName":"Central Pontine Myelinolysis","longName":"3210942","preferredDefinition":"A central nervous system disorder caused by demyelination within the central basis pontis of the brain. It is characterized by spastic quadriplegia, pseudobulbar palsy and encephalopathy. It is observed in patients with severe hyponatremia, particularly when the hyponatremia is corrected too rapidly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Pontine Myelinolysis","conceptCode":"C84623","definition":"A central nervous system disorder caused by demyelination within the central basis pontis of the brain. It is characterized by spastic quadriplegia, pseudobulbar palsy and encephalopathy. It is observed in patients with severe hyponatremia, particularly when the hyponatremia is corrected too rapidly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B7B0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B7C6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cerebellar Degeneration","valueDescription":"Cerebellar Degeneration","ValueMeaning":{"publicId":"3210943","version":"1","preferredName":"Cerebellar Degeneration","longName":"3210943","preferredDefinition":"Degeneration of the cerebellum. It may be an inherited condition, a paraneoplastic syndrome, or secondary to autoimmune disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerebellar Degeneration","conceptCode":"C84624","definition":"Degeneration of the cerebellum. It may be an inherited condition, a paraneoplastic syndrome, or secondary to autoimmune disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B7D2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B7E8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cerebral Amyloid Angiopathy","valueDescription":"Cerebral Amyloid Angiopathy","ValueMeaning":{"publicId":"3210944","version":"1","preferredName":"Cerebral Amyloid Angiopathy","longName":"3210944","preferredDefinition":"A disorder characterized by the deposition of amyloid in the wall of the vessels in the brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerebral Amyloid Angiopathy","conceptCode":"C84625","definition":"A disorder characterized by the deposition of amyloid in the wall of the vessels in the brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B7F4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B80A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cerebral Cavernous Malformation","valueDescription":"Cerebral Cavernous Malformation","ValueMeaning":{"publicId":"3210945","version":"1","preferredName":"Cerebral Cavernous Malformation","longName":"3210945","preferredDefinition":"A disorder characterized by malformations in the structure of the capillaries in the brain. It is caused by mutations in the CCM2, KRIT1 and PDCD10 genes. The capillaries fill with blood and stretch, thereby creating cavernous spaces. Some patients experience headaches, seizures, or visual and hearing disturbances. Cerebral hemorrhage may also occur.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerebral Cavernous Malformation","conceptCode":"C84626","definition":"A disorder characterized by malformations in the structure of the capillaries in the brain. It is caused by mutations in the CCM2, KRIT1 and PDCD10 genes. The capillaries fill with blood and stretch, thereby creating cavernous spaces. Some patients experience headaches, seizures, or visual and hearing disturbances. Cerebral hemorrhage may also occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B816-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B82C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cerebrospinal Fluid Otorrhea","valueDescription":"Cerebrospinal Fluid Otorrhea","ValueMeaning":{"publicId":"3210946","version":"1","preferredName":"Cerebrospinal Fluid Otorrhea","longName":"3210946","preferredDefinition":"Discharge of cerebrospinal fluid through the ear structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerebrospinal Fluid Otorrhea","conceptCode":"C34461","definition":"Discharge of cerebrospinal fluid through the ear structures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B838-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B84E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cerebrospinal Fluid Rhinorrhea","valueDescription":"Cerebrospinal Fluid Rhinorrhea","ValueMeaning":{"publicId":"3210947","version":"1","preferredName":"Cerebrospinal Fluid Rhinorrhea","longName":"3210947","preferredDefinition":"Discharge of cerebrospinal fluid through the nose.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerebrospinal Fluid Rhinorrhea","conceptCode":"C84627","definition":"Discharge of cerebrospinal fluid through the nose.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B85A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B870-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cerebrotendinous Xanthomatosis","valueDescription":"Cerebrotendinous Xanthomatosis","ValueMeaning":{"publicId":"3210948","version":"1","preferredName":"Cerebrotendinous Xanthomatosis","longName":"3210948","preferredDefinition":"A rare inherited lipid-storage disorder caused by defects in the CYP27A1 gene. It is characterized by progressive neurologic dysfunction, premature atherosclerosis and development of cataracts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerebrotendinous Xanthomatosis","conceptCode":"C84628","definition":"A rare inherited lipid-storage disorder caused by defects in the CYP27A1 gene. It is characterized by progressive neurologic dysfunction, premature atherosclerosis and development of cataracts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B87C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B892-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cervical Symmetrical Lipomatosis","valueDescription":"Cervical Symmetrical Lipomatosis","ValueMeaning":{"publicId":"3210949","version":"1","preferredName":"Cervical Symmetrical Lipomatosis","longName":"3210949","preferredDefinition":"A neoplastic process characterized by a symmetric poorly circumscribed overgrowth of adipose tissue in the neck.  It predominantly affects middle age men of Mediterranean origin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Symmetrical Lipomatosis","conceptCode":"C4392","definition":"A neoplastic process characterized by a symmetric poorly circumscribed overgrowth of adipose tissue in the neck.  It predominantly affects middle age men of Mediterranean origin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B89E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B8B4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cervicocranial Syndrome","valueDescription":"Cervicocranial Syndrome","ValueMeaning":{"publicId":"3210950","version":"1","preferredName":"Cervicocranial Syndrome","longName":"3210950","preferredDefinition":"A neurologic syndrome following injury of the spinal sympathetic nerves of the neck. The injury usually results from arthritis or pinching by the adjacent vertebrae. Symptoms include facial pain, chronic allergies, dizziness, neck pain, ear pain and vertigo.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervicocranial Syndrome","conceptCode":"C34411","definition":"A neurologic syndrome following injury of the spinal sympathetic nerves of the neck. The injury usually results from arthritis or pinching by the adjacent vertebrae. Symptoms include facial pain, chronic allergies, dizziness, neck pain, ear pain and vertigo.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B8C0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B8D6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chagas Disease","valueDescription":"Chagas Disease","ValueMeaning":{"publicId":"3210951","version":"1","preferredName":"Chagas Disease","longName":"3210951","preferredDefinition":"A parasitic infection caused by Trypanosoma cruzi. It is transmitted by insect bites. It is characterized by an acute and chronic phase; in the acute phase patients may have fever, malaise, and swelling at the site of the insect bite. In the chronic phase patients develop hepatosplenomegaly, lymphadenopathy, cardiomyopathy and arrhythmias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chagas Disease","conceptCode":"C84629","definition":"A parasitic infection caused by Trypanosoma cruzi. It is transmitted by insect bites. It is characterized by an acute and chronic phase; in the acute phase patients may have fever, malaise, and swelling at the site of the insect bite. In the chronic phase patients develop hepatosplenomegaly, lymphadenopathy, cardiomyopathy and arrhythmias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B8E2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B8F8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Charcot-Marie-Tooth Disease","valueDescription":"Charcot-Marie-Tooth Disease","ValueMeaning":{"publicId":"3210952","version":"1","preferredName":"Charcot-Marie-Tooth Disease","longName":"3210952","preferredDefinition":"An inherited degenerative disorder involving the peripheral nerves.  It is caused by mutations in the genes that are responsible for the production of proteins necessary for the function and structure of the peripheral nerves.  It is characterized by muscle atrophy and weakness in the feet, legs, hands, and arms and loss of sensation in the limbs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Charcot-Marie-Tooth Disease","conceptCode":"C75467","definition":"An inherited degenerative disorder involving the peripheral nerves. It is caused by mutations in the genes that are responsible for the production of proteins necessary for the function and structure of the peripheral nerves. It is characterized by muscle atrophy and weakness in the feet, legs, hands, and arms and loss of sensation in the limbs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B904-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B91A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chediak-Higashi Syndrome","valueDescription":"Chediak-Higashi syndrome","ValueMeaning":{"publicId":"2579849","version":"1","preferredName":"Chediak-Higashi syndrome","longName":"2579849","preferredDefinition":"A rare autosomal recessive immunodeficiency disorder characterized by abnormal intracellular protein transport. Chediak-Higashi syndrome (CHS) is characterized by immune deficiency; partial oculocutaneous albinism; a bleeding disorder due to deficient platelet dense bodies; neutropenia; neutrophils with impaired chemotaxis and bactericidal activity; recurrent infection; and abnormal natural killer (NK) cell function. CHS may be associated with hepatosplenomegaly, lymphadenopathy, anemia, thrombocytopenia, roentgenologic changes in bones, lungs and heart, and skin and psychomotor abnormalities; it is often fatal in childhood as a result of infection or an accelerated lymphoma-like phase. CHS occurs in mink, cattle, and mice, as well as man.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chediak-Higashi Syndrome","conceptCode":"C2941","definition":"A rare autosomal recessive immunodeficiency disorder characterized by abnormal intracellular protein transport. Chediak-Higashi syndrome (CHS) is characterized by immune deficiency; partial oculocutaneous albinism; a bleeding disorder due to deficient platelet dense bodies; neutropenia; neutrophils with impaired chemotaxis and bactericidal activity; recurrent infection; and abnormal natural killer (NK) cell function. CHS may be associated with hepatosplenomegaly, lymphadenopathy, anemia, thrombocytopenia, roentgenologic changes in bones, lungs and heart, and skin and psychomotor abnormalities; it is often fatal in childhood as a result of infection or an accelerated lymphoma-like phase. CHS occurs in mink, cattle, and mice, as well as man.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04F6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B924-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cherubism","valueDescription":"Cherubism","ValueMeaning":{"publicId":"3210953","version":"1","preferredName":"Cherubism","longName":"3210953","preferredDefinition":"A rare disorder usually caused by mutations in the SH3BP2 gene. It is characterized by prominence of the lower part of the face due to bilateral replacement of the mandible or maxilla bones by excessive fibrous tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cherubism","conceptCode":"C84630","definition":"A rare autosomal dominant inherited disorder usually caused by mutations in the SH3BP2 gene. It is characterized by a prominent lower part of the face due to bilateral replacement of the mandibular or maxillary bones by lesions. The lesions contain osteoclast-like cells admixed with spindle-shaped mononuclear stromal cells.  With time, the lesions become more fibrotic and less osteoclast-rich.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B930-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B946-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chilblains","valueDescription":"Chilblains","ValueMeaning":{"publicId":"3210954","version":"1","preferredName":"Chilblains","longName":"3210954","preferredDefinition":"A rare condition characterized by skin inflammation, blister formation, swelling and ulcerations in the extremities. It occurs in persons exposed to cold temperatures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chilblains","conceptCode":"C84631","definition":"A rare condition characterized by skin inflammation, blister formation, swelling and ulcerations in the extremities. It occurs in persons exposed to cold temperatures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B952-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B968-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Childhood Schizophrenia","valueDescription":"Childhood Schizophrenia","ValueMeaning":{"publicId":"3210955","version":"1","preferredName":"Childhood Schizophrenia","longName":"3210955","preferredDefinition":"Schizophrenia occurring in childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Schizophrenia","conceptCode":"C35004","definition":"Schizophrenia occurring in childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B974-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B98A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chlamydia Psittaci Infection","valueDescription":"Chlamydia Psittaci Infection","ValueMeaning":{"publicId":"3210956","version":"1","preferredName":"Chlamydia Psittaci Infection","longName":"3210956","preferredDefinition":"A bacterial infection caused by Chlamydia psittaci. Humans are infected by handling sick birds. The Chlamydia cause respiratory infection manifested with fever, malaise, cough, dyspnea, sore throat, photophobia and headaches.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlamydophila psittaci Infection","conceptCode":"C44959","definition":"A bacterial infection caused by Chlamydophila psittaci. Humans are infected by handling sick birds. The Chlamydiae cause respiratory infection manifests with fever, malaise, cough, dyspnea, sore throat, photophobia and headaches.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B996-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B9AC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pseudotumor Cerebri","valueDescription":"Pseudotumor Cerebri","ValueMeaning":{"publicId":"3211399","version":"1","preferredName":"Pseudotumor Cerebri","longName":"3211399","preferredDefinition":"An idiopathic disorder characterized by chronic increase in the intracranial pressure. It occurs predominantly in obese females of childbearing age. It is associated with papilledema.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pseudotumor Cerebri","conceptCode":"C85035","definition":"An idiopathic disorder characterized by chronic increase in the intracranial pressure. It occurs predominantly in obese females of childbearing age. It is associated with papilledema.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F865-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F87B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pseudoxanthoma Elasticum","valueDescription":"Pseudoxanthoma Elasticum","ValueMeaning":{"publicId":"3211400","version":"1","preferredName":"Pseudoxanthoma Elasticum","longName":"3211400","preferredDefinition":"A rare, progressive, autosomal recessive inherited disorder caused by mutations in the ABCC6 gene. It is characterized by calcification and fragmentation of the elastic fibers of the skin, retina, and cardiovascular system. Signs and symptoms include skin plaques and bumps, thickened skin, retinal hemorrhage and obstruction of the blood vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pseudoxanthoma Elasticum","conceptCode":"C85036","definition":"A rare, progressive, autosomal recessive inherited disorder caused by mutations in the ABCC6 gene. It is characterized by calcification and fragmentation of the elastic fibers of the skin, retina, and cardiovascular system. Signs and symptoms include skin plaques and bumps, thickened skin, retinal hemorrhage and obstruction of the blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F887-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F89D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pulmonary Alveolar Proteinosis","valueDescription":"Pulmonary Alveolar Proteinosis","ValueMeaning":{"publicId":"3211401","version":"1","preferredName":"Pulmonary Alveolar Proteinosis","longName":"3211401","preferredDefinition":"A rare lung disorder characterized by the filling of the pulmonary alveoli with proteinaceous material which stains positive with periodic acid-Schiff stain. It may be idiopathic or secondary due to hematologic malignancies or the inhalation of mineral dusts. Signs and symptoms include dyspnea, cough and low grade fever.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Alveolar Proteinosis","conceptCode":"C85037","definition":"A rare lung disorder characterized by the filling of the pulmonary alveoli with proteinaceous material which stains positive with periodic acid-Schiff stain. It may be idiopathic or secondary due to hematologic malignancies or the inhalation of mineral dusts. Signs and symptoms include dyspnea, cough and low grade fever.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F8A9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F8BF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pulmonary Blastoma","valueDescription":"Pulmonary Blastoma","ValueMeaning":{"publicId":"3211402","version":"1","preferredName":"Pulmonary Blastoma","longName":"3211402","preferredDefinition":"A malignant neoplasm of the lung composed of tubular structures and immature mesenchymal elements, which may differentiate towards skeletal and smooth muscle, cartilage or a combination of muscle and cartilage.  This is a nodular tumor found in the periphery of the lung.  It can occur at any age.  The prognosis is related to the stage of the disease at the time of resection.  Pulmonary blastoma is divided into two subtypes: epithelial predominant and biphasic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Blastoma","conceptCode":"C3732","definition":"A biphasic tumor that consists of fetal adenocarcinoma (typically low-grade) and primitive mesenchymal stroma. Foci of specific mesenchymal differentiation (osteosarcoma, chondrosarcoma, or rhabdomyosarcoma) may also be present, but are not required for the diagnosis. Most patients are smokers.  The prognosis is very poor. (WHO 2015)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F8CB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F8E1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pulmonary Sarcoidosis","valueDescription":"Pulmonary Sarcoidosis","ValueMeaning":{"publicId":"3211403","version":"1","preferredName":"Pulmonary Sarcoidosis","longName":"3211403","preferredDefinition":"Sarcoidosis affecting the lung parenchyma. It is characterized by the presence of non-necrotizing granulomas in the lung tissues. It is manifested with dyspnea, cough, fever, night sweats, fatigue, and weight loss.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Sarcoidosis","conceptCode":"C34997","definition":"Sarcoidosis affecting the lung parenchyma. It is characterized by the presence of non-necrotizing granulomas in the lung tissues. It is manifested with dyspnea, cough, fever, night sweats, fatigue, and weight loss.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F8ED-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F903-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pulmonary Veno-Occlusive Disease","valueDescription":"Pulmonary Veno-Occlusive Disease","ValueMeaning":{"publicId":"3211404","version":"1","preferredName":"Pulmonary Veno-Occlusive Disease","longName":"3211404","preferredDefinition":"A disorder characterized by pulmonary venous constriction or occlusion, resulting in pulmonary hypertension.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Veno-Occlusive Disease","conceptCode":"C85039","definition":"A disorder characterized by pulmonary venous constriction or occlusion, resulting in pulmonary hypertension.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F90F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F925-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pyruvate Carboxylase Deficiency","valueDescription":"Pyruvate Carboxylase Deficiency","ValueMeaning":{"publicId":"3211405","version":"1","preferredName":"Pyruvate Carboxylase Deficiency","longName":"3211405","preferredDefinition":"A rare autosomal recessive inherited metabolic disorder caused by mutations in the PC gene. It results in the accumulation of lactic acid and other toxic substances in the blood. Signs and symptoms appear early in life and include failure to thrive, mental and growth retardation, motor disturbances, seizures, and lactic acidosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pyruvate Carboxylase Deficiency","conceptCode":"C85040","definition":"A rare autosomal recessive inherited metabolic disorder caused by mutations in the PC gene. It results in the accumulation of lactic acid and other toxic substances in the blood. Signs and symptoms appear early in life and include failure to thrive, mental and growth retardation, motor disturbances, seizures, and lactic acidosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F931-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F947-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Q Fever","valueDescription":"Q Fever","ValueMeaning":{"publicId":"3211406","version":"1","preferredName":"Q Fever","longName":"3211406","preferredDefinition":"A bacterial infection caused by Coxiella burnetii. It is transmitted to humans by the inhalation of infected air particles or contact with fluids and feces of infected animals. Signs and symptoms include the abrupt onset of fever, headache, myalgias, and weakness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Q Fever","conceptCode":"C34970","definition":"A bacterial infection caused by Coxiella burnetii. It is transmitted to humans by the inhalation of infected air particles or contact with fluids and feces of infected animals. Signs and symptoms include the abrupt onset of fever, headache, myalgias, and weakness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F953-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F969-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Rabies","valueDescription":"Rabies","ValueMeaning":{"publicId":"3211407","version":"1","preferredName":"Rabies","longName":"3211407","preferredDefinition":"A life-threatening viral infection caused by the neurotropic Rabies virus. It is transmitted to humans usually from a bite by an infected dog. The initial signs and symptoms include malaise, fever, and headache, followed by the central nervous system manifestations which include abrupt behavioral changes. Paralysis, lethargy, and coma follow the behavioral changes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rabies","conceptCode":"C28182","definition":"A life-threatening viral infection caused by the neurotropic Rabies virus. It is transmitted to humans usually from a bite by an infected dog. The initial signs and symptoms include malaise, fever, and headache, followed by the central nervous system manifestations which include abrupt behavioral changes. Paralysis, lethargy, and coma follow the behavioral changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F975-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F98B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Reflex Epilepsy","valueDescription":"Reflex Epilepsy","ValueMeaning":{"publicId":"3211408","version":"1","preferredName":"Reflex Epilepsy","longName":"3211408","preferredDefinition":"Epilepsy triggered by an external stimulus or an internal mental process. Photosensitive epilepsy is the most common form of reflex epilepsy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reflex Epilepsy","conceptCode":"C85041","definition":"Epilepsy triggered by an external stimulus or an internal mental process. Photosensitive epilepsy is the most common form of reflex epilepsy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F997-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F9AD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Reflex Sympathetic Dystrophy Syndrome","valueDescription":"Reflex Sympathetic Dystrophy Syndrome","ValueMeaning":{"publicId":"3211409","version":"1","preferredName":"Reflex Sympathetic Dystrophy Syndrome","longName":"3211409","preferredDefinition":"A rare neurologic syndrome characterized by burning pain, tenderness, swelling, and changes in the skin color and temperature of a body part or extremity. It is usually caused by injury or surgery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complex Regional Pain Syndrome I","conceptCode":"C85042","definition":"A neurologic condition characterized by burning pain, tenderness, swelling, and changes in the skin color and temperature of a body part or extremity that has no identifiable nerve injury; most pediatric patients present with this form.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F9B9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F9CF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Refsum Disease","valueDescription":"Refsum Disease","ValueMeaning":{"publicId":"3211410","version":"1","preferredName":"Refsum Disease","longName":"3211410","preferredDefinition":"A rare autosomal recessive disorder characterized by abnormalities in the breakdown of phytanic acid and impaired growth of myelin sheaths. Signs and symptoms include neurologic damage, cerebellar degeneration, and neuropathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refsum Disease","conceptCode":"C85043","definition":"A rare autosomal recessive condition caused by mutation(s) in the PHYH gene, encoding phytanoyl-CoA dioxygenase, peroxisomal. It is characterized by abnormalities in the breakdown of phytanic acid and impaired growth of myelin sheaths. Signs and symptoms include neurologic damage, cerebellar degeneration, and neuropathy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F9DB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-F9F1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Renal Cell Carcinoma","valueDescription":"Renal Cell Carcinoma","ValueMeaning":{"publicId":"2581668","version":"1","preferredName":"Renal Cell Carcinoma","longName":"2581668","preferredDefinition":"Cancer that develops in the lining of the renal tubules, which filter the blood and produce urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Cell Carcinoma","conceptCode":"C9385","definition":"A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C11-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-09","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-09","modifiedBy":"ONEDATA","dateModified":"2006-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FA03-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Renal Tubular Acidosis","valueDescription":"Renal Tubular Acidosis","ValueMeaning":{"publicId":"3211411","version":"1","preferredName":"Renal Tubular Acidosis","longName":"3211411","preferredDefinition":"Failure of the renal tubules of the kidney to excrete urine of normal acidity resulting in metabolic acidosis. It may lead to hypercalcinuria, nephrolithiasis, and renal failure. Causes include autoimmune disorders (e.g., Sjogren syndrome, systemic lupus erythematosus, and rheumatoid arthritis), medications (e.g., non steroidal anti-inflammatory drugs, diuretics, and blood pressure medications), Fanconi syndrome, or it may be familiar.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Tubular Acidosis","conceptCode":"C28129","definition":"The inability of the kidneys to maintain acid-base homeostasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FA0F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FA25-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Renovascular Hypertension","valueDescription":"Renovascular Hypertension","ValueMeaning":{"publicId":"3211412","version":"1","preferredName":"Renovascular Hypertension","longName":"3211412","preferredDefinition":"High blood pressure secondary to renal artery stenosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renovascular Hypertension","conceptCode":"C85044","definition":"High blood pressure secondary to renal artery stenosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FA31-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FA47-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Retinal Neoplasm","valueDescription":"Retinal Neoplasm","ValueMeaning":{"publicId":"3211413","version":"1","preferredName":"Retinal Neoplasm","longName":"3211413","preferredDefinition":"A benign or malignant neoplasm affecting the retina. Representative examples of benign neoplasms include retinocytoma and hemangioma. Representative examples of malignant neoplasms include retinoblastoma, lymphoma and melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinal Neoplasm","conceptCode":"C4800","definition":"A benign or malignant neoplasm affecting the retina. Representative examples of benign neoplasms include retinocytoma and hemangioma. Representative examples of malignant neoplasms include retinoblastoma, lymphoma and melanoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FA53-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FA69-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Retinitis Pigmentosa","valueDescription":"Retinitis Pigmentosa","ValueMeaning":{"publicId":"3211414","version":"1","preferredName":"Retinitis Pigmentosa","longName":"3211414","preferredDefinition":"A rare inherited retinal dystrophy disorder characterized by spots of black bone-spicule pigmentation of the retinal pigment epithelium. It is manifested with decreased vision in low light or in the night, followed by decreased peripheral vision, and, eventual decreased central vision. It may lead to blindness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinitis Pigmentosa","conceptCode":"C85045","definition":"A rare inherited retinal dystrophy disorder characterized by spots of black bone-spicule pigmentation of the retinal pigment epithelium. It is manifested with decreased vision in low light or in the night, followed by decreased peripheral vision, and, eventual decreased central vision. It may lead to blindness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FA75-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FA8B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Retinoblastoma","valueDescription":"Retinoblastoma","ValueMeaning":{"publicId":"2573078","version":"1","preferredName":"Retinoblastoma","longName":"2573078","preferredDefinition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoblastoma","conceptCode":"C7541","definition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA83-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FA95-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Retinoschisis","valueDescription":"Retinoschisis","ValueMeaning":{"publicId":"3211415","version":"1","preferredName":"Retinoschisis","longName":"3211415","preferredDefinition":"An inherited or acquired disorder characterized by splitting of the retina into two layers. It results in loss of vision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoschisis","conceptCode":"C85046","definition":"An inherited or acquired disorder characterized by splitting of the retina into two layers. It results in loss of vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FAA1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FAB7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Retrolental Fibroplasia","valueDescription":"Retrolental Fibroplasia","ValueMeaning":{"publicId":"3211416","version":"1","preferredName":"Retrolental Fibroplasia","longName":"3211416","preferredDefinition":"A bilateral retinopathy characterized by neovascularization, scarring, retinal detachment, and eventually blindness. It may be mild or severe. It occurs in babies born prematurely. Causes include oxygen toxicity and hypoxia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinopathy of Prematurity","conceptCode":"C34982","definition":"A bilateral retinopathy characterized by neovascularization, scarring, retinal detachment, and eventually blindness. It may be mild or severe. It occurs in babies born prematurely. Causes include oxygen toxicity and hypoxia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FAC3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FAD9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Retroperitoneal Fibrosis","valueDescription":"Retroperitoneal Fibrosis","ValueMeaning":{"publicId":"3211417","version":"1","preferredName":"Retroperitoneal Fibrosis","longName":"3211417","preferredDefinition":"A rare, serious disorder characterized by extensive fibrosis in the retroperitoneum. In most cases its etiology is unknown. In some cases it is related to autoimmunity or metastatic cancer. It leads to the entrapment and obstruction of vital retroperitoneal structures including the ureters.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retroperitoneal Fibrosis","conceptCode":"C26876","definition":"A rare, serious disorder characterized by extensive fibrosis in the retroperitoneum. In most cases its etiology is unknown. In some cases it is related to autoimmunity or metastatic cancer. It leads to the entrapment and obstruction of vital retroperitoneal structures including the ureters.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FAE5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FAFB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Rett Syndrome","valueDescription":"Rett Syndrome","ValueMeaning":{"publicId":"3211418","version":"1","preferredName":"Rett Syndrome","longName":"3211418","preferredDefinition":"A progressive neurologic disorder caused by mutations in the MECP2 gene on chromosome X.  It almost exclusively affects girls.  It is characterized by language and learning difficulties, poor communication skills, and repetitive hand motions.  Other signs and symptoms include microcephaly, scoliosis, breathing abnormalities, and sleep disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rett Syndrome","conceptCode":"C75488","definition":"A progressive neurologic disorder caused by mutations in the MECP2 gene on chromosome X. It almost exclusively affects girls. It is characterized by language and learning difficulties, poor communication skills, and repetitive hand motions. Other signs and symptoms include microcephaly, scoliosis, breathing abnormalities, and sleep disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FB07-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FB1D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Reye Syndrome","valueDescription":"Reye Syndrome","ValueMeaning":{"publicId":"3211419","version":"1","preferredName":"Reye Syndrome","longName":"3211419","preferredDefinition":"An acute and potentially fatal metabolic disorder characterized by cerebral edema, fatty liver and hypoglycemia. It occurs primarily in children and has been associated with the use of aspirin for the treatment of viral infections. However, it can also occur in the absence of aspirin use.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reye Syndrome","conceptCode":"C34983","definition":"An acute and potentially fatal metabolic disorder characterized by cerebral edema, fatty liver and hypoglycemia. It occurs primarily in children and has been associated with the use of aspirin for the treatment of viral infections. However, it can also occur in the absence of aspirin use.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FB29-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FB3F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Rheumatic Fever","valueDescription":"Rheumatic Fever","ValueMeaning":{"publicId":"3211420","version":"1","preferredName":"Rheumatic Fever","longName":"3211420","preferredDefinition":"An inflammatory disorder that follows infection with group A streptococcus. It affects the heart, joints, and subcutaneous tissues. It is manifested with pericarditis, heart murmur, congestive heart failure, polyarthritis, subcutaneous nodules, and erythema marginatum. It is characterized by the formation of granulomatous lesions called Aschoff bodies usually in the heart tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rheumatic Fever","conceptCode":"C34984","definition":"An inflammatory disorder that follows infection with group A streptococcus. It affects the heart, joints, and subcutaneous tissues. It manifests with pericarditis, heart murmur, congestive heart failure, polyarthritis, subcutaneous nodules, and erythema marginatum. It is characterized by the formation of granulomatous lesions called Aschoff bodies usually in the heart tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FB4B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FB61-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Rhizomelic Chondrodysplasia Punctata","valueDescription":"Rhizomelic Chondrodysplasia Punctata","ValueMeaning":{"publicId":"3211421","version":"1","preferredName":"Rhizomelic Chondrodysplasia Punctata","longName":"3211421","preferredDefinition":"An autosomal recessive inherited peroxisomal disorder caused by mutations in the PEX7, DHAPAT, and AGP genes. It is characterized by short limbs, bones and cartilage abnormalities, congenital cataracts, and severe mental retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rhizomelic Chondrodysplasia Punctata","conceptCode":"C85047","definition":"An autosomal recessive inherited peroxisomal disorder caused by mutations in the PEX7, DHAPAT, and AGP genes. It is characterized by short limbs, bones and cartilage abnormalities, congenital cataracts, and severe mental retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FB6D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FB83-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Robinow Syndrome","valueDescription":"Robinow Syndrome","ValueMeaning":{"publicId":"3211422","version":"1","preferredName":"Robinow Syndrome","longName":"3211422","preferredDefinition":"A rare autosomal recessive or dominant inherited disorder. The autosomal recessive form is caused by mutations in the ROR2 gene. There is no causative mutation identified for the autosomal dominant form. It is manifested with short limbs, abnormal facial features, underdeveloped genitalia, and wedge-shaped vertebrae.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Robinow Syndrome","conceptCode":"C85048","definition":"A rare autosomal recessive or dominant inherited disorder. The autosomal recessive form is caused by mutations in the ROR2 gene. There is no causative mutation identified for the autosomal dominant form. It is manifested with short limbs, abnormal facial features, underdeveloped genitalia, and wedge-shaped vertebrae.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FB8F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FBA5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Romano-Ward Syndrome","valueDescription":"Romano-Ward Syndrome","ValueMeaning":{"publicId":"3211423","version":"1","preferredName":"Romano-Ward Syndrome","longName":"3211423","preferredDefinition":"An autosomal dominant form of long QT syndrome caused by mutations in the KCNE1, KCNE2, KCNH2, KCNQ1, SCN5A, and ANK2 genes. It is manifested with arrhythmias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Long QT Syndrome 1","conceptCode":"C85049","definition":"An autosomal dominant condition caused by mutation(s) in the KCNQ1 gene, encoding potassium voltage-gated channel subfamily KQT member 1. It is characterized by a prolonged QT interval that may result in torsade de pointes, ventricular fibrillation and/or sudden cardiac death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FBB1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FBC7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sinus Histiocytosis with Massive Lymphadenopathy","valueDescription":"Sinus Histiocytosis with Massive Lymphadenopathy","ValueMeaning":{"publicId":"3211424","version":"1","preferredName":"Sinus Histiocytosis with Massive Lymphadenopathy","longName":"3211424","preferredDefinition":"A rare non-neoplastic disorder of unknown etiology characterized by distention of the lymph node sinuses and sinusoidal histiocytic infiltration. The histiocytes characteristically contain ingested lymphocytes. It is usually manifested with cervical lymphadenopathy, fever, leukocytosis, and hypergammaglobulinemia. . It can affect extranodal sites, including the skin, bones, and the respiratory tract. It usually regresses spontaneously.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rosai-Dorfman-Destombes Disease","conceptCode":"C36075","definition":"A rare histiocytic disorder of unknown etiology, characterized by distention of the lymph node sinuses and sinusoidal histiocytic infiltration. The histiocytes characteristically contain ingested lymphocytes and are S100 and CD68 positive, and CD1a negative. Patients present with cervical lymphadenopathy, fever, leukocytosis, and hypergammaglobulinemia. It can affect extranodal sites, including skin, bones, and the respiratory tract. It occurs in isolation or may be associated with autoimmune disorders or malignancies. Mutations in NRAS, KRAS, MAP2K1, and ARAF genes have been identified in affected tissues, suggesting a clonal origin in some cases. It is a self-limited disorder, although some patients may have a poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FBD3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FBE9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Rothmund-Thomson Syndrome","valueDescription":"Rothmund-Thomson Syndrome","ValueMeaning":{"publicId":"3211425","version":"1","preferredName":"Rothmund-Thomson Syndrome","longName":"3211425","preferredDefinition":"An autosomal recessive inherited syndrome usually caused by mutations in the RECQL4 gene. It is characterized by poikilodermatous skin changes, sparse hair, cataracts, small stature, skeletal abnormalities, and an increased predisposition to cancer, particularly osteosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rothmund-Thomson Syndrome","conceptCode":"C3335","definition":"An autosomal recessive inherited syndrome usually caused by mutations in the RECQL4 gene. It is characterized by poikilodermatous skin changes, sparse hair, cataracts, small stature, skeletal abnormalities, and an increased predisposition to cancer, particularly osteosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FBF5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FC0B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Rubella","valueDescription":"Rubella Infection","ValueMeaning":{"publicId":"3211426","version":"1","preferredName":"Rubella Infection","longName":"3211426","preferredDefinition":"A viral infection caused by the rubella virus. It is initially manifested with flu-like symptoms that last one or two days, followed by the development of a characteristic red rash which lasts from one to five days. The rash first appears in the neck and face. It subsequently spreads to the rest of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rubella Infection","conceptCode":"C85051","definition":"A viral infection caused by the rubella virus. It is initially manifested with flu-like symptoms that last one or two days, followed by the development of a characteristic red rash which lasts from one to five days. The rash first appears in the neck and face. It subsequently spreads to the rest of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FC17-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FC2D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Rubinstein-Taybi Syndrome","valueDescription":"Rubinstein-Taybi Syndrome","ValueMeaning":{"publicId":"3211427","version":"1","preferredName":"Rubinstein-Taybi Syndrome","longName":"3211427","preferredDefinition":"A rare genetic syndrome mapped to chromosome 16p13.3 and associated with mutations in the CREBBP gene.  It is characterized by mental and growth retardation, distinctive facial features (prominent nose, low-set ears, microcephaly, and small mouth), and broad thumbs and great toes.  Patients are at an increased risk of developing benign and malignant neoplasms, including nervous system neoplasms and malignant lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rubinstein-Taybi Syndrome","conceptCode":"C75466","definition":"A rare genetic syndrome mapped to chromosome 16p13.3 and associated with mutations in the CREBBP gene. It is characterized by mental and growth retardation, distinctive facial features (prominent nose, low-set ears, microcephaly, and small mouth), and broad thumbs and great toes. Patients are at an increased risk of developing benign and malignant neoplasms, including nervous system neoplasms and malignant lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FC39-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FC4F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sandhoff Disease","valueDescription":"Sandhoff Disease","ValueMeaning":{"publicId":"3211428","version":"1","preferredName":"Sandhoff Disease","longName":"3211428","preferredDefinition":"An autosomal recessive inherited lysosomal storage disorder caused by mutations in the HEXB gene. It is characterized by deficiency of the enzyme hexosaminidase, resulting in the accumulation of gangiosides in the central nervous system and other body tissues. Signs and symptoms include progressive motor and mental deterioration, early blindness, macrocephaly, seizures, and hepatosplenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sandhoff Disease","conceptCode":"C85052","definition":"An autosomal recessive inherited lysosomal storage disorder caused by mutations in the HEXB gene. It is characterized by deficiency of the enzyme hexosaminidase, resulting in the accumulation of gangliosides in the central nervous system and other body tissues. Signs and symptoms include progressive motor and mental deterioration, early blindness, macrocephaly, seizures, and hepatosplenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FC5B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FC71-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Scheie Syndrome","valueDescription":"Scheie Syndrome","ValueMeaning":{"publicId":"2582069","version":"1","preferredName":"Scheie Syndrome","longName":"2582069","preferredDefinition":"An autosomal recessive disorder representing the milder form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include broad mouth with full lips, cloudy cornea which may lead to blindness, stiff joints, and hirsutism.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scheie Syndrome","conceptCode":"C61265","definition":"An autosomal recessive disorder representing the milder form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include broad mouth with full lips, cloudy cornea which may lead to blindness, stiff joints, and hirsutism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0DA2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FC7B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Schistosomiasis","valueDescription":"Schistosomiasis","ValueMeaning":{"publicId":"3211429","version":"1","preferredName":"Schistosomiasis","longName":"3211429","preferredDefinition":"A parasitic infection caused by flukes of the genus Schistosoma. Signs and symptoms include fever, abdominal pain, eosinophilia and hepatosplenomegaly. If left untreated it may eventually cause liver damage leading to cirrhosis, bladder cancer and kidney failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Schistosomiasis","conceptCode":"C35000","definition":"A parasitic infection caused by flukes of the genus Schistosoma. Signs and symptoms include fever, abdominal pain, eosinophilia and hepatosplenomegaly. If left untreated it may eventually cause liver damage leading to cirrhosis, bladder cancer and kidney failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FC87-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FC9D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Scimitar Syndrome","valueDescription":"Scimitar Syndrome","ValueMeaning":{"publicId":"3211430","version":"1","preferredName":"Scimitar Syndrome","longName":"3211430","preferredDefinition":"A rare congenital cardiopulmonary defect characterized by abnormal right-sided pulmonary venous drainage and right lung malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scimitar Syndrome","conceptCode":"C85056","definition":"A rare congenital cardiopulmonary defect characterized by abnormal right-sided pulmonary venous drainage and right lung malformations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FCA9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FCBF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Scleredema Adultorum","valueDescription":"Scleredema Adultorum","ValueMeaning":{"publicId":"3211431","version":"1","preferredName":"Scleredema Adultorum","longName":"3211431","preferredDefinition":"A usually benign and self-limited skin disorder of unknown etiology, characterized by induration of the skin. It may be associated with infection, diabetes mellitus, and hematologic malignancies. Morphologically, there is deposition of mucin in the dermis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scleredema Adultorum","conceptCode":"C85057","definition":"A usually benign and self-limited skin disorder of unknown etiology, characterized by induration of the skin. It may be associated with infection, diabetes mellitus, and hematologic malignancies. Morphologically, there is deposition of mucin in the dermis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FCCB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FCE1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Scleroderma","valueDescription":"Scleroderma","ValueMeaning":{"publicId":"2593560","version":"1","preferredName":"Scleroderma","longName":"2593560","preferredDefinition":"A chronic disorder marked by hardening and thickening of the skin.  Scleroderma can be localized or it can affect the entire body (systemic).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scleroderma","conceptCode":"C26746","definition":"A localized or systemic chronic and progressive autoimmune disorder characterized by thickening of the skin and the connective tissues. Localized scleroderma affects only the skin. Systemic scleroderma affects internal organs, including the heart, lungs, gastrointestinal tract, and kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BED1B6-B07C-6CBF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FCEB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Scleromyxedema","valueDescription":"Scleromyxedema","ValueMeaning":{"publicId":"3211432","version":"1","preferredName":"Scleromyxedema","longName":"3211432","preferredDefinition":"A rare chronic and progressive skin disorder characterized by mucin deposition in the skin, resulting in the thickening and hardening of the skin, predominantly in the face, fingers, and extremities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scleromyxedema","conceptCode":"C85061","definition":"A rare chronic and progressive skin disorder characterized by mucin deposition in the skin, resulting in the thickening and hardening of the skin, predominantly in the face, fingers, and extremities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FCF7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FD0D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sea-Blue Histiocyte Syndrome","valueDescription":"Sea-Blue Histiocyte Syndrome","ValueMeaning":{"publicId":"3211433","version":"1","preferredName":"Sea-Blue Histiocyte Syndrome","longName":"3211433","preferredDefinition":"A rare, inherited or acquired syndrome characterized by the presence of histiocytes in the bone marrow which contain granules stained blue with hematoxylin-eosin stain, mild thrombocytopenia and purpura, and splenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sea-Blue Histiocyte Syndrome","conceptCode":"C85062","definition":"A rare, inherited or acquired syndrome characterized by the presence of histiocytes in the bone marrow which contain granules stained blue with hematoxylin-eosin stain, mild thrombocytopenia and purpura, and splenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FD19-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FD2F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Seborrheic Keratosis","valueDescription":"Seborrheic Keratosis","ValueMeaning":{"publicId":"3211434","version":"1","preferredName":"Seborrheic Keratosis","longName":"3211434","preferredDefinition":"A common benign skin neoplasm usually affecting older individuals. The lesions usually are multiple and arise in the face, chest, and shoulders. They appear as black or brown, slightly elevated skin lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Seborrheic Keratosis","conceptCode":"C9006","definition":"A common benign neoplasm usually affecting older individuals. The lesions usually arise in the trunk, head and neck, but they can occur on any skin surface other than the palms, soles, and mucosal surfaces. They appear as flat-based papules or plaques. Histologically, there is intraepidermal proliferation of basaloid keratinocytes, acanthosis, hyperkeratosis, and cysts formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FD3B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FD51-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Selective Antibody Deficiency with Normal Immunoglobulins","valueDescription":"Selective Antibody Deficiency with Normal Immunoglobulins","ValueMeaning":{"publicId":"3211435","version":"1","preferredName":"Selective Antibody Deficiency with Normal Immunoglobulins","longName":"3211435","preferredDefinition":"A rare syndrome characterized by deficiency of specific antibodies to polysaccharide antigens while the specific antibodies to protein antigens are normal.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selective Antibody Deficiency with Normal Immunoglobulins","conceptCode":"C85073","definition":"A rare syndrome characterized by deficiency of specific antibodies to polysaccharide antigens while the specific antibodies to protein antigens are normal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FD5D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FD73-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Seminoma","valueDescription":"Seminoma","ValueMeaning":{"publicId":"2986277","version":"1","preferredName":"Seminoma","longName":"2986277","preferredDefinition":"A radiosensitive malignant germ cell tumor found in the testis (especially undescended), and extragonadal sites (anterior mediastinum and pineal gland).  It is characterized by the presence of uniform cells with clear or dense cytoplasm which contains glycogen, and by a large nucleus which contains one or more nucleoli.  The neoplastic germ cells form aggregates separated by fibrous septa.  The fibrous septa contain chronic inflammatory cells, mainly lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Seminoma","conceptCode":"C9309","definition":"A radiosensitive malignant germ cell tumor found in the testis (especially undescended), and extragonadal sites (anterior mediastinum and pineal gland).  It is characterized by the presence of uniform cells with clear or dense cytoplasm which contains glycogen, and by a large nucleus which contains one or more nucleoli.  The neoplastic germ cells form aggregates separated by fibrous septa.  The fibrous septa contain chronic inflammatory cells, mainly lymphocytes.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D112249-863E-E0FD-E040-BB89AD432FCB","latestVersionIndicator":"Yes","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-13","modifiedBy":"ONEDATA","dateModified":"2010-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FD7D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Septo-Optic Dysplasia","valueDescription":"Septo-Optic Dysplasia","ValueMeaning":{"publicId":"3211436","version":"1","preferredName":"Septo-Optic Dysplasia","longName":"3211436","preferredDefinition":"A very rare congenital syndrome characterized by hypoplasia of the optic nerve, impaired vision, absence of the septum pellucidum and hypopituitarism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Septo-Optic Dysplasia","conceptCode":"C85063","definition":"A very rare congenital syndrome characterized by hypoplasia of the optic nerve, impaired vision, absence of the septum pellucidum and hypopituitarism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FD89-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FD9F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Severe Acute Respiratory Syndrome","valueDescription":"Severe Acute Respiratory Syndrome","ValueMeaning":{"publicId":"3211437","version":"1","preferredName":"Severe Acute Respiratory Syndrome","longName":"3211437","preferredDefinition":"A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Acute Respiratory Syndrome","conceptCode":"C85064","definition":"A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FDAB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FDC1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Severe Combined Immunodeficiency","valueDescription":"Severe Combined Immunodeficiency","ValueMeaning":{"publicId":"2593386","version":"1","preferredName":"Severe Combined Immunodeficiency","longName":"2593386","preferredDefinition":"X-linked or autosomal recessive disorder characterized by defects of both humoral and cell mediated immunity, resulting in low or absent antibody levels, leukopenia, marked susceptibility to infections, and early death.--2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Combined Immunodeficiency","conceptCode":"C3472","definition":"X-linked or autosomal recessive disorder characterized by defects of both humoral and cell mediated immunity, resulting in low or absent antibody levels, leukopenia, marked susceptibility to infections, and early death.--2004","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2883B5F5-F046-4386-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FDCB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sex Cord-Stromal Tumor","valueDescription":"Sex Cord-Stromal Tumor","ValueMeaning":{"publicId":"3211438","version":"1","preferredName":"Sex Cord-Stromal Tumor","longName":"3211438","preferredDefinition":"A neoplasm arising in the ovary or testis. It is composed of granulosa cells, Leydig cells, Sertoli cells, and fibroblasts. Each of these cell types may constitute the only cellular component that is present in the neoplasm or it may be mixed with other cell types in various combinations. The prognosis can not always be predicted on histologic grounds alone. Approximately, 10% of these tumors may metastasize. Representative examples include granulosa cell tumor, Leydig cell tumor, Sertoli cell tumor, and tumors of the thecoma-fibroma group.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sex Cord-Stromal Tumor","conceptCode":"C3794","definition":"A neoplasm arising in the ovary or testis. It is composed of granulosa cells, Leydig cells, Sertoli cells, and fibroblasts. Each of these cell types may constitute the only cellular component that is present in the neoplasm or it may be mixed with other cell types in various combinations. The prognosis can not always be predicted on histologic grounds alone. Approximately, 10% of these tumors may metastasize. Representative examples include granulosa cell tumor, Leydig cell tumor, Sertoli cell tumor, and tumors of the thecoma-fibroma group.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FDD7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FDED-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sezary Syndrome","valueDescription":"Sezary Syndrome","ValueMeaning":{"publicId":"2560040","version":"1","preferredName":"Sezary Syndrome","longName":"2560040","preferredDefinition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sezary Syndrome","conceptCode":"C3366","definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B795-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FDF7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Short Rib-Polydactyly Syndrome","valueDescription":"Short Rib-Polydactyly Syndrome","ValueMeaning":{"publicId":"3211439","version":"1","preferredName":"Short Rib-Polydactyly Syndrome","longName":"3211439","preferredDefinition":"A rare congenital lethal syndrome characterized by the presence of extra fingers and toes and short ribs, the latter resulting in inability of the lungs to expand. The newborn dies shortly after birth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Short Rib-Polydactyly Syndrome","conceptCode":"C85065","definition":"A rare congenital lethal syndrome characterized by the presence of extra fingers and toes and short ribs, the latter resulting in inability of the lungs to expand. The newborn dies shortly after birth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FE03-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FE19-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Shy-Drager Syndrome","valueDescription":"Shy-Drager Syndrome","ValueMeaning":{"publicId":"3211440","version":"1","preferredName":"Shy-Drager Syndrome","longName":"3211440","preferredDefinition":"A rare, progressive neurodegenerative disorder affecting the autonomic functions. It is manifested with masked facial appearance or reduced ability to show facial expression, staring, chewing difficulties, impotence, sleep abnormalities, myalgias, muscle rigidity, movement abnormalities, tremors, voice and speech changes, depression, and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Shy-Drager Syndrome","conceptCode":"C85066","definition":"A rare, progressive neurodegenerative disorder affecting the autonomic functions. It is manifested with masked facial appearance or reduced ability to show facial expression, staring, chewing difficulties, impotence, sleep abnormalities, myalgias, muscle rigidity, movement abnormalities, tremors, voice and speech changes, depression, and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FE25-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FE3B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sialic Acid Storage Disease","valueDescription":"Sialic Acid Storage Disease","ValueMeaning":{"publicId":"3211441","version":"1","preferredName":"Sialic Acid Storage Disease","longName":"3211441","preferredDefinition":"A rare, autosomal recessive lysosomal storage disease caused by mutations in the SLC17A5 gene. It primarily affects the nervous system. Signs and symptoms include developmental delay, intellectual disability, hypotonia, failure to thrive, seizures, and ataxia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sialic Acid Storage Disease","conceptCode":"C85067","definition":"A rare, autosomal recessive lysosomal storage disease caused by mutations in the SLC17A5 gene. It primarily affects the nervous system. Signs and symptoms include developmental delay, intellectual disability, hypotonia, failure to thrive, seizures, and ataxia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FE47-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FE5D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sialadenitis","valueDescription":"Sialadenitis","ValueMeaning":{"publicId":"3211442","version":"1","preferredName":"Sialadenitis","longName":"3211442","preferredDefinition":"An acute or chronic inflammatory process affecting a salivary gland. Signs and symptoms include pain and tenderness in the affected area.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sialadenitis","conceptCode":"C26882","definition":"An acute or chronic inflammatory process affecting a salivary gland. Signs and symptoms include pain and tenderness in the affected area.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FE69-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FE7F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Silver-Russell Syndrome","valueDescription":"Silver-Russell Syndrome","ValueMeaning":{"publicId":"3211443","version":"1","preferredName":"Silver-Russell Syndrome","longName":"3211443","preferredDefinition":"A rare inherited growth disorder characterized by growth retardation, feeding difficulties, failure to thrive, facial abnormalities and asymmetry of limbs. Camptodactyly or clinodactyly may be present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Russell-Silver Syndrome","conceptCode":"C85068","definition":"A rare inherited growth disorder characterized by growth retardation, feeding difficulties, failure to thrive, facial abnormalities and asymmetry of limbs. Camptodactyly or clinodactyly may be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FE8B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FEA1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Long QT Syndrome","valueDescription":"Long QT Syndrome","ValueMeaning":{"publicId":"3210751","version":"1","preferredName":"Long QT Syndrome","longName":"3210751","preferredDefinition":"A ventricular arrhythmia characterized by syncopal episodes and a long QT interval, sometimes leading to sudden death due to paroxysmal ventricular arrhythmia. This arrhythmia is associated with a prolongation of repolarization following depolarization of the cardiac ventricles. The prolongation of the Q-T interval combined with torsades de pointes manifests as several different forms; some may be acquired or congenital; some may lead to serious arrhythmia and sudden cardiac death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Long QT Syndrome","conceptCode":"C34786","definition":"A ventricular arrhythmia characterized by a long QT interval, and accompanied by syncopal episodes sometimes leading to sudden death due to paroxysmal ventricular arrhythmia. This arrhythmia is associated with a prolongation of repolarization following depolarization of the cardiac ventricles. The prolongation of the Q-T interval combined with torsades de pointes manifests as several different forms; some may be acquired or congenital; some may lead to serious arrhythmia and sudden cardiac death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-99B2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-99C8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lymphopenia","valueDescription":"Lymphopenia","ValueMeaning":{"publicId":"2562733","version":"1","preferredName":"Lymphopenia","longName":"2562733","preferredDefinition":"An abnormally small number of lymphocytes in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphopenia","conceptCode":"C26823","definition":"An abnormally small number of lymphocytes in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C21A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-99D2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Marfan Syndrome","valueDescription":"Marfan Syndrome","ValueMeaning":{"publicId":"3210752","version":"1","preferredName":"Marfan Syndrome","longName":"3210752","preferredDefinition":"A genetic syndrome inherited as an autosomal dominant trait.  It is caused by mutations in the FBN1 gene.  It is characterized by tall stature, elongated extremities, mitral valve prolapse, aortic dilatation, aortic dissection, and sublaxation of the lens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marfan Syndrome","conceptCode":"C34807","definition":"A genetic syndrome inherited as an autosomal dominant trait. It is caused by mutations in the FBN1 gene. It is characterized by tall stature, elongated extremities, mitral valve prolapse, aortic dilatation, aortic dissection, and subluxation of the lens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-99DE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-99F4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Metabolic Syndrome","valueDescription":"Metabolic Syndrome","ValueMeaning":{"publicId":"3210753","version":"1","preferredName":"Metabolic Syndrome","longName":"3210753","preferredDefinition":"A term referring to a combination of medical conditions that, when present, increase the risk of heart attack, stroke, and diabetes mellitus.  It includes the following medical conditions: increased blood pressure, central obesity, abnormal cholesterol levels, and elevated fasting glucose.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metabolic Syndrome","conceptCode":"C84442","definition":"A combination of medical conditions that when present, increase the risk of heart attack, stroke, and diabetes mellitus. It includes the following medical conditions: increased blood pressure, central obesity, dyslipidemia, impaired glucose tolerance, and insulin resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9A00-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9A16-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cholecystitis","valueDescription":"Cholecystitis","ValueMeaning":{"publicId":"2566130","version":"1","preferredName":"Cholecystitis","longName":"2566130","preferredDefinition":"An acute or chronic inflammation involving the gallbladder wall. It may be associated with the presence of gallstones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cholecystitis","conceptCode":"C34465","definition":"An acute or chronic inflammation involving the gallbladder wall. It may be associated with the presence of gallstones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CF5F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-07-23","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-07-23","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B9B6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Choledochal Cyst","valueDescription":"Choledochal Cyst","ValueMeaning":{"publicId":"3210957","version":"1","preferredName":"Choledochal Cyst","longName":"3210957","preferredDefinition":"Congenital cystic dilatation of the hepatic duct or bile duct.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choledochal Cyst","conceptCode":"C2943","definition":"Cystic dilatation of the hepatic duct or bile duct.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B9C2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B9D8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chondrodysplasia Punctata","valueDescription":"Chondrodysplasia Punctata","ValueMeaning":{"publicId":"3210958","version":"1","preferredName":"Chondrodysplasia Punctata","longName":"3210958","preferredDefinition":"A rare congenital developmental disorder characterized by the presence of stippled foci of calcification in the hyaline cartilage, joint contractions, mental retardation and ichthyosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chondrodysplasia Punctata","conceptCode":"C84632","definition":"A rare congenital developmental disorder characterized by the presence of stippled foci of calcification in the hyaline cartilage, joint contractions, mental retardation and ichthyosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B9E4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B9FA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chondrosarcoma","valueDescription":"Chondrosarcoma","ValueMeaning":{"publicId":"3179236","version":"1","preferredName":"Chondrosarcoma","longName":"3179236","preferredDefinition":"A malignant mesenchymal tumor arising from cartilage-forming tissues involving the bones.  It affects middle-aged to elderly adults, and the pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chondrosarcoma","conceptCode":"C2946","definition":"A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue.  It usually affects middle-aged to elderly adults.  The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CDA1-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BA04-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chorea","valueDescription":"Chorea","ValueMeaning":{"publicId":"3210959","version":"1","preferredName":"Chorea","longName":"3210959","preferredDefinition":"A neurological condition affecting the involuntary movements. It is characterized by brief, non-repetitive irregular muscle contractions. It is seen in patients with Huntington's disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chorea","conceptCode":"C84633","definition":"A neurological condition affecting the involuntary movements. It is characterized by brief, non-repetitive irregular muscle contractions. It is seen in patients with Huntington's disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BA10-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BA26-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Choroid Plexus Papilloma","valueDescription":"Choroid Plexus Papilloma","ValueMeaning":{"publicId":"2572938","version":"1","preferredName":"Choroid Plexus Papilloma","longName":"2572938","preferredDefinition":"Choroid Plexus Papilloma (WHO grade I) is a benign, slow growing tumor which may cause symptoms by blocking CSF pathways. Surgical resection is usually curative. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroid Plexus Papilloma","conceptCode":"C3698","definition":"A benign, slow growing tumor which may cause symptoms by blocking cerebrospinal fluid pathways.  It is characterized by the presence of delicate fibrovascular connective tissue fronds covered by a single layer of epithelial cells.  Mitotic activity is extremely low.  Surgical resection is usually curative. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9F7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BA30-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Choroideremia","valueDescription":"Choroideremia","ValueMeaning":{"publicId":"3210960","version":"1","preferredName":"Choroideremia","longName":"3210960","preferredDefinition":"A rare, X-linked inherited disorder characterized by choroid atrophy and retinal degeneration. It leads to progressive loss of vision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroideremia","conceptCode":"C34469","definition":"A rare, X-linked inherited disorder characterized by choroid atrophy and retinal degeneration. It leads to progressive loss of vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BA3C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BA52-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cytogenetic Abnormality","valueDescription":"Cytogenetic Abnormality","ValueMeaning":{"publicId":"3210961","version":"1","preferredName":"Cytogenetic Abnormality","longName":"3210961","preferredDefinition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Abnormality","conceptCode":"C2950","definition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BA5E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BA74-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chromosome Disorder","valueDescription":"Chromosome Disorder","ValueMeaning":{"publicId":"3210962","version":"1","preferredName":"Chromosome Disorder","longName":"3210962","preferredDefinition":"A disorder that results from a chromosomal abnormality.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chromosome Disorder","conceptCode":"C34470","definition":"A disorder that results from a chromosomal abnormality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BA80-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BA96-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chromosome Fragile Site","valueDescription":"Chromosome Fragile Site","ValueMeaning":{"publicId":"3210963","version":"1","preferredName":"Chromosome Fragile Site","longName":"3210963","preferredDefinition":"Heritable sensitive regions of chromosomes which show up in vitro as non-staining bands. They are associated with chromosome breakage and other aberrations. No abnormal phenotype has been definitely identified with autosomal fragile sites, but some rare autosomal recessive disorders may be due to homozygosity for fragile sites. A fragile site on the X chromosome is associated with Fragile X Syndrome. Fragile sites are designated by the letters \"fra\" followed by the designation for the specific chromosome and locus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chromosome Fragile Site","conceptCode":"C13375","definition":"Heritable sensitive regions of chromosomes which show up in vitro as non-staining bands. They are associated with chromosome breakage and other aberrations. No abnormal phenotype has been definitely identified with autosomal fragile sites, but some rare autosomal recessive disorders may be due to homozygosity for fragile sites. A fragile site on the X chromosome is associated with Fragile X Syndrome. Fragile sites are designated by the letters \"fra\" followed by the designation for the specific chromosome and locus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BAA2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BAB8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chronic Inflammatory Demyelinating Polyneuropathy","valueDescription":"Chronic Inflammatory Demyelinating Polyneuropathy","ValueMeaning":{"publicId":"3210964","version":"1","preferredName":"Chronic Inflammatory Demyelinating Polyneuropathy","longName":"3210964","preferredDefinition":"An immunologic inflammatory disorder characterized by loss of myelin in the peripheral nerves. Patients present with progressive weakness and loss of sensory function in the legs and arms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Inflammatory Demyelinating Polyneuropathy","conceptCode":"C84636","definition":"An immunologic inflammatory disorder characterized by loss of myelin in the peripheral nerves. Patients present with progressive weakness and loss of sensory function in the legs and arms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BAC4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BADA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chronic Pancreatitis","valueDescription":"Chronic Pancreatitis","ValueMeaning":{"publicId":"3210965","version":"1","preferredName":"Chronic Pancreatitis","longName":"3210965","preferredDefinition":"A chronic inflammatory process causing damage and fibrosis of the pancreatic parenchyma. Signs and symptoms include abdominal pain, malabsorption and diabetes mellitus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Pancreatitis","conceptCode":"C84637","definition":"A chronic inflammatory process causing damage and fibrosis of the pancreatic parenchyma. Signs and symptoms include abdominal pain, malabsorption and diabetes mellitus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BAE6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BAFC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Churg-Strauss Syndrome","valueDescription":"Churg-Strauss Syndrome","ValueMeaning":{"publicId":"2593573","version":"1","preferredName":"Churg-Strauss Syndrome","longName":"2593573","preferredDefinition":"Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis. Eosinophilia and lung involvement differentiate this disease from POLYARTERITIS NODOSA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eosinophilic Granulomatosis with Polyangiitis","conceptCode":"C34481","definition":"An autoimmune necrotizing vasculitis with the formation of granulomas. It is a pulmonary and systemic vasculitis associated with eosinophilia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C01BC7-F115-0924-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BB06-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chylous Ascites","valueDescription":"Chylous Ascites","ValueMeaning":{"publicId":"3210966","version":"1","preferredName":"Chylous Ascites","longName":"3210966","preferredDefinition":"Accumulation of chyle (milky fluid) in the peritoneal cavity. It results from the disruption of the lymphatic vessels in the abdominal cavity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chylous Peritoneal Effusion","conceptCode":"C34482","definition":"Accumulation of chyle (milky fluid) in the peritoneal cavity. It results from the disruption of the lymphatic vessels in the abdominal cavity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BB12-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BB28-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ciliary Motility Defect","valueDescription":"Ciliary Motility Defect","ValueMeaning":{"publicId":"3210967","version":"1","preferredName":"Ciliary Motility Defect","longName":"3210967","preferredDefinition":"Defective movements of the cilia. It includes abnormal movements of the cilia in the nose and paranasal sinuses, the respiratory tract and spermatozoa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ciliary Motility Defect","conceptCode":"C84638","definition":"Defective movements of the cilia. It includes abnormal movements of the cilia in the nose and paranasal sinuses, the respiratory tract and spermatozoa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BB34-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BB4A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Citrullinemia","valueDescription":"Citrullinemia","ValueMeaning":{"publicId":"3210968","version":"1","preferredName":"Citrullinemia","longName":"3210968","preferredDefinition":"A rare autosomal recessive inherited disorder caused by mutations in the ASS1 and SLC25A13 genes. It is characterized by a defective urea cycle, resulting in the accumulation of ammonia and other toxic substances in the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Citrullinemia","conceptCode":"C84639","definition":"A rare autosomal recessive inherited disorder caused by mutations in the ASS1 and SLC25A13 genes. It is characterized by a defective urea cycle, resulting in the accumulation of ammonia and other toxic substances in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BB56-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BB6C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Classical Lissencephaly","valueDescription":"Classical Lissencephaly","ValueMeaning":{"publicId":"3210969","version":"1","preferredName":"Classical Lissencephaly","longName":"3210969","preferredDefinition":"A genetic disorder caused by mutations in the LIS1, XLIS, or TUBA1A genes. It results in brain malformation characterized by the underdevelopment or absence of gyri or ridges in the cerebral cortex. Signs and symptoms include epilepsy and mental retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classical Lissencephaly","conceptCode":"C84640","definition":"A genetic disorder caused by mutations in the LIS1, XLIS, or TUBA1A genes. It results in brain malformation characterized by the underdevelopment or absence of gyri or ridges in the cerebral cortex. Signs and symptoms include epilepsy and mental retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BB78-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BB8E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cleidocranial Dysplasia","valueDescription":"Cleidocranial Dysplasia","ValueMeaning":{"publicId":"3210970","version":"1","preferredName":"Cleidocranial Dysplasia","longName":"3210970","preferredDefinition":"A rare autosomal dominant disorder caused by mutations in the RUNX2 gene.  It is characterized by developmental abnormalities in the bones and teeth, including the complete or partial absence of the clavicles, delayed closure of the fontanels, protruding mandible, hypertelorism, scoliosis, and short stature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cleidocranial Dysplasia","conceptCode":"C75020","definition":"A rare autosomal dominant disorder caused by mutations in the RUNX2 gene.  It is characterized by developmental abnormalities in the bones and teeth, including the complete or partial absence of the clavicles, delayed closure of the fontanels, protruding mandible, hypertelorism, scoliosis, and short stature.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BB9A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BBB0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mastocytosis","valueDescription":"Mastocytosis","ValueMeaning":{"publicId":"3210971","version":"1","preferredName":"Mastocytosis","longName":"3210971","preferredDefinition":"A clonal myeloproliferative neoplasm characterized by the proliferation and accumulation of neoplastic mast cells in one or multiple organs or organ systems.  It is a heterogeneous group of neoplasms, ranging from cutaneous proliferations which may regress spontaneously, to aggressive neoplasms associated with organ failure and short survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mastocytosis","conceptCode":"C84269","definition":"A clonal myeloproliferative neoplasm characterized by the proliferation and accumulation of neoplastic mast cells in one or multiple organs or organ systems. It is a heterogeneous group of neoplasms, ranging from cutaneous proliferations which may regress spontaneously, to aggressive neoplasms associated with organ failure and short survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BBBC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BBD2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Clubfoot","valueDescription":"Clubfoot","ValueMeaning":{"publicId":"3210972","version":"1","preferredName":"Clubfoot","longName":"3210972","preferredDefinition":"The most common congenital deformation of the foot, occurring in 1 of 1,000 live births. The most common form is talipes equinovarus, where the deformed foot is turned downward and inward sharply.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clubfoot","conceptCode":"C84641","definition":"The most common congenital deformation of the foot, occurring in 1 of 1,000 live births. The most common form is talipes equinovarus, where the deformed foot is turned downward and inward sharply.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BBDE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BBF4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Anthracosis","valueDescription":"Anthracosis","ValueMeaning":{"publicId":"3210973","version":"1","preferredName":"Anthracosis","longName":"3210973","preferredDefinition":"A chronic lung disorder characterized by deposition of coal dust in the lung parenchyma leading to the formation of black nodules and emphysema. It occurs in coal miners.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anthracosis","conceptCode":"C34390","definition":"A chronic lung disorder characterized by deposition of coal dust in the lung parenchyma leading to the formation of black nodules and emphysema. It occurs in coal miners.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BC00-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BC16-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Coccidioidomycosis","valueDescription":"Coccidioidomycosis","ValueMeaning":{"publicId":"3210974","version":"1","preferredName":"Coccidioidomycosis","longName":"3210974","preferredDefinition":"A fungal infection caused by Coccidioides immitis. Affected individuals usually have mild flu-like symptoms. However, pneumonia and systemic involvement with the formation of abscesses may develop as complications of the disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coccidioidomycosis","conceptCode":"C84642","definition":"A fungal infection caused by Coccidioides immitis. Affected individuals usually have mild flu-like symptoms. However, pneumonia and systemic involvement with the formation of abscesses may develop as complications of the disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BC22-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BC38-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Coccidiosis","valueDescription":"Coccidiosis","ValueMeaning":{"publicId":"3210975","version":"1","preferredName":"Coccidiosis","longName":"3210975","preferredDefinition":"A parasitic infection caused by Coccidia. It affects livestock, birds and humans. In humans the parasite infests the intestinal tract and may cause watery diarrhea, abdominal pain, fever, nausea and vomiting.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coccidiosis","conceptCode":"C34493","definition":"A parasitic infection caused by Coccidia. It affects livestock, birds and humans. In humans the parasite infests the intestinal tract and may cause watery diarrhea, abdominal pain, fever, nausea and vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BC44-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BC5A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cockayne Syndrome","valueDescription":"Cockayne Syndrome","ValueMeaning":{"publicId":"3210976","version":"1","preferredName":"Cockayne Syndrome","longName":"3210976","preferredDefinition":"An autosomal recessive syndrome caused by mutations in the ERCC8 and ERCC6 genes. It is characterized by growth and developmental delay, vision and hearing impairment, and impairment of the peripheral nervous system function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cockayne Syndrome","conceptCode":"C9460","definition":"An autosomal recessive syndrome caused by mutations in the ERCC8 and ERCC6 genes. It is characterized by growth and developmental delay, vision and hearing impairment, and impairment of the peripheral nervous system function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BC66-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BC7C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Coffin-Lowry Syndrome","valueDescription":"Coffin-Lowry Syndrome","ValueMeaning":{"publicId":"3210977","version":"1","preferredName":"Coffin-Lowry Syndrome","longName":"3210977","preferredDefinition":"An inherited syndrome caused by mutations in the RPS6KA3 gene. It is characterized by mental retardation, developmental delay, microcephaly, short stature and kyphoscoliosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coffin-Lowry Syndrome","conceptCode":"C84643","definition":"An inherited syndrome caused by mutations in the RPS6KA3 gene. It is characterized by mental retardation, developmental delay, microcephaly, short stature and kyphoscoliosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BC88-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BC9E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cogan-Reese Syndrome","valueDescription":"Cogan-Reese Syndrome","ValueMeaning":{"publicId":"3210978","version":"1","preferredName":"Cogan-Reese Syndrome","longName":"3210978","preferredDefinition":"A very rare syndrome characterized by eye abnormalities that lead to vision impairment. These abnormalities include iris atrophy, decreased corneal endothelium, iris nodules, adhesion of the iris to the lens and glaucoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cogan-Reese Syndrome","conceptCode":"C84644","definition":"A very rare syndrome characterized by eye abnormalities that lead to vision impairment. These abnormalities include iris atrophy, decreased corneal endothelium, iris nodules, adhesion of the iris to the lens and glaucoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BCAA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BCC0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Coma","valueDescription":"Coma","ValueMeaning":{"publicId":"2561838","version":"1","preferredName":"Coma","longName":"2561838","preferredDefinition":"A state of profound unconsciousness associated with markedly depressed cerebral activity. Causes include central nervous system damage, intoxication, and metabolic abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coma","conceptCode":"C34497","definition":"A state of profound unconsciousness associated with markedly depressed cerebral activity. Causes include central nervous system damage, intoxication, and metabolic abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE9B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-15","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-07-15","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BCD2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Common Variable Immunodeficiency","valueDescription":"Common Variable Immunodeficiency","ValueMeaning":{"publicId":"2579841","version":"1","preferredName":"Common Variable Immunodeficiency","longName":"2579841","preferredDefinition":"A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Variable Immunodeficiency","conceptCode":"C26725","definition":"A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04EE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"COOPERM","dateModified":"2020-10-16","changeDescription":"10.16.20 Updated definition to use current NCIt. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BCDC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Congenital Adrenal Gland Hyperplasia","valueDescription":"Congenital Adrenal Gland Hyperplasia","ValueMeaning":{"publicId":"3210979","version":"1","preferredName":"Congenital Adrenal Gland Hyperplasia","longName":"3210979","preferredDefinition":"A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Adrenal Hyperplasia","conceptCode":"C34360","definition":"A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BCE8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BCFE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Congenital Cortical Hyperostosis","valueDescription":"Congenital Cortical Hyperostosis","ValueMeaning":{"publicId":"3210980","version":"1","preferredName":"Congenital Cortical Hyperostosis","longName":"3210980","preferredDefinition":"A rare congenital disorder characterized by thickening or expansion of the bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Cortical Hyperostosis","conceptCode":"C84645","definition":"A rare congenital disorder characterized by thickening or expansion of the bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BD0A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BD20-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Congenital Dyserythropoietic Anemia","valueDescription":"Congenital Dyserythropoietic Anemia","ValueMeaning":{"publicId":"3210981","version":"1","preferredName":"Congenital Dyserythropoietic Anemia","longName":"3210981","preferredDefinition":"A rare congenital anemia caused by mutations in the CDAN1 and SEC23B genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Dyserythropoietic Anemia","conceptCode":"C84646","definition":"A rare group of disorders that result in anemia that is caused by ineffective erythropoiesis, which is associated with multinuclear erythroblasts, and which may present in childhood. The most common mutations are in the CDAN1 and SEC23B genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BD2C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BD42-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Congenital Myasthenic Syndrome","valueDescription":"Congenital Myasthenic Syndrome","ValueMeaning":{"publicId":"3210982","version":"1","preferredName":"Congenital Myasthenic Syndrome","longName":"3210982","preferredDefinition":"A group of rare genetic neuromuscular disorders characterized by neuromuscular junction defects. The defects are classified as presynaptic, synaptic, or postsynaptic. Signs and symptoms include muscle weakness, easy fatigability, feeding and respiratory difficulties, and scoliosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Myasthenic Syndrome","conceptCode":"C84647","definition":"A group of rare genetic neuromuscular disorders characterized by neuromuscular junction defects. The defects are classified as presynaptic, synaptic, or postsynaptic. Signs and symptoms include muscle weakness, easy fatigability, feeding and respiratory difficulties, and scoliosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BD4E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BD64-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Congenital Structural Myopathy","valueDescription":"Congenital Structural Myopathy","ValueMeaning":{"publicId":"3210983","version":"1","preferredName":"Congenital Structural Myopathy","longName":"3210983","preferredDefinition":"A group of rare genetic muscle disorders characterized by hypotonia, muscle weakness, and delayed development of motor skills.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Structural Myopathy","conceptCode":"C84648","definition":"A group of rare genetic muscle disorders characterized by hypotonia, muscle weakness, and delayed development of motor skills.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BD70-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BD86-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Congenital Syphilis","valueDescription":"Congenital Syphilis","ValueMeaning":{"publicId":"3210984","version":"1","preferredName":"Congenital Syphilis","longName":"3210984","preferredDefinition":"A life-threatening bacterial infection of the newborn caused by Treponema pallidum. It is transmitted to the infant from a mother with syphilis through the placenta during pregnancy. Signs and symptoms include irritability, fever, failure to thrive, saddle nose, cutaneous rash, and pneumonia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Syphilis","conceptCode":"C84649","definition":"A life-threatening bacterial infection of the newborn caused by Treponema pallidum. It is transmitted to the infant from a mother with syphilis through the placenta during pregnancy. Signs and symptoms include irritability, fever, failure to thrive, saddle nose, cutaneous rash, and pneumonia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BD92-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BDA8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Connexin 26 Gene Anomaly","valueDescription":"Connexin 26 Gene Anomaly","ValueMeaning":{"publicId":"3210985","version":"1","preferredName":"Connexin 26 Gene Anomaly","longName":"3210985","preferredDefinition":"Congenital deafness caused by mutations in the gene GJB2 (deafness gene).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deafness due to Connexin 26 Gene Anomaly","conceptCode":"C84650","definition":"Congenital deafness caused by mutations in the gene GJB2 (deafness gene).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BDB4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BDCA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cor Triatriatum","valueDescription":"Cor Triatriatum","ValueMeaning":{"publicId":"3210986","version":"1","preferredName":"Cor Triatriatum","longName":"3210986","preferredDefinition":"A rare congenital abnormality of the heart characterized by the presence of three atria. The right or left atrium is divided into two parts by fibromuscular tissue or a membrane. It may be associated with other heart congenital abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cor Triatriatum","conceptCode":"C84651","definition":"A rare congenital abnormality of the heart characterized by the presence of three atria. The right or left atrium is divided into two parts by fibromuscular tissue or a membrane. It may be associated with other heart congenital abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BDD6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BDEC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cornelia De Lange Syndrome","valueDescription":"Cornelia De Lange Syndrome","ValueMeaning":{"publicId":"3210987","version":"1","preferredName":"Cornelia De Lange Syndrome","longName":"3210987","preferredDefinition":"A rare syndrome characterized by low birth weight, delayed growth, mental retardation, behavioral problems, and a distinctive facial appearance (thin, arched eyebrows, low set ears, small teeth, and small nose).  The majority of cases are caused by mutations in the NIPBL gene.  Less severe forms of the syndrome are caused by mutations in the SMC1A and SMC3 genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cornelia De Lange Syndrome","conceptCode":"C75016","definition":"A rare syndrome characterized by low birth weight, delayed growth, mental retardation, behavioral problems, and a distinctive facial appearance (thin, arched eyebrows, low set ears, small teeth, and small nose). The majority of cases are caused by mutations in the NIPBL gene. Less severe forms of the syndrome are caused by mutations in the SMC1A and SMC3 genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BDF8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BE0E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Costello Syndrome","valueDescription":"Costello Syndrome","ValueMeaning":{"publicId":"3210988","version":"1","preferredName":"Costello Syndrome","longName":"3210988","preferredDefinition":"A genetic syndrome caused by mutations in the HRAS gene. It is characterized by developmental delay, mental retardation, loose skin folds, cardiomyopathy, tachycardia, and structural heart defects. Patients are at an increased risk of developing benign or malignant neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Costello Syndrome","conceptCode":"C84652","definition":"A genetic syndrome caused by mutations in the HRAS gene. It is characterized by developmental delay, mental retardation, loose skin folds, cardiomyopathy, tachycardia, and structural heart defects. Patients are at an increased risk of developing benign or malignant neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BE1A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BE30-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cowden Syndrome","valueDescription":"Cowden Syndrome","ValueMeaning":{"publicId":"3210989","version":"1","preferredName":"Cowden Syndrome","longName":"3210989","preferredDefinition":"An autosomal dominant hereditary syndrome characterized by a variety of hamartomas and neoplasms including verrucous skin lesions, fibromas of the oral cavity, facial trichilemmomas, hamartomatous colonic polyps, thyroid neoplasms, breast cancer, and dysplastic gangliocytomas of the cerebellum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cowden Syndrome","conceptCode":"C3076","definition":"An autosomal dominant hereditary syndrome characterized by a variety of hamartomas and neoplasms including verrucous skin lesions, fibromas of the oral cavity, facial trichilemmomas, hamartomatous colonic polyps, thyroid neoplasms, breast cancer, and dysplastic gangliocytomas of the cerebellum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BE3C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BE52-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Craniofacial Dysostosis","valueDescription":"Craniofacial Dysostosis","ValueMeaning":{"publicId":"3210990","version":"1","preferredName":"Craniofacial Dysostosis","longName":"3210990","preferredDefinition":"A syndrome inherited in an autosomal dominant pattern. It is characterized by early fusion of the bones of the skull and face. Patients have a distinctive facial appearance which includes low-set ears, brachycephaly, hypertelorism, exophthalmos, and mandibular prognathism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Craniofacial Dysostosis","conceptCode":"C84653","definition":"A syndrome inherited in an autosomal dominant pattern. It is characterized by early fusion of the bones of the skull and face. Patients have a distinctive facial appearance which includes low-set ears, brachycephaly, hypertelorism, exophthalmos, and mandibular prognathism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BE5E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BE74-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Craniomandibular Disorder","valueDescription":"Craniomandibular Disorder","ValueMeaning":{"publicId":"3210991","version":"1","preferredName":"Craniomandibular Disorder","longName":"3210991","preferredDefinition":"A term referring to disorders affecting the muscles of the head and neck, particularly the masticatory muscles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Craniomandibular Disorder","conceptCode":"C84654","definition":"A disorder that affects the muscles of head and neck and temporomandibular joint.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BE80-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BE96-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sinus Histiocytosis","valueDescription":"Sinus Histiocytosis","ValueMeaning":{"publicId":"3211444","version":"1","preferredName":"Sinus Histiocytosis","longName":"3211444","preferredDefinition":"A morphologic finding indicating the presence of histiocytic infiltrates within distended lymph node sinuses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sinus Histiocytosis","conceptCode":"C85069","definition":"A morphologic finding indicating the presence of histiocytic infiltrates within distended lymph node sinuses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FEAD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FEC3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sjogren Syndrome","valueDescription":"Sjogren's Syndrome","ValueMeaning":{"publicId":"2593564","version":"1","preferredName":"Sjogren's Syndrome","longName":"2593564","preferredDefinition":"Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sjogren Syndrome","conceptCode":"C26883","definition":"An autoimmune disorder affecting the salivary and lacrimal glands. Morphologically, it is characterized by the presence of lymphocytic and plasmacytic infiltrates which cause destruction of these glands. It results in dry mouth and dry eyes. It may be associated with the presence of other autoimmune disorders, including rheumatoid arthritis and lupus erythematosus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BED297-469F-6CF9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FECD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sjogren-Larsson Syndrome","valueDescription":"Sjogren-Larsson Syndrome","ValueMeaning":{"publicId":"3211445","version":"1","preferredName":"Sjogren-Larsson Syndrome","longName":"3211445","preferredDefinition":"A rare autosomal recessive inherited metabolic syndrome caused by mutations in the ALDH3A2 gene. It is characterized by deficiency of fatty aldehyde dehydrogenase. It is manifested with congenital ichthyosis, mental retardation, and leg paralysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sjogren-Larsson Syndrome","conceptCode":"C85070","definition":"An autosomal recessive condition caused by mutation(s) in the ALDH3A2 gene, encoding fatty aldehyde dehydrogenase. It is a characterized by dry and scaly skin, neurological dysfunction and mild to moderate intellectual disability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FED9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FEEF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Skin Pigmentation Disorder","valueDescription":"Skin Pigmentation Disorder","ValueMeaning":{"publicId":"3211446","version":"1","preferredName":"Skin Pigmentation Disorder","longName":"3211446","preferredDefinition":"A disorder of the skin characterized by loss or reduction of the skin color. It is caused by loss of melanocytes or abnormalities in melanin production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Pigmentation Disorder","conceptCode":"C34557","definition":"A disorder of the skin characterized by loss or reduction of the skin color. It is caused by loss of melanocytes or abnormalities in melanin production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FEFB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FF11-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sly Syndrome","valueDescription":"Sly Syndrome","ValueMeaning":{"publicId":"3028420","version":"1","preferredName":"Sly Syndrome","longName":"3028420","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta-glucuronidase. It is characterized by hepatosplenomegaly, skeletal deformities, enlarged head, and mental retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sly Syndrome","conceptCode":"C84903","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta-glucuronidase. It is characterized by hepatosplenomegaly, skeletal deformities, enlarged head, and mental retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FD23-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FF23-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Smith-Lemli-Opitz Syndrome","valueDescription":"Smith-Lemli-Opitz Syndrome","ValueMeaning":{"publicId":"3211447","version":"1","preferredName":"Smith-Lemli-Opitz Syndrome","longName":"3211447","preferredDefinition":"A rare, autosomal recessive syndrome caused by mutations in the DHCR7 gene. It is characterized by deficiency of the enzyme 3 beta-hydroxysterol-delta 7-reductase resulting in defects in the cholesterol synthesis. It is manifested with multiple congenital malformations, including facial abnormalities, microcephaly, and syndactyly. Behavioral abnormalities may also be present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Smith-Lemli-Opitz Syndrome","conceptCode":"C85071","definition":"A rare, autosomal recessive syndrome caused by mutations in the DHCR7 gene. It is characterized by deficiency of the enzyme 3 beta-hydroxysterol-delta 7-reductase resulting in defects in the cholesterol synthesis. It is manifested with multiple congenital malformations, including facial abnormalities, microcephaly, and syndactyly. Behavioral abnormalities may also be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FF2F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FF45-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Spasmodic Torticollis","valueDescription":"Spasmodic Torticollis","ValueMeaning":{"publicId":"3211448","version":"1","preferredName":"Spasmodic Torticollis","longName":"3211448","preferredDefinition":"A rare movement disorder of unknown etiology, characterized by painful, involuntary turns of the head to the right, left, upwards, or downwards.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spasmodic Torticollis","conceptCode":"C85072","definition":"A rare movement disorder of unknown etiology, characterized by painful, involuntary turns of the head to the right, left, upwards, or downwards.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FF51-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FF67-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Speech Manifestations","valueDescription":"Speech Manifestations","ValueMeaning":{"publicId":"3211449","version":"1","preferredName":"Speech Manifestations","longName":"3211449","preferredDefinition":"A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Speech Disorder","conceptCode":"C5041","definition":"A term referring to disorders characterized by the disruption of normal speech. It includes stuttering, lisps, dysarthria and voice disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FF73-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FF89-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Spherocytosis","valueDescription":"Spherocytosis","ValueMeaning":{"publicId":"3211450","version":"1","preferredName":"Spherocytosis","longName":"3211450","preferredDefinition":"A hereditary or acquired blood disorder characterized by the presence of smaller than normal, sphere-shaped erythrocytes. It results in hemolytic anemia and splenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spherocytosis","conceptCode":"C85074","definition":"A hereditary or acquired blood disorder characterized by the presence of smaller than normal, sphere-shaped erythrocytes. It results in hemolytic anemia and splenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FF95-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FFAB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Spinal Muscular Atrophy","valueDescription":"Spinal Muscular Atrophy","ValueMeaning":{"publicId":"3211451","version":"1","preferredName":"Spinal Muscular Atrophy","longName":"3211451","preferredDefinition":"An inherited disorder characterized by degeneration of the spinal cord and the cerebellum. Symptoms may appear at any age and include progressive loss of coordination of gait, hands, speech, and eye movements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spinal Muscular Atrophy","conceptCode":"C85075","definition":"An inherited disorder characterized by degeneration of the spinal cord and the cerebellum. Symptoms may appear at any age and include progressive loss of coordination of gait, hands, speech, and eye movements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FFB7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FFCD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Spinal Muscular Atrophy of Childhood","valueDescription":"Spinal Muscular Atrophy of Childhood","ValueMeaning":{"publicId":"3211452","version":"1","preferredName":"Spinal Muscular Atrophy of Childhood","longName":"3211452","preferredDefinition":"A group of congenital neurodegenerative disorders affecting motor neurons, resulting in muscle weakness and atrophy in childhood. Signs and symptoms include hypotonia, difficulty breathing, poor feeding, and flaccid quadriplegia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spinal Muscular Atrophy of Childhood","conceptCode":"C85076","definition":"A group of congenital neurodegenerative disorders affecting motor neurons, resulting in muscle weakness and atrophy in childhood. Signs and symptoms include hypotonia, difficulty breathing, poor feeding, and flaccid quadriplegia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FFD9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-FFEF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Spinocerebellar Ataxia","valueDescription":"Spinocerebellar Ataxia","ValueMeaning":{"publicId":"3211453","version":"1","preferredName":"Spinocerebellar Ataxia","longName":"3211453","preferredDefinition":"An inherited disorder characterized by degeneration of the spinal cord and the cerebellum.  Symptoms may appear at any age and include progressive loss of coordination of gait, hands, speech, and eye movements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spinocerebellar Ataxia","conceptCode":"C82341","definition":"An inherited disorder characterized by degeneration of the spinal cord and the cerebellum.  Symptoms may appear at any age and include progressive loss of coordination of gait, hands, speech, and eye movements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FFFB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0011-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Staphylococcal Scalded Skin Syndrome","valueDescription":"Staphylococcal Scalded Skin Syndrome","ValueMeaning":{"publicId":"3211454","version":"1","preferredName":"Staphylococcal Scalded Skin Syndrome","longName":"3211454","preferredDefinition":"A blistering skin disorder caused by exfoliative toxins produced by Staphylococcus aureus infection. The toxins cause the formation of bullae and diffuse skin desquamation. The lesions may be localized or generalized, far away from the initial site of infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Staphylococcal Scalded Skin Syndrome","conceptCode":"C85077","definition":"A blistering skin disorder caused by exfoliative toxins produced by Staphylococcus aureus infection. The toxins cause the formation of bullae and diffuse skin desquamation. The lesions may be localized or generalized, far away from the initial site of infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-001D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0033-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Stargardt Disease","valueDescription":"Stargardt Disease","ValueMeaning":{"publicId":"3211455","version":"1","preferredName":"Stargardt Disease","longName":"3211455","preferredDefinition":"An autosomal recessive and rarely autosomal dominant inherited disorder caused by mutations in the ABCA4 or ELOVL4 genes respectively. It is characterized by macular degeneration that begins in late childhood resulting in progressive loss of vision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stargardt Disease","conceptCode":"C85078","definition":"An autosomal recessive and rarely autosomal dominant inherited disorder caused by mutations in the ABCA4 or ELOVL4 genes respectively. It is characterized by macular degeneration that begins in late childhood resulting in progressive loss of vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-003F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0055-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Status Epilepticus","valueDescription":"Status Epilepticus","ValueMeaning":{"publicId":"3211456","version":"1","preferredName":"Status Epilepticus","longName":"3211456","preferredDefinition":"A life-threatening situation in which the brain is in a continuous state of seizure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status Epilepticus","conceptCode":"C85079","definition":"A life-threatening situation in which the brain is in a continuous state of seizure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0061-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0077-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Stevens-Johnson Syndrome","valueDescription":"Stevens-Johnson Syndrome","ValueMeaning":{"publicId":"2944576","version":"1","preferredName":"Stevens-Johnson Syndrome","longName":"2944576","preferredDefinition":"A systemic, serious, and life-threatening disorder characterized by lesions in the skin and mucous membranes that may lead to necrosis. The lesions may appear anywhere in the body but they occur more commonly in the palms, soles, dorsum of the hands, and extensor surfaces. The lesions are vesicular or necrotic in the center, surrounded by an erythematous zone and occupy less than 10% of the body surfaces. The appearance of the mucocutaneous lesions is preceded by an upper respiratory tract infection. It is an immune complex hypersensitivity reaction usually caused by drugs (e.g., sulfa, phenytoin, penicillin), viruses (e.g., herpes simplex, influenza, hepatitis), and malignancies (e.g., carcinoma and lymphoma).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stevens-Johnson Syndrome","conceptCode":"C79484","definition":"A systemic, serious, and life-threatening disorder characterized by lesions in the skin and mucous membranes that may lead to necrosis. The lesions may appear anywhere in the body but they occur more commonly in the palms, soles, dorsum of the hands, and extensor surfaces. The lesions are vesicular or necrotic in the center, surrounded by an erythematous zone and occupy less than 10% of the body surfaces. The appearance of the mucocutaneous lesions is preceded by an upper respiratory tract infection. It is an immune complex hypersensitivity reaction usually caused by drugs (e.g., sulfa, phenytoin, penicillin), viruses (e.g., herpes simplex, influenza, hepatitis), and malignancies (e.g., carcinoma and lymphoma).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"743D5322-CF8C-677A-E040-BB89AD434340","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0089-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Stiff Person Syndrome","valueDescription":"Stiff Person Syndrome","ValueMeaning":{"publicId":"3211457","version":"1","preferredName":"Stiff Person Syndrome","longName":"3211457","preferredDefinition":"A rare neurologic disorder characterized by muscle rigidity. It usually affects the axial muscles and eventually extends to the proximal limb muscles. It is associated with muscle spasms which may lead to muscle damage and fractures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stiff Person Syndrome","conceptCode":"C85170","definition":"A rare neurologic disorder characterized by muscle rigidity. It usually affects the axial muscles and eventually extends to the proximal limb muscles. It is associated with muscle spasms which may lead to muscle damage and fractures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0095-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-00AB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sturge-Weber Syndrome","valueDescription":"Sturge-Weber Syndrome","ValueMeaning":{"publicId":"2962082","version":"1","preferredName":"Sturge-Weber Syndrome","longName":"2962082","preferredDefinition":"A congenital syndrome characterized by a port-wine nevus covering portions of the face and cranium (in the distribution of the ophthalmic division of the TRIGEMINAL NERVE) and angiomas of the meninges and choroid. Clinical manifestations include the onset of focal SEIZURES, progressive hemiparesis, GLAUCOMA, hemianopsia, and cognitive deficits in the first decade of life. By age two years, skull radiographs reveal \"tramline calcifications\" of the margins of the occipital and parietal lobes. Pathologically cortical neurons are replaced by glial tissue that undergoes calcification. (From Adams et al., Principles of Neurology, 6th ed, pp1018-9)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sturge-Weber Syndrome","conceptCode":"C3391","definition":"A congenital disorder characterized by the presence of a port-wine nevus birthmark on one or both sides of the face. Additional clinical manifestations may include seizures, leptomenigeal angiomas, glaucoma, progressive hemiparesis and cognitive deficits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78BA0E7A-4AB3-2225-E040-BB89AD436E34","latestVersionIndicator":"Yes","beginDate":"2009-11-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-00BD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Subacute Sclerosing Panencephalitis","valueDescription":"Subacute Sclerosing Panencephalitis","ValueMeaning":{"publicId":"3211458","version":"1","preferredName":"Subacute Sclerosing Panencephalitis","longName":"3211458","preferredDefinition":"A rare, slowly progressive post-infectious neurological disorder affecting the central nervous system. It is characterized by seizures, ataxia, myoclonus, personality changes, spasticity, and coma. The symptoms appear several years following measles infection at an early age.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subacute Sclerosing Panencephalitis","conceptCode":"C85171","definition":"A rare, slowly progressive post-infectious neurological disorder affecting the central nervous system. It is characterized by seizures, ataxia, myoclonus, personality changes, spasticity, and coma. The symptoms appear several years following measles infection at an early age.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-00C9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-00DF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","valueDescription":"Subcutaneous Panniculitis-Like T-Cell ","ValueMeaning":{"publicId":"2560116","version":"1","preferredName":"Subcutaneous Panniculitis-Like T-Cell ","longName":"2560116","preferredDefinition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","conceptCode":"C6918","definition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7E1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-00E9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Subependymoma","valueDescription":"Subependymoma","ValueMeaning":{"publicId":"2578710","version":"1","preferredName":"Subependymoma","longName":"2578710","preferredDefinition":"Subependymoma (WHO grade I) is a benign, slow growing neoplasm which is typically attached to a ventricular wall. It is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic change. Some lesions have the histological features of both subependymoma and ependymoma. It is often detected incidentally and has a very favorable prognosis. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subependymoma","conceptCode":"C3795","definition":"A benign, slow growing neoplasm which is typically attached to a ventricular wall. It is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic change. Some lesions have the histological features of both subependymoma and ependymoma. It is often detected incidentally and has a very favorable prognosis. (Adapted from WHO.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0083-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-00F3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Subvalvular Aortic Stenosis","valueDescription":"Subvalvular Aortic Stenosis","ValueMeaning":{"publicId":"3211459","version":"1","preferredName":"Subvalvular Aortic Stenosis","longName":"3211459","preferredDefinition":"An aortic stenosis caused by fibromuscular stenosis or hypertrophic cardiomyopathy. It may be associated with congenital heart defects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subvalvular Aortic Stenosis","conceptCode":"C85172","definition":"An aortic stenosis caused by fibromuscular stenosis or hypertrophic cardiomyopathy. It may be associated with congenital heart defects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-00FF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0115-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sudden Infant Death Syndrome","valueDescription":"Sudden Infant Death Syndrome","ValueMeaning":{"publicId":"3211460","version":"1","preferredName":"Sudden Infant Death Syndrome","longName":"3211460","preferredDefinition":"Unexpected death in infancy which remains unexplained following autopsy, review of the medical history, and investigation of the death circumstances and death scene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sudden Infant Death Syndrome","conceptCode":"C85173","definition":"Unexpected death in infancy which remains unexplained following autopsy, review of the medical history, and investigation of the death circumstances and death scene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0121-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0137-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"SUNCT Syndrome","valueDescription":"SUNCT Syndrome","ValueMeaning":{"publicId":"3211461","version":"1","preferredName":"SUNCT Syndrome","longName":"3211461","preferredDefinition":"A rare disorder characterized by episodes of short-lasting pain in one eye or one side of the head. The pain attacks are associated with watery eyes, swelling of the eyelids, sweaty forehead, and nasal congestion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"SUNCT Syndrome","conceptCode":"C85174","definition":"A rare disorder characterized by episodes of short-lasting pain in one eye or one side of the head. The pain attacks are associated with watery eyes, swelling of the eyelids, sweaty forehead, and nasal congestion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0143-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0159-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Superior Mesenteric Artery Syndrome","valueDescription":"Superior Mesenteric Artery Syndrome","ValueMeaning":{"publicId":"3211462","version":"1","preferredName":"Superior Mesenteric Artery Syndrome","longName":"3211462","preferredDefinition":"A very rare syndrome characterized by compression of the third portion of the duodenum against the aorta. The compression is caused by the superior mesenteric artery. It results in complete or partial duodenal obstruction. Signs and symptoms include nausea, vomiting, abdominal pain and distention, failure to gain weight, and weight loss.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Superior Mesenteric Artery Syndrome","conceptCode":"C85175","definition":"A very rare syndrome characterized by compression of the third portion of the duodenum against the aorta. The compression is caused by the superior mesenteric artery. It results in complete or partial duodenal obstruction. Signs and symptoms include nausea, vomiting, abdominal pain and distention, failure to gain weight, and weight loss.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0165-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-017B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Superior Vena Cava Syndrome","valueDescription":"Superior Vena Cava Syndrome","ValueMeaning":{"publicId":"2944537","version":"1","preferredName":"Superior Vena Cava Syndrome","longName":"2944537","preferredDefinition":"Obstruction of the blood flow in the superior vena cava caused by a malignant neoplasm, thrombosis, or aneurysm.  It is a medical emergency requiring immediate treatment.  Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea, and headache.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Superior Vena Cava Syndrome","conceptCode":"C3396","definition":"Obstruction of the blood flow in the superior vena cava caused by a malignant neoplasm, thrombosis, or aneurysm. It is a medical emergency requiring immediate treatment. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea, and headache.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"743D5322-CD7D-677A-E040-BB89AD434340","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-018D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Supravalvular Aortic Stenosis","valueDescription":"Supravalvular Aortic Stenosis","ValueMeaning":{"publicId":"3211463","version":"1","preferredName":"Supravalvular Aortic Stenosis","longName":"3211463","preferredDefinition":"A rare, congenital or acquired aortic stenosis characterized by localized or diffuse narrowing of the ascending aorta.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Supravalvular Aortic Stenosis","conceptCode":"C85176","definition":"A rare, congenital or acquired aortic stenosis characterized by localized or diffuse narrowing of the ascending aorta.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0199-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-01AF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sweet Syndrome","valueDescription":"Sweet Syndrome","ValueMeaning":{"publicId":"3211464","version":"1","preferredName":"Sweet Syndrome","longName":"3211464","preferredDefinition":"A rare syndrome characterized by fever, skin papules and plaques, and leukocytosis. Morphologically, the skin lesions show neutrophilic infiltrates and dermal edema. It may occur in the absence of underlying conditions. It may also be associated with the presence of cancer or may be a side effect of medications.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sweet Syndrome","conceptCode":"C85177","definition":"A rare syndrome characterized by fever, skin papules and plaques, and leukocytosis. Morphologically, the skin lesions show neutrophilic infiltrates and dermal edema. It may occur in the absence of underlying conditions. It may also be associated with the presence of cancer or may be a side effect of medications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-01BB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-01D1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Swyer James Syndrome","valueDescription":"Swyer James Syndrome","ValueMeaning":{"publicId":"3211465","version":"1","preferredName":"Swyer James Syndrome","longName":"3211465","preferredDefinition":"A rare syndrome characterized by the presence of a small lung as a result of unilateral post-infectious bronchiolitis obliterans.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Swyer James Syndrome","conceptCode":"C85178","definition":"A rare syndrome characterized by the presence of a small lung as a result of unilateral post-infectious bronchiolitis obliterans.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-01DD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-01F3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Syphilis","valueDescription":"Syphilis","ValueMeaning":{"publicId":"2577420","version":"1","preferredName":"Syphilis","longName":"2577420","preferredDefinition":"A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Syphilis","conceptCode":"C35055","definition":"A contagious bacterial infection caused by the spirochete Treponema pallidum. It is a sexually transmitted disorder, although it can also be transmitted from the mother to the fetus in utero. Typically, it is initially manifested with a single sore which heals without treatment. If the infection is left untreated, the initial stage is followed by skin rash and mucous membrane lesions. A late stage follows, which is characterized by damage of the internal organs, including the nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FB79-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-18","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-01-18","modifiedBy":"ONEDATA","dateModified":"2006-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-01FD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Syringomyelia","valueDescription":"Syringomyelia","ValueMeaning":{"publicId":"3211466","version":"1","preferredName":"Syringomyelia","longName":"3211466","preferredDefinition":"A rare disorder characterized by the formation of a cyst in the spinal cord. It results in weakness, pain, and stiffness in the shoulders, arms, legs, or back. It may be associated with Chiari malformation. Other causes include spinal cord injury, inflammation, or tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Syringomyelia","conceptCode":"C85179","definition":"A rare disorder characterized by the formation of a cyst in the spinal cord. It results in weakness, pain, and stiffness in the shoulders, arms, legs, or back. It may be associated with Chiari malformation. Other causes include spinal cord injury, inflammation, or tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0209-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-021F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Systemic Mastocytosis","valueDescription":"Systemic Mastocytosis","ValueMeaning":{"publicId":"3211467","version":"1","preferredName":"Systemic Mastocytosis","longName":"3211467","preferredDefinition":"A variant of mastocytosis characterized by multifocal, dense infiltrates of mast cells (15 or more mast cells in aggregates) detected in the bone marrow and/or other extracutaneous sites. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Mastocytosis","conceptCode":"C9235","definition":"Systemic infiltration of extracutaneous sites by clonal mast cells, with or without evidence of skin involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-022B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0241-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Systemic Scleroderma","valueDescription":"Systemic Scleroderma","ValueMeaning":{"publicId":"3211468","version":"1","preferredName":"Systemic Scleroderma","longName":"3211468","preferredDefinition":"A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Scleroderma","conceptCode":"C72070","definition":"A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin. A relationship exists between the extent of skin area affected and degree of internal organ/system involvement. Systemic scleroderma can manifest itself in pulmonary fibrosis, Raynaud's syndrome, digestive system telangiectasias, renal hypertension and/or pulmonary hypertension.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-024D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0263-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tabes Dorsalis","valueDescription":"Tabes Dorsalis","ValueMeaning":{"publicId":"3211469","version":"1","preferredName":"Tabes Dorsalis","longName":"3211469","preferredDefinition":"A form of neurosyphilis characterized by slowly progressive degeneration of the spinal cord. Signs and symptoms include pain, ataxia, loss of coordination, personality changes, blindness, urinary incontinence, dementia, and degeneration of the joints.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tabes Dorsalis","conceptCode":"C35057","definition":"A form of neurosyphilis characterized by slowly progressive degeneration of the spinal cord. Signs and symptoms include pain, ataxia, loss of coordination, personality changes, blindness, urinary incontinence, dementia, and degeneration of the joints.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-026F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0285-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Taeniasis","valueDescription":"Taeniasis","ValueMeaning":{"publicId":"3211470","version":"1","preferredName":"Taeniasis","longName":"3211470","preferredDefinition":"A parasitic infection caused by tapeworms of the genus Taenia. Humans are infected by eating undercooked or raw meat of infected animals. It is usually an asymptomatic infection and patients may become aware of the infection by noticing segments of the tapeworm in their feces. If symptoms are present, they include nausea, abdominal pain, indigestion, constipation, or diarrhea.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Taeniasis","conceptCode":"C85180","definition":"A parasitic infection caused by tapeworms of the genus Taenia. Humans are infected by eating undercooked or raw meat of infected animals. It is usually an asymptomatic infection and patients may become aware of the infection by noticing segments of the tapeworm in their feces. If symptoms are present, they include nausea, abdominal pain, indigestion, constipation, or diarrhea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0291-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-02A7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Takayasu Arteritis","valueDescription":"Takayasu's Arteritis","ValueMeaning":{"publicId":"2593577","version":"1","preferredName":"Takayasu's Arteritis","longName":"2593577","preferredDefinition":"A thrombo-obliterative process of the great vessels stemming from the aortic arch, occurring generally in young women. Radial and carotid pulses are typically obliterated. Skin changes are due to the disturbed circulation. There may be loss of hair and atrophy of the skin and its appendages with underlying muscle atrophy. (Andrews' Diseases of the Skin, 8th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Takayasu Arteritis","conceptCode":"C35062","definition":"A large vessel vasculitis affecting the aorta and its branches. It usually affects young females. It causes vascular obstruction, resulting in asymmetric pulses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C01C94-A173-0932-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-02B9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Takotsubo Cardiomyopathy","valueDescription":"Takotsubo Cardiomyopathy","ValueMeaning":{"publicId":"3211471","version":"1","preferredName":"Takotsubo Cardiomyopathy","longName":"3211471","preferredDefinition":"A rare disorder characterized by transient left ventricular wall systolic dysfunction, resulting in apical ballooning appearance, chest pain, and ST segment elevation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Takotsubo Cardiomyopathy","conceptCode":"C85181","definition":"A rare disorder characterized by transient left ventricular wall systolic dysfunction, resulting in apical ballooning appearance, chest pain, and ST segment elevation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-02C5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-02DB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tangier Disease","valueDescription":"Tangier Disease","ValueMeaning":{"publicId":"3211472","version":"1","preferredName":"Tangier Disease","longName":"3211472","preferredDefinition":"A rare, autosomal recessive inherited disorder of cholesterol transport, resulting in severe reduction of the amount of high density lipoprotein in the plasma and accumulation of cholesterol esters in the tissues. Signs and symptoms include large tonsils, hepatosplenomegaly, lymphadenopathy, and hypocholesterolemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tangier Disease","conceptCode":"C85182","definition":"A rare, autosomal recessive inherited disorder of cholesterol transport, resulting in severe reduction of the amount of high density lipoprotein in the plasma and accumulation of cholesterol esters in the tissues. Signs and symptoms include large tonsils, hepatosplenomegaly, lymphadenopathy, and hypocholesterolemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-02E7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-02FD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tarsal Tunnel Syndrome","valueDescription":"Tarsal Tunnel Syndrome","ValueMeaning":{"publicId":"3211473","version":"1","preferredName":"Tarsal Tunnel Syndrome","longName":"3211473","preferredDefinition":"A syndrome resulting from the entrapment and compression of the tibial nerve. Signs and symptoms include burning sensation, tingling, and pain in the foot sole.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tarsal Tunnel Syndrome","conceptCode":"C85183","definition":"A syndrome resulting from the entrapment and compression of the tibial nerve. Signs and symptoms include burning sensation, tingling, and pain in the foot sole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0309-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-031F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tay-Sachs Disease","valueDescription":"Tay-Sachs Disease","ValueMeaning":{"publicId":"3211474","version":"1","preferredName":"Tay-Sachs Disease","longName":"3211474","preferredDefinition":"A rare, fatal, autosomal recessive lipid storage disorder caused by mutations in the HEXA gene. It is characterized by deficiency of beta-hexosaminidase A, resulting in accumulation of gangliosides in the neurons of the brain and spinal cord. Signs and symptoms include progressive deterioration of the mental and physical abilities early in life, accompanied by blindness, deafness, muscle atrophy, and paralysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tay-Sachs Disease","conceptCode":"C85184","definition":"A rare, fatal, autosomal recessive lipid storage disorder caused by mutations in the HEXA gene. It is characterized by deficiency of beta-hexosaminidase A, resulting in accumulation of gangliosides in the neurons of the brain and spinal cord. Signs and symptoms include progressive deterioration of the mental and physical abilities early in life, accompanied by blindness, deafness, muscle atrophy, and paralysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-032B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0341-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"T-Cell Large Granular Lymphocyte Leukemia","valueDescription":"T-Cell Large Granular Lymphocyte Leukemia","ValueMeaning":{"publicId":"2590775","version":"1","preferredName":"T-Cell Large Granular Lymphocyte Leukemia","longName":"2590775","preferredDefinition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Large Granular Lymphocyte Leukemia","conceptCode":"C4664","definition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F6CF08-5979-36DF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-034B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Temporal Arteritis","valueDescription":"Temporal Arteritis","ValueMeaning":{"publicId":"2593575","version":"1","preferredName":"Temporal Arteritis","longName":"2593575","preferredDefinition":"A systemic autoimmune vasculitis occurring primarily in people over the age of 50. Pathologic features include a necrotizing panarteritis including granulomas and giant cells. There is a predilection for involvement of central nervous system blood vessels and the most frequent neurologic complication is an OPTIC NEUROPATHY, ISCHEMIC. Large blood vessels may become involved, including the aorta. Clinical manifestations may include myalgias, weight loss, headache, visual loss, necrosis of the skin or tongue, and chest discomfort. Superficial scalp arteries may become tender and enlarged. A related condition, juvenile temporal arteritis, tends to occur in the first or second decade of life. (From Adams et al., Principles of Neurology, 6th ed, p856)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temporal Arteritis","conceptCode":"C35065","definition":"An autoimmune, systemic, giant cell granulomatous arteritis predominantly involving the arteries that supply blood to the central nervous system, head and eyes. Superficial arteries of the scalp that are involved tend to be enlarged and tender. Signs and symptoms include headaches, myalgias, visual disturbances, and skin necrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C01C2C-F0F2-0929-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0355-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Androgen Insensitivity Syndrome","valueDescription":"Androgen Insensitivity Syndrome","ValueMeaning":{"publicId":"3211475","version":"1","preferredName":"Androgen Insensitivity Syndrome","longName":"3211475","preferredDefinition":"A disorder of sexual development in persons with 46XY karyotype, characterized by an abnormality of the genes encoding androgen receptors. It results in a female sex appearance or the development of both male and female characteristics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Androgen Insensitivity Syndrome","conceptCode":"C27226","definition":"A disorder of sexual development in persons with 46XY karyotype, characterized by an abnormality of the genes encoding androgen receptors. It results in a female sex appearance or the development of both male and female characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0361-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0377-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Testicular Neoplasm","valueDescription":"Testicular Neoplasm","ValueMeaning":{"publicId":"2580143","version":"1","preferredName":"Testicular Neoplasm","longName":"2580143","preferredDefinition":"Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testicular Neoplasm","conceptCode":"C3404","definition":"A benign or malignant neoplasm that affects the testis.  Representative examples include fibroma, thecoma, benign Sertoli cell tumor, seminoma, embryonal carcinoma, sarcoma, leukemia, and lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-061C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-03","modifiedBy":"ONEDATA","dateModified":"2006-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0389-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tetanus","valueDescription":"Tetanus","ValueMeaning":{"publicId":"3211476","version":"1","preferredName":"Tetanus","longName":"3211476","preferredDefinition":"A serious infectious disorder that follows wound contamination by the Gram-positive bacterium Clostridium tetani. The bacteria produce a neurotoxin called tetanospasmin, which causes muscle spasm in the jaw and other anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tetanus","conceptCode":"C85185","definition":"A serious infectious disorder that follows wound contamination by the Gram-positive bacterium Clostridium tetani. The bacteria produce a neurotoxin called tetanospasmin, which causes muscle spasm in the jaw and other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0395-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-03AB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thalamic Disease","valueDescription":"Thalamic Disease","ValueMeaning":{"publicId":"3211477","version":"1","preferredName":"Thalamic Disease","longName":"3211477","preferredDefinition":"A disorder of the thalamus. Causes include brain neoplasms, cerebrovascular disorders, brain trauma, brain hypoxia, infections, and brain hemorrhage. Signs and symptoms include movement and sensory abnormalities, visual abnormalities, ataxia, and coma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalamic Disease","conceptCode":"C85186","definition":"A disorder of the thalamus. Causes include brain neoplasms, cerebrovascular disorders, brain trauma, brain hypoxia, infections, and brain hemorrhage. Signs and symptoms include movement and sensory abnormalities, visual abnormalities, ataxia, and coma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-03B7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-03CD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thalassemia Major","valueDescription":"Thalassemia Major","ValueMeaning":{"publicId":"3211478","version":"1","preferredName":"Thalassemia Major","longName":"3211478","preferredDefinition":"An autosomal recessive disorder that affects the production of beta polypeptide chains which are necessary for the hemoglobin synthesis. Anemia and failure to thrive are characteristic features.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beta Thalassemia","conceptCode":"C34375","definition":"An autosomal recessive disorder that affects the production of beta polypeptide chains which are necessary for the hemoglobin synthesis. Anemia and failure to thrive are characteristic features.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-03D9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-03EF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thanatophoric Dysplasia","valueDescription":"Thanatophoric Dysplasia","ValueMeaning":{"publicId":"3211479","version":"1","preferredName":"Thanatophoric Dysplasia","longName":"3211479","preferredDefinition":"A severe autosomal dominant inherited disorder caused by mutations in the FGFR3 gene. It is characterized by multiple skeletal abnormalities, including extremely short limbs. It results in the death of the neonate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thanatophoric Dysplasia","conceptCode":"C85187","definition":"A severe autosomal dominant inherited disorder caused by mutations in the FGFR3 gene. It is characterized by multiple skeletal abnormalities, including extremely short limbs. It results in the death of the neonate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-03FB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0411-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thoracic Outlet Syndrome","valueDescription":"Thoracic Outlet Syndrome","ValueMeaning":{"publicId":"3211480","version":"1","preferredName":"Thoracic Outlet Syndrome","longName":"3211480","preferredDefinition":"A syndrome resulting from the compression of the blood vessels or nerves in the space between the clavicle and first rib (thoracic outlet). It is caused by car accident injuries or repetitive job or sport-related injuries. Signs and symptoms include pain in the shoulders and neck, numbness in the fingers, and weakening grip.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thoracic Outlet Syndrome","conceptCode":"C85188","definition":"A syndrome resulting from the compression of the blood vessels or nerves in the space between the clavicle and first rib (thoracic outlet). It is caused by car accident injuries or repetitive job or sport-related injuries. Signs and symptoms include pain in the shoulders and neck, numbness in the fingers, and weakening grip.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-041D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0433-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thyroglossal Duct Cyst","valueDescription":"Thyroglossal Duct Cyst","ValueMeaning":{"publicId":"3211481","version":"1","preferredName":"Thyroglossal Duct Cyst","longName":"3211481","preferredDefinition":"A congenital benign cyst arising from the remnants of the thyroglossal duct. It is usually located in the midline of the neck.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroglossal Duct Cyst","conceptCode":"C85189","definition":"A congenital benign cyst arising from the remnants of the thyroglossal duct. It is usually located in the midline of the neck.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-043F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0455-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thyroid Dysgenesis","valueDescription":"Thyroid Dysgenesis","ValueMeaning":{"publicId":"3211482","version":"1","preferredName":"Thyroid Dysgenesis","longName":"3211482","preferredDefinition":"A congenital condition characterized by hypoplasia, absence, or ectopic position of the thyroid gland. It is manifested with congenital hypoparathyroidism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Dysgenesis","conceptCode":"C85190","definition":"A congenital condition characterized by hypoplasia, absence, or ectopic position of the thyroid gland. It is manifested with congenital hypoparathyroidism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0461-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0477-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thyroid Hormone Resistance Syndrome","valueDescription":"Thyroid Hormone Resistance Syndrome","ValueMeaning":{"publicId":"3211483","version":"1","preferredName":"Thyroid Hormone Resistance Syndrome","longName":"3211483","preferredDefinition":"A rare, autosomal recessive inherited disorder usually caused by mutations in the THRB gene. It is characterized by a defective physiological resistance to thyroid hormones, resulting in the elevation of thyroxin and triiodothyronine in the serum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Hormone Resistance Syndrome","conceptCode":"C85191","definition":"A rare, autosomal recessive inherited disorder usually caused by mutations in the THRB gene. It is characterized by a defective physiological resistance to thyroid hormones, resulting in the elevation of thyroxin and triiodothyronine in the serum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0483-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0499-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Craniosynostosis","valueDescription":"Craniosynostosis","ValueMeaning":{"publicId":"3210992","version":"1","preferredName":"Craniosynostosis","longName":"3210992","preferredDefinition":"A congenital disorder characterized by earlier than normal closure of some or all sutures of the infant skull.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Craniosynostosis","conceptCode":"C84655","definition":"A congenital disorder characterized by earlier than normal closure of some or all sutures of the infant skull.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BEA2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BEB8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"CREST Syndrome","valueDescription":"CREST Syndrome","ValueMeaning":{"publicId":"2749581","version":"1","preferredName":"CREST Syndrome","longName":"2749581","preferredDefinition":"A variant of systemic sclerosis characterized by calcinosis, Raynaud phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CREST Syndrome","conceptCode":"C70646","definition":"A variant of systemic sclerosis characterized by calcinosis, Raynaud phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D22ACD9-29A4-4DC9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BECA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Creutzfeldt-Jacob Disease","valueDescription":"Creutzfeldt-Jacob Disease","ValueMeaning":{"publicId":"3210993","version":"1","preferredName":"Creutzfeldt-Jacob Disease","longName":"3210993","preferredDefinition":"A rare transmittable degenerative disorder of the brain caused by prions. Morphologically it is characterized by spongiform degeneration of the cerebral and cerebellar cortex. Signs and symptoms include sleep disturbances, personality changes, aphasia, ataxia, muscle atrophy and weakness, visual loss, and myoclonus. It usually leads to death within a year from the onset of the disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Creutzfeldt-Jakob Disease","conceptCode":"C26802","definition":"A rare transmittable degenerative disorder of the brain caused by prions. Morphologically it is characterized by spongiform degeneration of the cerebral and cerebellar cortex. Signs and symptoms include sleep disturbances, personality changes, aphasia, ataxia, muscle atrophy and weakness, visual loss, and myoclonus. It usually leads to death within a year from the onset of the disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BED6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BEEC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cri du Chat Syndrome","valueDescription":"Cri du Chat Syndrome","ValueMeaning":{"publicId":"3210994","version":"1","preferredName":"Cri du Chat Syndrome","longName":"3210994","preferredDefinition":"A genetic syndrome resulting from a partial deletion on the short arm of chromosome 5.  It is characterized by a cat-like cry in infancy, microcephaly, mental retardation, growth failure, round face, hypertelorism, and cardiac failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cri du Chat Syndrome","conceptCode":"C34518","definition":"A genetic syndrome resulting from a partial deletion on the short arm of chromosome 5. It is characterized by a cat-like cry in infancy, microcephaly, mental retardation, growth failure, round face, hypertelorism, and cardiac failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BEF8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BF0E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Crigler-Najjar Syndrome","valueDescription":"Crigler-Najjar Syndrome","ValueMeaning":{"publicId":"3210995","version":"1","preferredName":"Crigler-Najjar Syndrome","longName":"3210995","preferredDefinition":"A rare autosomal recessive inherited syndrome characterized by abnormalities in the metabolism of bilirubin. It results in the development of jaundice. It may cause brain damage in infancy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crigler-Najjar Syndrome","conceptCode":"C84656","definition":"A rare autosomal recessive inherited syndrome characterized by abnormalities in the metabolism of bilirubin. It results in the development of jaundice. It may cause brain damage in infancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BF1A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BF30-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cryopyrin-Associated Periodic Syndrome","valueDescription":"Cryopyrin-Associated Periodic Syndrome","ValueMeaning":{"publicId":"3210996","version":"1","preferredName":"Cryopyrin-Associated Periodic Syndrome","longName":"3210996","preferredDefinition":"A group of autoinflammatory syndromes caused by mutations in the NLRP3 gene. Signs and symptoms include rash, fever, headache, joint pain, conjunctivitis, and weakness. The symptoms may exacerbate with exposure to cold weather.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cryopyrin-Associated Periodic Syndrome","conceptCode":"C84657","definition":"A group of autoinflammatory syndromes caused by mutations in the NLRP3 gene. Signs and symptoms include rash, fever, headache, joint pain, conjunctivitis, and weakness. The symptoms may exacerbate with exposure to cold weather.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BF3C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BF52-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cutaneous Leishmaniasis","valueDescription":"Cutaneous Leishmaniasis","ValueMeaning":{"publicId":"3210997","version":"1","preferredName":"Cutaneous Leishmaniasis","longName":"3210997","preferredDefinition":"Leishmaniasis affecting the skin. It is the most common form of leishmaniasis. It presents with erythematous macules and papules, and nodules which may eventually ulcerate. The lesions appear in the bite site in the exposed skin areas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous Leishmaniasis","conceptCode":"C34768","definition":"Leishmaniasis affecting the skin. It is the most common form of leishmaniasis. It presents with erythematous macules and papules, and nodules which may eventually ulcerate. The lesions appear in the bite site in the exposed skin areas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BF5E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BF74-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cutaneous T-Cell Non-Hodgkin Lymphoma","valueDescription":"Cutaneous T-Cell Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"3210998","version":"1","preferredName":"Cutaneous T-Cell Non-Hodgkin Lymphoma","longName":"3210998","preferredDefinition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","conceptCode":"C3467","definition":"A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BF80-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BF96-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cutis Laxa","valueDescription":"Cutis Laxa","ValueMeaning":{"publicId":"3210999","version":"1","preferredName":"Cutis Laxa","longName":"3210999","preferredDefinition":"A congenital or acquired disorder affecting the elastic fibers of the skin. It is characterized by loss of elasticity resulting in loosening and folding of the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutis Laxa","conceptCode":"C84663","definition":"A congenital or acquired disorder affecting the elastic fibers of the skin. It is characterized by loss of elasticity resulting in loosening and folding of the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BFA2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BFB8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cysticercosis","valueDescription":"Cysticercosis","ValueMeaning":{"publicId":"3211000","version":"1","preferredName":"Cysticercosis","longName":"3211000","preferredDefinition":"A parasitic infection caused by the larval form of Taenia solium. It is a disseminated infection affecting the central nervous system, subcutaneous tissues, lungs, heart and liver. The most serious complications result from infection of the brain parenchyma. Patients may develop seizures, hydrocephalus, encephalopathy and meningoencephalitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cysticercosis","conceptCode":"C34520","definition":"A parasitic infection caused by the larval form of Taenia solium. It is a disseminated infection affecting the central nervous system, subcutaneous tissues, lungs, heart and liver. The most serious complications result from infection of the brain parenchyma. Patients may develop seizures, hydrocephalus, encephalopathy and meningoencephalitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BFC4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BFDA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cystinosis","valueDescription":"Cystinosis","ValueMeaning":{"publicId":"3211001","version":"1","preferredName":"Cystinosis","longName":"3211001","preferredDefinition":"An autosomal recessive hereditary disorder characterized by defective transportation of cystine across the lysosomal membranes and systemic deposition of cystine crystals in the body.  It is associated with slight increase of the plasma cystine, cystinuria, aminoaciduria, glycosuria, polyuria, hypophosphatemia, rickets, and renal tubular dysfunction. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cystinosis","conceptCode":"C2976","definition":"An autosomal recessive hereditary disorder characterized by defective transportation of cystine across the lysosomal membranes and systemic deposition of cystine crystals in the body. It is associated with slight increase of the plasma cystine, cystinuria, aminoaciduria, glycosuria, polyuria, hypophosphatemia, rickets, and renal tubular dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BFE6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-BFFC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cystinuria","valueDescription":"Cystinuria","ValueMeaning":{"publicId":"3211002","version":"1","preferredName":"Cystinuria","longName":"3211002","preferredDefinition":"An autosomal recessive inherited metabolic disorder caused by mutations in the SLC3A1 and SLC7A9 genes. It is characterized by deficient re-absorption of cystine in the proximal tubules of the kidney. It results in the formation of stones in the kidney, ureter, and urinary bladder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cystinuria","conceptCode":"C84664","definition":"An autosomal recessive inherited metabolic disorder caused by mutations in the SLC3A1 and SLC7A9 genes. It is characterized by deficient re-absorption of cystine in the proximal tubules of the kidney. It results in the formation of stones in the kidney, ureter, and urinary bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C008-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C01E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cytomegaloviral Infection","valueDescription":"Cytomegaloviral Infection","ValueMeaning":{"publicId":"3211003","version":"1","preferredName":"Cytomegaloviral Infection","longName":"3211003","preferredDefinition":"A herpesvirus infection caused by Cytomegalovirus. Healthy individuals generally do not produce symptoms. However, the infection may be life-threatening in affected immunocompromised patients. The virus may cause retinitis, esophagitis, gastritis, and colitis. Morphologically, it is characterized by the presence of intranuclear inclusion bodies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytomegaloviral Infection","conceptCode":"C53649","definition":"A herpesvirus infection caused by Cytomegalovirus. Healthy individuals generally do not produce symptoms. However, the infection may be life-threatening in affected immunocompromised patients. The virus may cause retinitis, esophagitis, gastritis, and colitis. Morphologically, it is characterized by the presence of intranuclear inclusion bodies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C02A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C040-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dandy-Walker Malformation","valueDescription":"Dandy-Walker Malformation","ValueMeaning":{"publicId":"3211004","version":"1","preferredName":"Dandy-Walker Malformation","longName":"3211004","preferredDefinition":"A rare congenital brain malformation disorder characterized by agenesis or hypoplasia of the cerebellar vermis, cystic dilatation of the fourth ventricle, and enlargement of the posterior fossa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dandy-Walker Malformation","conceptCode":"C75012","definition":"A rare congenital brain malformation disorder characterized by agenesis or hypoplasia of the cerebellar vermis, cystic dilatation of the fourth ventricle, and enlargement of the posterior fossa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C04C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C062-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Darier Disease","valueDescription":"Darier Disease","ValueMeaning":{"publicId":"3211005","version":"1","preferredName":"Darier Disease","longName":"3211005","preferredDefinition":"An autosomal dominant inherited chronic skin disorder caused by mutations in the ATP2A2 gene. It is characterized by the development of yellow-brown keratotic skin papules in the neck, ears, forehead, chest, back and groin. It is associated with fragility of the free margins of the nails.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darier Disease","conceptCode":"C84665","definition":"An autosomal dominant inherited chronic skin disorder caused by mutations in the ATP2A2 gene. It is characterized by the development of yellow-brown keratotic skin papules in the neck, ears, forehead, chest, back and groin. It is associated with fragility of the free margins of the nails.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C06E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C084-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"De Sanctis-Cacchione Syndrome","valueDescription":"De Sanctis-Cacchione Syndrome","ValueMeaning":{"publicId":"3211006","version":"1","preferredName":"De Sanctis-Cacchione Syndrome","longName":"3211006","preferredDefinition":"A rare autosomal recessive inherited syndrome. It is characterized by xeroderma pigmentosum, mental retardation, dwarfism, hypogonadism, and neurologic abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"De Sanctis-Cacchione Syndrome","conceptCode":"C84666","definition":"A rare autosomal recessive inherited syndrome. It is characterized by xeroderma pigmentosum, mental retardation, dwarfism, hypogonadism, and neurologic abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C090-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C0A6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Deafness","valueDescription":"Deafness","ValueMeaning":{"publicId":"3211007","version":"1","preferredName":"Deafness","longName":"3211007","preferredDefinition":"An inherited or acquired condition characterized by a partial or complete loss of hearing in one or both ears. The level of impairment varies from a mild but important loss of sensitivity to a total loss of hearing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deafness","conceptCode":"C27644","definition":"An inherited or acquired condition characterized by the inability to hear in one or both ears.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C0B2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C0C8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Deletion 18p Syndrome","valueDescription":"Deletion 18p Syndrome","ValueMeaning":{"publicId":"3211008","version":"1","preferredName":"Deletion 18p Syndrome","longName":"3211008","preferredDefinition":"A rare genetic syndrome characterized by the deletion of the short arm of chromosome 18. It is associated with mental and growth retardation, prominent ears and ptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deletion 18p Syndrome","conceptCode":"C84521","definition":"A rare genetic syndrome characterized by the deletion of the short arm of chromosome 18. It is associated with mental and growth retardation, prominent ears and ptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C0D4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C0EA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Deletion 18q Syndrome","valueDescription":"Deletion 18q Syndrome","ValueMeaning":{"publicId":"3211009","version":"1","preferredName":"Deletion 18q Syndrome","longName":"3211009","preferredDefinition":"A rare genetic syndrome characterized by the deletion of the long arm of chromosome 18. It is associated with short stature, hypotonia, mental retardation, and hand, foot, skull and facial abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deletion 18q Syndrome","conceptCode":"C84522","definition":"A condition in which some or all of the cells of the body contain extra genetic material from chromosome 18. Clinical features of this condition may include the following: spina bifida, hearing loss, cleft lip, cleft palate, undescended testes, rocker bottom feet, micrognathia, low set ears, cardiac anomalies (ventricular septal defect, atrial septal defect, patent ductus arteriosus, tetralogy of Fallot), intellectual disability, holoprosencephaly, pituitary dysplasia, seizures, autoimmune disorders, hip dysplasia, and/or congenital cataracts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C0F6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C10C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dengue Fever","valueDescription":"Dengue Fever","ValueMeaning":{"publicId":"3211010","version":"1","preferredName":"Dengue Fever","longName":"3211010","preferredDefinition":"An acute infection caused by Dengue virus. Signs and symptoms include sudden onset of fever, headache, rash, arthralgia, and myalgia. It is transmitted through mosquitoes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dengue Fever","conceptCode":"C34528","definition":"An acute infection caused by Dengue virus. Signs and symptoms include sudden onset of fever, headache, rash, arthralgia, and myalgia. It is transmitted through mosquitoes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C118-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C12E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dengue Hemorrhagic Fever","valueDescription":"Dengue Hemorrhagic Fever","ValueMeaning":{"publicId":"3211011","version":"1","preferredName":"Dengue Hemorrhagic Fever","longName":"3211011","preferredDefinition":"A serious condition caused by Dengue virus infection. Patients present with an acute febrile illness followed by restlessness, irritability, and bleeding. It may lead to hemorrhagic shock and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dengue Hemorrhagic Fever","conceptCode":"C34683","definition":"A serious condition caused by Dengue virus infection. Patients present with an acute febrile illness followed by restlessness, irritability, and bleeding. It may lead to hemorrhagic shock and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C13A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C150-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dentinogenesis Imperfecta","valueDescription":"Dentinogenesis Imperfecta","ValueMeaning":{"publicId":"3211012","version":"1","preferredName":"Dentinogenesis Imperfecta","longName":"3211012","preferredDefinition":"A congenital tooth development disorder caused by mutations in the DSPP gene. The teeth are weak, discolored, and translucent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dentinogenesis Imperfecta","conceptCode":"C84667","definition":"A congenital tooth development disorder caused by mutations in the DSPP gene. The teeth are weak, discolored, and translucent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C15C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C172-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Denys-Drash Syndrome","valueDescription":"Denys-Drash Syndrome","ValueMeaning":{"publicId":"3211013","version":"1","preferredName":"Denys-Drash Syndrome","longName":"3211013","preferredDefinition":"A rare congenital syndrome caused by mutations in the WT1 gene. It is characterized by the presence of congenital nephropathy (diffuse mesangial sclerosis), Wilms tumor, and intersex disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denys-Drash Syndrome","conceptCode":"C84668","definition":"A rare congenital syndrome caused by mutations in the WT1 gene. It is characterized by the presence of congenital nephropathy (diffuse mesangial sclerosis), Wilms tumor, and intersex disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C17E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C194-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dermatitis Herpetiformis","valueDescription":"Dermatitis Herpetiformis","ValueMeaning":{"publicId":"3211014","version":"1","preferredName":"Dermatitis Herpetiformis","longName":"3211014","preferredDefinition":"A chronic autoimmune skin disorder characterized by the development of pruritic papulovesicular and bullous lesions in the elbows, knees, buttocks, and back. It is associated with an increased expression of HLA-A1, HLA-B8, and HLA-DR3 antibodies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dermatitis Herpetiformis","conceptCode":"C26742","definition":"A chronic autoimmune skin disorder characterized by the development of pruritic papulovesicular and bullous lesions in the elbows, knees, buttocks, and back. It is associated with an increased expression of HLA-A1, HLA-B8, and HLA-DR3 antibodies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C1A0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C1B6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dextrocardia","valueDescription":"Dextrocardia","ValueMeaning":{"publicId":"3211015","version":"1","preferredName":"Dextrocardia","longName":"3211015","preferredDefinition":"A rare congenital abnormality in which the heart is located in the right side of the chest. It is associated with other congenital heart defects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dextrocardia","conceptCode":"C84669","definition":"A rare congenital abnormality in which the heart is located in the right side of the chest. It is associated with other congenital heart defects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C1C2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C1D8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Diabetes Insipidus","valueDescription":"Diabetes Insipidus","ValueMeaning":{"publicId":"3211016","version":"1","preferredName":"Diabetes Insipidus","longName":"3211016","preferredDefinition":"A disorder characterized by excretion of large amounts of urine, accompanied by excessive thirst. Causes include deficiency of antidiuretic hormone or failure of the kidneys to respond to antidiuretic hormone. It may also be drug-related.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diabetes Insipidus","conceptCode":"C43263","definition":"A disorder characterized by excretion of large amounts of urine, accompanied by excessive thirst. Causes include deficiency of antidiuretic hormone or failure of the kidneys to respond to antidiuretic hormone. It may also be drug-related.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C1E4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C1FA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Diffuse Cerebral Sclerosis of Schilder","valueDescription":"Diffuse Cerebral Sclerosis of Schilder","ValueMeaning":{"publicId":"3211017","version":"1","preferredName":"Diffuse Cerebral Sclerosis of Schilder","longName":"3211017","preferredDefinition":"A rare congenital demyelinating disorder affecting the central nervous system. It is characterized by a demyelinating destructive lesion affecting an entire brain lobe or hemisphere. Signs and symptoms include dementia, cortical deafness and blindness, pseudobulbar palsy, and hemiplegia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Cerebral Sclerosis of Schilder","conceptCode":"C84670","definition":"A rare congenital demyelinating disorder affecting the central nervous system. It is characterized by a demyelinating destructive lesion affecting an entire brain lobe or hemisphere. Signs and symptoms include dementia, cortical deafness and blindness, pseudobulbar palsy, and hemiplegia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C218-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C22E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Diffuse Idiopathic Skeletal Hyperostosis","valueDescription":"Diffuse Idiopathic Skeletal Hyperostosis","ValueMeaning":{"publicId":"3211018","version":"1","preferredName":"Diffuse Idiopathic Skeletal Hyperostosis","longName":"3211018","preferredDefinition":"A rare degenerative disorder that affects the spine. It is characterized by ossification of ligaments resulting in calcifications along the sides of the spinal vertebrae.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Idiopathic Skeletal Hyperostosis","conceptCode":"C84671","definition":"A rare degenerative disorder that affects the spine. It is characterized by ossification of ligaments resulting in calcifications along the sides of the spinal vertebrae.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C23A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C250-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Diffuse Palmoplantar Keratoderma","valueDescription":"Diffuse Palmoplantar Keratoderma","ValueMeaning":{"publicId":"3211019","version":"1","preferredName":"Diffuse Palmoplantar Keratoderma","longName":"3211019","preferredDefinition":"An inherited disorder characterized by the development of keratotic lesions on the palms and soles. It appears in childhood as redness on the palms and soles which progresses to well demarcated, thickened, yellowish and waxy lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tylosis","conceptCode":"C3147","definition":"An inherited disorder characterized by the development of keratotic lesions on the palms and soles. It appears in childhood as redness on the palms and soles which progresses to well demarcated, thickened, yellowish and waxy lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C25C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C272-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"DiGeorge Syndrome","valueDescription":"DiGeorge Syndrome","ValueMeaning":{"publicId":"2593391","version":"1","preferredName":"DiGeorge Syndrome","longName":"2593391","preferredDefinition":"A congenital anomaly characterized by immunodeficiency, abnormal facies, congenital heart disease, hypocalcemia, and increased susceptibility to infections. Pathologic characteristics include conotruncal abnormalities and absence or hypoplasia of thymus and parathyroid glands. DiGeorge syndrome is associated with abnormalities of chromosome 22. Also known as DiGeorge anomaly. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"22q11.2 Deletion Syndrome","conceptCode":"C2989","definition":"A congenital anomaly characterized by immunodeficiency, abnormal facies, congenital heart disease, hypocalcemia, and increased susceptibility to infections. Pathologic characteristics include conotruncal abnormalities and absence or hypoplasia of thymus and parathyroid glands. DiGeorge syndrome is associated with abnormalities of chromosome 22. Also known as DiGeorge anomaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28850FD4-AA29-5B37-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C284-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dihydropyrimidine Dehydrogenase Deficiency","valueDescription":"Dihydropyrimidine Dehydrogenase Deficiency","ValueMeaning":{"publicId":"3211020","version":"1","preferredName":"Dihydropyrimidine Dehydrogenase Deficiency","longName":"3211020","preferredDefinition":"A rare disorder characterized by an inborn error in pyrimidine metabolism. It results in the deficiency or complete absence of the enzyme dihydropyrimidine dehydrogenase. Individuals with this disorder may develop a severe toxicity reaction if they are exposed to the chemotherapeutic agent 5-fluorouracil.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dihydropyrimidine Dehydrogenase Deficiency","conceptCode":"C84672","definition":"A rare disorder characterized by an inborn error in pyrimidine metabolism. It results in the deficiency or complete absence of the enzyme dihydropyrimidine dehydrogenase. Individuals with this disorder may develop a severe toxicity reaction if they are exposed to the chemotherapeutic agent 5-fluorouracil.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C290-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C2A6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dilated Cardiomyopathy","valueDescription":"Dilated Cardiomyopathy","ValueMeaning":{"publicId":"3211021","version":"1","preferredName":"Dilated Cardiomyopathy","longName":"3211021","preferredDefinition":"Cardiomyopathy which is characterized by dilation and contractile dysfunction of the left and right ventricles. It may be idiopathic, or it may result from a myocardial infarction, myocardial infection, or alcohol abuse. It is a cause of congestive heart failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dilated Cardiomyopathy","conceptCode":"C84673","definition":"Cardiomyopathy which is characterized by dilation and contractile dysfunction of the left and right ventricles. It may be idiopathic, or it may result from a myocardial infarction, myocardial infection, or alcohol abuse. It is a cause of congestive heart failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C2B2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C2C8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dipetalonemiasis","valueDescription":"Dipetalonemiasis","ValueMeaning":{"publicId":"3211022","version":"1","preferredName":"Dipetalonemiasis","longName":"3211022","preferredDefinition":"A parasitic infection caused by genus of filarial worms called Dipetalonema. It produces microfilariae in the blood and body fluids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dipetalonemiasis","conceptCode":"C34540","definition":"A parasitic infection caused by genus of filarial worms called Dipetalonema. It produces microfilariae in the blood and body fluids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C2D4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C2EA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Distal Muscular Dystrophy","valueDescription":"Distal Muscular Dystrophy","ValueMeaning":{"publicId":"3211023","version":"1","preferredName":"Distal Muscular Dystrophy","longName":"3211023","preferredDefinition":"A group of genetic degenerative muscle disorders affecting the muscles of the lower arms, hands, lower legs, and feet.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Distal Muscular Dystrophy","conceptCode":"C84675","definition":"A group of genetic degenerative muscle disorders affecting the muscles of the lower arms, hands, lower legs, and feet.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C2F6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C30C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Donohue Syndrome","valueDescription":"Donohue Syndrome","ValueMeaning":{"publicId":"3211024","version":"1","preferredName":"Donohue Syndrome","longName":"3211024","preferredDefinition":"A rare autosomal recessive genetic disorder caused by mutations in the insulin receptor gene. Signs and symptoms include a characteristic facial appearance (protuberant and low-set ears, thick lips, and flaring nostrils), intrauterine growth retardation, insulin resistance, and enlarged genitalia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Donohue Syndrome","conceptCode":"C84676","definition":"A rare autosomal recessive genetic disorder caused by mutations in the insulin receptor gene. Signs and symptoms include a characteristic facial appearance (protuberant and low-set ears, thick lips, and flaring nostrils), intrauterine growth retardation, insulin resistance, and enlarged genitalia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C318-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C32E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Down Syndrome","valueDescription":"Down Syndrome","ValueMeaning":{"publicId":"2730288","version":"1","preferredName":"Down Syndrome","longName":"2730288","preferredDefinition":"A disorder caused by the presence of an extra chromosome 21 and characterized by mental retardation and distinguishing physical features.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Down Syndrome","conceptCode":"C2993","definition":"A chromosomal dysgenesis syndrome resulting from a triplication or translocation of chromosome 21. Down syndrome occurs in approximately 1:700 live births. Abnormalities are variable from individual to individual and may include mental retardation, retarded growth, flat hypoplastic face with short nose, prominent epicanthic skin folds, small low-set ears with prominent antihelix, fissured and thickened tongue, laxness of joint ligaments, pelvic dysplasia, broad hands and feet, stubby fingers, transverse palmar crease, lenticular opacities and heart disease. Patients with Down syndrome have an estimated 10 to 30-fold increased risk for leukemia; most have symptoms of Alzheimer's disease by age 40. Also known as trisomy 21 syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"468669DD-300B-4A98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C338-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dracunculiasis","valueDescription":"Dracunculiasis","ValueMeaning":{"publicId":"3211025","version":"1","preferredName":"Dracunculiasis","longName":"3211025","preferredDefinition":"A parasitic infection caused by Dracunculus medinensis. It is caused by drinking water contaminated with water fleas. The larvae enter the body through the intestine. Signs and symptoms include pain, edema, blisters, and ulcers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dracunculiasis","conceptCode":"C84677","definition":"A parasitic infection caused by Dracunculus medinensis. It is caused by drinking water contaminated with water fleas. The larvae enter the body through the intestine. Signs and symptoms include pain, edema, blisters, and ulcers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C344-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C35A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dry Eye Syndrome","valueDescription":"Dry Eye Syndrome","ValueMeaning":{"publicId":"2944487","version":"1","preferredName":"Dry Eye Syndrome","longName":"2944487","preferredDefinition":"A syndrome characterized by dryness of the cornea and conjunctiva. It is usually caused by a deficiency in tear production. Symptoms include a feeling of burning eyes and a possible foreign body presence in the eye.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dry Eye Syndrome","conceptCode":"C34553","definition":"A syndrome characterized by dryness of the cornea and conjunctiva. It is usually caused by a deficiency in tear production. Symptoms include a feeling of burning eyes and a possible foreign body presence in the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74331C4B-D72C-D41C-E040-BB89AD435AA5","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C36C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Duane Syndrome","valueDescription":"Duane Syndrome","ValueMeaning":{"publicId":"3211026","version":"1","preferredName":"Duane Syndrome","longName":"3211026","preferredDefinition":"A rare disorder affecting the muscles of the eye. It is characterized by an abnormal contraction of some eye muscles and failure of contraction of other eye muscles. It leads to limited abduction and adduction of the affected eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duane Syndrome","conceptCode":"C84678","definition":"A rare disorder affecting the muscles of the eye. It is characterized by an abnormal contraction of some eye muscles and failure of contraction of other eye muscles. It leads to limited abduction and adduction of the affected eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C378-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C38E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dubin-Johnson Syndrome","valueDescription":"Dubin-Johnson Syndrome","ValueMeaning":{"publicId":"3211027","version":"1","preferredName":"Dubin-Johnson Syndrome","longName":"3211027","preferredDefinition":"An inherited autosomal recessive disorder characterized by the presence of mild jaundice due to abnormalities in the bilirubin transportation from the liver parenchyma to the biliary system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dubin-Johnson Syndrome","conceptCode":"C34741","definition":"An inherited autosomal recessive disorder characterized by the presence of mild jaundice due to abnormalities in the bilirubin transportation from the liver parenchyma to the biliary system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C39A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C3B0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Duchenne Muscular Dystrophy","valueDescription":"Duchenne Muscular Dystrophy","ValueMeaning":{"publicId":"3211028","version":"1","preferredName":"Duchenne Muscular Dystrophy","longName":"3211028","preferredDefinition":"An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome.  It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body.  It affects males whereas females can be carriers.  The symptoms start before the age of six and may appear at infancy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duchenne Muscular Dystrophy","conceptCode":"C75482","definition":"An X-linked inherited disorder caused by mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C3BC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C3D2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dystrophia Myotonica 1","valueDescription":"Dystrophia Myotonica 1","ValueMeaning":{"publicId":"3211029","version":"1","preferredName":"Dystrophia Myotonica 1","longName":"3211029","preferredDefinition":"A rare autosomal dominant disorder caused by mutations in the DMPK gene. It is characterized by myotonia, muscular dystrophy, hypogonadism, heart conduction defects and cataracts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dystrophia Myotonica 1","conceptCode":"C84679","definition":"A rare autosomal dominant disorder caused by mutations in the DMPK gene. It is characterized by myotonia, muscular dystrophy, hypogonadism, heart conduction defects and cataracts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C3DE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C3F4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dystrophia Myotonica 2","valueDescription":"Dystrophia Myotonica 2","ValueMeaning":{"publicId":"3211030","version":"1","preferredName":"Dystrophia Myotonica 2","longName":"3211030","preferredDefinition":"A rare autosomal dominant disorder caused by mutations in the CNBP gene. It is characterized by muscle pain, fatigue, and weakness of the proximal muscles of the lower extremities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dystrophia Myotonica 2","conceptCode":"C84680","definition":"A rare autosomal dominant disorder caused by mutations in the CNBP gene. It is characterized by muscle pain, fatigue, and weakness of the proximal muscles of the lower extremities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C400-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C416-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ebstein Anomaly","valueDescription":"Ebstein Anomaly","ValueMeaning":{"publicId":"3211031","version":"1","preferredName":"Ebstein Anomaly","longName":"3211031","preferredDefinition":"A congenital heart malformation characterized by apical displacement of the opening of the tricuspid valve. It is often associated with other congenital heart malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ebstein Anomaly","conceptCode":"C84681","definition":"A rare congenital heart malformation characterized by apical displacement of the opening of the tricuspid valve. The defect involves both the right ventricle and the tricuspid valve, and can lead to cardiomyopathy and tachyarrhythmias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C422-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C438-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Eccrine Porocarcinoma","valueDescription":"Eccrine Porocarcinoma","ValueMeaning":{"publicId":"3211032","version":"1","preferredName":"Eccrine Porocarcinoma","longName":"3211032","preferredDefinition":"A carcinoma with eccrine differentiation arising from the sweat glands. It may arise de novo or as a malignant transformation of a pre-existing poroma. It usually grows in the legs, buttocks, feet, and trunk and usually presents as an ulcerative plaque. It is characterized by the presence of intraepidermal and dermal nests of malignant epithelial cells. It may recur after excision and metastasize to the lymph nodes and less frequently to distal anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Porocarcinoma","conceptCode":"C5560","definition":"A carcinoma with eccrine differentiation arising from the sweat glands. It may arise de novo or as a malignant transformation of a pre-existing poroma. It usually grows in the legs, buttocks, feet, and trunk and usually presents as an ulcerative plaque. It is characterized by the presence of intraepidermal and dermal nests of malignant epithelial cells. It may recur after excision and metastasize to the lymph nodes and less frequently to distal anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C444-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C45A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Echinococcosis","valueDescription":"Echinococcosis","ValueMeaning":{"publicId":"3211033","version":"1","preferredName":"Echinococcosis","longName":"3211033","preferredDefinition":"A parasitic infection caused by tapeworm larvae of Echinococcus. It affects livestock and humans. It is characterized by the formation of hydatid cysts mainly in the liver, lungs, spleen, and kidneys. Rupture of the cysts may lead to shock.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Echinococcosis","conceptCode":"C84682","definition":"A parasitic infection caused by tapeworm larvae of Echinococcus. It affects livestock and humans. It is characterized by the formation of hydatid cysts mainly in the liver, lungs, spleen, and kidneys. Rupture of the cysts may lead to shock.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C466-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C47C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ectodermal Dysplasia","valueDescription":"Ectodermal Dysplasia","ValueMeaning":{"publicId":"3211034","version":"1","preferredName":"Ectodermal Dysplasia","longName":"3211034","preferredDefinition":"A group of inherited disorders characterized by malformations of the structures that derive from the ectoderm, such as hair, teeth, nails and sweat glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ectodermal Dysplasia","conceptCode":"C84683","definition":"A group of inherited disorders characterized by malformations of the structures that derive from the ectoderm, such as hair, teeth, nails and sweat glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C488-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C49E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ectromelia","valueDescription":"Ectromelia","ValueMeaning":{"publicId":"3211035","version":"1","preferredName":"Ectromelia","longName":"3211035","preferredDefinition":"A congenital defect characterized by the absence or hypoplasia of one or more extremities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ectromelia","conceptCode":"C34567","definition":"A congenital defect characterized by the absence or hypoplasia of one or more extremities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C4AA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C4C0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ehlers-Danlos Syndrome","valueDescription":"Ehlers-Danlos Syndrome","ValueMeaning":{"publicId":"3211036","version":"1","preferredName":"Ehlers-Danlos Syndrome","longName":"3211036","preferredDefinition":"An inherited connective tissue disorder characterized by loose and fragile skin and joint hypermobility.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ehlers-Danlos Syndrome","conceptCode":"C34568","definition":"An inherited connective tissue disorder characterized by loose and fragile skin and joint hypermobility.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C4CC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C4E2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ellis-Van Creveld Syndrome","valueDescription":"Ellis-Van Creveld Syndrome","ValueMeaning":{"publicId":"3211037","version":"1","preferredName":"Ellis-Van Creveld Syndrome","longName":"3211037","preferredDefinition":"A rare autosomal recessive syndrome caused by mutations in the EVC gene. It is characterized by dwarfism, small chest, ectodermal dysplasia, and postaxial polydactyly. There is an increased frequency of congenital heart malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ellis-Van Creveld Syndrome","conceptCode":"C84684","definition":"A rare autosomal recessive syndrome caused by mutations in the EVC gene. It is characterized by dwarfism, small chest, ectodermal dysplasia, and postaxial polydactyly. There is an increased frequency of congenital heart malformations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C4EE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C504-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Emery-Dreifuss Muscular Dystrophy","valueDescription":"Emery-Dreifuss Muscular Dystrophy","ValueMeaning":{"publicId":"3211038","version":"1","preferredName":"Emery-Dreifuss Muscular Dystrophy","longName":"3211038","preferredDefinition":"An X-linked or autosomal dominant inherited muscular dystrophy. It is characterized by slowly progressive muscle weakness, atrial conduction defects, cardiomyopathy, and early contractures of the elbow, ankle and neck.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emery-Dreifuss Muscular Dystrophy","conceptCode":"C84685","definition":"An X-linked or autosomal dominant inherited muscular dystrophy. It is characterized by slowly progressive muscle weakness, atrial conduction defects, cardiomyopathy, and early contractures of the elbow, ankle and neck.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C510-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C526-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Togaviridae Infection","valueDescription":"Togaviridae Infection","ValueMeaning":{"publicId":"3211484","version":"1","preferredName":"Togaviridae Infection","longName":"3211484","preferredDefinition":"A viral infection caused by any of the arboviruses of the Togaviridae family. It is transmitted by arthropods. Signs and symptoms include fever, headache, nausea, vomiting, rash, confusion, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Togaviridae Infection","conceptCode":"C85192","definition":"A viral infection caused by any of the arboviruses of the Togaviridae family. It is transmitted by arthropods. Signs and symptoms include fever, headache, nausea, vomiting, rash, confusion, and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-04A5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-04BB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tolosa-Hunt Syndrome","valueDescription":"Tolosa-Hunt Syndrome","ValueMeaning":{"publicId":"3211485","version":"1","preferredName":"Tolosa-Hunt Syndrome","longName":"3211485","preferredDefinition":"A disorder characterized by unilateral acute orbital pain associated with muscle weakness or paralysis of the orbital muscles. It is caused by non-specific inflammation of the cavernous sinus or superior orbital fissure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tolosa-Hunt Syndrome","conceptCode":"C85193","definition":"A disorder characterized by unilateral acute orbital pain associated with muscle weakness or paralysis of the orbital muscles. It is caused by non-specific inflammation of the cavernous sinus or superior orbital fissure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-04C7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-04DD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tourette Syndrome","valueDescription":"Tourette Syndrome","ValueMeaning":{"publicId":"3189981","version":"1","preferredName":"Tourette Syndrome","longName":"3189981","preferredDefinition":"A neurologic disorder caused by defective metabolism of the neurotransmitters in the brain. It is characterized by repeated involuntary movements (motor tics) and uncontrollable vocal sounds (vocal tics). The symptoms are usually manifested before the age of eighteen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tourette Syndrome","conceptCode":"C35078","definition":"A neurologic disorder caused by defective metabolism of the neurotransmitters in the brain. It is characterized by repeated involuntary movements (motor tics) and uncontrollable vocal sounds (vocal tics). The symptoms are usually manifested before the age of eighteen.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BB79EEF-2AD6-2B91-E040-BB89AD430720","latestVersionIndicator":"Yes","beginDate":"2011-02-07","endDate":null,"createdBy":"LUY","dateCreated":"2011-02-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-04E7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bacterial Toxemia","valueDescription":"Bacterial Toxemia","ValueMeaning":{"publicId":"3211486","version":"1","preferredName":"Bacterial Toxemia","longName":"3211486","preferredDefinition":"The condition resulting from the spread of bacterial products (toxins) by the bloodstream.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bacterial Toxemia","conceptCode":"C50780","definition":"The condition resulting from the spread of bacterial products (toxins) by the bloodstream.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-04F3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0509-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Toxic Epidermal Necrolysis","valueDescription":"Toxic Epidermal Necrolysis","ValueMeaning":{"publicId":"2944519","version":"1","preferredName":"Toxic Epidermal Necrolysis","longName":"2944519","preferredDefinition":"A systemic, serious, and life-threatening disorder characterized by erythematous and necrotic lesions in the skin and mucous membranes that are associated with bullous detachment of the epidermis. The epidermal and mucous membranes detachment leads to sepsis and may be fatal. The lesions appear throughout the body and occupy more than 30% of the body surfaces. It is a hypersensitivity reaction usually caused by drugs (e.g., sulfonamides, nonsteroidal anti-inflammatory drugs, anticonvulsants, and antiretroviral drugs).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toxic Epidermal Necrolysis","conceptCode":"C79777","definition":"A systemic, serious, and life-threatening disorder characterized by erythematous and necrotic lesions in the skin and mucous membranes that are associated with bullous detachment of the epidermis. The epidermal and mucous membranes detachment leads to sepsis and may be fatal. The lesions appear throughout the body and occupy more than 30% of the body surfaces. It is a hypersensitivity reaction usually caused by drugs (e.g., sulfonamides, nonsteroidal anti-inflammatory drugs, anticonvulsants, and antiretroviral drugs).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"743C896C-214F-79F1-E040-BB89AD4359CF","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-051B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Toxocariasis","valueDescription":"Toxocariasis","ValueMeaning":{"publicId":"3211487","version":"1","preferredName":"Toxocariasis","longName":"3211487","preferredDefinition":"A parasitic infection caused by Toxocara. Humans are infected by the larvae of Toxocara canis and Toxocara cati from dogs and cats respectively. Most cases remain asymptomatic. The parasites may affect the eye, causing diminished vision, or other major organs, causing hepatomegaly, eosinophilia, wheezing, and coughing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toxocariasis","conceptCode":"C85194","definition":"A parasitic infection caused by Toxocara. Humans are infected by the larvae of Toxocara canis and Toxocara cati from dogs and cats respectively. Most cases remain asymptomatic. The parasites may affect the eye, causing diminished vision, or other major organs, causing hepatomegaly, eosinophilia, wheezing, and coughing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0527-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-053D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tracheobronchomalacia","valueDescription":"Tracheobronchomalacia","ValueMeaning":{"publicId":"3211488","version":"1","preferredName":"Tracheobronchomalacia","longName":"3211488","preferredDefinition":"A rare congenital or acquired disorder characterized by excessive collapsibility of the trachea and major bronchi resulting in breathing problems. It is caused by damage to the tracheobronchial cartilage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tracheobronchomalacia","conceptCode":"C85195","definition":"A rare congenital or acquired disorder characterized by excessive collapsibility of the trachea and major bronchi resulting in breathing problems. It is caused by damage to the tracheobronchial cartilage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0549-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-055F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tracheobronchomegaly","valueDescription":"Tracheobronchomegaly","ValueMeaning":{"publicId":"3211489","version":"1","preferredName":"Tracheobronchomegaly","longName":"3211489","preferredDefinition":"A rare syndrome of unknown etiology, characterized by marked dilatation of the lumen of the trachea and the main bronchi. It results in bronchiectasis and recurrent lung infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tracheobronchomegaly","conceptCode":"C85196","definition":"A rare syndrome of unknown etiology, characterized by marked dilatation of the lumen of the trachea and the main bronchi. It results in bronchiectasis and recurrent lung infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-056B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0581-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tracheoesophageal Fistula","valueDescription":"Tracheoesophageal Fistula","ValueMeaning":{"publicId":"3211490","version":"1","preferredName":"Tracheoesophageal Fistula","longName":"3211490","preferredDefinition":"A congenital or acquired abnormal communication between the trachea and the esophagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tracheoesophageal Fistula","conceptCode":"C35080","definition":"A congenital or acquired abnormal communication between the trachea and the esophagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-058D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-05A3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Transient Global Amnesia","valueDescription":"Transient Global Amnesia","ValueMeaning":{"publicId":"3211491","version":"1","preferredName":"Transient Global Amnesia","longName":"3211491","preferredDefinition":"A condition characterized by sudden, temporary, usually short-lived memory loss, not associated with a neurologic disorder. Affected individuals lose memory function for recent events and have a decreased ability to retain new information. It is usually a solitary event.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transient Global Amnesia","conceptCode":"C85198","definition":"A condition characterized by sudden, temporary, usually short-lived memory loss, not associated with a neurologic disorder. Affected individuals lose memory function for recent events and have a decreased ability to retain new information. It is usually a solitary event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-05AF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-05C5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Treacher Collins Syndrome","valueDescription":"Treacher Collins Syndrome","ValueMeaning":{"publicId":"3211492","version":"1","preferredName":"Treacher Collins Syndrome","longName":"3211492","preferredDefinition":"A rare autosomal dominant syndrome caused by mutations in the TCOF1 gene.  Its characteristics include underdevelopment of the facial bones, small jaw and chin, absent or small ears, defects in the middle ear resulting in hearing loss, and downward sloping palpebral fissures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treacher Collins Syndrome","conceptCode":"C75018","definition":"A rare autosomal dominant syndrome caused by mutations in the TCOF1 gene. Its characteristics include underdevelopment of the facial bones, small jaw and chin, absent or small ears, defects in the middle ear resulting in hearing loss, and downward sloping palpebral fissures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-05D1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-05E7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Treponemal Infection","valueDescription":"Treponemal Infection","ValueMeaning":{"publicId":"3211493","version":"1","preferredName":"Treponemal Infection","longName":"3211493","preferredDefinition":"A sexually transmitted infection caused by the Gram-negative spirochete Treponema pallidum. It is manifested as syphilis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treponemal Infection","conceptCode":"C85197","definition":"A sexually transmitted infection caused by the Gram-negative spirochete Treponema pallidum. It is manifested as syphilis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-05F3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0609-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Trichinosis","valueDescription":"Trichinosis","ValueMeaning":{"publicId":"3211494","version":"1","preferredName":"Trichinosis","longName":"3211494","preferredDefinition":"A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trichinosis","conceptCode":"C85199","definition":"A parasitic infection caused by larvae of worms of the genus Trichinella. It is transmitted to humans by ingesting raw or undercooked meat from infected animals. Signs and symptoms include abdominal discomfort, nausea, vomiting, fever, diarrhea, headache, coughing, myalgias, arthralgias, and eye swelling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0615-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-062B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Trichorhinophalangeal Syndrome Type II","valueDescription":"Trichorhinophalangeal Syndrome Type II","ValueMeaning":{"publicId":"3211495","version":"1","preferredName":"Trichorhinophalangeal Syndrome Type II","longName":"3211495","preferredDefinition":"A rare, usually sporadic and less frequently familiar syndrome caused by deletions on the long arm of chromosome 8.  It is characterized by distinctive facial appearance (sparse hair, pear-shaped nose, and large ears), multiple exostoses, redundant skin, and mental retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trichorhinophalangeal Syndrome Type II","conceptCode":"C75118","definition":"A rare, usually sporadic and less frequently familiar syndrome caused by deletions on the long arm of chromosome 8. It is characterized by distinctive facial appearance (sparse hair, pear-shaped nose, and large ears), multiple exostoses, redundant skin, and mental retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0637-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-064D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Trichothiodystrophy","valueDescription":"Trichothiodystrophy","ValueMeaning":{"publicId":"3211496","version":"1","preferredName":"Trichothiodystrophy","longName":"3211496","preferredDefinition":"A rare, autosomal recessive inherited syndrome characterized by brittle hair, mental and physical retardation, and decreased fertility.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trichothiodystrophy","conceptCode":"C4924","definition":"A rare, autosomal recessive inherited syndrome characterized by brittle hair, mental and physical retardation, and decreased fertility.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0659-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-066F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tricuspid Atresia","valueDescription":"Tricuspid Atresia","ValueMeaning":{"publicId":"3211497","version":"1","preferredName":"Tricuspid Atresia","longName":"3211497","preferredDefinition":"A congenital heart defect characterized by the complete lack of formation of the tricuspid valve. Cyanosis is the predominant clinical symptom.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tricuspid Valve Atresia","conceptCode":"C85202","definition":"A congenital heart defect characterized by the complete lack of formation of the tricuspid valve. Cyanosis is the predominant clinical symptom.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-067B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0691-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Trigger Finger Disorder","valueDescription":"Trigger Finger Disorder","ValueMeaning":{"publicId":"3211498","version":"1","preferredName":"Trigger Finger Disorder","longName":"3211498","preferredDefinition":"A painful hand deformity affecting the fingers. It is due to damage of the finger flexor tendons, causing the finger to remain in a locked position.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trigger Finger Disorder","conceptCode":"C85203","definition":"A painful hand deformity affecting the fingers. It is due to damage of the finger flexor tendons, causing the finger to remain in a locked position.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-069D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-06B3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Triploidy Syndrome","valueDescription":"Triploidy Syndrome","ValueMeaning":{"publicId":"3211499","version":"1","preferredName":"Triploidy Syndrome","longName":"3211499","preferredDefinition":"A very rare congenital syndrome characterized by the presence of three haploid sets of chromosomes. The surviving infants have multiple severe birth defects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triploidy Syndrome","conceptCode":"C85204","definition":"A very rare congenital syndrome characterized by the presence of three haploid sets of chromosomes. The surviving infants have multiple severe birth defects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-06BF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-06D5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Trismus","valueDescription":"Trismus","ValueMeaning":{"publicId":"2944001","version":"1","preferredName":"Trismus","longName":"2944001","preferredDefinition":"Lack of ability to open the mouth fully due to decreased range of motion of the muscles of mastication. It may be a symptom of tetanus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trismus","conceptCode":"C78651","definition":"Lack of ability to open the mouth fully due to decreased range of motion of the muscles of mastication. It may be a symptom of tetanus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742DD56B-1107-A7E6-E040-BB89AD43063D","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-06DF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Trisomy 12","valueDescription":"Trisomy 12","ValueMeaning":{"publicId":"3211500","version":"1","preferredName":"Trisomy 12","longName":"3211500","preferredDefinition":"A chromosomal abnormality consisting of the presence of a third copy of chromosome 12 in somatic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trisomy 12","conceptCode":"C36420","definition":"A chromosomal abnormality consisting of the presence of a third copy of chromosome 12 in somatic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-06EB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0701-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Trisomy 8","valueDescription":"Trisomy 8","ValueMeaning":{"publicId":"2762293","version":"1","preferredName":"Trisomy 8","longName":"2762293","preferredDefinition":"A chromosomal abnormality consisting of the presence of a third copy of chromosome 8 in somatic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trisomy 8","conceptCode":"C36396","definition":"A chromosomal abnormality consisting of the presence of a third copy of chromosome 8 in somatic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"510ADE83-013B-56CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0725-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Trisomy 9","valueDescription":"Trisomy 9","ValueMeaning":{"publicId":"3211501","version":"1","preferredName":"Trisomy 9","longName":"3211501","preferredDefinition":"A chromosomal abnormality consisting of the presence of a third copy of chromosome 9 in somatic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trisomy 9","conceptCode":"C84282","definition":"A chromosomal abnormality consisting of the presence of a third copy of chromosome 9 in somatic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0731-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0747-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Trophoblastic Tumor","valueDescription":"Trophoblastic Tumor","ValueMeaning":{"publicId":"3211502","version":"1","preferredName":"Trophoblastic Tumor","longName":"3211502","preferredDefinition":"A gestational or non-gestational neoplasm composed of neoplastic trophoblastic cells. Representative examples include hydatidiform mole and choriocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trophoblastic Tumor","conceptCode":"C3422","definition":"A gestational or non-gestational neoplasm characterized by excessive proliferation of trophoblastic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0753-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0769-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"True Hermaphroditism","valueDescription":"True Hermaphroditism","ValueMeaning":{"publicId":"3211503","version":"1","preferredName":"True Hermaphroditism","longName":"3211503","preferredDefinition":"A rare condition characterized by the unequivocal presence of both testicular and ovarian tissues in an individual. It is usually manifested with ambiguous external genitalia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"True Hermaphroditism","conceptCode":"C85207","definition":"A rare condition characterized by the unequivocal presence of both testicular and ovarian tissues in an individual. It is usually manifested with ambiguous external genitalia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0775-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-078B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tuberculosis","valueDescription":"Tuberculosis","ValueMeaning":{"publicId":"2567544","version":"1","preferredName":"Tuberculosis","longName":"2567544","preferredDefinition":"Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tuberculosis","conceptCode":"C3423","definition":"A chronic, recurrent infection caused by the bacterium Mycobacterium tuberculosis. Tuberculosis (TB) may affect almost any tissue or organ of the body with the lungs being the most common site of infection. The clinical stages of TB are primary or initial infection, latent or dormant infection, and recrudescent or adult-type TB. Ninety to 95% of primary TB infections may go unrecognized. Histopathologically, tissue lesions consist of granulomas which usually undergo central caseation necrosis. Local symptoms of TB vary according to the part affected; acute symptoms include hectic fever, sweats, and emaciation; serious complications include granulomatous erosion of pulmonary bronchi associated with hemoptysis. If untreated, progressive TB may be associated with a high degree of mortality. This infection is frequently observed in immunocompromised individuals with AIDS or a history of illicit IV drug use.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D4E5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-19","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0795-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tuberous Sclerosis","valueDescription":"Tuberous Sclerosis","ValueMeaning":{"publicId":"2962075","version":"1","preferredName":"Tuberous Sclerosis","longName":"2962075","preferredDefinition":"Hereditary disease characterized by seizures, mental retardation, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tuberous Sclerosis","conceptCode":"C3424","definition":"Hereditary disease characterized by seizures, mental retardation, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78BA0E7A-4A1B-2225-E040-BB89AD436E34","latestVersionIndicator":"Yes","beginDate":"2009-11-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-07A7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tularemia","valueDescription":"Tularemia","ValueMeaning":{"publicId":"3211504","version":"1","preferredName":"Tularemia","longName":"3211504","preferredDefinition":"A serious Gram-negative bacterial infection caused by Francisella tularensis. It is transmitted to humans through bites from infected insects, inhaling airborne bacteria, handling infected animals, or consuming contaminated food or water. Signs and symptoms include skin ulcers, mouth sores, lymphadenopathy, sore throat, fever and pneumonia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tularemia","conceptCode":"C85208","definition":"A serious Gram-negative bacterial infection caused by Francisella tularensis. It is transmitted to humans through bites from infected insects, inhaling airborne bacteria, handling infected animals, or consuming contaminated food or water. Signs and symptoms include skin ulcers, mouth sores, lymphadenopathy, sore throat, fever and pneumonia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-07B3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-07C9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Turner Syndrome","valueDescription":"Turner Syndrome","ValueMeaning":{"publicId":"3211505","version":"1","preferredName":"Turner Syndrome","longName":"3211505","preferredDefinition":"A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the absence of a part or all of one of the sex chromosomes. Signs and symptoms include short stature, webbing of neck, low-set ears, hypogonadism, and sterility.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Turner Syndrome","conceptCode":"C26900","definition":"A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the absence of a part or all of one of the sex chromosomes. Signs and symptoms include short stature, webbing of neck, low-set ears, hypogonadism, and sterility.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-07D5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-07EB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hyperlipoproteinemia Type II","valueDescription":"Hyperlipoproteinemia Type II","ValueMeaning":{"publicId":"3211506","version":"1","preferredName":"Hyperlipoproteinemia Type II","longName":"3211506","preferredDefinition":"A disorder of lipoprotein metabolism characterized by high levels of cholesterol and triglycerides in the blood. It is caused by elevation of low density and very low density lipoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperlipoproteinemia Type II","conceptCode":"C34708","definition":"A disorder of lipoprotein metabolism characterized by high levels of cholesterol and triglycerides in the blood. It is caused by elevation of low density and very low density lipoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-07F7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-080D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Uniparental Disomy","valueDescription":"Uniparental Disomy","ValueMeaning":{"publicId":"3211507","version":"1","preferredName":"Uniparental Disomy","longName":"3211507","preferredDefinition":"A condition characterized by the inheritance of a chromosome pair from one parent and no chromosomal copies from the other parent. It results in developmental abnormalities or rare recessive disorders. Examples of uniparental disomy include the Prader-Willi syndrome and Angelman syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uniparental Disomy","conceptCode":"C85215","definition":"A condition characterized by the inheritance of a chromosome pair from one parent and no chromosomal copies from the other parent. It results in developmental abnormalities or rare recessive disorders. Examples of uniparental disomy include the Prader-Willi syndrome and Angelman syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0819-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-082F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Urachal Cyst","valueDescription":"Urachal Cyst","ValueMeaning":{"publicId":"3211508","version":"1","preferredName":"Urachal Cyst","longName":"3211508","preferredDefinition":"A cyst that develops from the remnants of the urachus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urachal Cyst","conceptCode":"C85216","definition":"A cyst that develops from the remnants of the urachus. Since urachal cysts are non-communicating, they are usually asymptomatic unless infected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-083B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0851-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis","valueDescription":"Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis","ValueMeaning":{"publicId":"3211509","version":"1","preferredName":"Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis","longName":"3211509","preferredDefinition":"The most frequent form of cutaneous mastocytosis.  In children, the lesions tend to be papular, and are characterized by aggregates of elongated or spindle-shaped mast cells which fill the papillary dermis and extend into the reticular dermis.  In adults, the lesions tend to have fewer mast cells compared to those in children.  The lesions are located most commonly on the trunk, but they can be seen on the extremities, head and neck. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis","conceptCode":"C3433","definition":"The most frequent form of cutaneous mastocytosis.  In children, the lesions tend to be papular, and are characterized by aggregates of elongated or spindle-shaped mast cells which fill the papillary dermis and extend into the reticular dermis.  In adults, the lesions tend to have fewer mast cells compared to those in children.  The lesions are located most commonly on the trunk, but they can be seen on the extremities, head and neck. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-085D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0873-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Usher Syndrome","valueDescription":"Usher Syndrome","ValueMeaning":{"publicId":"3211510","version":"1","preferredName":"Usher Syndrome","longName":"3211510","preferredDefinition":"A rare, autosomal recessive inherited syndrome caused by mutations in the CDH23, CLRN1, GPR98, MYO7A, PCDH15, USH1C, USH1G, and USH2A genes. It is characterized by hearing loss or deafness and progressive loss of vision. The loss of vision is the result of retinitis pigmentosa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Usher Syndrome","conceptCode":"C85217","definition":"A rare, autosomal recessive inherited syndrome caused by mutations in the CDH23, CLRN1, GPR98, MYO7A, PCDH15, USH1C, USH1G, and USH2A genes. It is characterized by hearing loss or deafness and progressive loss of vision. The loss of vision is the result of retinitis pigmentosa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-087F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0895-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Uveomeningoencephalitic Syndrome","valueDescription":"Uveomeningoencephalitic Syndrome","ValueMeaning":{"publicId":"3211511","version":"1","preferredName":"Uveomeningoencephalitic Syndrome","longName":"3211511","preferredDefinition":"A systemic inflammatory process affecting the inner ear, eyes, skin, and meninges. It is manifested with hearing disorders, panuveitis, alopecia, poliosis, vitiligo, neck stiffness, headaches, and focal neurologic signs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uveomeningoencephalitic Syndrome","conceptCode":"C85218","definition":"A systemic inflammatory process affecting the inner ear, eyes, skin, and meninges. It is manifested with hearing disorders, panuveitis, alopecia, poliosis, vitiligo, neck stiffness, headaches, and focal neurologic signs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-08A1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-08B7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Vaginal Neoplasm","valueDescription":"Vaginal Neoplasm","ValueMeaning":{"publicId":"2593186","version":"1","preferredName":"Vaginal Neoplasm","longName":"2593186","preferredDefinition":"Tumors or cancer of the VAGINA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaginal Neoplasm","conceptCode":"C3437","definition":"A benign or malignant neoplasm affecting the vagina. Representative examples of benign neoplasms include squamous papilloma and melanocytic nevus. Representative examples of malignant neoplasms include carcinoma, melanoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-669F-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-08C1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Variant Angina","valueDescription":"Variant Angina","ValueMeaning":{"publicId":"2804936","version":"1","preferredName":"Variant Angina","longName":"2804936","preferredDefinition":"A variant form of angina pectoris caused by coronary artery vasospasm, usually occurring spontaneously and frequently associated with ST segment elevation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Variant Angina","conceptCode":"C66915","definition":"A variant form of angina pectoris caused by coronary artery vasospasm, usually occurring spontaneously and frequently associated with ST segment elevation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C776BF9-584C-1B32-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-24","endDate":null,"createdBy":"UMLLOADER_CARDIAC","dateCreated":"2008-11-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-08D3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Variegate Porphyria","valueDescription":"Variegate Porphyria","ValueMeaning":{"publicId":"3211512","version":"1","preferredName":"Variegate Porphyria","longName":"3211512","preferredDefinition":"An autosomal dominant disorder of porphyria-heme metabolism. It is manifested with acute attacks including abdominal pain, vomiting, diarrhea, constipation, seizures, anxiety, and confusion. Patients may experience skin sensitivity to sunlight.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Variegate Porphyria","conceptCode":"C85219","definition":"An autosomal dominant disorder of porphyria-heme metabolism. It is manifested with acute attacks including abdominal pain, vomiting, diarrhea, constipation, seizures, anxiety, and confusion. Patients may experience skin sensitivity to sunlight.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-08DF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-08F5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Vascular Dementia","valueDescription":"Vascular Dementia","ValueMeaning":{"publicId":"3211513","version":"1","preferredName":"Vascular Dementia","longName":"3211513","preferredDefinition":"A degenerative vascular disorder affecting the brain. It is caused by the blockage of the blood supply to the brain. It is manifested with decline of memory and cognitive functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vascular Dementia","conceptCode":"C34525","definition":"A degenerative vascular disorder affecting the brain. It is caused by the blockage of the blood supply to the brain. It is manifested with decline of memory and cognitive functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0901-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0917-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"VIP Producing Tumor","valueDescription":"VIP Producing Tumor","ValueMeaning":{"publicId":"3211514","version":"1","preferredName":"VIP Producing Tumor","longName":"3211514","preferredDefinition":"An often clinically aggressive endocrine neoplasm located in the pancreas or small intestine.  It is composed of cells containing vasoactive intestinal peptide.  It may cause intractable diarrhea and metabolic disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VIP-Producing Neuroendocrine Tumor","conceptCode":"C26749","definition":"An often clinically aggressive neuroendocrine tumor located in the pancreas or small intestine.  It is composed of cells containing vasoactive intestinal peptide.  It may cause intractable diarrhea and metabolic disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0923-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0939-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Visceral Larva Migrans","valueDescription":"Visceral Larva Migrans","ValueMeaning":{"publicId":"3211515","version":"1","preferredName":"Visceral Larva Migrans","longName":"3211515","preferredDefinition":"A parasitic infection caused by worms found in domestic animals. In humans nematode larvae enter the portal system from the small intestine and disseminate in visceral organs causing inflammatory reactions. Signs and symptoms include eosinophilia, hepatomegaly, splenomegaly, and lung infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Visceral Larva Migrans","conceptCode":"C34758","definition":"A parasitic infection caused by worms found in domestic animals. In humans nematode larvae enter the portal system from the small intestine and disseminate in visceral organs causing inflammatory reactions. Signs and symptoms include eosinophilia, hepatomegaly, splenomegaly, and lung infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0945-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-095B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Empty Sella Syndrome","valueDescription":"Empty Sella Syndrome","ValueMeaning":{"publicId":"3211039","version":"1","preferredName":"Empty Sella Syndrome","longName":"3211039","preferredDefinition":"A syndrome characterized by flattening or regression of the pituitary gland within the sella turcica cavity, resulting in an MRI image of an empty sella turcica. Signs and symptoms are secondary to pituitary gland hypofunction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Empty Sella Syndrome","conceptCode":"C84686","definition":"A syndrome characterized by flattening or regression of the pituitary gland within the sella turcica cavity, resulting in an MRI image of an empty sella turcica. Signs and symptoms are secondary to pituitary gland hypofunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C532-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C548-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Encephalitis","valueDescription":"Encephalitis","ValueMeaning":{"publicId":"3211040","version":"1","preferredName":"Encephalitis","longName":"3211040","preferredDefinition":"An acute inflammatory process affecting the brain parenchyma. Causes include viral infections and less frequently bacterial infections, toxins, and immune-mediated processes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Encephalitis","conceptCode":"C26760","definition":"An inflammatory process affecting the brain parenchyma. Causes include viral infections and less frequently bacterial infections, toxins, and immune-mediated processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C554-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C56A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Encephalocele","valueDescription":"Encephalocele","ValueMeaning":{"publicId":"3211041","version":"1","preferredName":"Encephalocele","longName":"3211041","preferredDefinition":"A congenital neural tube closure defect resulting in the protrusion of the brain through a skull opening. When the protrusion includes the meninges, the term encephalomeningocele is used.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Encephalocele","conceptCode":"C84687","definition":"A congenital neural tube closure defect resulting in the protrusion of the brain through a skull opening. When the protrusion includes the meninges, the term encephalomeningocele is used.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C576-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C58C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Enchondromatosis","valueDescription":"Enchondromatosis","ValueMeaning":{"publicId":"3211042","version":"1","preferredName":"Enchondromatosis","longName":"3211042","preferredDefinition":"A rare benign disorder characterized by lack of normal endchondral ossification, and the growth of multiple enchondromas.  It primarily affects the bones of the hand, in children and young adults.  Extent of the disease varies; in some cases, neoplastic involvement may be wide spread causing considerable deformity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enchondromatosis","conceptCode":"C3008","definition":"A rare benign disorder characterized by lack of normal endochondral ossification, and the growth of multiple enchondromas.  It primarily affects the bones of the hand, in children and young adults.  Extent of the disease varies; in some cases, neoplastic involvement may be widespread causing considerable deformity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C598-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C5AE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Endemic Typhus Fever","valueDescription":"Endemic Typhus Fever","ValueMeaning":{"publicId":"3211043","version":"1","preferredName":"Endemic Typhus Fever","longName":"3211043","preferredDefinition":"A bacterial infection caused by Rickettsia typhi or Rickettsia felis. It is transmitted to humans from infected rat fleas. Symptoms include fever, headache, joint and muscle pain, and weakness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endemic Typhus Fever","conceptCode":"C84688","definition":"A bacterial infection caused by Rickettsia typhi or Rickettsia felis. It is transmitted to humans from infected rat fleas. Symptoms include fever, headache, joint and muscle pain, and weakness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C5BA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C5D0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Endometrial Stromal Sarcoma","valueDescription":"Endometrial Stromal Sarcoma","ValueMeaning":{"publicId":"2567186","version":"1","preferredName":"Endometrial Stromal Sarcoma","longName":"2567186","preferredDefinition":"A malignant, infiltrating mesenchymal tumor arising from the uterine corpus, cervix, vagina, and the ovary. Based on its morphologic characteristics, it is classified as either a low grade or an undifferentiated (high grade) stromal sarcoma. The low grade endometrial stromal sarcoma is characterized by the presence of oval to spindle-shape cells that resemble the cells of the endometrial stroma, without evidence of significant atypia and pleomorphism. Numerous small vessels are also present. The undifferentiated stromal sarcoma is characterized by an aggressive clinical course, the presence of significant cellular atypia, pleomorphism, and high mitotic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrioid Stromal Sarcoma","conceptCode":"C8973","definition":"A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D37F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C5E2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Enteritis","valueDescription":"Enteritis","ValueMeaning":{"publicId":"3211044","version":"1","preferredName":"Enteritis","longName":"3211044","preferredDefinition":"Inflammation of the small intestine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enteritis","conceptCode":"C26765","definition":"Inflammation of the small intestine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C5EE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C604-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Eosinophilic Granuloma","valueDescription":"Eosinophilic Granuloma","ValueMeaning":{"publicId":"3211045","version":"1","preferredName":"Eosinophilic Granuloma","longName":"3211045","preferredDefinition":"A clinical variant of Langerhans cell histiocytosis characterised by unifocal involvement of a bone (most often), skin, or lung.  Patients are usually older children or adults usually presenting with a lytic bone lesion.  The etiology is unknown.  Morphologically, eosinophilic granuloma is characterised by the presence of Langerhans cells in a characteristic milieu which includes histiocytes, eosinophiles neutrophiles, and small, mature lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eosinophilic Granuloma","conceptCode":"C3016","definition":"A clinical variant of Langerhans cell histiocytosis characterized by unifocal involvement of a bone (most often), skin, or lung.  Patients are usually older children or adults usually presenting with a lytic bone lesion.  The etiology is unknown.  Morphologically, eosinophilic granuloma is characterized by the presence of Langerhans cells in a characteristic milieu which includes histiocytes, eosinophils, neutrophils, and small, mature lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C610-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C626-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ependymoma","valueDescription":"Ependymoma","ValueMeaning":{"publicId":"2578706","version":"1","preferredName":"Ependymoma","longName":"2578706","preferredDefinition":"Ependymoma (WHO grade II) is the most common ependymal neoplasm. It is a slow growing tumor of children and young adults and is usually located intraventricularly.  It often causes clinical symptoms by blocking CSF pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes.(Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ependymoma","conceptCode":"C3017","definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C630-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Epidemic Louse-Borne Typhus","valueDescription":"Epidemic Louse-Borne Typhus","ValueMeaning":{"publicId":"3211046","version":"1","preferredName":"Epidemic Louse-Borne Typhus","longName":"3211046","preferredDefinition":"A gram-negative bacterial infection caused by Rickettsia prowazekii. It is spread by lice infected with the bacteria. Signs and symptoms include sudden headache, generalized muscle pain, malaise, and macular skin lesions. The infection may affect the central nervous system causing encephalitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidemic Louse-Borne Typhus","conceptCode":"C84689","definition":"A gram-negative bacterial infection caused by Rickettsia prowazekii. It is spread by lice infected with the bacteria. Signs and symptoms include sudden headache, generalized muscle pain, malaise, and macular skin lesions. The infection may affect the central nervous system causing encephalitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C63C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C652-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Epidermolysis Bullosa","valueDescription":"Epidermolysis Bullosa","ValueMeaning":{"publicId":"3211047","version":"1","preferredName":"Epidermolysis Bullosa","longName":"3211047","preferredDefinition":"An autosomal recessive inherited skin disorder caused by mutations in the genes encoding keratins 5 and 14, collagen VII or laminin 5. It is characterized by skin fragility and the formation of blisters. The blisters may become large and ulcerated, resulting in skin infections and loss of body fluids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidermolysis Bullosa","conceptCode":"C67383","definition":"An autosomal recessive inherited skin disorder caused by mutations in the genes encoding keratins 5 and 14, collagen VII or laminin 5. It is characterized by skin fragility and the formation of blisters. The blisters may become large and ulcerated, resulting in skin infections and loss of body fluids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C65E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C674-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Epidermolysis Bullosa Acquisita","valueDescription":"Epidermolysis Bullosa Acquisita","ValueMeaning":{"publicId":"3211048","version":"1","preferredName":"Epidermolysis Bullosa Acquisita","longName":"3211048","preferredDefinition":"A chronic autoimmune inflammatory disorder characterized by the formation of subepidermal blisters in the skin and the mucous membranes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidermolysis Bullosa Acquisita","conceptCode":"C84690","definition":"A chronic autoimmune inflammatory disorder characterized by the formation of subepidermal blisters in the skin and the mucous membranes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C680-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C696-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Epidermolysis Bullosa Dystrophica","valueDescription":"Epidermolysis Bullosa Dystrophica","ValueMeaning":{"publicId":"3211049","version":"1","preferredName":"Epidermolysis Bullosa Dystrophica","longName":"3211049","preferredDefinition":"A genetic skin disorder caused by mutations in the type VII collagen gene (COL7A1). It is characterized by the formation of blisters and scarring in the skin and mucous membranes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidermolysis Bullosa Dystrophica","conceptCode":"C84691","definition":"A genetic skin disorder caused by mutations in the type VII collagen gene (COL7A1). It is characterized by the formation of blisters and scarring in the skin and mucous membranes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C6A2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C6B8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Epidermolysis Bullosa Simplex","valueDescription":"Epidermolysis Bullosa Simplex","ValueMeaning":{"publicId":"3211050","version":"1","preferredName":"Epidermolysis Bullosa Simplex","longName":"3211050","preferredDefinition":"A genetic skin disorder caused by mutations in the KRT5 and KRT14 genes. It is characterized by the formation of blisters and increased fragility of the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidermolysis Bullosa Simplex","conceptCode":"C84692","definition":"A genetic skin disorder caused by mutations in the KRT5 and KRT14 genes. It is characterized by the formation of blisters and increased fragility of the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C6C4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C6DA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Epidermolytic Hyperkeratosis","valueDescription":"Epidermolytic Hyperkeratosis","ValueMeaning":{"publicId":"3211051","version":"1","preferredName":"Epidermolytic Hyperkeratosis","longName":"3211051","preferredDefinition":"An autosomal dominant inherited skin disorder caused by mutations in the KRT1 and KRT10 genes. It is manifested at birth and is characterized by generalized erythema, skin blisters and skin fragility.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidermolytic Ichthyosis","conceptCode":"C62569","definition":"An autosomal dominant inherited skin disorder caused by mutations in the KRT1 and KRT10 genes. It is manifested at birth and is characterized by generalized erythema, skin blisters and skin fragility.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C6E6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C6FC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Epidermolytic Palmoplantar Keratoderma","valueDescription":"Epidermolytic Palmoplantar Keratoderma","ValueMeaning":{"publicId":"3211052","version":"1","preferredName":"Epidermolytic Palmoplantar Keratoderma","longName":"3211052","preferredDefinition":"A genetic skin disorder caused by mutations in the KRT9 gene. It is characterized by hyperkeratosis in the palms and soles resulting in abnormal thickening of the skin in these areas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidermolytic Palmoplantar Keratoderma","conceptCode":"C84693","definition":"A genetic skin disorder caused by mutations in the KRT9 gene. It is characterized by hyperkeratosis in the palms and soles resulting in abnormal thickening of the skin in these areas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C708-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C71E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Epilepsy","valueDescription":"Epilepsy","ValueMeaning":{"publicId":"2971317","version":"1","preferredName":"Epilepsy","longName":"2971317","preferredDefinition":"brain disorder characterized by recurring excessive neuronal discharge, exhibited by transient episodes of motor, sensory, or psychic dysfunction, with or without unconsciousness or convulsive movements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Seizure Disorder","conceptCode":"C3020","definition":"A brain disorder characterized by episodes of abnormally increased neuronal discharge resulting in transient episodes of sensory or motor neurological dysfunction, or psychic dysfunction. These episodes may or may not be associated with loss of consciousness or convulsions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B198A4F-67A2-7611-E040-BB89AD430A1F","latestVersionIndicator":"Yes","beginDate":"2009-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C728-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Epithelioid Hemangioma","valueDescription":"Epithelioid Hemangioma","ValueMeaning":{"publicId":"3211053","version":"1","preferredName":"Epithelioid Hemangioma","longName":"3211053","preferredDefinition":"A hemangioma characterized by the presence of epithelioid endothelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epithelioid Hemangioma","conceptCode":"C4298","definition":"A hemangioma characterized by the presence of epithelioid endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C734-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C74A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Erythema Infectiosum","valueDescription":"Erythema Infectiosum","ValueMeaning":{"publicId":"3211054","version":"1","preferredName":"Erythema Infectiosum","longName":"3211054","preferredDefinition":"A self-limited viral infectious disorder caused by the human parvovirus B19. It affects predominantly children and is characterized by the development of a bright red skin eruption in the cheeks. It is followed by a maculopapular skin eruption in the extremities which eventually fades into a lacey pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythema Infectiosum","conceptCode":"C84695","definition":"A self-limited viral infectious disorder caused by the human parvovirus B19. It affects predominantly children and is characterized by the development of a bright red skin eruption in the cheeks. It is followed by a maculopapular skin eruption in the extremities which eventually fades into a lacey pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C756-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C76C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Erythrokeratodermia Variabilis","valueDescription":"Erythrokeratodermia Variabilis","ValueMeaning":{"publicId":"3211055","version":"1","preferredName":"Erythrokeratodermia Variabilis","longName":"3211055","preferredDefinition":"A rare genetic chronic skin disorder characterized by hyperkeratosis and transient erythema. Mutations in GJB3 and GJB4 genes have been identified as causative agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythrokeratodermia Variabilis","conceptCode":"C84696","definition":"A rare genetic chronic skin disorder characterized by hyperkeratosis and transient erythema. Mutations in GJB3 and GJB4 genes have been identified as causative agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C778-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C78E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Erythromelalgia","valueDescription":"Erythromelalgia","ValueMeaning":{"publicId":"3211056","version":"1","preferredName":"Erythromelalgia","longName":"3211056","preferredDefinition":"A rare disorder characterized by periodic inflammation and blockage of the vessels of the extremities, resulting in skin redness, swelling, and burning pain in the affected sites. It may manifest as a primary disorder caused by mutations of the SCN9A gene or as a secondary disorder due to hematologic disorders or medication side effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythromelalgia","conceptCode":"C34593","definition":"A rare disorder characterized by periodic inflammation and blockage of the vessels of the extremities, resulting in skin redness, swelling, and burning pain in the affected sites. It may manifest as a primary disorder caused by mutations of the SCN9A gene or as a secondary disorder due to hematologic disorders or medication side effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C79A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C7B0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Erythropoietic Porphyria","valueDescription":"Erythropoietic Porphyria","ValueMeaning":{"publicId":"3211057","version":"1","preferredName":"Erythropoietic Porphyria","longName":"3211057","preferredDefinition":"A rare congenital metabolic disorder characterized by an inborn error of porphyrin-heme biosynthesis. It is caused by deficiency of the enzyme uroporphyrinogen III cosynthetase. It results in cutaneous photosensitivity leading to blistering and scarring of the exposed skin areas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythropoietic Porphyria","conceptCode":"C84697","definition":"A rare congenital metabolic disorder characterized by an inborn error of porphyrin-heme biosynthesis. It is caused by deficiency of the enzyme uroporphyrinogen III cosynthetase. It results in cutaneous photosensitivity leading to blistering and scarring of the exposed skin areas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C7BC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C7D2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Erythropoietic Protoporphyria","valueDescription":"Erythropoietic Protoporphyria","ValueMeaning":{"publicId":"3211058","version":"1","preferredName":"Erythropoietic Protoporphyria","longName":"3211058","preferredDefinition":"A rare congenital metabolic disorder characterized by an inborn error of porphyrin-heme biosynthesis. It is caused by deficiency of the enzyme ferrochelatase. Signs and symptoms include painful cutaneous photosensitivity leading to blistering and scarring of the exposed skin areas, erythrodontia, red discoloration of urine, hemolytic anemia, and splenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythropoietic Protoporphyria","conceptCode":"C84698","definition":"A rare congenital metabolic disorder characterized by an inborn error of porphyrin-heme biosynthesis. It is caused by deficiency of the enzyme ferrochelatase. Signs and symptoms include painful cutaneous photosensitivity leading to blistering and scarring of the exposed skin areas, erythrodontia, red discoloration of urine, hemolytic anemia, and splenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C7DE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C7F4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Esophageal Achalasia","valueDescription":"Esophageal Achalasia","ValueMeaning":{"publicId":"3211059","version":"1","preferredName":"Esophageal Achalasia","longName":"3211059","preferredDefinition":"A finding indicating the lack of adequate relaxation of the lower esophageal sphincter resulting in difficulty swallowing food.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophageal Achalasia","conceptCode":"C84699","definition":"A finding indicating the lack of adequate relaxation of the lower esophageal sphincter resulting in difficulty swallowing food.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C800-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C816-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Extramammary Paget Disease","valueDescription":"Extramammary Paget Disease","ValueMeaning":{"publicId":"3211060","version":"1","preferredName":"Extramammary Paget Disease","longName":"3211060","preferredDefinition":"A malignant neoplasm in which there is infiltration of the skin by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (Paget cells). It may affect the anus, penis, scrotum, and vulva.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extramammary Paget Disease","conceptCode":"C3302","definition":"A malignant neoplasm in which there is infiltration of the skin by neoplastic large cells with abundant pale cytoplasm and large nuclei with prominent nucleoli (Paget cells). It may affect the anus, penis, scrotum, and vulva.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C822-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C838-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fabry Disease","valueDescription":"Fabry Disease","ValueMeaning":{"publicId":"3211061","version":"1","preferredName":"Fabry Disease","longName":"3211061","preferredDefinition":"A rare X-linked inherited lysosomal storage disorder characterized by deficiency of the enzyme alpha-galactosidase A. It results in the accumulation of glycolipids in the blood vessels and tissues. Signs and symptoms include hypertension, cardiomyopathy, angiokeratomas, neuropathy, hypohidrosis, keratopathy, proteinuria, and renal failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fabry Disease","conceptCode":"C84701","definition":"A rare X-linked inherited lysosomal storage disorder characterized by deficiency of the enzyme alpha-galactosidase A. It results in the accumulation of glycolipids in the blood vessels and tissues. Signs and symptoms include hypertension, cardiomyopathy, angiokeratomas, neuropathy, hypohidrosis, keratopathy, proteinuria, and renal failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C844-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C85A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Facial Asymmetry","valueDescription":"Facial Asymmetry","ValueMeaning":{"publicId":"3211062","version":"1","preferredName":"Facial Asymmetry","longName":"3211062","preferredDefinition":"A finding indicating the absence of balanced proportions between parts of the face.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Facial Asymmetry","conceptCode":"C84702","definition":"A finding indicating the absence of balanced proportions between parts of the face.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C866-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C87C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Facial Hemiatrophy","valueDescription":"Facial Hemiatrophy","ValueMeaning":{"publicId":"3211063","version":"1","preferredName":"Facial Hemiatrophy","longName":"3211063","preferredDefinition":"Progressive atrophy of the tissues that comprise half of the face.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Facial Hemiatrophy","conceptCode":"C84703","definition":"Progressive atrophy of the tissues that comprise half of the face.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C888-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C89E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Facioscapulohumeral Muscular Dystrophy","valueDescription":"Facioscapulohumeral Muscular Dystrophy","ValueMeaning":{"publicId":"3211064","version":"1","preferredName":"Facioscapulohumeral Muscular Dystrophy","longName":"3211064","preferredDefinition":"An autosomal dominant disorder affecting the skeletal muscles of the face, scapula, and upper arm. Patients present with muscle weakness in these anatomic areas. The muscle weakness eventually spreads to other skeletal muscles as well.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Facioscapulohumeral Muscular Dystrophy","conceptCode":"C84704","definition":"An autosomal dominant disorder affecting the skeletal muscles of the face, scapula, and upper arm. Patients present with muscle weakness in these anatomic areas. The muscle weakness eventually spreads to other skeletal muscles as well.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C8AA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C8C0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Factor I Deficiency","valueDescription":"Factor I Deficiency","ValueMeaning":{"publicId":"3211065","version":"1","preferredName":"Factor I Deficiency","longName":"3211065","preferredDefinition":"A usually inherited blood coagulation disorder characterized by the lack of fibrinogen in the blood, resulting in bleeding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Factor I Deficiency","conceptCode":"C26692","definition":"A usually inherited blood coagulation disorder characterized by the partial or complete absence of fibrinogen in the blood, resulting in bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C8CC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C8E2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Factor XI Deficiency","valueDescription":"Factor XI Deficiency","ValueMeaning":{"publicId":"3211066","version":"1","preferredName":"Factor XI Deficiency","longName":"3211066","preferredDefinition":"A rare inherited bleeding disorder caused by deficiency of coagulation factor XI. It may be asymptomatic or manifest with bleeding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Factor XI Deficiency","conceptCode":"C84705","definition":"A rare inherited bleeding disorder caused by deficiency of coagulation factor XI. It may be asymptomatic or manifest with bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C8EE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C904-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Factor XII Deficiency","valueDescription":"Factor XII Deficiency","ValueMeaning":{"publicId":"3211067","version":"1","preferredName":"Factor XII Deficiency","longName":"3211067","preferredDefinition":"A rare autosomal recessive inherited bleeding disorder caused by deficiency of coagulation factor XII. It may be asymptomatic or manifest with bleeding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Factor XII Deficiency","conceptCode":"C26770","definition":"A rare autosomal recessive inherited bleeding disorder caused by deficiency of coagulation factor XII. It may be asymptomatic or manifest with bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C910-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C926-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fallopian Tube Neoplasm","valueDescription":"Fallopian Tube Neoplasm","ValueMeaning":{"publicId":"3211068","version":"1","preferredName":"Fallopian Tube Neoplasm","longName":"3211068","preferredDefinition":"A benign or malignant neoplasm affecting the fallopian tube. Representative examples of benign neoplasms include papilloma, adenofibroma, and leiomyoma. Representative examples of malignant neoplasms include carcinoma, carcinosarcoma, and adenosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fallopian Tube Neoplasm","conceptCode":"C3032","definition":"A benign or malignant neoplasm affecting the fallopian tube. Representative examples of benign neoplasms include papilloma, adenofibroma, and leiomyoma. Representative examples of malignant neoplasms include carcinoma, carcinosarcoma, and adenosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C932-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C948-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Adenomatous Polyposis Coli","valueDescription":"Adenomatous Polyposis Coli","ValueMeaning":{"publicId":"2577526","version":"1","preferredName":"Adenomatous Polyposis Coli","longName":"2577526","preferredDefinition":"An autosomal dominant disorder, characterized by the presence of multiple adenomas in the colon and rectum. It is caused by a germline mutation in the adenomatous polyposis coli (APC) gene which is located on the long arm of chromosome 5. The adenomas are most often tubular, and they have the tendency to progress to adenocarcinoma. They can occur throughout the colon, but they tend to concentrate in the rectum and sigmoid colon. The colorectal adenomas are detected during endoscopic examination between the age of 10 and 20 years. The adenomas increase in size and numbers with age, and there is usually progression of one or more adenomas to adenocarcinoma. The mean age of development of adenocarcinoma is about 40 years. Signs include rectal bleeding and mucousy diarrhea.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Adenomatous Polyposis","conceptCode":"C3339","definition":"An autosomal dominant disorder, characterized by the presence of multiple adenomas in the colon and rectum. It is caused by a germline mutation in the adenomatous polyposis coli (APC) gene which is located on the long arm of chromosome 5. The adenomas are most often tubular, and they have the tendency to progress to adenocarcinoma. They can occur throughout the colon, but they tend to concentrate in the rectum and sigmoid colon. The colorectal adenomas are detected during endoscopic examination between the age of 10 and 20 years. The adenomas increase in size and numbers with age, and there is usually progression of one or more adenomas to adenocarcinoma. The mean age of development of adenocarcinoma is about 40 years. Signs include rectal bleeding and mucousy diarrhea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"COOPERM","dateModified":"2018-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C95A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Familial Amyloid Neuropathy","valueDescription":"Familial Amyloid Neuropathy","ValueMeaning":{"publicId":"3211069","version":"1","preferredName":"Familial Amyloid Neuropathy","longName":"3211069","preferredDefinition":"A rare inherited neuropathy characterized by deposition of amyloid in the peripheral nerves.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Amyloid Neuropathy","conceptCode":"C84554","definition":"A rare inherited neuropathy characterized by deposition of amyloid in the peripheral nerves.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C966-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C97C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Familial Amyloidosis","valueDescription":"Familial Amyloidosis","ValueMeaning":{"publicId":"3211070","version":"1","preferredName":"Familial Amyloidosis","longName":"3211070","preferredDefinition":"A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Amyloidosis","conceptCode":"C84555","definition":"An autosomal dominant inherited form of amyloidosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C988-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C99E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Familial Benign Pemphigus","valueDescription":"Familial Benign Pemphigus","ValueMeaning":{"publicId":"3211071","version":"1","preferredName":"Familial Benign Pemphigus","longName":"3211071","preferredDefinition":"An autosomal dominant disorder characterized by a history of multiple relapses and remissions of pemphigus lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Benign Pemphigus","conceptCode":"C82865","definition":"An autosomal dominant disorder characterized by a history of multiple relapses and remissions of pemphigus lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C9AA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C9C0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Familial Dysautonomia","valueDescription":"Familial Dysautonomia","ValueMeaning":{"publicId":"3211072","version":"1","preferredName":"Familial Dysautonomia","longName":"3211072","preferredDefinition":"A congenital disorder caused by mutations in the IKBKAP gene. It is characterized by damage of the sympathetic and parasympathetic and sensory nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Dysautonomia","conceptCode":"C84706","definition":"A congenital disorder caused by mutations in the IKBKAP gene. It is characterized by damage of the sympathetic and parasympathetic and sensory nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C9CC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-C9E2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Familial Hypertrophic Cardiomyopathy","valueDescription":"Familial Hypertrophic Cardiomyopathy","ValueMeaning":{"publicId":"3211073","version":"1","preferredName":"Familial Hypertrophic Cardiomyopathy","longName":"3211073","preferredDefinition":"Hypertrophic cardiomyopathy caused by mutations in the genes encoding components of the sarcomere, in the absence of predisposing conditions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Hypertrophic Cardiomyopathy","conceptCode":"C84773","definition":"Hypertrophic cardiomyopathy caused by mutations in the genes encoding components of the sarcomere, in the absence of predisposing conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-C9EE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CA04-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Familial Mediterranean Fever","valueDescription":"Familial Mediterranean Fever","ValueMeaning":{"publicId":"3211074","version":"1","preferredName":"Familial Mediterranean Fever","longName":"3211074","preferredDefinition":"A usually autosomal recessive inherited inflammatory disorder caused by mutations in the MEFV gene. It is characterized by recurrent painful inflammatory attacks in the abdomen, joints, and chest. The inflammatory attacks are associated with fever.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Mediterranean Fever","conceptCode":"C84707","definition":"A usually autosomal recessive inherited inflammatory disorder caused by mutations in the MEFV gene. It is characterized by recurrent painful inflammatory attacks in the abdomen, joints, and chest. The inflammatory attacks are associated with fever.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CA10-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CA26-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Familial Partial Lipodystrophy","valueDescription":"Familial Partial Lipodystrophy","ValueMeaning":{"publicId":"3211075","version":"1","preferredName":"Familial Partial Lipodystrophy","longName":"3211075","preferredDefinition":"An autosomal dominant inherited disorder that appears in childhood or adolescence. It is characterized by loss of adipose tissue in the extremities and accumulation of adipose tissue in the face and neck.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Partial Lipodystrophy","conceptCode":"C84708","definition":"An autosomal dominant inherited disorder that appears in childhood or adolescence. It is characterized by loss of adipose tissue in the extremities and accumulation of adipose tissue in the face and neck.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CA32-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CA48-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Familial Periodic Paralysis","valueDescription":"Familial Periodic Paralysis","ValueMeaning":{"publicId":"3211076","version":"1","preferredName":"Familial Periodic Paralysis","longName":"3211076","preferredDefinition":"A group of genetic neurological disorders caused by mutations in genes involved in the sodium and calcium channels in nerve cells. It is characterized by episodes of muscle paralysis in which the affected muscles become flaccid and the deep tendon reflexes disappear. Between the episodes the affected muscles usually work normally.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Familial Periodic Paralysis","conceptCode":"C84709","definition":"A group of genetic neurological disorders caused by mutations in genes involved in the sodium and calcium channels in nerve cells. It is characterized by episodes of muscle paralysis in which the affected muscles become flaccid and the deep tendon reflexes disappear. Between the episodes the affected muscles usually work normally.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CA54-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CA6A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fanconi Syndrome","valueDescription":"Fanconi Syndrome","ValueMeaning":{"publicId":"3211077","version":"1","preferredName":"Fanconi Syndrome","longName":"3211077","preferredDefinition":"A genetic or acquired disorder characterized by impairment of the function of the proximal tubules of the kidney. It results in decreased reabsorption of electrolytes, glucose, amino acids, and other nutrients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fanconi Syndrome","conceptCode":"C3034","definition":"A genetic or acquired disorder characterized by impairment of the function of the proximal tubules of the kidney. It results in decreased reabsorption of electrolytes, glucose, amino acids, and other nutrients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CA76-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CA8C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Farber Lipogranulomatosis","valueDescription":"Farber Lipogranulomatosis","ValueMeaning":{"publicId":"3211078","version":"1","preferredName":"Farber Lipogranulomatosis","longName":"3211078","preferredDefinition":"A very rare autosomal recessive metabolic disorder affecting lipid metabolism. It is caused by mutations in the ASAH1 gene and is characterized by fatty accumulation in the body tissues. Patients develop lipogranulomas in the skin and internal organs, edema and pain in the joints and a hoarse voice. It may be associated with intellectual disability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Farber Lipogranulomatosis","conceptCode":"C84710","definition":"A very rare autosomal recessive metabolic disorder affecting lipid metabolism. It is caused by mutations in the ASAH1 gene and is characterized by fatty accumulation in the body tissues. Patients develop lipogranulomas in the skin and internal organs, edema and pain in the joints and a hoarse voice. It may be associated with intellectual disability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CA98-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CAAE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fatal Familial Insomnia","valueDescription":"Fatal Familial Insomnia","ValueMeaning":{"publicId":"3211079","version":"1","preferredName":"Fatal Familial Insomnia","longName":"3211079","preferredDefinition":"A very rare autosomal dominant inherited sleep disorder caused by a mutation in the gene responsible for the prion protein. It affects individuals usually in their fourth decade. Its initial manifestation is difficulty in falling asleep. It is followed by complete inability to sleep. Patients develop deterioration of their mental and motor functions and die soon after the first symptoms appear, because of the total absence of sleep.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fatal Familial Insomnia","conceptCode":"C84711","definition":"A very rare autosomal dominant inherited sleep disorder caused by a mutation in the gene responsible for the prion protein. It affects individuals usually in their fourth decade. Its initial manifestation is difficulty in falling asleep. It is followed by complete inability to sleep. Patients develop deterioration of their mental and motor functions and die soon after the first symptoms appear, because of the total absence of sleep.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CABA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CAD0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Felty Syndrome","valueDescription":"Felty Syndrome","ValueMeaning":{"publicId":"3211080","version":"1","preferredName":"Felty Syndrome","longName":"3211080","preferredDefinition":"A syndrome characterized by the presence of rheumatoid arthritis, splenomegaly, and granulocytopenia. Patients are at an increased risk of infection because of the low white cell counts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Felty Syndrome","conceptCode":"C84712","definition":"A syndrome characterized by the presence of rheumatoid arthritis, splenomegaly, and granulocytopenia. Patients are at an increased risk of infection because of the low white cell counts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CADC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CAF2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fetal Alcohol Syndrome","valueDescription":"Fetal Alcohol Syndrome","ValueMeaning":{"publicId":"3211081","version":"1","preferredName":"Fetal Alcohol Syndrome","longName":"3211081","preferredDefinition":"A syndrome that can develop in infants whose mothers consumed alcohol during pregnancy. Manifestations of this syndrome include low birth weight, failure to thrive, developmental defects, organ dysfunction, mental deficiencies, behavioral problems and poor motor coordination.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fetal Alcohol Syndrome","conceptCode":"C84713","definition":"A teratogenic disorder observed in a newborn or child of a mother who consumed alcohol during pregnancy. Manifestations of the syndrome include low birth weight, atypical facies, microcephaly, failure to thrive, developmental defects, organ dysfunction, mental deficiencies, poor motor coordination and behavioral problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CAFE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CB14-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fibromuscular Dysplasia","valueDescription":"Fibromuscular Dysplasia","ValueMeaning":{"publicId":"3211082","version":"1","preferredName":"Fibromuscular Dysplasia","longName":"3211082","preferredDefinition":"A disorder characterized by fibrous thickening of the arterial wall resulting in narrowing of the arterial lumen. It most often affects the renal artery and less often the carotid artery and abdominal arteries. It can cause hypertension and aneurysm formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibromuscular Dysplasia","conceptCode":"C84714","definition":"A disorder characterized by fibrous thickening of the arterial wall resulting in narrowing of the arterial lumen. It most often affects the renal artery and less often the carotid artery and abdominal arteries. It can cause hypertension and aneurysm formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CB20-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CB36-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Focal Dermal Hypoplasia","valueDescription":"Focal Dermal Hypoplasia","ValueMeaning":{"publicId":"3211083","version":"1","preferredName":"Focal Dermal Hypoplasia","longName":"3211083","preferredDefinition":"A genetic multisystem disorder caused by mutations in the PORCN gene. It is characterized by atrophy and hypoplasia of skin, eye defects, face defects, skeletal abnormalities, and limb malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Focal Dermal Hypoplasia","conceptCode":"C84715","definition":"A genetic multisystem disorder caused by mutations in the PORCN gene. It is characterized by atrophy and hypoplasia of skin, eye defects, face defects, skeletal abnormalities, and limb malformations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CB42-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CB58-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fox-Fordyce Disease","valueDescription":"Fox-Fordyce Disease","ValueMeaning":{"publicId":"3211084","version":"1","preferredName":"Fox-Fordyce Disease","longName":"3211084","preferredDefinition":"A chronic inflammatory skin disorder characterized by pruritic papular eruptions in areas with apocrine glands. It usually affects the axillae bilaterally. There is rupture of the apocrine ducts resulting in inflammation and formation of the papular skin lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fox-Fordyce Disease","conceptCode":"C84716","definition":"A chronic inflammatory skin disorder characterized by pruritic papular eruptions in areas with apocrine glands. It usually affects the axillae bilaterally. There is rupture of the apocrine ducts resulting in inflammation and formation of the papular skin lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CB64-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CB7A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fragile X Syndrome","valueDescription":"Fragile X Syndrome","ValueMeaning":{"publicId":"3211085","version":"1","preferredName":"Fragile X Syndrome","longName":"3211085","preferredDefinition":"A genetic syndrome caused by mutations in the FMR1 gene which is responsible for the expression of the fragile X mental retardation 1 protein. This protein participates in neural development. This syndrome is manifested with mental, emotional, behavioral, physical, and learning disabilities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fragile X Syndrome","conceptCode":"C84717","definition":"A genetic syndrome caused by mutations in the FMR1 gene which is responsible for the expression of the fragile X mental retardation 1 protein. This protein participates in neural development. This syndrome is manifested with mental, emotional, behavioral, physical, and learning disabilities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CB86-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CB9C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Friedreich Ataxia","valueDescription":"Friedreich Ataxia","ValueMeaning":{"publicId":"3211086","version":"1","preferredName":"Friedreich Ataxia","longName":"3211086","preferredDefinition":"An autosomal recessive inherited disorder caused by mutations in the FXN gene. It is characterized by progressive degeneration of the nerve tissues of the spinal cord. The main symptoms include gait and balance disturbances, lack of limb coordination, and speech disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Friedreich Ataxia","conceptCode":"C84718","definition":"An autosomal recessive inherited disorder caused by mutations in the FXN gene. It is characterized by progressive degeneration of the nerve tissues of the spinal cord. The main symptoms include gait and balance disturbances, lack of limb coordination, and speech disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CBA8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CBBE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Vitamin A Deficiency","valueDescription":"Vitamin A Deficiency","ValueMeaning":{"publicId":"3211516","version":"1","preferredName":"Vitamin A Deficiency","longName":"3211516","preferredDefinition":"Deficiency of vitamin A due to malnutrition, malabsorption, or dietary lack. It is manifested with reduced night vision, night blindness, and xerophthalmia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitamin A Deficiency","conceptCode":"C85220","definition":"Deficiency of vitamin A due to malnutrition, malabsorption, or dietary lack. It is manifested with reduced night vision, night blindness, and xerophthalmia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0967-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-097D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Vitamin B6 Deficiency","valueDescription":"Vitamin B6 Deficiency","ValueMeaning":{"publicId":"3211517","version":"1","preferredName":"Vitamin B6 Deficiency","longName":"3211517","preferredDefinition":"Deficiency of vitamin B6. It is usually caused by alcoholism, malabsorption, or as a side effect of medications. Signs and symptoms include stomatitis, glossitis, dermatitis, peripheral neuropathy, irritability, seizures, and anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitamin B6 Deficiency","conceptCode":"C85221","definition":"Deficiency of vitamin B6. It is usually caused by alcoholism, malabsorption, or as a side effect of medications. Signs and symptoms include stomatitis, glossitis, dermatitis, peripheral neuropathy, irritability, seizures, and anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0989-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-099F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Von Hippel-Lindau Syndrome","valueDescription":"Von Hippel-Lindau Syndrome","ValueMeaning":{"publicId":"2962084","version":"1","preferredName":"Von Hippel-Lindau Syndrome","longName":"2962084","preferredDefinition":"An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Von Hippel Lindau Syndrome","conceptCode":"C3105","definition":"An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78BA0E7A-4AD9-2225-E040-BB89AD436E34","latestVersionIndicator":"Yes","beginDate":"2009-11-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-09B1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"von Willebrand Disease, Type 3","valueDescription":"Von Willebrand Disease, Type 3","ValueMeaning":{"publicId":"3211518","version":"1","preferredName":"Von Willebrand Disease, Type 3","longName":"3211518","preferredDefinition":"The most severe form of von Willebrand disease, inherited in an autosomal recessive pattern. It is characterized by marked deficiency or absence of von Willebrand factor in the plasma and platelets, and low plasma levels of factor VIII. It may cause severe bleeding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"von Willebrand Disease, Type 3","conceptCode":"C85213","definition":"The most severe form of von Willebrand disease, inherited in an autosomal recessive pattern. It is characterized by marked deficiency or absence of von Willebrand factor in the plasma and platelets, and low plasma levels of factor VIII. It may cause severe bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-09BD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-09D3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Waardenburg Syndrome","valueDescription":"Waardenburg Syndrome","ValueMeaning":{"publicId":"3211519","version":"1","preferredName":"Waardenburg Syndrome","longName":"3211519","preferredDefinition":"A rare, autosomal dominant inherited syndrome caused by mutations in the PAX3, MITF, and SNAI2 genes. Signs and symptoms include hearing loss, dystopia canthorum (widely spaced inner corners of the eyes), and changes in the color of the skin, hair, and eyes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Waardenburg Syndrome","conceptCode":"C85222","definition":"A rare, autosomal dominant inherited syndrome caused by mutations in the PAX3, MITF, and SNAI2 genes. Signs and symptoms include hearing loss, dystopia canthorum (widely spaced inner corners of the eyes), and changes in the color of the skin, hair, and eyes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-09DF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-09F5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Waldenstrom Macroglobulinemia","valueDescription":"Waldenstrom Macroglobulinemia","ValueMeaning":{"publicId":"3040402","version":"1","preferredName":"Waldenstrom Macroglobulinemia","longName":"3040402","preferredDefinition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Waldenstrom Macroglobulinemia","conceptCode":"C80307","definition":"Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"832F1E62-11E1-273F-E040-BB89AD432C6A","latestVersionIndicator":"Yes","beginDate":"2010-04-01","endDate":null,"createdBy":"ALEYR","dateCreated":"2010-04-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-09FF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wallerian Degeneration","valueDescription":"Wallerian Degeneration","ValueMeaning":{"publicId":"3211520","version":"1","preferredName":"Wallerian Degeneration","longName":"3211520","preferredDefinition":"A condition caused by degeneration, atrophy, and destruction of the distal part of a nerve fiber's axon and myelin, when continuity with the neural cell nucleus has been severed due to injury. Signs and symptoms include muscle weakness, altered sensation, and limb numbness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wallerian Degeneration","conceptCode":"C85223","definition":"A condition caused by degeneration, atrophy, and destruction of the distal part of a nerve fiber's axon and myelin, when continuity with the neural cell nucleus has been severed due to injury. Signs and symptoms include muscle weakness, altered sensation, and limb numbness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0A0B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0A21-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wandering Spleen","valueDescription":"Wandering Spleen","ValueMeaning":{"publicId":"3211521","version":"1","preferredName":"Wandering Spleen","longName":"3211521","preferredDefinition":"A condition characterized by an abnormal spleen position due to loss, weakness, or malformation of one or more of the ligaments that hold the spleen in its normal position in the left upper abdomen. It may present as a birth defect or follow injuries or pregnancy. Signs and symptoms include abdominal discomfort and splenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wandering Spleen","conceptCode":"C85224","definition":"A condition characterized by an abnormal spleen position due to loss, weakness, or malformation of one or more of the ligaments that hold the spleen in its normal position in the left upper abdomen. It may present as a birth defect or follow injuries or pregnancy. Signs and symptoms include abdominal discomfort and splenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0A2D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0A43-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Waterhouse-Friderichsen Syndrome","valueDescription":"Waterhouse-Friderichsen Syndrome","ValueMeaning":{"publicId":"3211522","version":"1","preferredName":"Waterhouse-Friderichsen Syndrome","longName":"3211522","preferredDefinition":"A serious disorder characterized by massive adrenal gland hemorrhage secondary to a bacterial infection, most often Neisseria meningitidis infection. It is manifested with decreased blood pressure, shock, disseminated intravascular coagulation, and adrenocortical insufficiency.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Waterhouse-Friderichsen Syndrome","conceptCode":"C85225","definition":"A serious disorder characterized by massive adrenal gland hemorrhage secondary to a bacterial infection, most often Neisseria meningitidis infection. It is manifested with decreased blood pressure, shock, disseminated intravascular coagulation, and adrenocortical insufficiency.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0A4F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0A65-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wegener Granulomatosis","valueDescription":"Wegener's Granulomatosis","ValueMeaning":{"publicId":"2593570","version":"1","preferredName":"Wegener's Granulomatosis","longName":"2593570","preferredDefinition":"A multisystem disease chiefly affecting males, characterized by necrotizing granulomatous vasculitis involving the upper and lower respiratory tracts, glomerulonephritis, and variable degrees of systemic, small vessel vasculitis, which is generally considered to represent an aberrant hypersensitivity reaction to an unknown antigen. (Dorland, 27th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granulomatosis with Polyangiitis","conceptCode":"C3444","definition":"A rare, autoimmune, systemic medium and small size vasculitis. It is characterized by the formation of necrotizing granulomas in the respiratory tract, necrotizing angiitis, and glomerulonephritis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C01AFF-5E3F-08FB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0A6F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Weill-Marchesani Syndrome","valueDescription":"Weill-Marchesani Syndrome","ValueMeaning":{"publicId":"3211523","version":"1","preferredName":"Weill-Marchesani Syndrome","longName":"3211523","preferredDefinition":"A rare, autosomal recessive or dominant inherited connective tissue disorder. The autosomal recessive variant is caused by mutations in the ADAMTS10 gene. It is characterized by abnormalities in the lens of the eye, short stature, brachydactyly, and joint stiffness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Weill-Marchesani Syndrome","conceptCode":"C85226","definition":"A rare, autosomal recessive or dominant inherited connective tissue disorder. The autosomal recessive variant is caused by mutations in the ADAMTS10 gene. It is characterized by abnormalities in the lens of the eye, short stature, brachydactyly, and joint stiffness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0A7B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0A91-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wernicke-Korsakoff Syndrome","valueDescription":"Wernicke-Korsakoff Syndrome","ValueMeaning":{"publicId":"3211524","version":"1","preferredName":"Wernicke-Korsakoff Syndrome","longName":"3211524","preferredDefinition":"A syndrome caused by thiamine deficiency. It usually occurs in alcoholics and is characterized by confusion, ataxia, and ophthalmoplegia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wernicke-Korsakoff Syndrome","conceptCode":"C35764","definition":"A syndrome caused by thiamine deficiency. It usually occurs in alcoholics and is characterized by confusion, ataxia, and ophthalmoplegia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0A9D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0AB3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"West Syndrome","valueDescription":"West Syndrome","ValueMeaning":{"publicId":"3211525","version":"1","preferredName":"West Syndrome","longName":"3211525","preferredDefinition":"A rare autosomal recessive inherited neurodegenerative disorder caused by mutations in the PLA2G6 gene. It is characterized by the development of swellings called spheroids along the axons of the central nervous system. Signs and symptoms appear early in life and include movement difficulties, muscle hypotonia and spasticity, and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"West Syndrome","conceptCode":"C84788","definition":"A rare autosomal recessive inherited neurodegenerative disorder caused by mutations in the PLA2G6 gene. It is characterized by the development of swellings called spheroids along the axons of the central nervous system. Signs and symptoms appear early in life and include movement difficulties, muscle hypotonia and spasticity, and cognitive dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0ABF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0AD5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Western Equine Encephalomyelitis","valueDescription":"Western Equine Encephalomyelitis","ValueMeaning":{"publicId":"3211526","version":"1","preferredName":"Western Equine Encephalomyelitis","longName":"3211526","preferredDefinition":"A mosquito-born viral infection caused by the Western equine encephalitis virus. The signs and symptoms range from flu-like illness to permanent central nervous system damage, coma, and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Western Equine Encephalomyelitis","conceptCode":"C85227","definition":"A mosquito-born viral infection caused by the Western equine encephalitis virus. The signs and symptoms range from flu-like illness to permanent central nervous system damage, coma, and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0AE1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0AF7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Whipple Disease","valueDescription":"Whipple Disease","ValueMeaning":{"publicId":"3211527","version":"1","preferredName":"Whipple Disease","longName":"3211527","preferredDefinition":"A systemic infection caused by the Gram-positive bacterium Tropheryma whipplei. It affects the small intestine resulting in malabsorption. Other sites or systems affected by the infection are the joints, central nervous system, and the cardiovascular system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Whipple Disease","conceptCode":"C85228","definition":"A systemic infection caused by the Gram-positive bacterium Tropheryma whipplei. It affects the small intestine resulting in malabsorption. Other sites or systems affected by the infection are the joints, central nervous system, and the cardiovascular system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0B03-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0B19-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Whooping Cough","valueDescription":"Whooping Cough","ValueMeaning":{"publicId":"3211528","version":"1","preferredName":"Whooping Cough","longName":"3211528","preferredDefinition":"A contagious bacterial respiratory infection caused by Bordetella pertussis. It is characterized by severe and uncontrollable cough, resulting in a whooping sound during breathing following the cough.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Whooping Cough","conceptCode":"C85231","definition":"A contagious bacterial respiratory infection caused by Bordetella pertussis. It is characterized by severe and uncontrollable cough, resulting in a whooping sound during breathing following the cough.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0B25-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0B3B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Williams Syndrome","valueDescription":"Williams Syndrome","ValueMeaning":{"publicId":"3211529","version":"1","preferredName":"Williams Syndrome","longName":"3211529","preferredDefinition":"A rare syndrome caused by multiple gene deletions from a region of chromosome 7, including the deletion of CLIP2, ELN, GTF2I, GTF2IRD1 and LIMK1 genes. It is characterized by distinctive facial appearance (elfin facies), mild-to-moderate mental retardation, cheerfulness, cardiovascular abnormalities and infantile hypercalcemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Williams Syndrome","conceptCode":"C85232","definition":"A rare syndrome caused by multiple gene deletions from a region of chromosome 7, including the deletion of CLIP2, ELN, GTF2I, GTF2IRD1 and LIMK1 genes. It is characterized by distinctive facial appearance (elfin facies), mild-to-moderate mental retardation, cheerfulness, cardiovascular abnormalities and infantile hypercalcemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0B47-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0B5D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation Syndrome","valueDescription":"Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation Syndrome","ValueMeaning":{"publicId":"3211530","version":"1","preferredName":"Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation Syndrome","longName":"3211530","preferredDefinition":"A very rare congenital condition involving the complex of Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation. Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation (WAGR) syndrome involves deletions of several adjacent genes in chromosome region 11p13. Two or more of the four conditions must be present for an individual to be diagnosed with WAGR Syndrome. The clinical picture varies, depending upon the combination of abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WAGR Syndrome","conceptCode":"C3718","definition":"A very rare congenital condition involving the complex of Wilms tumor, aniridia, genitourinary abnormalities, and mental retardation. Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation (WAGR) syndrome involves deletions of several adjacent genes in chromosome region 11p13. Two or more of the four conditions must be present for an individual to be diagnosed with WAGR Syndrome. The clinical picture varies, depending upon the combination of abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0B69-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0B7F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wiskott-Aldrich Syndrome","valueDescription":"Wiskott-Aldrich syndrome","ValueMeaning":{"publicId":"2579850","version":"1","preferredName":"Wiskott-Aldrich syndrome","longName":"2579850","preferredDefinition":"A rare, X-linked immunodeficiency syndrome characterized by eczema, thrombocytopenia, and recurrent pyogenic infection. It is seen exclusively in young boys. Typically, IgM levels are low and IgA and IgE levels are elevated. Lymphoreticular malignancies are common.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wiskott-Aldrich Syndrome","conceptCode":"C3448","definition":"A rare, X-linked immunodeficiency syndrome characterized by eczema, thrombocytopenia, and recurrent pyogenic infection. It is seen exclusively in young boys. Typically, IgM levels are low and IgA and IgE levels are elevated. Lymphoreticular malignancies are common.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04F7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0B89-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wolff-Parkinson-White Syndrome","valueDescription":"Wolff-Parkinson-White Syndrome","ValueMeaning":{"publicId":"2569804","version":"1","preferredName":"Wolff-Parkinson-White Syndrome","longName":"2569804","preferredDefinition":"A congenital electrical function abnormality in the heart. It is characterized by the presence of an accessory conductive pathway between the atria and the ventricles which causes the activation of the ventricles earlier than anticipated. Characteristic electrocardiographic findings are a short PR interval and a wide QRS complex with a delta wave.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wolff-Parkinson-White Syndrome","conceptCode":"C35132","definition":"A cardiac conduction disorder characterized by an electrocardiographic finding of ventricular pre-excitation, which is a short PR interval and a long QRS interval with a delta wave. Most individuals are asymptomatic; however they can experience periods of palpitations, shortness of breath or syncope during tachycardic episodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DDB9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-04","endDate":null,"createdBy":"PWEST","dateCreated":"2004-06-04","modifiedBy":"REEVESD","dateModified":"2013-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0B93-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wolf-Hirschhorn Syndrome","valueDescription":"Wolf-Hirschhorn Syndrome","ValueMeaning":{"publicId":"3211531","version":"1","preferredName":"Wolf-Hirschhorn Syndrome","longName":"3211531","preferredDefinition":"A genetic syndrome resulting from a partial deletion on the short arm of chromosome 4 (4p deletion syndrome).  It is characterized by mental retardation, microcephaly, seizures, muscle hypotonia, a distinctive facial appearance with prominent forehead and wide set eyes, growth failure with malformations of the spine, hands, and feet, congenital heart defects, and genitourinary malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wolf-Hirschhorn Syndrome","conceptCode":"C35528","definition":"A genetic syndrome resulting from a partial deletion on the short arm of chromosome 4 (4p deletion syndrome). It is characterized by mental retardation, microcephaly, seizures, muscle hypotonia, a distinctive facial appearance with prominent forehead and wide set eyes, growth failure with malformations of the spine, hands, and feet, congenital heart defects, and genitourinary malformations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0B9F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0BB5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wolfram Syndrome","valueDescription":"Wolfram Syndrome","ValueMeaning":{"publicId":"3211532","version":"1","preferredName":"Wolfram Syndrome","longName":"3211532","preferredDefinition":"A rare inherited syndrome caused by mutations in the WFS1 and CISD2 genes. It is characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wolfram Syndrome","conceptCode":"C35133","definition":"A rare inherited syndrome caused by mutations in the WFS1 and CISD2 genes. It is characterized by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0BC1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0BD7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Xeroderma Pigmentosum","valueDescription":"Xeroderma Pigmentosum","ValueMeaning":{"publicId":"3211533","version":"1","preferredName":"Xeroderma Pigmentosum","longName":"3211533","preferredDefinition":"An inherited skin disorder characterized by photosensitivity with severe sunburn in infancy, the development of numerous pigmented spots resembling freckles, larger atrophic lesions associated with telangiectasis, and multiple solar keratoses. Transmitted in an autosomal recessive manner, xeroderma pigmentosa involves a defect in nucleotide excision repair (NER), leading to deficient repair of DNA damaged by UV radiation and chromosome breakage. Individuals with this disease develop multiple malignant cutaneous neoplasms at an early age and may suffer from severe ophthalmic and neurologic abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Xeroderma Pigmentosum","conceptCode":"C3452","definition":"An inherited skin disorder characterized by photosensitivity with severe sunburn in infancy, the development of numerous pigmented spots resembling freckles, larger atrophic lesions associated with telangiectasis, and multiple solar keratoses. Transmitted in an autosomal recessive manner, xeroderma pigmentosa involves a defect in nucleotide excision repair (NER), leading to deficient repair of DNA damaged by UV radiation and chromosome breakage. Individuals with this disease develop multiple malignant cutaneous neoplasms at an early age and may suffer from severe ophthalmic and neurologic abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0BED-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0C03-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Xerophthalmia","valueDescription":"Xerophthalmia","ValueMeaning":{"publicId":"3211534","version":"1","preferredName":"Xerophthalmia","longName":"3211534","preferredDefinition":"Dryness of the eye due to inadequate production of tears. Causes include vitamin A deficiency, Sjogren syndrome, rheumatoid arthritis, systemic lupus erythematosus, and scleroderma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Xerophthalmia","conceptCode":"C34503","definition":"Dryness of the eye due to inadequate production of tears. Causes include vitamin A deficiency, Sjogren syndrome, rheumatoid arthritis, systemic lupus erythematosus, and scleroderma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0C0F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0C25-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"X-Linked Bulbar-Muscular Atrophy","valueDescription":"X-Linked Bulbar-Muscular Atrophy","ValueMeaning":{"publicId":"3211535","version":"1","preferredName":"X-Linked Bulbar-Muscular Atrophy","longName":"3211535","preferredDefinition":"A rare, slowly progressive degenerative disorder affecting males. It is caused by mutations in the androgen receptor (AR) gene. It is characterized by bulbar and limb muscle weakness and atrophy, and gynecomastia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spinal and Bulbar Muscular Atrophy, X-linked 1","conceptCode":"C85233","definition":"A rare, slowly progressive degenerative disorder affecting males. It is caused by mutations in the androgen receptor (AR) gene. It is characterized by bulbar and limb muscle weakness and atrophy, and gynecomastia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0C31-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0C47-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"X-Linked Dominant Hypophosphatemic Rickets","valueDescription":"X-Linked Dominant Hypophosphatemic Rickets","ValueMeaning":{"publicId":"3211536","version":"1","preferredName":"X-Linked Dominant Hypophosphatemic Rickets","longName":"3211536","preferredDefinition":"An X-linked dominant disorder caused by mutations in the PHEX gene. It is characterized by growth retardation, rickets, osteomalacia, hypophosphatemia, and defects in the renal reabsorption of phosphorus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"X-Linked Dominant Hypophosphatemic Rickets","conceptCode":"C85234","definition":"An X-linked dominant disorder caused by mutations in the PHEX gene. It is characterized by growth retardation, osteomalacia, hypophosphatemia, and defects in the renal reabsorption of phosphorus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0C53-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0C69-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"X-Linked Ichthyosis","valueDescription":"X-Linked Ichthyosis","ValueMeaning":{"publicId":"3211537","version":"1","preferredName":"X-Linked Ichthyosis","longName":"3211537","preferredDefinition":"The second most common form of ichthyosis. It is an X-linked inherited disorder with mild skin manifestations. The skin changes appear at birth and include keratinization and scaling.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"X-Linked Ichthyosis","conceptCode":"C84779","definition":"The second most common form of ichthyosis. It is an X-linked inherited disorder with mild skin manifestations. The skin changes appear at birth and include keratinization and scaling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0C75-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0C8B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"X-Linked Severe Combined Immunodeficiency","valueDescription":"X-Linked Severe Combined Immunodeficiency","ValueMeaning":{"publicId":"2593406","version":"1","preferredName":"X-Linked Severe Combined Immunodeficiency","longName":"2593406","preferredDefinition":"Rare congenital disorder inherited as an X-linked defect characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"X-Linked Severe Combined Immunodeficiency","conceptCode":"C4682","definition":"Rare congenital disorder inherited as an X-linked defect characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28856182-985A-6F60-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0C95-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"XO Syndrome","valueDescription":"XO Syndrome","ValueMeaning":{"publicId":"3211538","version":"1","preferredName":"XO Syndrome","longName":"3211538","preferredDefinition":"A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the complete absence of one of the sex chromosomes. Signs and symptoms include short stature and hypogonadism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"XO Syndrome","conceptCode":"C85210","definition":"A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the complete absence of one of the sex chromosomes. Signs and symptoms include short stature and hypogonadism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0CA1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0CB7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"XXXY and XXXXY Syndrome","valueDescription":"XXXY and XXXXY Syndrome","ValueMeaning":{"publicId":"3211539","version":"1","preferredName":"XXXY and XXXXY Syndrome","longName":"3211539","preferredDefinition":"Rare syndromes caused by chromosomal defects and characterized by the presence of multiple X chromosomes and one Y chromosome. Signs and symptoms include short stature, mental retardation, hypogonadism, undescended testes, gynecomastia, and hypotonia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"XXXY and XXXXY Syndrome","conceptCode":"C85236","definition":"Rare syndromes caused by chromosomal defects and characterized by the presence of multiple X chromosomes and one Y chromosome. Signs and symptoms include short stature, mental retardation, hypogonadism, undescended testes, gynecomastia, and hypotonia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0CC3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0CD9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"XYY Syndrome","valueDescription":"XYY Syndrome","ValueMeaning":{"publicId":"3211540","version":"1","preferredName":"XYY Syndrome","longName":"3211540","preferredDefinition":"A rare syndrome affecting males. It is characterized by the presence of an extra Y chromosome. Individuals with this disorder are taller than other males of their age. Signs and symptoms include learning disabilities and difficulties with speech and language development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"47,XYY Syndrome","conceptCode":"C85237","definition":"A condition caused by the presence of an extra Y chromosome resulting in 47,XYY karyotype in an individual with male phenotype. The condition is characterized by tall stature, increased risk of learning disabilities, and delayed development of speech and language. Testicular function and size are normal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0CE5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0CFB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Yaws","valueDescription":"Yaws","ValueMeaning":{"publicId":"3211541","version":"1","preferredName":"Yaws","longName":"3211541","preferredDefinition":"An endemic, infectious, nonvenereal disease in humans that presents mainly in children younger than 15 years. The disease occurs primarily in warm, humid, tropical areas of Africa, Asia, South America, and Oceania, among poor rural populations where conditions of overcrowding and poor sanitation prevail. Infection with Treponema pertenue, a subspecies of Treponema pallidum, causes the disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yaws","conceptCode":"C41353","definition":"An endemic, infectious, nonvenereal disease in humans that presents mainly in children younger than 15 years. The disease occurs primarily in warm, humid, tropical areas of Africa, Asia, South America, and Oceania, among poor rural populations where conditions of overcrowding and poor sanitation prevail. Infection with Treponema pertenue, a subspecies of Treponema pallidum, causes the disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0D07-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0D1D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Yellow Fever Virus Infection","valueDescription":"Yellow Fever Virus Infection","ValueMeaning":{"publicId":"3211542","version":"1","preferredName":"Yellow Fever Virus Infection","longName":"3211542","preferredDefinition":"A viral infection caused by a flavivirus called yellow fever virus. It is transmitted to humans from infected mosquitoes. The signs and symptoms range from a mild febrile illness to liver damage with jaundice and hemorrhages.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yellow Fever Virus Infection","conceptCode":"C35547","definition":"A viral infection caused by a flavivirus called yellow fever virus. It is transmitted to humans from infected mosquitoes. The signs and symptoms range from a mild febrile illness to liver damage with jaundice and hemorrhages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0D29-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0D3F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Yellow Nail Syndrome","valueDescription":"Yellow Nail Syndrome","ValueMeaning":{"publicId":"3211543","version":"1","preferredName":"Yellow Nail Syndrome","longName":"3211543","preferredDefinition":"A rare syndrome characterized by the presence of thickened yellow nails, lymphedema, and respiratory abnormalities, including pleural effusion, bronchiectasis, chronic sinusitis, and persistent cough. Some cases are associated with mutations in the FOXC2 gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yellow Nail Syndrome","conceptCode":"C85238","definition":"A rare syndrome characterized by the presence of thickened yellow nails, lymphedema, and respiratory abnormalities, including pleural effusion, bronchiectasis, chronic sinusitis, and persistent cough. Some cases are associated with mutations in the FOXC2 gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0D4B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0D61-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Yolk Sac Tumor","valueDescription":"Yolk Sac Tumor","ValueMeaning":{"publicId":"2566024","version":"1","preferredName":"Yolk Sac Tumor","longName":"2566024","preferredDefinition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells. It is the most common malignant germ cell tumor in the pediatric population. It occurs in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax, and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation, and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yolk Sac Tumor","conceptCode":"C3011","definition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells.  It is the most common malignant germ cell tumor in the pediatric population. It occurs in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax, and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation, and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CEF5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-05-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-05-30","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0D6B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Zellweger Syndrome","valueDescription":"Zellweger Syndrome","ValueMeaning":{"publicId":"3211544","version":"1","preferredName":"Zellweger Syndrome","longName":"3211544","preferredDefinition":"A rare group of autosomal recessive inherited disorders characterized by the reduction or absence of peroxisomes in the tissues. Signs and symptoms include increased levels of iron and copper in the blood and tissues, hepatomegaly, facial abnormalities, mental retardation, seizures, and hypotonia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zellweger Syndrome","conceptCode":"C85239","definition":"A rare group of autosomal recessive inherited disorders characterized by the reduction or absence of peroxisomes in the tissues. Signs and symptoms include increased levels of iron and copper in the blood and tissues, hepatomegaly, facial abnormalities, mental retardation, seizures, and hypotonia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0D77-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0D8D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Zollinger Ellison Syndrome","valueDescription":"Zollinger Ellison Syndrome","ValueMeaning":{"publicId":"3211545","version":"1","preferredName":"Zollinger Ellison Syndrome","longName":"3211545","preferredDefinition":"A syndrome characterized by the presence of a gastrin-secreting tumor, usually in the pancreas or duodenum, resulting in increased gastric acidity and formation of gastric ulcers. Signs and symptoms include abdominal pain and diarrhea. It may be sporadic or a manifestation of multiple endocrine neoplasia type 1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zollinger Ellison Syndrome","conceptCode":"C3453","definition":"A syndrome characterized by the presence of a gastrin-secreting tumor, usually in the pancreas or duodenum, resulting in increased gastric acidity and formation of gastric ulcers. Signs and symptoms include abdominal pain and diarrhea. It may be sporadic or a manifestation of multiple endocrine neoplasia type 1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-0D99-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0DAF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Zygomycosis","valueDescription":"Zygomycosis","ValueMeaning":{"publicId":"2803523","version":"1","preferredName":"Zygomycosis","longName":"2803523","preferredDefinition":"Any infection due to a fungus of the Zygomycota phylum. The disease typically involves the rhino-facial-cranial area, lungs, gastrointestinal tract, skin, or less commonly other organ systems. The infecting fungi have a predilection for invading vessels of the arterial system, causing embolization and subsequent necrosis of surrounding tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zygomycosis","conceptCode":"C77212","definition":"Any infection due to a fungus of the Zygomycota phylum. The disease typically involves the rhino-facial-cranial area, lungs, gastrointestinal tract, skin, or less commonly other organ systems. The infecting fungi have a predilection for invading vessels of the arterial system, causing embolization and subsequent necrosis of surrounding tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C214C8C-AACF-4A00-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ZHANGW","dateCreated":"2008-11-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0DC1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"No Evidence of Disease","valueDescription":"No Evidence of Disease","ValueMeaning":{"publicId":"2559523","version":"1","preferredName":"No Evidence of Disease","longName":"2559523","preferredDefinition":"Diagnostic tests fail to detect presence of disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No Evidence of Disease","conceptCode":"C40413","definition":"Diagnostic tests fail to detect presence of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B590-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E162-0DD3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mitral Valve Prolapse","valueDescription":"Mitral Valve Prolapse","ValueMeaning":{"publicId":"3210754","version":"1","preferredName":"Mitral Valve Prolapse","longName":"3210754","preferredDefinition":"A fairly common and often benign valvular heart disorder characterized by redundancy or hooding of mitral valve leaflets so that they prolapse into the left atrium, often causing mitral regurgitation. It is often a symptomless condition but may be marked by varied symptoms (e.g. chest pain, fatigue, dizziness, dyspnea, or palpitations) leading in some cases to endocarditis or ventricular tachycardia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitral Valve Prolapse","conceptCode":"C50655","definition":"A fairly common and often benign valvular heart disorder characterized by redundancy or hooding of mitral valve leaflets so that they prolapse into the left atrium, often causing mitral regurgitation. It is often a symptomless condition but may be marked by varied symptoms (e.g. chest pain, fatigue, dizziness, dyspnea, or palpitations) leading in some cases to endocarditis or ventricular tachycardia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9A22-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9A38-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Myocardial Infarction","valueDescription":"Myocardial infarction","ValueMeaning":{"publicId":"2569449","version":"1","preferredName":"Myocardial infarction","longName":"2569449","preferredDefinition":"Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area. (Dorland, 27th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myocardial Infarction","conceptCode":"C27996","definition":"Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DC56-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-04-26","modifiedBy":"ALAIS","dateModified":"2006-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9A42-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Narcolepsy","valueDescription":"Narcolepsy","ValueMeaning":{"publicId":"3210755","version":"1","preferredName":"Narcolepsy","longName":"3210755","preferredDefinition":"A sleep disorder characterized by a tendency for excessive sleepiness during the day which occurs even after an adequate sleep in the nighttime. The persons who suffer from this condition experience fatigue and may fall asleep at inappropriate times during the day.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Narcolepsy","conceptCode":"C84489","definition":"A sleep disorder characterized by a tendency for excessive sleepiness during the day which occurs even after adequate sleep in the nighttime. The persons who suffer from this condition experience fatigue and may fall asleep at inappropriate times during the day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9A4E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9A64-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Obesity","valueDescription":"Obesity","ValueMeaning":{"publicId":"2566203","version":"1","preferredName":"Obesity","longName":"2566203","preferredDefinition":"Having a high amount of body fat (body mass index [BMI] of 30 or more).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Obesity","conceptCode":"C3283","definition":"Having a high amount of body fat (body mass index [BMI] of 30 or more).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CFA8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-07-23","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-07-23","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9A6E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Palpitation","valueDescription":"Palpitation","ValueMeaning":{"publicId":"2945899","version":"1","preferredName":"Palpitation","longName":"2945899","preferredDefinition":"Palpitations; unpleasant sensation of irregular and/or forceful beating of the heart.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palpitation","conceptCode":"C37999","definition":"An unpleasant sensation of irregular and/or forceful beating of the heart.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74597246-1A5A-6D19-E040-BB89AD431E08","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9A80-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Patent Ductus Arteriosus","valueDescription":"Patent Ductus Arteriosus","ValueMeaning":{"publicId":"3210756","version":"1","preferredName":"Patent Ductus Arteriosus","longName":"3210756","preferredDefinition":"A congenital defect characterized by the failure of the ductus arteriosus to close soon after birth. As a consequence, blood from the aorta mixes with blood from the pulmonary artery. If untreated, it may lead to congestive heart failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patent Ductus Arteriosus","conceptCode":"C84492","definition":"A congenital defect characterized by the failure of the ductus arteriosus to close soon after birth. As a consequence, blood from the aorta mixes with blood from the pulmonary artery. If untreated, it may lead to congestive heart failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9A8C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9AA2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pericarditis","valueDescription":"Pericarditis","ValueMeaning":{"publicId":"2566218","version":"1","preferredName":"Pericarditis","longName":"2566218","preferredDefinition":"An inflammatory process affecting the pericardium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pericarditis","conceptCode":"C34915","definition":"An inflammatory process affecting the pericardium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CFB7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-07-24","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-07-24","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9AAC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Peripheral Arterial Disorder","valueDescription":"Peripheral Arterial Disorder","ValueMeaning":{"publicId":"3210757","version":"1","preferredName":"Peripheral Arterial Disorder","longName":"3210757","preferredDefinition":"A disorder caused by atherosclerosis of the arteries that supply the arms and legs. Patients experience cramping and pain usually in the calves and thighs while walking. The symptoms subside with rest.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral Artery Disease","conceptCode":"C84496","definition":"A disorder of the arteries supplying the upper and lower extremity and the visceral organs. This includes the mesenteric arteries, the renal arteries and the aorta and excludes cerebrovascular arterial disease. Patients experience cramping and pain usually in the calves and thighs while walking. The symptoms subside with rest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9AB8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9ACE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pernicious Anemia","valueDescription":"Pernicious Anemia","ValueMeaning":{"publicId":"3210758","version":"1","preferredName":"Pernicious Anemia","longName":"3210758","preferredDefinition":"Megaloblastic anemia caused by vitamin B-12 deficiency due to impaired absorption. The impaired absorption of vitamin B-12 is secondary to atrophic gastritis and loss of gastric parietal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pernicious Anemia","conceptCode":"C2871","definition":"Megaloblastic anemia caused by vitamin B-12 deficiency due to impaired absorption. The impaired absorption of vitamin B-12 is secondary to atrophic gastritis and loss of gastric parietal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9ADA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9AF0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Polycythemia Vera","valueDescription":"Polycythemia Vera","ValueMeaning":{"publicId":"2559822","version":"1","preferredName":"Polycythemia Vera","longName":"2559822","preferredDefinition":"A chronic myeloproliferative disorder characterized by an increased red blood cell production.  Excessive proliferation of the myeloid lineage is observed as well.  The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass.  The cause is unknown.  With currently available treatment, the median survival exceeds 10 years.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycythemia Vera","conceptCode":"C3336","definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6BB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9AFA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pulmonary Embolism","valueDescription":"Pulmonary Embolism","ValueMeaning":{"publicId":"2770974","version":"1","preferredName":"Pulmonary Embolism","longName":"2770974","preferredDefinition":"The closure of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Embolism","conceptCode":"C50713","definition":"The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53F2DD1F-DD5A-0AF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9B04-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pulmonary Hypertension","valueDescription":"Pulmonary Hypertension","ValueMeaning":{"publicId":"2566228","version":"1","preferredName":"Pulmonary Hypertension","longName":"2566228","preferredDefinition":"Increased pressure within the pulmonary circulation due to lung or heart disorder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Hypertension","conceptCode":"C3120","definition":"Increased pressure within the pulmonary circulation due to lung or heart disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CFC1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-07-24","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-07-24","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9B16-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Raynaud's Disease","valueDescription":"Raynaud's Disease","ValueMeaning":{"publicId":"3210759","version":"1","preferredName":"Raynaud's Disease","longName":"3210759","preferredDefinition":"An idiopathic vascular disorder characterized by ischemic attacks in the fingers, toes, ears, or nose, associated with pain and pallor. The attacks occur during exposure to cold temperatures or stress.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raynaud's Disease","conceptCode":"C34972","definition":"An idiopathic vascular disorder characterized by ischemic attacks in the fingers, toes, ears, or nose, associated with pain and pallor. The attacks occur during exposure to cold temperatures or stress.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9B22-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9B38-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Respiratory Distress Syndrome","valueDescription":"Respiratory Distress Syndrome","ValueMeaning":{"publicId":"3210760","version":"1","preferredName":"Respiratory Distress Syndrome","longName":"3210760","preferredDefinition":"A group of conditions characterized by failure of normal respiration caused by lack of lung surfactant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Respiratory Distress Syndrome","conceptCode":"C27561","definition":"A condition beginning in the first day of life that results from inadequate surfactant production, causing increased work of breathing and impaired gas exchange.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9B44-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9B5A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Restless Leg Syndrome","valueDescription":"Restless Leg Syndrome","ValueMeaning":{"publicId":"3210761","version":"1","preferredName":"Restless Leg Syndrome","longName":"3210761","preferredDefinition":"A condition that occurs while resting or lying in bed; it is characterized by an irresistible urgency to move the legs to obtain relief from a strange and uncomfortable sensation in the legs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Restless Leg Syndrome","conceptCode":"C84501","definition":"A condition that occurs while resting or lying in bed; it is characterized by an irresistible urgency to move the legs to obtain relief from a strange and uncomfortable sensation in the legs.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9B66-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9B7C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Rh Incompatibility","valueDescription":"Rh Incompatibility","ValueMeaning":{"publicId":"3210762","version":"1","preferredName":"Rh Incompatibility","longName":"3210762","preferredDefinition":"A complication during pregnancy; it occurs when the mother is Rh-negative and the infant is Rh-positive. The mother's body develops antibodies against the fetal red blood cells leading to their destruction. This complication generally does not affect first-born Rh-positive babies. Rh-positive newborn babies from subsequent pregnancies develop complications of Rh incompatibility which include hemolysis, jaundice, enlarged liver and spleen, petechiae, hypotonia, neurologic damage, and heart problems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rh Incompatibility","conceptCode":"C84504","definition":"A complication during pregnancy; it occurs when the mother is Rh-negative and the infant is Rh-positive. This complication generally does not affect first-born Rh-positive babies. Rh-positive newborn babies from subsequent pregnancies develop complications of Rh incompatibility which include hemolysis, jaundice, enlarged liver and spleen, petechiae, hypotonia, neurologic damage, and heart problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9B88-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9B9E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sarcoidosis","valueDescription":"Sarcoidosis","ValueMeaning":{"publicId":"2975598","version":"1","preferredName":"Sarcoidosis","longName":"2975598","preferredDefinition":"inflammatory disease characterized by small lumps or granulomas in lymph nodes and other organs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoidosis","conceptCode":"C34995","definition":"An idiopathic inflammatory disorder characterized by the formation of non-necrotizing epithelioid granulomas which contain giant cells. It usually affects the lungs, lymph nodes, liver, and skin. Cardiac involvement is also possible.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C084539-0F50-6AD0-E040-BB89AD43189B","latestVersionIndicator":"Yes","beginDate":"2009-12-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9BA8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sickle Cell Disease","valueDescription":"sickle cell disease","ValueMeaning":{"publicId":"2579911","version":"1","preferredName":"sickle cell disease","longName":"2579911","preferredDefinition":"A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sickle Cell Disease","conceptCode":"C34383","definition":"A blood disorder characterized by the appearance of sickle-shaped red blood cells and anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0534-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9BB2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Sleep Apnea","valueDescription":"Sleep Apnea","ValueMeaning":{"publicId":"2757881","version":"1","preferredName":"Sleep Apnea","longName":"2757881","preferredDefinition":"Cessation of breathing for short periods during sleep. It is classified as obstructive, central, or mixed obstructive-central. It can occur at any age but it is more frequent in people over forty. Risk factors include male sex and obesity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sleep Apnea","conceptCode":"C26884","definition":"Cessation of breathing for short periods during sleep. It is classified as obstructive, central, or mixed obstructive-central. It can occur at any age but it is more frequent in people over forty. Risk factors include male sex and obesity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F3F8B84-D578-3BC8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-06-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9BBC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bronchial Intraepithelial Neoplasia","valueDescription":"Bronchial Intraepithelial Neoplasia","ValueMeaning":{"publicId":"3210763","version":"1","preferredName":"Bronchial Intraepithelial Neoplasia","longName":"3210763","preferredDefinition":"A term referring to neoplastic changes in the bronchial epithelium manifested as dysplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bronchial Intraepithelial Neoplasia","conceptCode":"C7436","definition":"A term referring to neoplastic changes in the bronchial epithelium manifested as dysplasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9BC8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9BDE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Tetralogy of Fallot","valueDescription":"Tetralogy of Fallot","ValueMeaning":{"publicId":"3210764","version":"1","preferredName":"Tetralogy of Fallot","longName":"3210764","preferredDefinition":"A congenital heart disorder characterized by the presence of the following four abnormalities: ventricular septal defect, pulmonary stenosis, overriding aorta, and right ventricular hypertrophy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tetralogy of Fallot","conceptCode":"C84505","definition":"A congenital heart disorder characterized by the presence of the following four abnormalities: ventricular septal defect, pulmonary stenosis, overriding aorta, and right ventricular hypertrophy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9BEA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9C00-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thalassemia","valueDescription":"Thalassemia","ValueMeaning":{"publicId":"2593293","version":"1","preferredName":"Thalassemia","longName":"2593293","preferredDefinition":"A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalassemia","conceptCode":"C35069","definition":"An inherited blood disorder characterized by a decreased synthesis of one of the polypeptide chains that form hemoglobin. Anemia results from this abnormal hemoglobin formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28821A33-CC97-19A3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9C0A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thrombocytopenia","valueDescription":"Thrombocytopenia","ValueMeaning":{"publicId":"2946035","version":"1","preferredName":"Thrombocytopenia","longName":"2946035","preferredDefinition":"A condition in which there is an abnormally small number of platelets in the circulating blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thrombocytopenia","conceptCode":"C3408","definition":"A laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D443-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9C14-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Thrombotic Thrombocytopenic Purpura","valueDescription":"Thrombotic Thrombocytopenic Purpura","ValueMeaning":{"publicId":"2944528","version":"1","preferredName":"Thrombotic Thrombocytopenic Purpura","longName":"2944528","preferredDefinition":"An acute or subacute syndrome characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. Drugs and bacteria have been implicated as etiologic factors.  The introduction of plasma exchange has significantly lowered the mortality rate. If untreated, the mortality rate is high.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thrombotic Thrombocytopenic Purpura","conceptCode":"C78797","definition":"A coagulation disorder characterized by extensive formation of thrombi in small blood vessels throughout the body due to low levels of ADAMTS13 protein, and resulting in consumption of circulating platelets, which is characterized by thrombocytopenia, anemia, neurologic changes, and sometimes fever and renal dysfunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"743D5322-CCC1-677A-E040-BB89AD434340","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-23","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9C26-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Valvular Heart Disorder","valueDescription":"Valvular Heart Disorder","ValueMeaning":{"publicId":"3210765","version":"1","preferredName":"Valvular Heart Disorder","longName":"3210765","preferredDefinition":"Any heart disorder characterized by a defect in valve structure or function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valvular Heart Disorder","conceptCode":"C45525","definition":"Any heart disorder characterized by a defect in valve structure or function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9C32-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9C48-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Varicose Vein","valueDescription":"Varicose Vein","ValueMeaning":{"publicId":"3210766","version":"1","preferredName":"Varicose Vein","longName":"3210766","preferredDefinition":"A vascular abnormality characterized by the presence of enlarged and tortuous veins, particularly in the legs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Varicose Vein","conceptCode":"C35114","definition":"A vascular abnormality characterized by the presence of enlarged and tortuous veins, particularly in the legs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9C54-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9C6A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Vasculitis","valueDescription":"Vasculitis","ValueMeaning":{"publicId":"2569497","version":"1","preferredName":"Vasculitis","longName":"2569497","preferredDefinition":"Inflammation of a blood vessel.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vasculitis","conceptCode":"C26912","definition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DC86-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-10","modifiedBy":"CZECHS","dateModified":"2008-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9C74-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ventricular Septal Defect","valueDescription":"Ventricular Septal Defect","ValueMeaning":{"publicId":"3210767","version":"1","preferredName":"Ventricular Septal Defect","longName":"3210767","preferredDefinition":"A congenital disorder characterized by the presence of a defect (opening) in the septum that separates the two ventricles of the heart. It causes oxygenated blood to flow from the left to the right ventricle and to the pulmonary circulation. If untreated, it may result in pulmonary hypertension.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ventricular Septal Defect","conceptCode":"C84506","definition":"The presence of a defect (opening) in the septum that separates the two ventricles of the heart. It can be congenital or acquired.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9C80-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9C96-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"von Willebrand Disease","valueDescription":"Von Willebrand Disease","ValueMeaning":{"publicId":"3210768","version":"1","preferredName":"Von Willebrand Disease","longName":"3210768","preferredDefinition":"Hereditary or acquired coagulation disorder characterized by a qualitative or quantitative deficiency of the von Willebrand factor. The latter plays an important role in platelet adhesion. Signs and symptoms include bruises, nose bleeding, gum bleeding following a dental procedure, heavy menstrual bleeding, and gastrointestinal bleeding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"von Willebrand Disease","conceptCode":"C68677","definition":"Hereditary or acquired coagulation disorder characterized by a qualitative or quantitative deficiency of the von Willebrand factor. The latter plays an important role in platelet adhesion. Signs and symptoms include bruises, nose bleeding, gum bleeding following a dental procedure, heavy menstrual bleeding, and gastrointestinal bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9CA2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9CB8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acute Liver Failure","valueDescription":"Acute Liver Failure","ValueMeaning":{"publicId":"3210769","version":"1","preferredName":"Acute Liver Failure","longName":"3210769","preferredDefinition":"Rapid deterioration of liver function causing encephalopathy and coagulopathy. It results from damage to the liver parenchyma usually secondary to acetaminophen overdose or viral infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Liver Failure","conceptCode":"C84396","definition":"Rapid deterioration of liver function causing encephalopathy and coagulopathy. It results from damage to the liver parenchyma usually secondary to acetaminophen overdose or viral infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9CC4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9CDA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acute Renal Failure","valueDescription":"Acute renal failure","ValueMeaning":{"publicId":"2943963","version":"1","preferredName":"Acute renal failure","longName":"2943963","preferredDefinition":"Sudden and sustained deterioration of the kidney function characterized by decreased glomerular filtration rate, increased serum creatinine or oliguria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Renal Failure","conceptCode":"C26808","definition":"Sudden and sustained deterioration of the kidney function characterized by decreased glomerular filtration rate, increased serum creatinine or oliguria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742CB3BE-B95F-F51E-E040-BB89AD432000","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-22","modifiedBy":"MAESKEB","dateModified":"2022-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9CEC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alagille Syndrome","valueDescription":"Alagille Syndrome","ValueMeaning":{"publicId":"3210770","version":"1","preferredName":"Alagille Syndrome","longName":"3210770","preferredDefinition":"An autosomal dominant genetic syndrome caused by mutations in the JAG1 gene.  It is characterized by cholestatic jaundice in infancy, hepatosplenomegaly, distinctive facial features (prominent forehead, elongated nose, and pointed chin), cardiac murmurs, bone malformations, and sometimes mild mental retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alagille Syndrome","conceptCode":"C35139","definition":"An autosomal dominant genetic syndrome caused by mutations in the JAG1 gene. It is characterized by cholestatic jaundice in infancy, hepatosplenomegaly, distinctive facial features (prominent forehead, elongated nose, and pointed chin), cardiac murmurs, bone malformations, and sometimes mild mental retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9CF8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9D0E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alcoholic Liver Disease","valueDescription":"Alcoholic Liver Disease","ValueMeaning":{"publicId":"3210771","version":"1","preferredName":"Alcoholic Liver Disease","longName":"3210771","preferredDefinition":"A disorder caused by damage to the liver parenchyma due to alcohol consumption. It may present with an acute onset or follow a chronic course, leading to cirrhosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alcoholic Liver Disease","conceptCode":"C34783","definition":"A disorder caused by damage to the liver parenchyma due to alcohol consumption. It may present with an acute onset or follow a chronic course, leading to cirrhosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9D1A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9D30-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bariatric Surgery","valueDescription":"Bariatric Surgery","ValueMeaning":{"publicId":"3210772","version":"1","preferredName":"Bariatric Surgery","longName":"3210772","preferredDefinition":"Surgery performed in morbidly obese patients to help promote weight loss. The procedure aims at the reduction of the stomach size and it is usually achieved either with the implantation of a medical device or the removal of part of the stomach.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bariatric Surgery","conceptCode":"C84399","definition":"Surgery performed in morbidly obese patients to help promote weight loss. The procedure aims at the reduction of the stomach size and it is usually achieved either with the implantation of a medical device or the removal of part of the stomach.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9D3C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9D52-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Barrett Esophagus","valueDescription":"Barrett Esophagus","ValueMeaning":{"publicId":"3210773","version":"1","preferredName":"Barrett Esophagus","longName":"3210773","preferredDefinition":"Esophageal segment lined with columnar metaplastic epithelium which is flat or villiform.  Barrett's epithelium is characterized by two different types of cells: goblet cells and columnar cells.  The symptomatology of Barrett's esophagus is that of gastro-esophageal reflux.  It is the precursor of most esophageal adenocarcinomas.  (WHO, 2000) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Barrett Esophagus","conceptCode":"C2891","definition":"Esophageal lesion lined with columnar metaplastic epithelium which is flat or villiform. Barrett epithelium is characterized by two different types of cells: goblet cells and columnar cells. The symptomatology of Barrett esophagus is that of gastro-esophageal reflux. It is the precursor of most esophageal adenocarcinomas.  (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9D5E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9D74-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Benign Prostatic Hyperplasia","valueDescription":"Benign Prostatic Hyperplasia","ValueMeaning":{"publicId":"2577137","version":"1","preferredName":"Benign Prostatic Hyperplasia","longName":"2577137","preferredDefinition":"A non-cancerous nodular enlargement of the prostate gland.  It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements.  It is the most common urologic disorder in men, causing blockage of urine flow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Prostatic Hyperplasia","conceptCode":"C2897","definition":"A non-cancerous nodular enlargement of the prostate gland.  It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements.  It is the most common urologic disorder in men, causing blockage of urine flow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA5E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"COOPERM","dateModified":"2019-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9D7E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Benign Recurrent Intrahepatic Cholestasis","valueDescription":"Benign Recurrent Intrahepatic Cholestasis","ValueMeaning":{"publicId":"3210774","version":"1","preferredName":"Benign Recurrent Intrahepatic Cholestasis","longName":"3210774","preferredDefinition":"Reappearance of cholestasis caused by obstruction within the liver by non-cancerous conditions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Recurrent Intrahepatic Cholestasis","conceptCode":"C84402","definition":"Reappearance of cholestasis caused by obstruction within the liver by non-cancerous conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9D8A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9DA0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bile Acid Synthesis Defect","valueDescription":"Bile Acid Synthesis Defect","ValueMeaning":{"publicId":"3210775","version":"1","preferredName":"Bile Acid Synthesis Defect","longName":"3210775","preferredDefinition":"A congenital or acquired defect in the bile acid biosynthesis, resulting in progressive liver disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bile Acid Synthesis Defect","conceptCode":"C84403","definition":"A congenital or acquired defect in the bile acid biosynthesis, resulting in progressive liver disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9DAC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9DC2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Biliary Atresia","valueDescription":"Biliary Atresia","ValueMeaning":{"publicId":"3210776","version":"1","preferredName":"Biliary Atresia","longName":"3210776","preferredDefinition":"A congenital disorder characterized by blockage or absence of an extrahepatic bile duct.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biliary Atresia","conceptCode":"C34421","definition":"A congenital disorder characterized by blockage or absence of the intrahepatic or extrahepatic bile ducts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9DCE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9DE4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Biliary Tract Disorder","valueDescription":"Biliary Tract Disorder","ValueMeaning":{"publicId":"3210777","version":"1","preferredName":"Biliary Tract Disorder","longName":"3210777","preferredDefinition":"A non-neoplastic or neoplastic disorder affecting the intrahepatic or extrahepatic biliary tract. Examples of non-neoplastic disorders include infection and atresia. Examples of neoplastic disorders include adenoma and carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biliary System Disorder","conceptCode":"C2899","definition":"A non-neoplastic or neoplastic disorder that affects the intrahepatic or extrahepatic bile ducts or the gallbladder. Representative examples of non-neoplastic disorders include cholangitis and cholecystitis. Representative examples of neoplastic disorders include extrahepatic bile duct adenoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9DF0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9E06-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bladder Disorder","valueDescription":"Bladder Disorder","ValueMeaning":{"publicId":"3210778","version":"1","preferredName":"Bladder Disorder","longName":"3210778","preferredDefinition":"A non-neoplastic or neoplastic disorder affecting the urinary bladder. A representative example of non-neoplastic bladder disorder is bacterial bladder infection. A representative example of neoplastic bladder disorder is bladder carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Disorder","conceptCode":"C2900","definition":"A non-neoplastic or neoplastic disorder affecting the urinary bladder. A representative example of non-neoplastic bladder disorder is bacterial bladder infection. A representative example of neoplastic bladder disorder is bladder carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9E12-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9E28-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cardiovascular Disorder","valueDescription":"Cardiovascular Disorder","ValueMeaning":{"publicId":"2630208","version":"1","preferredName":"Cardiovascular Disorder","longName":"2630208","preferredDefinition":"A non-neoplastic or neoplastic disorder affecting the heart or the vessels (arteries, veins and lymph vessels).  Representative examples of non-neoplastic cardiovascular disorders are endocarditis and hypertension.  Representative examples of neoplastic cardiovascular disorders are endocardial myxoma and angiosarcoma. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cardiovascular Disorder","conceptCode":"C2931","definition":"A non-neoplastic or neoplastic disorder affecting the heart or the vessels (arteries, veins and lymph vessels). Representative examples of non-neoplastic cardiovascular disorders are endocarditis and hypertension. Representative examples of neoplastic cardiovascular disorders are endocardial myxoma and angiosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E8C3390-BBE2-1B34-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-04-20","modifiedBy":"COLBERTM","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9E3A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Childhood Diabetes Mellitus","valueDescription":"Childhood Diabetes Mellitus","ValueMeaning":{"publicId":"3210779","version":"1","preferredName":"Childhood Diabetes Mellitus","longName":"3210779","preferredDefinition":"Diabetes mellitus that develops during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Diabetes Mellitus","conceptCode":"C84433","definition":"Diabetes mellitus that develops during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9E46-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9E5C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Childhood Renal Disorder","valueDescription":"Childhood Renal Disorder","ValueMeaning":{"publicId":"3210780","version":"1","preferredName":"Childhood Renal Disorder","longName":"3210780","preferredDefinition":"A kidney disorder that appears during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Kidney Disorder","conceptCode":"C84448","definition":"A kidney disorder that appears during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9E68-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9E7E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chronic Kidney Disease","valueDescription":"Chronic Kidney Disease","ValueMeaning":{"publicId":"2944301","version":"1","preferredName":"Chronic Kidney Disease","longName":"2944301","preferredDefinition":"Gradual and usually permanent loss of kidney function resulting in renal failure. Causes include diabetes, hypertension, and glomerulonephritis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Kidney Disease","conceptCode":"C80078","definition":"Impairment of the renal function secondary to chronic kidney damage persisting for three or more months.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74301D2A-4EFE-F34C-E040-BB89AD430317","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9E90-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Chronic Renal Failure","valueDescription":"Chronic Renal Failure","ValueMeaning":{"publicId":"3210781","version":"1","preferredName":"Chronic Renal Failure","longName":"3210781","preferredDefinition":"Impairment of the renal function due to chronic kidney damage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Renal Failure","conceptCode":"C9438","definition":"Impairment of the renal function due to chronic kidney damage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9E9C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9EB2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cirrhosis","valueDescription":"Cirrhosis","ValueMeaning":{"publicId":"2558505","version":"1","preferredName":"Cirrhosis","longName":"2558505","preferredDefinition":"A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholisms, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cirrhosis","conceptCode":"C2951","definition":"A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B196-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9EBC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Crohn Disease","valueDescription":"Crohn Disease","ValueMeaning":{"publicId":"2577525","version":"1","preferredName":"Crohn Disease","longName":"2577525","preferredDefinition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn's disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crohn Disease","conceptCode":"C2965","definition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9EC6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Frontotemporal Dementia","valueDescription":"Frontotemporal Dementia","ValueMeaning":{"publicId":"3211087","version":"1","preferredName":"Frontotemporal Dementia","longName":"3211087","preferredDefinition":"A syndrome caused by progressive degeneration of the frontal or temporal lobes of the brain. It is manifested with personality changes and deterioration of the language skills.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Frontotemporal Dementia","conceptCode":"C84719","definition":"A syndrome caused by progressive degeneration of the frontal or temporal lobes of the brain. It is manifested with personality changes and deterioration of the language skills.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CBCA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CBE0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fuchs Endothelial Dystrophy","valueDescription":"Fuchs Endothelial Dystrophy","ValueMeaning":{"publicId":"3211088","version":"1","preferredName":"Fuchs Endothelial Dystrophy","longName":"3211088","preferredDefinition":"An autosomal dominant, bilateral, slowly progressive degeneration of corneal endothelial cells with thickening of Descemet's membrane and accumulation of excrescences. It results in corneal edema and loss of vision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fuchs Endothelial Dystrophy","conceptCode":"C84721","definition":"An autosomal dominant, bilateral, slowly progressive degeneration of corneal endothelial cells with thickening of Descemet's membrane and accumulation of excrescences. It results in corneal edema and loss of vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CBEC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CC02-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Fusobacterium Infection","valueDescription":"Fusobacterium Infection","ValueMeaning":{"publicId":"3211089","version":"1","preferredName":"Fusobacterium Infection","longName":"3211089","preferredDefinition":"Infection with anaerobic gram-negative bacteria of the genus Fusobacterium. It results in abscess formation and tissue damage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fusobacterium Infection","conceptCode":"C84722","definition":"Infection with anaerobic gram-negative bacteria of the genus Fusobacterium. It results in abscess formation and tissue damage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CC18-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CC2E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Galactosemia","valueDescription":"Galactosemia","ValueMeaning":{"publicId":"3211090","version":"1","preferredName":"Galactosemia","longName":"3211090","preferredDefinition":"An autosomal recessive inherited metabolic disorder caused by mutations in the GALE, GALK1, and GALT genes. It is characterized by deficiency of the enzymes responsible for the metabolism of galactose. Signs and symptoms include intellectual disability, hepatomegaly, hepatic failure, and renal failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Galactosemia","conceptCode":"C84723","definition":"An autosomal recessive inherited metabolic disorder caused by mutations in the GALE, GALK1, and GALT genes. It is characterized by deficiency of the enzymes responsible for the metabolism of galactose. Signs and symptoms include intellectual disability, hepatomegaly, hepatic failure, and renal failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CC3A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CC50-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gallbladder Neoplasm","valueDescription":"Gallbladder Neoplasm","ValueMeaning":{"publicId":"3211091","version":"1","preferredName":"Gallbladder Neoplasm","longName":"3211091","preferredDefinition":"A benign or malignant neoplasm affecting the gallbladder. Representative examples of benign neoplasms include lipoma, leiomyoma, and neurofibroma. Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gallbladder Neoplasm","conceptCode":"C3048","definition":"A benign or malignant neoplasm affecting the gallbladder. Representative examples of benign neoplasms include lipoma, leiomyoma, and neurofibroma. Representative examples of malignant neoplasms include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CC5C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CC72-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ganglioglioma","valueDescription":"Ganglioglioma","ValueMeaning":{"publicId":"2578714","version":"1","preferredName":"Ganglioglioma","longName":"2578714","preferredDefinition":"Ganglioglioma (WHO grade I or II) and Gangliocytoma (WHO grade I) are well differentiated, slow growing neuroepithelial neoplasms composed of neoplastic, mature ganglion cells either alone (gangliocytoma), or in combination with neoplastic glial cells (ganglioglioma). Some Gangliogliomas show anaplastic features in their glial component and are considered to be WHO grade III (see 'Anaplastic Ganglioglioma). There are rare cases of newly diagnosed Gangliogliomas with grade IV (Glioblastoma) changes in the glial component. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganglioglioma","conceptCode":"C3788","definition":"A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and neoplastic glial cells. Some gangliogliomas show anaplastic features in their glial component and are considered to be WHO grade III. Rare cases of newly diagnosed gangliogliomas with grade IV (glioblastoma) changes in the glial component have also been reported. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0087-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CC7C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gardner Syndrome","valueDescription":"Gardner's Syndrome","ValueMeaning":{"publicId":"2577527","version":"1","preferredName":"Gardner's Syndrome","longName":"2577527","preferredDefinition":"An autosomal dominant syndrome characterised by multiple colonic polyps predisposing to carcinoma of the colon, osteomas of the skull, epidermoid cysts, and fibromas.  It is associated with mutation of the APC gene. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gardner Syndrome","conceptCode":"C6728","definition":"A variant of familial adenomatous polyposis. It is an autosomal dominant syndrome characterized by multiple colonic polyps predisposing to carcinoma of the colon, osteomas of the skull, epidermoid cysts, and fibromas. It is associated with mutation of the APC gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"ONEDATA","dateModified":"2006-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CC8E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gastric Antral Vascular Ectasia","valueDescription":"Gastric Antral Vascular Ectasia","ValueMeaning":{"publicId":"3211092","version":"1","preferredName":"Gastric Antral Vascular Ectasia","longName":"3211092","preferredDefinition":"Dilatation of the vessels in the antrum of the stomach. It is associated with portal hypertension, scleroderma, and chronic renal failure. It may cause gastric bleeding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Antral Vascular Ectasia","conceptCode":"C84724","definition":"Dilatation of the vessels in the antrum of the stomach. It is associated with portal hypertension, scleroderma, and chronic renal failure. It may cause gastric bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CC9A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CCB0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gastrointestinal Stromal Tumor","valueDescription":"Gastrointestinal Stromal Tumor","ValueMeaning":{"publicId":"3179352","version":"1","preferredName":"Gastrointestinal Stromal Tumor","longName":"3179352","preferredDefinition":"GIST. A type of tumor that usually begins in cells in the wall of the gastrointestinal tract.  It can be benign or malignant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastrointestinal Stromal Tumor","conceptCode":"C3868","definition":"A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-84AF-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CCC2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gastroschisis","valueDescription":"Gastroschisis","ValueMeaning":{"publicId":"3211093","version":"1","preferredName":"Gastroschisis","longName":"3211093","preferredDefinition":"A congenital birth defect characterized by the exposure of the fetal intestines outside the abdominal wall through an abdominal wall opening.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastroschisis","conceptCode":"C84725","definition":"A congenital birth defect characterized by the exposure of the fetal intestines outside the abdominal wall through an abdominal wall opening.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CCCE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CCE4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Genu Varum","valueDescription":"Genu Varum","ValueMeaning":{"publicId":"3211094","version":"1","preferredName":"Genu Varum","longName":"3211094","preferredDefinition":"A deformity of the legs characterized by medial angulation, resulting in a bow appearance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Genu Varum","conceptCode":"C84726","definition":"A deformity of the legs characterized by medial angulation, resulting in a bow appearance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CCFA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CD10-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gerstmann-Straussler-Scheinker Disease","valueDescription":"Gerstmann-Straussler-Scheinker Disease","ValueMeaning":{"publicId":"3211095","version":"1","preferredName":"Gerstmann-Straussler-Scheinker Disease","longName":"3211095","preferredDefinition":"A very rare and fatal disorder of spongiform encephalopathy usually caused by mutations of the prion protein (PRNP) gene. It is characterized by the accumulation of amyloid in the brain. Signs and symptoms include lack of motor coordination, unsteady gait, and difficulty walking. As the disease progresses, patients develop speech difficulties and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gerstmann-Straussler-Scheinker Disease","conceptCode":"C84727","definition":"A very rare and fatal disorder of spongiform encephalopathy usually caused by mutations of the prion protein (PRNP) gene. It is characterized by the accumulation of amyloid in the brain. Signs and symptoms include lack of motor coordination, unsteady gait, and difficulty walking. As the disease progresses, patients develop speech difficulties and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CD1C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CD32-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Giant Axonal Neuropathy","valueDescription":"Giant Axonal Neuropathy","ValueMeaning":{"publicId":"3211096","version":"1","preferredName":"Giant Axonal Neuropathy","longName":"3211096","preferredDefinition":"A rare inherited disorder affecting the neurofilaments. It is caused by mutations in the GAN gene. It is characterized by the presence of abnormally large nerve cell axons. Signs and symptoms include difficulty walking, sensory disturbances, lack of motor coordination and abnormal reflexes in the limbs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Giant Axonal Neuropathy","conceptCode":"C84728","definition":"A rare inherited disorder affecting the neurofilaments. It is caused by mutations in the GAN gene. It is characterized by the presence of abnormally large nerve cell axons. Signs and symptoms include difficulty walking, sensory disturbances, lack of motor coordination and abnormal reflexes in the limbs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CD3E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CD54-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Giant Hypertrophic Gastritis","valueDescription":"Giant Hypertrophic Gastritis","ValueMeaning":{"publicId":"3211097","version":"1","preferredName":"Giant Hypertrophic Gastritis","longName":"3211097","preferredDefinition":"Gastritis characterized by hypertrophy of the gastric mucosa with creation of giant gastric folds. It is associated with hypoalbuminemia due to albumin loss from the stomach. Signs and symptoms include nausea, vomiting, abdominal pain, edema, and weight loss.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Giant Hypertrophic Gastritis","conceptCode":"C67277","definition":"Gastritis characterized by hypertrophy of the gastric mucosa with creation of giant gastric folds. It is associated with hypoalbuminemia due to albumin loss from the stomach. Signs and symptoms include nausea, vomiting, abdominal pain, edema, and weight loss.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CD60-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CD76-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gilbert Syndrome","valueDescription":"Gilbert Syndrome","ValueMeaning":{"publicId":"3211098","version":"1","preferredName":"Gilbert Syndrome","longName":"3211098","preferredDefinition":"An autosomal recessive inherited disorder characterized by unconjugated hyperbilirubinemia, resulting in harmless intermittent jaundice.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gilbert Syndrome","conceptCode":"C84729","definition":"An autosomal recessive inherited disorder characterized by unconjugated hyperbilirubinemia, resulting in harmless intermittent jaundice.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CD82-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CD98-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gitelman Syndrome","valueDescription":"Gitelman Syndrome","ValueMeaning":{"publicId":"3211099","version":"1","preferredName":"Gitelman Syndrome","longName":"3211099","preferredDefinition":"An inherited disorder caused by mutations in the SLC12A3 gene. It is characterized by deficient reabsorption of electrolytes in the distal convoluted tubules of the kidneys. It results in hypochloremic metabolic alkalosis, hypokalemia, hypocalciuria, and hypomagnesemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gitelman Syndrome","conceptCode":"C84730","definition":"An inherited disorder caused by mutations in the SLC12A3 gene. It is characterized by deficient reabsorption of electrolytes in the distal convoluted tubules of the kidneys. It results in hypochloremic metabolic alkalosis, hypokalemia, hypocalciuria, and hypomagnesemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CDA4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CDBA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glanzmann Thrombasthenia","valueDescription":"Glanzmann Thrombasthenia","ValueMeaning":{"publicId":"2579852","version":"1","preferredName":"Glanzmann Thrombasthenia","longName":"2579852","preferredDefinition":"A rare, autosomal recessive inherited and less frequently acquired platelet disorder. It is characterized by deficient or dysfunctional glycoprotein IIb/IIIa complex. It leads to defective platelet aggregation, resulting in bleeding.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glanzmann Thrombasthenia","conceptCode":"C61249","definition":"A rare, autosomal recessive inherited and less frequently acquired platelet disorder. It is characterized by deficient or dysfunctional glycoprotein IIb/IIIa complex. It leads to defective platelet aggregation, resulting in bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04F9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CDC4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glomus Tumor","valueDescription":"Glomus Tumor","ValueMeaning":{"publicId":"3211100","version":"1","preferredName":"Glomus Tumor","longName":"3211100","preferredDefinition":"A rare benign or malignant mesenchymal neoplasm arising from cells that resemble the modified smooth muscle cells of the glomus body. The majority of glomus tumors occur in the distal extremities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glomus Tumor","conceptCode":"C3060","definition":"A rare benign or malignant mesenchymal neoplasm arising from cells that resemble the modified smooth muscle cells of the glomus body. The majority of glomus tumors occur in the distal extremities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CDD0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CDE6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glycine Encephalopathy","valueDescription":"Glycine Encephalopathy","ValueMeaning":{"publicId":"3211101","version":"1","preferredName":"Glycine Encephalopathy","longName":"3211101","preferredDefinition":"An autosomal recessive inherited metabolic disorder caused by mutations in the AMT and GLDC genes. It is characterized by abnormal accumulation of glycine in the brain and other tissues. Signs and symptoms include lethargy, feeding difficulties, hypotonia, intellectual deformities, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycine Encephalopathy","conceptCode":"C84937","definition":"An autosomal recessive metabolic disorder caused by mutations in the AMT and GLDC genes. It is characterized by abnormal accumulation of glycine in the brain and other tissues. Signs and symptoms include lethargy, feeding difficulties, hypotonia, intellectual deformities, and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CDF2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CE08-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glycogen Storage Disease","valueDescription":"Glycogen Storage Disease","ValueMeaning":{"publicId":"2593481","version":"1","preferredName":"Glycogen Storage Disease","longName":"2593481","preferredDefinition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease","conceptCode":"C61272","definition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BD3AD6-BCD6-64E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CE12-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glycogen Storage Disease Type I","valueDescription":"Glycogen Storage Disease Type I","ValueMeaning":{"publicId":"3211102","version":"1","preferredName":"Glycogen Storage Disease Type I","longName":"3211102","preferredDefinition":"An autosomal recessive inherited type of glycogen storage disease. It is characterized by a deficiency of the enzyme glucose-6-phosphatase, resulting in the inability of the liver to produce free glucose causing severe hypoglycemia. There is abnormal accumulation of glycogen in the liver and kidneys.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease Type I","conceptCode":"C84733","definition":"An autosomal recessive inherited type of glycogen storage disease. It is characterized by a deficiency of the enzyme glucose-6-phosphatase, resulting in the inability of the liver to produce free glucose causing severe hypoglycemia. There is abnormal accumulation of glycogen in the liver and kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CE1E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CE34-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glycogen Storage Disease Type II","valueDescription":"Glycogen Storage Disease Type II","ValueMeaning":{"publicId":"3211103","version":"1","preferredName":"Glycogen Storage Disease Type II","longName":"3211103","preferredDefinition":"An autosomal recessive inherited type of glycogen storage disease caused by deficiency of the enzyme acid alpha-glucosidase. It results in the abnormal accumulation of glycogen in the heart, skeletal muscles, liver, and nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease Type II","conceptCode":"C84734","definition":"An autosomal recessive inherited type of glycogen storage disease caused by deficiency of the enzyme acid alpha-glucosidase. It results in the abnormal accumulation of glycogen in the heart, skeletal muscles, liver, and nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CE40-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CE56-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glycogen Storage Disease Type IIb","valueDescription":"Glycogen Storage Disease Type IIb","ValueMeaning":{"publicId":"3211104","version":"1","preferredName":"Glycogen Storage Disease Type IIb","longName":"3211104","preferredDefinition":"A genetic metabolic disorder causing hypertrophic cardiomyopathy. Mutations of the LAMP2 gene have been reported in association with this disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease Type IIb","conceptCode":"C84735","definition":"A genetic metabolic disorder causing hypertrophic cardiomyopathy. Mutations of the LAMP2 gene have been reported in association with this disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CE62-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CE78-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glycogen Storage Disease Type III","valueDescription":"Glycogen Storage Disease Type III","ValueMeaning":{"publicId":"3211105","version":"1","preferredName":"Glycogen Storage Disease Type III","longName":"3211105","preferredDefinition":"An autosomal recessive inherited type of glycogen storage disease caused by deficiency of the glycogen debranching enzyme. It results in the accumulation of structurally abnormal glycogen in the heart, skeletal muscles, and/or liver.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease Type III","conceptCode":"C84736","definition":"An autosomal recessive inherited type of glycogen storage disease caused by deficiency of the glycogen debranching enzyme. It results in the accumulation of structurally abnormal glycogen in the heart, skeletal muscles, and/or liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CE84-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CE9A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glycogen Storage Disease Type IV","valueDescription":"Glycogen Storage Disease Type IV","ValueMeaning":{"publicId":"3211106","version":"1","preferredName":"Glycogen Storage Disease Type IV","longName":"3211106","preferredDefinition":"A rare inherited type of glycogen storage disease caused by deficiency of amylo-1,4-1,6 transglucosidase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease Type IV","conceptCode":"C84737","definition":"A rare inherited type of glycogen storage disease caused by deficiency of amylo-1,4-1,6 transglucosidase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CEA6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CEBC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glycogen Storage Disease Type V","valueDescription":"Glycogen Storage Disease Type V","ValueMeaning":{"publicId":"3211107","version":"1","preferredName":"Glycogen Storage Disease Type V","longName":"3211107","preferredDefinition":"An autosomal recessive inherited type of glycogen storage disease caused by deficiency of myophosphorylase. It results in myalgias, muscle cramping and stiffness, and exercise intolerance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease Type V","conceptCode":"C84738","definition":"An autosomal recessive inherited type of glycogen storage disease caused by deficiency of myophosphorylase. It results in myalgias, muscle cramping and stiffness, and exercise intolerance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CEC8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CEDE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"GM1 Gangliosidosis","valueDescription":"GM1 Gangliosidosis","ValueMeaning":{"publicId":"3211108","version":"1","preferredName":"GM1 Gangliosidosis","longName":"3211108","preferredDefinition":"An autosomal recessive lysosomal storage disease characterized by deficiency of the enzyme acid beta-galactosidase, resulting in the accumulation of acid lipids in the nervous system. Signs and symptoms include neurologic disturbances, muscle atrophy, dystonia, eye abnormalities, and formation of angiokeratomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GM1 Gangliosidosis","conceptCode":"C84739","definition":"An autosomal recessive lysosomal storage disease characterized by deficiency of the enzyme acid beta-galactosidase, resulting in the accumulation of acid lipids in the nervous system. Signs and symptoms include neurologic disturbances, muscle atrophy, dystonia, eye abnormalities, and formation of angiokeratomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CEEA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CF00-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Goldenhar Syndrome","valueDescription":"Goldenhar Syndrome","ValueMeaning":{"publicId":"3211109","version":"1","preferredName":"Goldenhar Syndrome","longName":"3211109","preferredDefinition":"A congenital birth defect characterized by incomplete development or absence of face structures, usually affecting one side of the face. The defects include partially formed or absent ear, nose, lip, mandible, and/or soft palate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goldenhar Syndrome","conceptCode":"C84740","definition":"A congenital birth defect characterized by incomplete development or absence of face structures, usually affecting one side of the face. The defects include partially formed or absent ear, nose, lip, mandible, and/or soft palate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CF0C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CF22-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Goodpasture Syndrome","valueDescription":"Goodpasture Syndrome","ValueMeaning":{"publicId":"3211110","version":"1","preferredName":"Goodpasture Syndrome","longName":"3211110","preferredDefinition":"An autoimmune disorder characterized by pulmonary hemorrhage and glomerulonephritis. It is a hypersensitivity reaction resulting in the formation of antibodies against the pulmonary alveoli and the basement membrane of the glomeruli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goodpasture Syndrome","conceptCode":"C34649","definition":"An autoimmune disorder characterized by pulmonary hemorrhage and glomerulonephritis. It is a hypersensitivity reaction resulting in the formation of antibodies against the pulmonary alveoli and the basement membrane of the glomeruli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CF2E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CF44-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Granuloma Annulare","valueDescription":"Granuloma Annulare","ValueMeaning":{"publicId":"3211111","version":"1","preferredName":"Granuloma Annulare","longName":"3211111","preferredDefinition":"A localized or generalized inflammatory skin disorder characterized by the formation of papules and ring-shaped plaques in the skin. Morphologically these lesions are granulomatous inflammatory processes with central necrosis surrounded by palisading histiocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granuloma Annulare","conceptCode":"C3470","definition":"A localized or generalized inflammatory skin disorder characterized by the formation of papules and ring-shaped plaques in the skin. Morphologically these lesions are granulomatous inflammatory processes with central necrosis surrounded by palisading histiocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CF50-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CF66-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Granulosa Cell Tumor","valueDescription":"Granulosa Cell Tumor","ValueMeaning":{"publicId":"2567190","version":"1","preferredName":"Granulosa Cell Tumor","longName":"2567190","preferredDefinition":"A slow-growing, malignant tumor, characterize by the presence of granulosa-like cells and Call-Exner bodies, that is almost always found in the ovary. In rare cases, it has also been found in the testicle.  There are two types of granulosa cell tumor that can be distinguished under the microscope: the adult and the juvenile.  The testicular juvenile granulosa cell tumors are perhaps the most common congenital testicular neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granulosa Cell Tumor","conceptCode":"C3070","definition":"A slow-growing sex cord-stromal tumor characterized by the presence of granulosa-like cells and Call-Exner bodies. It is almost always found in the ovary and rarely in the testis. There are two types of granulosa cell tumors: the adult and the juvenile.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D383-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CF78-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Graves' Disease","valueDescription":"Graves' Disease","ValueMeaning":{"publicId":"3211112","version":"1","preferredName":"Graves' Disease","longName":"3211112","preferredDefinition":"Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells.  As a result, the thyroid gland enlarges and secrets increased amounts of thyroid hormones. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graves Disease","conceptCode":"C3071","definition":"Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secretes increased amounts of thyroid hormones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CF84-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CF9A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gray Platelet Syndrome","valueDescription":"Gray Platelet Syndrome","ValueMeaning":{"publicId":"3211113","version":"1","preferredName":"Gray Platelet Syndrome","longName":"3211113","preferredDefinition":"A rare inherited bleeding disorder characterized by the decrease or absence of the platelet alpha-granules and their proteins in the peripheral blood platelets.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gray Platelet Syndrome","conceptCode":"C84741","definition":"A rare inherited bleeding disorder characterized by the decrease or absence of the platelet alpha-granules and their proteins in the peripheral blood platelets.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CFA6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CFBC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cryptogenic Cirrhosis","valueDescription":"Cryptogenic Cirrhosis","ValueMeaning":{"publicId":"3210782","version":"1","preferredName":"Cryptogenic Cirrhosis","longName":"3210782","preferredDefinition":"Cirrhosis in which no causative agent can be identified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cryptogenic Cirrhosis","conceptCode":"C84411","definition":"Cirrhosis in which no causative agent can be identified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9ED2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9EE8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Diabetes Complication","valueDescription":"Diabetes Complication","ValueMeaning":{"publicId":"3185651","version":"1","preferredName":"Diabetes Complication","longName":"3185651","preferredDefinition":"Organ or tissue damage due to diabetes mellitus. It includes heart disease and stroke, renal disease and renal failure, retinopathy, neuropathies, and erectile dysfunction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diabetes Complication","conceptCode":"C84415","definition":"Organ or tissue damage due to diabetes mellitus. It includes heart disease and stroke, renal disease and renal failure, retinopathy, neuropathies, and erectile dysfunction.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A9A5F9B-3483-35BA-E040-BB89AD430E58","latestVersionIndicator":"Yes","beginDate":"2011-01-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9EFA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Diabetes Mellitus","valueDescription":"Diabetes Mellitus","ValueMeaning":{"publicId":"2573558","version":"1","preferredName":"Diabetes Mellitus","longName":"2573558","preferredDefinition":"(dye-a-BEE-teez) A disease in which the body does not properly control the amount of sugar in the blood. As a result, the level of sugar in the blood is too high. This disease occurs when the body does not produce enough insulin or does not use it properly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diabetes Mellitus","conceptCode":"C2985","definition":"A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC63-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CZECHS","dateModified":"2008-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9F04-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Diabetic Eye Disease","valueDescription":"Diabetic Eye Disease","ValueMeaning":{"publicId":"3210783","version":"1","preferredName":"Diabetic Eye Disease","longName":"3210783","preferredDefinition":"A group of disorders affecting the eye in patients with diabetes mellitus. It includes cataract, glaucoma, retinopathy, and blindness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diabetic Eye Disease","conceptCode":"C84420","definition":"A group of disorders affecting the eye in patients with diabetes mellitus. It includes cataract, glaucoma, retinopathy, and blindness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9F10-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9F26-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Diabetic Nephropathy","valueDescription":"Diabetic Nephropathy","ValueMeaning":{"publicId":"3210784","version":"1","preferredName":"Diabetic Nephropathy","longName":"3210784","preferredDefinition":"Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus.  It is usually manifested with nephritic syndrome and glomerulosclerosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diabetic Nephropathy","conceptCode":"C84417","definition":"Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9F32-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9F48-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Drug Induced Liver Injury","valueDescription":"Drug Induced Liver Injury","ValueMeaning":{"publicId":"3210785","version":"1","preferredName":"Drug Induced Liver Injury","longName":"3210785","preferredDefinition":"Damage to the liver tissue due to drug overdose.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Drug Induced Liver Injury","conceptCode":"C84427","definition":"Damage to the liver tissue due to drug overdose.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9F54-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9F6A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"End Stage Liver Disease","valueDescription":"End Stage Liver Disease","ValueMeaning":{"publicId":"3210786","version":"1","preferredName":"End Stage Liver Disease","longName":"3210786","preferredDefinition":"A disorder characterized by irreversible damage to the liver tissue, leading to complete liver failure. Causes include cirrhosis, viral hepatitis, metastases to the liver, genetic disorders, toxins, and drugs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"End Stage Liver Disease","conceptCode":"C84428","definition":"A disorder characterized by irreversible damage to the liver tissue, leading to complete liver failure. Causes include cirrhosis, viral hepatitis, metastases to the liver, genetic disorders, toxins, and drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9F76-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9F8C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Eye Disorder","valueDescription":"Eye Disorder","ValueMeaning":{"publicId":"2581018","version":"1","preferredName":"Eye Disorder","longName":"2581018","preferredDefinition":"A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eye Disorder","conceptCode":"C26767","definition":"A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0987-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-05","modifiedBy":"HARTLEYG","dateModified":"2019-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9F96-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Focal Segmental Glomerulosclerosis","valueDescription":"Focal Segmental Glomerulosclerosis","ValueMeaning":{"publicId":"3210787","version":"1","preferredName":"Focal Segmental Glomerulosclerosis","longName":"3210787","preferredDefinition":"A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Focal Segmental Glomerulosclerosis","conceptCode":"C37308","definition":"A renal disorder characterized by sclerotic lesions in the glomeruli. Causes include drugs, viruses, and malignancies (lymphomas), or it may be idiopathic. It presents with asymptomatic proteinuria or nephritic syndrome and it may lead to renal failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9FA2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9FB8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gastroparesis","valueDescription":"Gastroparesis","ValueMeaning":{"publicId":"2944835","version":"1","preferredName":"Gastroparesis","longName":"2944835","preferredDefinition":"Paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastroparesis","conceptCode":"C80512","definition":"Paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74450F48-3488-F0DB-E040-BB89AD437C48","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9FC2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glomerulonephritis","valueDescription":"Glomerulonephritis","ValueMeaning":{"publicId":"3210788","version":"1","preferredName":"Glomerulonephritis","longName":"3210788","preferredDefinition":"A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glomerulonephritis","conceptCode":"C26784","definition":"A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9FCE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9FE4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Heart Disorder","valueDescription":"Cardiac disorders","ValueMeaning":{"publicId":"2578541","version":"1","preferredName":"Cardiac disorders","longName":"2578541","preferredDefinition":"Any deviation from the normal structure or function of the cardiac system that is manifested by a characteristic set of symptoms and signs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heart Disorder","conceptCode":"C3079","definition":"A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FFDA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-05","modifiedBy":"REEVESD","dateModified":"2009-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-9FEE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hepatic Disorder","valueDescription":"Hepatic Disorder","ValueMeaning":{"publicId":"3210789","version":"1","preferredName":"Hepatic Disorder","longName":"3210789","preferredDefinition":"Any disease or dysfunction of the liver and the intrahepatic bile ducts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liver and Intrahepatic Bile Duct Disorder","conceptCode":"C3196","definition":"A non-neoplastic or neoplastic disorder that affects the liver parenchyma and intrahepatic bile ducts. Representative examples of non-neoplastic disorders include hepatitis, cirrhosis, cholangitis, and polycystic liver disease. Representative examples of neoplastic disorders include hepatocellular adenoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, lymphoma, and angiosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9FFA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A010-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hepatitis B Infection","valueDescription":"Hepatitis B","ValueMeaning":{"publicId":"2946400","version":"1","preferredName":"Hepatitis B","longName":"2946400","preferredDefinition":"A viral hepatitis caused by the Hepatitis B virus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis B Infection","conceptCode":"C3097","definition":"A viral infection caused by the hepatitis B virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7472988E-D1A5-00A0-E040-BB89AD433FCF","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A01A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hepatitis C Infection","valueDescription":"Hepatitis C","ValueMeaning":{"publicId":"2567488","version":"1","preferredName":"Hepatitis C","longName":"2567488","preferredDefinition":"viral disease caused by hepatitis C virus; most common form of post transfusion hepatitis, also is a common acute sporadic hepatitis; may also follow parental drug abuse.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis C Infection","conceptCode":"C3098","definition":"A viral infection caused by the hepatitis C virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D4AD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-19","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A02C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Inflammation","valueDescription":"Inflammation","ValueMeaning":{"publicId":"2581231","version":"1","preferredName":"Inflammation","longName":"2581231","preferredDefinition":"A localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inflammation","conceptCode":"C3137","definition":"A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A5C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-17","modifiedBy":"COOPERM","dateModified":"2019-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A036-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Type 1 Diabetes Mellitus","valueDescription":"Type 1 Diabetes Mellitus","ValueMeaning":{"publicId":"2976116","version":"1","preferredName":"Type 1 Diabetes Mellitus","longName":"2976116","preferredDefinition":"Diabetes mellitus characterized by insulin deficiency, sudden onset, severe hyperglycemia, rapid progression to ketoacidosis, and death unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type 1 Diabetes Mellitus","conceptCode":"C2986","definition":"A chronic condition characterized by minimal or absent production of insulin by the pancreas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C59A54D-BA2F-5B26-E040-BB89AD432407","latestVersionIndicator":"Yes","beginDate":"2010-01-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-01-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A048-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Interstitial Cystitis","valueDescription":"Interstitial Cystitis","ValueMeaning":{"publicId":"3210790","version":"1","preferredName":"Interstitial Cystitis","longName":"3210790","preferredDefinition":"Inflammation of the urinary bladder wall leading to urinary frequency, urgency, and discomfort, pelvic pain, and pain during intercourse. Morphologically it is characterized by a transmural bladder inflammatory infiltrate containing mast cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interstitial Cystitis","conceptCode":"C27189","definition":"Inflammation of the urinary bladder wall leading to urinary frequency, urgency, and discomfort, pelvic pain, and pain during intercourse. Morphologically it is characterized by a transmural bladder inflammatory infiltrate containing mast cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A054-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A06A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Irritable Bowel Syndrome","valueDescription":"Irritable Bowel Syndrome","ValueMeaning":{"publicId":"3210791","version":"1","preferredName":"Irritable Bowel Syndrome","longName":"3210791","preferredDefinition":"A common syndrome manifested by symptoms of bloating, abdominal cramping, constipation, and/or diarrhea.  In most patients the symptoms are not severe and they can be controlled with diet, stress, and lifestyle management.  A small percentage of individuals may experience severe symptoms.  The cause is unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irritable Bowel Syndrome","conceptCode":"C82343","definition":"Gastrointestinal symptoms characterized by chronic abdominal pain and altered bowel habits in the absence of any organic cause.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A076-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A08C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Liver Disease Associated with Cystic Fibrosis","valueDescription":"Liver Disease Associated with Cystic Fibrosis","ValueMeaning":{"publicId":"3210792","version":"1","preferredName":"Liver Disease Associated with Cystic Fibrosis","longName":"3210792","preferredDefinition":"A spectrum of liver disorders that develop in patients with cystic fibrosis. It includes asymptomatic elevation of the liver function tests, steatosis, cholecystitis with cholelithiasis, sclerosing cholangitis, biliary cirrhosis, and cholangiocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liver Disease Associated with Cystic Fibrosis","conceptCode":"C84412","definition":"A spectrum of liver disorders that develop in patients with cystic fibrosis. It includes asymptomatic elevation of the liver function tests, steatosis, cholecystitis with cholelithiasis, sclerosing cholangitis, biliary cirrhosis, and cholangiocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A098-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A0AE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Great Vessels Transposition","valueDescription":"Great Vessels Transposition","ValueMeaning":{"publicId":"3211114","version":"1","preferredName":"Great Vessels Transposition","longName":"3211114","preferredDefinition":"A congenital defect characterized by the abnormal positioning of any of the following vessels: pulmonary artery, pulmonary vein, superior vena cava, inferior vena cava, and aorta.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transposition of Great Vessels","conceptCode":"C84742","definition":"A congenital cardiac defect in which two heart vessels are reversed (transposed).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CFC8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-CFDE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gynatresia","valueDescription":"Gynatresia","ValueMeaning":{"publicId":"3211115","version":"1","preferredName":"Gynatresia","longName":"3211115","preferredDefinition":"A congenital or acquired occlusion of an opening in any part of the female genital tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gynatresia","conceptCode":"C84743","definition":"A congenital or acquired occlusion of an opening in any part of the female genital tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-CFEA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D000-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Gyrate Atrophy","valueDescription":"Gyrate Atrophy","ValueMeaning":{"publicId":"3211116","version":"1","preferredName":"Gyrate Atrophy","longName":"3211116","preferredDefinition":"A rare autosomal recessive inherited disorder caused by mutations in the OAT gene. It is characterized by progressive atrophy of the retina and choroid, leading to loss of vision and blindness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gyrate Atrophy","conceptCode":"C84744","definition":"A rare autosomal recessive inherited disorder caused by mutations in the OAT gene. It is characterized by progressive atrophy of the retina and choroid, leading to loss of vision and blindness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D00C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D022-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alopecia","valueDescription":"Alopecia","ValueMeaning":{"publicId":"2946575","version":"1","preferredName":"Alopecia","longName":"2946575","preferredDefinition":"Hair loss usually from the scalp. It may result in bald spots or spread to the entire scalp or the entire epidermis. It may be androgenetic or caused by chemotherapeutic agents, compulsive hair pulling, autoimmune disorders or congenital conditions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alopecia","conceptCode":"C50575","definition":"Hair loss usually from the scalp. It may result in bald spots or spread to the entire scalp or the entire epidermis. It may be androgenetic or caused by chemotherapeutic agents, compulsive hair pulling, autoimmune disorders or congenital conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74A54D4F-9F68-0EDF-E040-BB89AD430BAB","latestVersionIndicator":"Yes","beginDate":"2009-09-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-09-28","modifiedBy":"COOPERM","dateModified":"2020-04-16","changeDescription":"Updated definition to current NCIt. mc 4/16/20","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D02C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hairy Cell Leukemia","valueDescription":"Hairy Cell Leukemia","ValueMeaning":{"publicId":"2558848","version":"1","preferredName":"Hairy Cell Leukemia","longName":"2558848","preferredDefinition":"A rare neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen and peripheral blood.  Most patients are middle-aged to elderly adults and present with splenomegaly and pancytopenia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hairy Cell Leukemia","conceptCode":"C7402","definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B2ED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D036-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hairy Tongue","valueDescription":"Hairy Tongue","ValueMeaning":{"publicId":"3211117","version":"1","preferredName":"Hairy Tongue","longName":"3211117","preferredDefinition":"A benign condition affecting the dorsum of the tongue. It is characterized by defective desquamation resulting in elongation of the filiform papillae. The dorsum of the tongue has a furry appearance and is usually stained black.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hairy Tongue","conceptCode":"C35075","definition":"A benign condition affecting the dorsum of the tongue. It is characterized by defective desquamation resulting in elongation of the filiform papillae. The dorsum of the tongue has a furry appearance and is usually stained black.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D042-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D058-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hajdu-Cheney Syndrome","valueDescription":"Hajdu-Cheney Syndrome","ValueMeaning":{"publicId":"3211118","version":"1","preferredName":"Hajdu-Cheney Syndrome","longName":"3211118","preferredDefinition":"A very rare inherited connective tissue disorder characterized by osteoporosis, skull deformities, short stature, and bone flexibility.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hajdu-Cheney Syndrome","conceptCode":"C84745","definition":"A very rare inherited connective tissue disorder characterized by osteoporosis, skull deformities, short stature, and bone flexibility.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D064-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D07A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hallermann Syndrome","valueDescription":"Hallermann Syndrome","ValueMeaning":{"publicId":"3211119","version":"1","preferredName":"Hallermann Syndrome","longName":"3211119","preferredDefinition":"A very rare syndrome characterized by multiple congenital abnormalities including abnormally shaped head, mandibular hypoplasia, parrot nose, bilateral congenital cataracts, microphthalmia, dwarfism and hypotrichosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hallermann Syndrome","conceptCode":"C84746","definition":"A very rare syndrome characterized by multiple congenital abnormalities including abnormally shaped head, mandibular hypoplasia, parrot nose, bilateral congenital cataracts, microphthalmia, dwarfism and hypotrichosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D086-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D09C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Halo Nevus","valueDescription":"Halo Nevus","ValueMeaning":{"publicId":"3211120","version":"1","preferredName":"Halo Nevus","longName":"3211120","preferredDefinition":"A benign melanocytic nevus with a halo appearance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Halo Nevus","conceptCode":"C7602","definition":"A melanocytic nevus characterized by circumferential depigmentation. It is usually associated with a brisk lymphocytic infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D0A8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D0BE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hantavirus Pulmonary Syndrome","valueDescription":"Hantavirus Pulmonary Syndrome","ValueMeaning":{"publicId":"3211121","version":"1","preferredName":"Hantavirus Pulmonary Syndrome","longName":"3211121","preferredDefinition":"An infection caused by Hantaviruses. It manifests with flu-like symptoms but it rapidly progresses to life-threatening respiratory problems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hantavirus Pulmonary Syndrome","conceptCode":"C84747","definition":"An infection caused by Hantaviruses. It manifests with flu-like symptoms but it rapidly progresses to life-threatening respiratory problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D0CA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D0E0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hartnup Disease","valueDescription":"Hartnup Disease","ValueMeaning":{"publicId":"3211122","version":"1","preferredName":"Hartnup Disease","longName":"3211122","preferredDefinition":"An autosomal recessive inherited metabolic disorder caused by mutations in the SLC6A19 gene. It is characterized by defective absorption of neutral amino acids. Signs and symptoms include skin eruptions reminiscent of pellagra, aminoaciduria, and cerebellar ataxia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hartnup Disease","conceptCode":"C84748","definition":"An autosomal recessive inherited metabolic disorder caused by mutations in the SLC6A19 gene. It is characterized by defective absorption of neutral amino acids. Signs and symptoms include skin eruptions reminiscent of pellagra, aminoaciduria, and cerebellar ataxia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D0EC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D102-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hashimoto Thyroiditis","valueDescription":"Hashimoto Thyroiditis","ValueMeaning":{"publicId":"3211123","version":"1","preferredName":"Hashimoto Thyroiditis","longName":"3211123","preferredDefinition":"An autoimmune disorder caused by the production of autoantibodies against thyroid tissue. There is progressive destruction of the thyroid follicles leading to hypothyroidism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hashimoto Thyroiditis","conceptCode":"C27191","definition":"An autoimmune disorder caused by the production of autoantibodies against thyroid tissue. There is progressive destruction of the thyroid follicles leading to hypothyroidism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D10E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D124-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"HELLP Syndrome","valueDescription":"HELLP Syndrome","ValueMeaning":{"publicId":"3211124","version":"1","preferredName":"HELLP Syndrome","longName":"3211124","preferredDefinition":"A life-threatening complication of pregnancy usually occurring in women with preeclampsia or eclampsia. It is characterized by hemolytic anemia, elevated liver enzymes, and low platelet count. Signs and symptoms include headaches, nausea, vomiting, blurred vision, and upper abdominal pain. It may lead to diffuse intravascular coagulation and acute renal failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HELLP Syndrome","conceptCode":"C84750","definition":"Severe preeclampsia associated with any of the following findings: thrombocytopenia (platelets less than 100,000 per microliter), impaired liver function (twice normal elevation of hepatic transaminases; severe, persistent right upper quadrant or epigastric pain), progressive renal insufficiency (serum creatinine greater than 1.1 mg/dL or doubling of baseline in the absence of other renal disease), pulmonary edema, or new-onset cerebral or visual disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D130-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D146-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Helminthiasis","valueDescription":"Helminthiasis","ValueMeaning":{"publicId":"3211125","version":"1","preferredName":"Helminthiasis","longName":"3211125","preferredDefinition":"A parasitic infection characterized by the infestation with worms, mainly in the intestine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Helminthiasis","conceptCode":"C84751","definition":"A parasitic infection characterized by the infestation with worms, mainly in the intestine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D152-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D168-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Capillary Hemangioblastoma","valueDescription":"Capillary Hemangioblastoma","ValueMeaning":{"publicId":"2838583","version":"1","preferredName":"Capillary Hemangioblastoma","longName":"2838583","preferredDefinition":"A WHO grade I tumor of uncertain histogenesis which is composed of stromal cells and abundant capillaries. Approximately 25% of hemangioblastomas are associated with Von Hippel-Lindau disease, a disease inherited through an autosomal dominant trait and characterized by the development of capillary hemangioblastomas of the central nervous system and retina, clear cell renal carcinoma, pheochromocytoma, and pancreatic and inner ear tumors. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemangioblastoma","conceptCode":"C3801","definition":"A rare, slow-growing tumor of uncertain histogenesis. It affects the central nervous system and infrequently other sites. It is composed of stromal cells and abundant capillaries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-591E-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D17A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemangiopericytoma","valueDescription":"Hemangiopericytoma","ValueMeaning":{"publicId":"3211126","version":"1","preferredName":"Hemangiopericytoma","longName":"3211126","preferredDefinition":"A mesenchymal tumor composed of dilated vascular spaces (some with a staghorn or bifed shape) throughout.  The individual tumor cells are surrounded by reticulin everywhere, are negative for muscle, nerve sheath, and epithelial markers, and are positive for CD34 and CD99.  The biologic behavior of hemangiopericytoma cannot always be predicted from the morphologic features.  The 5- and 10-year survival rates of malignant hemangiopericytomas have been reported to be 40% and 29% respectively (partially adapted from S. Sternberg's Diagnostic Surgical Pathology, 4th ed., 2004).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemangiopericytoma","conceptCode":"C3087","definition":"An antiquated term that refers to benign or malignant mesenchymal neoplasms characterized by the presence of neoplastic spindle-shaped to round cells arranged around thin-walled branching vascular spaces.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D186-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D19C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemoglobin C Disease","valueDescription":"Hemoglobin C Disease","ValueMeaning":{"publicId":"3211127","version":"1","preferredName":"Hemoglobin C Disease","longName":"3211127","preferredDefinition":"A blood disorder characterized by the appearance of sickle-shaped red blood cells and anemia. This disorder is caused by a specific mutation in the beta-globin HBB gene, whereby a lysine is substituted for a glutamic acid at the sixth amino acid in the protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemoglobin C Disease","conceptCode":"C34675","definition":"An autosomal recessive hemoglobinopathy with a mild clinical course. Most patients are asymptomatic. When symptoms appear, they include mild hemolytic anemia and occasionally jaundice.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D1A8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D1BE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemoglobinopathy","valueDescription":"Hemoglobinopathy","ValueMeaning":{"publicId":"2593295","version":"1","preferredName":"Hemoglobinopathy","longName":"2593295","preferredDefinition":"A group of inherited disorders characterized by structural alterations within the hemoglobin molecule.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemoglobinopathy","conceptCode":"C3092","definition":"An inherited disorder characterized by structural alterations of a globin chain within the hemoglobin molecule.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28821A9F-371A-19B1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D1C8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemolytic Uremic Syndrome","valueDescription":"Hemolytic Uremic Syndrome","ValueMeaning":{"publicId":"2944885","version":"1","preferredName":"Hemolytic Uremic Syndrome","longName":"2944885","preferredDefinition":"A form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia and purpura","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemolytic Uremic Syndrome","conceptCode":"C75545","definition":"Acute kidney injury associated with microangiopathic hemolytic anemia and thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74464933-C5C9-B990-E040-BB89AD4340F0","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-23","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D1DA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemophagocytic Lymphohistiocytosis","valueDescription":"Hemophagocytic Lymphohistiocytosis","ValueMeaning":{"publicId":"3211128","version":"1","preferredName":"Hemophagocytic Lymphohistiocytosis","longName":"3211128","preferredDefinition":"A rare but potentially life-threatening disorder characterized by the proliferation of histiocytes and macrophages and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary, due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemophagocytic Lymphohistiocytosis","conceptCode":"C34792","definition":"A rare, but potentially life-threatening disorder, characterized by the proliferation of histiocytes and macrophages, and phagocytosis of red blood cells, white blood cells, and platelets. It may be inherited or secondary due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D1E6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D1FC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemophilia A","valueDescription":"Hemophilia A","ValueMeaning":{"publicId":"3211129","version":"1","preferredName":"Hemophilia A","longName":"3211129","preferredDefinition":"An inherited deficiency of coagulation factor VIII characterized by the tendency to spontaneous or exaggerated post-traumatic hemorrhage. Inherited as an x-linked recessive disease, hemophilia A is the most common hemophilia, occurring in approximately 1 in 10,000 male births.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemophilia A","conceptCode":"C27146","definition":"An inherited deficiency of coagulation factor VIII characterized by the tendency to spontaneous or exaggerated post-traumatic hemorrhage. Inherited as an X-linked recessive disease, hemophilia A is the most common hemophilia, occurring in approximately 1 in 10,000 male births.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D208-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D21E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemophilia B","valueDescription":"Hemophilia B","ValueMeaning":{"publicId":"3211130","version":"1","preferredName":"Hemophilia B","longName":"3211130","preferredDefinition":"An X-linked inherited bleeding disorder caused by deficiency of the coagulation factor IX.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemophilia B","conceptCode":"C26721","definition":"An X-linked inherited bleeding disorder caused by deficiency of the coagulation factor IX.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D22A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D240-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hemorrhagic Fever with Renal Syndrome","valueDescription":"Hemorrhagic Fever with Renal Syndrome","ValueMeaning":{"publicId":"3211131","version":"1","preferredName":"Hemorrhagic Fever with Renal Syndrome","longName":"3211131","preferredDefinition":"A disorder caused by hantaviruses of the family Bunyaviridae. It is transmitted by rodents and is manifested with fever, hemorrhage, and renal failure. Other symptoms include headaches, abdominal and back pain, and blurred vision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemorrhagic Fever with Renal Syndrome","conceptCode":"C84753","definition":"A disorder caused by hantaviruses of the family Bunyaviridae. It is transmitted by rodents and is manifested with fever, hemorrhage, and renal failure. Other symptoms include headaches, abdominal and back pain, and blurred vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D24C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D262-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Henoch-Schonlein Purpura","valueDescription":"Henoch-Schonlein Purpura","ValueMeaning":{"publicId":"3211132","version":"1","preferredName":"Henoch-Schonlein Purpura","longName":"3211132","preferredDefinition":"A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Henoch-Schnlein Purpura","conceptCode":"C34963","definition":"A systemic, usually self-limited immune complex vasculitis, characterized by immunoglobulin A deposition in the small vessels and kidneys. It is manifested with small hemorrhages in the skin, gastrointestinal symptoms, arthritis, and nephropathy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D26E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D284-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hepatoerythropoietic Porphyria","valueDescription":"Hepatoerythropoietic Porphyria","ValueMeaning":{"publicId":"3211133","version":"1","preferredName":"Hepatoerythropoietic Porphyria","longName":"3211133","preferredDefinition":"A very rare form of porphyria cutanea tarda. It is characterized by deficiency of the enzyme uroporphyrinogen III. Signs and symptoms appear early in childhood and include extreme photosensitivity in the sun exposed areas of the skin with blistering and scar formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatoerythropoietic Porphyria","conceptCode":"C84754","definition":"A very rare form of porphyria cutanea tarda. It is characterized by deficiency of the enzyme uroporphyrinogen decarboxylase. Signs and symptoms appear early in childhood and include extreme photosensitivity in the sun exposed areas of the skin with blistering and scar formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D290-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D2A6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hepatolenticular Degeneration","valueDescription":"Hepatolenticular Degeneration","ValueMeaning":{"publicId":"3211134","version":"1","preferredName":"Hepatolenticular Degeneration","longName":"3211134","preferredDefinition":"A rare autosomal recessive inherited disorder caused by mutations in the ATP7B gene. It is characterized by copper accumulation in the tissues, particularly brain and liver. It results in liver failure, neurologic, and psychotic manifestations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatolenticular Degeneration","conceptCode":"C84756","definition":"A rare autosomal recessive inherited disorder caused by mutations in the ATP7B gene. It is characterized by copper accumulation in the tissues, particularly brain and liver. It results in liver failure, neurologic, and psychotic manifestations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D2B2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D2C8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hereditary Angioedema","valueDescription":"Hereditary Angioedema","ValueMeaning":{"publicId":"3211135","version":"1","preferredName":"Hereditary Angioedema","longName":"3211135","preferredDefinition":"Autosomal dominant inherited disorder characterized by abnormalities of C1 inhibitor. Patients present with swelling of the skin, subcutaneous tissues, and mucosa sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Angioedema","conceptCode":"C84758","definition":"Autosomal dominant inherited disorder characterized by abnormalities of C1 inhibitor. Patients present with swelling of the skin, subcutaneous tissues, and mucosa sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D2D4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D2EA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hereditary Angioedema Types I and II","valueDescription":"Hereditary Angioedema Types I and II","ValueMeaning":{"publicId":"3211136","version":"1","preferredName":"Hereditary Angioedema Types I and II","longName":"3211136","preferredDefinition":"Autosomal dominant inherited disorders characterized by abnormalities of C1 inhibitor. Patients present with swelling of the skin, subcutaneous tissues, and mucosa sites. In type I hereditary angioedema, the plasma levels of C1 inhibitor are decreased. In type II hereditary angioedema, the C1 inhibitor is dysfunctional and its plasma levels may be normal or elevated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Angioedema Types I and II","conceptCode":"C84757","definition":"Autosomal dominant inherited disorders characterized by abnormalities of C1 inhibitor. Patients present with swelling of the skin, subcutaneous tissues, and mucosa sites. In type I hereditary angioedema, the plasma levels of C1 inhibitor are decreased. In type II hereditary angioedema, the C1 inhibitor is dysfunctional and its plasma levels may be normal or elevated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D2F6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D30C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hereditary Coproporphyria","valueDescription":"Hereditary Coproporphyria","ValueMeaning":{"publicId":"3211137","version":"1","preferredName":"Hereditary Coproporphyria","longName":"3211137","preferredDefinition":"An autosomal dominant inherited disorder of porphyrin metabolism caused by deficiency of the enzyme coproporphyrinogen oxidase. It results in neurologic damage and can include abdominal pain, constipation and psychiatric manifestations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Coproporphyria","conceptCode":"C84759","definition":"An autosomal dominant inherited disorder of porphyrin metabolism caused by deficiency of the enzyme coproporphyrinogen oxidase. It results in neurologic damage and can include abdominal pain, constipation and psychiatric manifestations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D318-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D32E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hereditary Fructose Intolerance","valueDescription":"Hereditary Fructose Intolerance","ValueMeaning":{"publicId":"3211138","version":"1","preferredName":"Hereditary Fructose Intolerance","longName":"3211138","preferredDefinition":"A genetic disorder characterized by the absence of the enzyme aldolase-B from the liver. This enzyme is essential for the metabolism of fructose. Signs and symptoms from fructose ingestion are evident in infancy and include vomiting, abdominal pain and hypoglycemia. Long term complications include hepatic and renal failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Fructose Intolerance","conceptCode":"C84720","definition":"A genetic disorder characterized by the absence of the enzyme aldolase-B from the liver. This enzyme is essential for the metabolism of fructose. Signs and symptoms from fructose ingestion are evident in infancy and include vomiting, abdominal pain and hypoglycemia. Long term complications include hepatic and renal failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D33A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D350-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hereditary Hemolytic Anemia","valueDescription":"Hereditary Hemolytic Anemia","ValueMeaning":{"publicId":"3211139","version":"1","preferredName":"Hereditary Hemolytic Anemia","longName":"3211139","preferredDefinition":"A congenital hemolytic anemia caused by defects of the erythrocyte membrane, enzyme deficiencies, or hemoglobinopathies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Hemolytic Anemia","conceptCode":"C34379","definition":"A congenital hemolytic anemia caused by defects of the erythrocyte membrane, enzyme deficiencies, or hemoglobinopathies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D35C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D372-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hereditary Hemorrhagic Telangiectasia","valueDescription":"Hereditary Hemorrhagic Telangiectasia","ValueMeaning":{"publicId":"3211140","version":"1","preferredName":"Hereditary Hemorrhagic Telangiectasia","longName":"3211140","preferredDefinition":"An autosomal dominant hereditary disorder caused by mutations in the ACVRL1, ENG, and SMAD4 genes. It is characterized by the presence of telangiectasias in the skin, mucous membranes, lungs, brain, liver, and gastrointestinal tract. It results in hemorrhages from the affected areas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Hemorrhagic Telangiectasia","conceptCode":"C35064","definition":"An autosomal dominant hereditary disorder caused by mutations in the ACVRL1, ENG, and SMAD4 genes. It is characterized by the presence of telangiectasias in the skin, mucous membranes, lungs, brain, liver, and gastrointestinal tract. It results in hemorrhages from the affected areas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D37E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D394-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hereditary Melanoma","valueDescription":"Hereditary Melanoma","ValueMeaning":{"publicId":"3211141","version":"1","preferredName":"Hereditary Melanoma","longName":"3211141","preferredDefinition":"A melanoma defined by the presence of multiple cases of cutaneous melanoma among blood-relatives on the same side of the family.  It is caused by germline mutations in the CDKN2A or CDK4 genes.  It is associated with an increased risk of pancreatic cancer in a subset of CDKN2A families (WHO, 2006).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Melanoma","conceptCode":"C8498","definition":"A melanoma defined by the presence of multiple cases of cutaneous melanoma among blood-relatives on the same side of the family.  It is caused by germline mutations in the CDKN2A or CDK4 genes.  It is associated with an increased risk of pancreatic cancer in a subset of CDKN2A families (WHO, 2006).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D3A0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D3B6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hereditary Mucosal Leukokeratosis","valueDescription":"Hereditary Mucosal Leukokeratosis","ValueMeaning":{"publicId":"3211142","version":"1","preferredName":"Hereditary Mucosal Leukokeratosis","longName":"3211142","preferredDefinition":"An autosomal dominant inherited disorder characterized by thickened and spongy oral mucosa with a white tint. It may affect other anatomic sites as well.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Leukokeratosis","conceptCode":"C84760","definition":"An autosomal dominant inherited disorder characterized by thickened and spongy oral mucosa with a white tint. It may affect other anatomic sites as well.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D3C2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D3D8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hereditary Non-Polyposis Colon Cancer","valueDescription":"Hereditary Non-Polyposis Colon Cancer","ValueMeaning":{"publicId":"2716424","version":"1","preferredName":"Hereditary Non-Polyposis Colon Cancer","longName":"2716424","preferredDefinition":"An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma.  Patients often develop colorectal carcinomas at an early age (mean, 45 years).  In the majority of the cases the lesions arise from the proximal colon.  At the molecular level, high-frequency microsatellite instability is present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lynch Syndrome","conceptCode":"C8494","definition":"An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma. Patients often develop colorectal carcinomas at an early age (mean, 45 years). In the majority of the cases the lesions arise from the proximal colon. At the molecular level, high-frequency microsatellite instability is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41B659B0-44F3-5521-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2007-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D3EA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hereditary Hyperbilirubinemia","valueDescription":"Hereditary Hyperbilirubinemia","ValueMeaning":{"publicId":"3211143","version":"1","preferredName":"Hereditary Hyperbilirubinemia","longName":"3211143","preferredDefinition":"An inherited disorder affecting the metabolism of bilirubin. It results in increased levels of bilirubin in the blood. Representative examples of this condition include Gilbert syndrome and Crigler-Najjar syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Hyperbilirubinemia","conceptCode":"C84761","definition":"An inherited disorder affecting the metabolism of bilirubin. It results in increased levels of bilirubin in the blood. Representative examples of this condition include Gilbert syndrome and Crigler-Najjar syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D3F6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D40C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hermansky-Pudlak Syndrome","valueDescription":"Hermansky-Pudlak Syndrome","ValueMeaning":{"publicId":"3211144","version":"1","preferredName":"Hermansky-Pudlak Syndrome","longName":"3211144","preferredDefinition":"A group of autosomal recessive inherited disorders characterized by albinism, bleeding tendency, and lung disorders such as pulmonary fibrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hermansky-Pudlak Syndrome","conceptCode":"C37261","definition":"A group of autosomal recessive inherited disorders characterized by albinism, bleeding tendency, and lung disorders such as pulmonary fibrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D418-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D42E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hermaphrodite","valueDescription":"Hermaphrodite","ValueMeaning":{"publicId":"2574869","version":"1","preferredName":"Hermaphrodite","longName":"2574869","preferredDefinition":"An organism having both male and female sexual characteristics and organs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hermaphrodite","conceptCode":"C45909","definition":"An organism having both male and female sexual characteristics and organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F182-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-19","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-05-19","modifiedBy":"KLINGERK","dateModified":"2005-07-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D438-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Herpes Simplex Encephalitis","valueDescription":"Herpes Simplex Encephalitis","ValueMeaning":{"publicId":"3211145","version":"1","preferredName":"Herpes Simplex Encephalitis","longName":"3211145","preferredDefinition":"A serious viral disorder characterized by infection of the brain by herpes simplex virus type 1 or 2. Herpes simplex virus type 1 affects adults, whereas herpes simplex virus type 2 affects newborns. Signs and symptoms include fever, headaches, vomiting, seizures and psychiatric manifestations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Herpes Simplex Encephalitis","conceptCode":"C84762","definition":"A serious viral disorder characterized by infection of the brain by herpes simplex virus type 1 or 2. Herpes simplex virus type 1 affects adults, whereas herpes simplex virus type 2 affects newborns. Signs and symptoms include fever, headaches, vomiting, seizures and psychiatric manifestations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D444-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D45A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Herpes Zoster Oticus","valueDescription":"Herpes Zoster Oticus","ValueMeaning":{"publicId":"3211146","version":"1","preferredName":"Herpes Zoster Oticus","longName":"3211146","preferredDefinition":"A viral ear infection caused by the spread of varicella-zoster virus to the facial nerves. It is characterized by intense otalgia and a cutaneous vesicular eruption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Herpes Zoster Oticus","conceptCode":"C84763","definition":"A viral ear infection caused by the spread of varicella-zoster virus to the facial nerves. It is characterized by intense otalgia and a cutaneous vesicular eruption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D466-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D47C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"HFE-Associated Hereditary Hemochromatosis","valueDescription":"HFE-Associated Hereditary Hemochromatosis","ValueMeaning":{"publicId":"3211147","version":"1","preferredName":"HFE-Associated Hereditary Hemochromatosis","longName":"3211147","preferredDefinition":"A hereditary disorder of iron metabolism caused by mutations in the HFE gene. It is characterized by increased absorption of iron in the gastrointestinal mucosa. It results in abnormal iron accumulation in the liver, pancreas, skin, joints, heart, and testes. It may lead to skin pigmentation, liver failure, heart failure, and hypogonadism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HFE-Associated Hereditary Hemochromatosis","conceptCode":"C84764","definition":"A hereditary disorder of iron metabolism caused by mutations in the HFE gene. It is characterized by increased absorption of iron in the gastrointestinal mucosa. It results in abnormal iron accumulation in the liver, pancreas, skin, joints, heart, and testes. It may lead to skin pigmentation, liver failure, heart failure, and hypogonadism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D488-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D49E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hidradenoma","valueDescription":"Hidradenoma","ValueMeaning":{"publicId":"3211148","version":"1","preferredName":"Hidradenoma","longName":"3211148","preferredDefinition":"A benign epithelial neoplasm arising from the sweat glands. Variants include the clear cell and nodular hidradenoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hidradenoma","conceptCode":"C7563","definition":"A benign epithelial neoplasm arising from the sweat glands. Variants include the clear cell and nodular hidradenoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D4AA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D4C0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hilar Cholangiocarcinoma","valueDescription":"Hilar Cholangiocarcinoma","ValueMeaning":{"publicId":"3211149","version":"1","preferredName":"Hilar Cholangiocarcinoma","longName":"3211149","preferredDefinition":"A cholangiocarcinoma arising from the hilar ducts located at the hilar area of the liver.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hilar Cholangiocarcinoma","conceptCode":"C36077","definition":"A carcinoma that arises from the junction, or adjacent to the junction, of the right and left hepatic ducts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D4CC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D4E2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Histiocytic Necrotizing Lymphadenitis","valueDescription":"Histiocytic Necrotizing Lymphadenitis","ValueMeaning":{"publicId":"3211150","version":"1","preferredName":"Histiocytic Necrotizing Lymphadenitis","longName":"3211150","preferredDefinition":"A benign and self-limited localized disorder characterized by histiocytic proliferation and necrotic changes in the lymph nodes. It is rarely associated with lupus erythematosus. Signs and symptoms include localized lymphadenitis, fever, and leucopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kikuchi-Fujimoto Disease","conceptCode":"C71719","definition":"A benign and self-limited localized disorder characterized by histiocytic proliferation and necrotic changes in the lymph nodes. It is rarely associated with lupus erythematosus. Signs and symptoms include localized lymphadenitis, fever, and leucopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D4EE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D504-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"HMG-CoA Lyase Deficiency","valueDescription":"HMG-CoA Lyase Deficiency","ValueMeaning":{"publicId":"3211151","version":"1","preferredName":"HMG-CoA Lyase Deficiency","longName":"3211151","preferredDefinition":"A rare genetic inherited disorder characterized by inability of the body to process the amino acid leucine. Signs and symptoms include vomiting, dehydration, lethargy, convulsions, and coma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HMG-CoA Lyase Deficiency","conceptCode":"C84523","definition":"A rare genetic inherited disorder characterized by inability of the body to process the amino acid leucine. Signs and symptoms include vomiting, dehydration, lethargy, convulsions, and coma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D510-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D526-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Holmes-Adie Syndrome","valueDescription":"Holmes-Adie Syndrome","ValueMeaning":{"publicId":"3211152","version":"1","preferredName":"Holmes-Adie Syndrome","longName":"3211152","preferredDefinition":"A rare syndrome characterized by an abnormally dilated pupil, hypoflexia, and diaphoresis. The syndrome is usually caused by a viral or bacterial infection. The abnormally dilated pupil is caused by damage to postganglionic parasympathetic fibers innervating the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Holmes-Adie Syndrome","conceptCode":"C34357","definition":"A rare syndrome characterized by an abnormally dilated pupil, hypoflexia, and diaphoresis. The syndrome is usually caused by a viral or bacterial infection. The abnormally dilated pupil is caused by damage to postganglionic parasympathetic fibers innervating the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D532-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D548-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Holoprosencephaly","valueDescription":"Holoprosencephaly","ValueMeaning":{"publicId":"3211153","version":"1","preferredName":"Holoprosencephaly","longName":"3211153","preferredDefinition":"A rare disorder characterized by the failure of the forebrain to divide into distinct hemispheres.  It is associated with craniofacial abnormalities, developmental abnormalities, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Holoprosencephaly","conceptCode":"C74988","definition":"A rare disorder characterized by the failure of the forebrain to divide into distinct hemispheres. It is associated with craniofacial abnormalities, developmental abnormalities, and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D554-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D56A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Homocystinuria","valueDescription":"Homocystinuria","ValueMeaning":{"publicId":"3211154","version":"1","preferredName":"Homocystinuria","longName":"3211154","preferredDefinition":"An autosomal recessive inherited metabolic disorder caused by mutations in the CBS, MTHFR, MTR, and MTRR genes. It is characterized by abnormalities in the methionine metabolism and is associated with deficiency of cystathionine synthase. It results in the accumulation of homocysteine in the serum. It may affect the cardiovascular, musculoskeletal and the central nervous systems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Homocystinuria","conceptCode":"C84765","definition":"An autosomal recessive inherited metabolic disorder caused by mutations in the CBS, MTHFR, MTR, and MTRR genes. It is characterized by abnormalities in the methionine metabolism and is associated with deficiency of cystathionine synthase. It results in the accumulation of homocysteine in the serum. It may affect the cardiovascular, musculoskeletal and the central nervous systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D576-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D58C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Huntington's Disease","valueDescription":"Huntington's Disease","ValueMeaning":{"publicId":"3211155","version":"1","preferredName":"Huntington's Disease","longName":"3211155","preferredDefinition":"A progressive hereditary neurodegenerative disorder inherited in an autosomal dominant fashion. Symptoms may appear at any age and include uncontrolled movements, clumsiness, balance problems, difficulty walking, talking, or swallowing. The disease has a progressive course with a decline in mental abilities, and the development of psychiatric problems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Huntington's Disease","conceptCode":"C82342","definition":"A progressive hereditary neurodegenerative disorder inherited in an autosomal dominant fashion. Symptoms may appear at any age and include uncontrolled movements, clumsiness, balance problems, difficulty walking, talking, or swallowing. The disease has a progressive course with a decline in mental abilities, and the development of psychiatric problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D5A2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D5B8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hyaline Membrane Syndrome","valueDescription":"Hyaline Membrane Syndrome","ValueMeaning":{"publicId":"3211156","version":"1","preferredName":"Hyaline Membrane Syndrome","longName":"3211156","preferredDefinition":"A serious disorder affecting newborns, particularly premature infants. It is caused by deficiency of surfactant, resulting in the formation of a membrane in the alveoli lining. This membrane contains fibrin and cellular debris and interferes with respiration. Infants with this disorder develop breathing problems immediately or in a few hours after delivery. It may lead to respiratory failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyaline Membrane Syndrome","conceptCode":"C27562","definition":"A serious disorder affecting newborns, particularly premature infants. It is caused by deficiency of surfactant, resulting in the formation of a membrane in the alveoli lining. This membrane contains fibrin and cellular debris and interferes with respiration. Infants with this disorder develop breathing problems immediately or in a few hours after delivery. It may lead to respiratory failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D5CE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D5E4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mitochondrial Hepatopathy","valueDescription":"Mitochondrial Hepatopathy","ValueMeaning":{"publicId":"3210793","version":"1","preferredName":"Mitochondrial Hepatopathy","longName":"3210793","preferredDefinition":"A liver disorder caused by primary or secondary defects in the function of the mitochondria in the hepatocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitochondrial Hepatopathy","conceptCode":"C84443","definition":"A liver disorder caused by primary or secondary defects in the function of the mitochondria in the hepatocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A0BA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A0D0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Neonatal Hepatitis","valueDescription":"Neonatal Hepatitis","ValueMeaning":{"publicId":"3210794","version":"1","preferredName":"Neonatal Hepatitis","longName":"3210794","preferredDefinition":"Hepatitis developing during the neonatal period.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neonatal Hepatitis","conceptCode":"C84446","definition":"Hepatitis developing during the neonatal period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A0DC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A0F2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nephropathy","valueDescription":"Nephropathy","ValueMeaning":{"publicId":"3210795","version":"1","preferredName":"Nephropathy","longName":"3210795","preferredDefinition":"A term referring to any disease affecting the kidneys.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nephropathy","conceptCode":"C34843","definition":"A term referring to any disease affecting the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A0FE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A114-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nonalcoholic Fatty Liver Disease","valueDescription":"Nonalcoholic Fatty Liver Disease","ValueMeaning":{"publicId":"3171842","version":"1","preferredName":"Nonalcoholic Fatty Liver Disease","longName":"3171842","preferredDefinition":"A term referring to fatty replacement of the hepatic parenchyma which is not related to alcohol use.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nonalcoholic Fatty Liver Disease","conceptCode":"C84444","definition":"A term referring to fatty replacement of the hepatic parenchyma which is not related to alcohol use.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DDA7EA-016C-07E7-E040-BB89AD4351C6","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"WHITES","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A126-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nonalcoholic Steatohepatitis","valueDescription":"Nonalcoholic Steatohepatitis","ValueMeaning":{"publicId":"3210796","version":"1","preferredName":"Nonalcoholic Steatohepatitis","longName":"3210796","preferredDefinition":"Fatty replacement and damage to the hepatocytes not related to alcohol use. It may lead to cirrhosis and liver failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nonalcoholic Steatohepatitis","conceptCode":"C84445","definition":"Fatty replacement and damage to the hepatocytes not related to alcohol use. It may lead to cirrhosis and liver failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A132-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A148-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Type 2 Diabetes Mellitus","valueDescription":"Type 2 Diabetes Mellitus","ValueMeaning":{"publicId":"2976115","version":"1","preferredName":"Type 2 Diabetes Mellitus","longName":"2976115","preferredDefinition":"A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type 2 Diabetes Mellitus","conceptCode":"C26747","definition":"A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C59A54D-BA0C-5B26-E040-BB89AD432407","latestVersionIndicator":"Yes","beginDate":"2010-01-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-01-04","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A15A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pediatric Obesity","valueDescription":"Pediatric Obesity","ValueMeaning":{"publicId":"3210797","version":"1","preferredName":"Pediatric Obesity","longName":"3210797","preferredDefinition":"Having a high amount of body fat during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Obesity","conceptCode":"C84449","definition":"A condition in which a child's body mass index (BMI) falls at or above the 95th percentile based on the normative values for the age and sex of the reference population.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A166-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A17C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Polycystic Kidney Disease","valueDescription":"Polycystic Kidney Disease","ValueMeaning":{"publicId":"3210798","version":"1","preferredName":"Polycystic Kidney Disease","longName":"3210798","preferredDefinition":"A usually autosomal dominant and less frequently autosomal recessive genetic disorder characterized by the presence of numerous cysts in the kidneys leading to end-stage renal failure.  The autosomal dominant trait is associated with abnormalities on the short arm of chromosome 16. Symptoms in patients with the autosomal dominant trait usually appear at middle age and include abdominal pain, hematuria, and high blood pressure.  Patients may develop brain aneurysms and liver cysts.  Patients with the autosomal recessive trait present with progressive renal failure early in life and symptoms resulting from hepatic fibrosis.  The autosomal recessive trait is associated with abnormalities of chromosome 6.  Polycystic kidney disease may also result as a side effect in patients on renal dialysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycystic Kidney Disease","conceptCode":"C75464","definition":"A usually autosomal dominant and less frequently autosomal recessive genetic disorder characterized by the presence of numerous cysts in the kidneys leading to end-stage renal failure. The autosomal dominant trait is associated with abnormalities on the short arm of chromosome 16. Symptoms in patients with the autosomal dominant trait usually appear at middle age and include abdominal pain, hematuria, and high blood pressure. Patients may develop brain aneurysms and liver cysts. Patients with the autosomal recessive trait present with progressive renal failure early in life and symptoms resulting from hepatic fibrosis. The autosomal recessive trait is associated with abnormalities of chromosome 6. Polycystic kidney disease may also result as a side effect in patients on renal dialysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A188-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A19E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Primary Biliary Cirrhosis","valueDescription":"Primary Biliary Cirrhosis","ValueMeaning":{"publicId":"3210799","version":"1","preferredName":"Primary Biliary Cirrhosis","longName":"3210799","preferredDefinition":"An autoimmune inflammatory disorder characterized by destruction of the small intrahepatic bile ducts. It affects predominantly females and it may lead to cirrhosis and liver failure. Patients have antimitochondrial and antinuclear antibodies in the peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Biliary Cirrhosis","conceptCode":"C27167","definition":"An autoimmune inflammatory disorder characterized by destruction of the small intrahepatic bile ducts. It affects predominantly females and it may lead to cirrhosis and liver failure. Patients have antimitochondrial and antinuclear antibodies in the peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A1AA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A1C0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Primary Sclerosing Cholangitis","valueDescription":"Primary Sclerosing Cholangitis","ValueMeaning":{"publicId":"3210800","version":"1","preferredName":"Primary Sclerosing Cholangitis","longName":"3210800","preferredDefinition":"A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Sclerosing Cholangitis","conceptCode":"C4828","definition":"A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A1CC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A1E2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Progressive Familial Intrahepatic Cholestasis","valueDescription":"Progressive Familial Intrahepatic Cholestasis","ValueMeaning":{"publicId":"3210801","version":"1","preferredName":"Progressive Familial Intrahepatic Cholestasis","longName":"3210801","preferredDefinition":"A genetic syndrome affecting infants and children. It is characterized by chronic intrahepatic cholestasis usually progressing to cirrhosis within the first ten years of life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Familial Intrahepatic Cholestasis","conceptCode":"C84453","definition":"A genetic syndrome affecting infants and children. It is characterized by chronic intrahepatic cholestasis usually progressing to cirrhosis within the first ten years of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A1EE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A204-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Proliferative Diabetic Retinopathy","valueDescription":"Proliferative Diabetic Retinopathy","ValueMeaning":{"publicId":"3210802","version":"1","preferredName":"Proliferative Diabetic Retinopathy","longName":"3210802","preferredDefinition":"Advanced retinopathy due to diabetes mellitus characterized by the formation of new vessels in the retina. The new vessels are abnormal and fragile. If hemorrhage occurs due to the vascular fragility, there is increased risk of vision loss or blindness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Proliferative Diabetic Retinopathy","conceptCode":"C84457","definition":"Advanced retinopathy due to diabetes mellitus characterized by the formation of new vessels in the retina. The new vessels are abnormal and fragile. If hemorrhage occurs due to the vascular fragility, there is increased risk of vision loss or blindness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A210-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A226-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Prostate Disorder","valueDescription":"Prostate Disorder","ValueMeaning":{"publicId":"3210803","version":"1","preferredName":"Prostate Disorder","longName":"3210803","preferredDefinition":"A non-neoplastic or neoplastic disorder affecting the prostate gland. Representative examples include prostatitis, benign prostatic hyperplasia, and cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Disorder","conceptCode":"C26865","definition":"A non-neoplastic or neoplastic disorder that affects the prostate gland.  Representative examples include prostatitis, prostatic intraepithelial neoplasia, and carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A232-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A248-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Retinopathy","valueDescription":"Retinopathy","ValueMeaning":{"publicId":"2944687","version":"1","preferredName":"Retinopathy","longName":"2944687","preferredDefinition":"Any disease or disorder of the retina.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinopathy","conceptCode":"C62601","definition":"Any non-neoplastic pathologic conditions of the retina, including non-neoplastic structural anomalies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74419E3D-8A74-7FAC-E040-BB89AD434C1B","latestVersionIndicator":"Yes","beginDate":"2009-09-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A264-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ulcerative Colitis","valueDescription":"Ulcerative Colitis","ValueMeaning":{"publicId":"2577524","version":"1","preferredName":"Ulcerative Colitis","longName":"2577524","preferredDefinition":"Inflammatory disease of unknown cause which involves the mucosa of the colon. Onset may be acute and fulminant, and its course often continues chronically in an intermittent or continuous form. Diarrhea is a common symptom and bleeding an almost constant concomitant symptom.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ulcerative Colitis","conceptCode":"C2952","definition":"An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"CZECHS","dateModified":"2008-06-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A26E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Urinary System Disorder","valueDescription":"Urinary Tract Disorder","ValueMeaning":{"publicId":"2578554","version":"1","preferredName":"Urinary Tract Disorder","longName":"2578554","preferredDefinition":"Disorders of any part of the urologic system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urinary System Disorder","conceptCode":"C3430","definition":"A non-neoplastic or neoplastic disorder affecting the urinary system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FFE7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-05","modifiedBy":"ONEDATA","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A280-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Urinary Tract Infection","valueDescription":"Urinary Tract Infection","ValueMeaning":{"publicId":"2943940","version":"1","preferredName":"Urinary Tract Infection","longName":"2943940","preferredDefinition":"A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urinary Tract Infection","conceptCode":"C50791","definition":"A bacterial infectious process affecting any part of the urinary tract, most commonly the bladder and the urethra. Symptoms include urinary urgency and frequency, burning sensation during urination, lower abdominal discomfort, and cloudy urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742BAE86-9B0F-9F01-E040-BB89AD435E50","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A292-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Vascular Access Graft Failure","valueDescription":"Vascular Access Graft Failure","ValueMeaning":{"publicId":"3210804","version":"1","preferredName":"Vascular Access Graft Failure","longName":"3210804","preferredDefinition":"Failure to achieve vascular access due to damage of the graft that was created for this purpose.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vascular Access Graft Failure","conceptCode":"C84459","definition":"Failure to achieve vascular access due to damage of the graft that was created for this purpose.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A29E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A2B4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Vascular Disorder","valueDescription":"Vascular Disorder","ValueMeaning":{"publicId":"2578557","version":"1","preferredName":"Vascular Disorder","longName":"2578557","preferredDefinition":"A non-neoplastic or neoplastic disorder affecting the arteries, veins, or lymphatic vessels. Examples include vasculitis, thrombophlebitis, arteriosclerosis, lymphedema, hemangioma, and angiosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vascular Disorder","conceptCode":"C35117","definition":"A non-neoplastic or neoplastic disorder affecting the arteries, veins, or lymphatic vessels. Examples include vasculitis, thrombophlebitis, arteriosclerosis, lymphedema, hemangioma, and angiosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FFEA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-05","modifiedBy":"HARTLEYG","dateModified":"2019-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A2BE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Vesicoureteral Reflux","valueDescription":"Vesicoureteral Reflux","ValueMeaning":{"publicId":"3210805","version":"1","preferredName":"Vesicoureteral Reflux","longName":"3210805","preferredDefinition":"Abnormal flow of urine from the urinary bladder back into the ureters.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vesicoureteral Reflux","conceptCode":"C84467","definition":"Abnormal flow of urine from the urinary bladder back into the ureters.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A2CA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A2E0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Arteriosclerosis","valueDescription":"Arteriosclerosis","ValueMeaning":{"publicId":"3210806","version":"1","preferredName":"Arteriosclerosis","longName":"3210806","preferredDefinition":"A vascular disorder characterized by thickening and hardening of the walls of the arteries.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arteriosclerosis","conceptCode":"C34398","definition":"A vascular disorder characterized by thickening and hardening of the walls of the arteries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A2EC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A302-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Arthritis","valueDescription":"Arthritis","ValueMeaning":{"publicId":"2569498","version":"1","preferredName":"Arthritis","longName":"2569498","preferredDefinition":"Inflammation of a joint or a state characterized by inflammation of joints.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arthritis","conceptCode":"C2883","definition":"An inflammatory process affecting a joint. Causes include infection, autoimmune processes, degenerative processes, and trauma. Signs and symptoms may include swelling around the affected joint and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DC87-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A30C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Benign Neoplasm","valueDescription":"Benign Neoplasm","ValueMeaning":{"publicId":"2938141","version":"1","preferredName":"Benign Neoplasm","longName":"2938141v1.00","preferredDefinition":"A neoplasm characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Neoplasm","conceptCode":"C3677","definition":"A neoplasm characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7289D43E-7E19-ACC7-E040-BB89AD431D77","latestVersionIndicator":"Yes","beginDate":"2009-09-01","endDate":null,"createdBy":"UMLLOADER_TCGA","dateCreated":"2009-09-01","modifiedBy":"GDEEN","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A31E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Bullous Pemphigoid","valueDescription":"Bullous Pemphigoid","ValueMeaning":{"publicId":"3210807","version":"1","preferredName":"Bullous Pemphigoid","longName":"3210807","preferredDefinition":"An autoimmune chronic skin disorder characterized by the presence of large blisters. It usually affects elderly people and tends to subside spontaneously.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bullous Pemphigoid","conceptCode":"C84389","definition":"An autoimmune chronic skin disorder characterized by the presence of large blisters. It usually affects elderly people and tends to subside spontaneously.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A32A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A340-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cataract","valueDescription":"Cataract","ValueMeaning":{"publicId":"2797325","version":"1","preferredName":"Cataract","longName":"2797325","preferredDefinition":"Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness.  Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Diagnostic Surgical Pathology, 3rd ed.) --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cataract","conceptCode":"C26713","definition":"Partial or complete opacity of the crystalline lens of one or both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD63DAD-D834-12B9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-11-03","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A34A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cerebral Palsy","valueDescription":"Cerebral Palsy","ValueMeaning":{"publicId":"3210808","version":"1","preferredName":"Cerebral Palsy","longName":"3210808","preferredDefinition":"A group of disorders affecting the development of movement and posture, often accompanied by disturbances of sensation, perception, cognition, and behavior. It results from damage to the fetal or infant brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerebral Palsy","conceptCode":"C34460","definition":"A group of disorders affecting the development of movement and posture, often accompanied by disturbances of sensation, perception, cognition, and behavior. It results from damage to the fetal or infant brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A356-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A36C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cerebrovascular Accident","valueDescription":"Cerebrovascular Accident","ValueMeaning":{"publicId":"2569507","version":"1","preferredName":"Cerebrovascular Accident","longName":"2569507","preferredDefinition":"A sudden, nonconvulsive loss of neurologic function due to an ischemic or hemorrhagic intracranial vascular event. In general, cerebrovascular accidents are classified by anatomic location in the brain, vascular distribution, etiology, age of the affected individual, and hemorrhagic vs. nonhemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stroke","conceptCode":"C3390","definition":"A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DC90-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-10","modifiedBy":"CZECHS","dateModified":"2008-06-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A376-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Congestive Heart Failure","valueDescription":"Congestive heart failure","ValueMeaning":{"publicId":"2565944","version":"1","preferredName":"Congestive heart failure","longName":"2565944","preferredDefinition":"Failure of the heart to pump a sufficient amount of blood to meet the needs of the body tissues, resulting in tissue congestion and edema. Signs and symptoms include shortness of breath, pitting edema, enlarged tender liver, engorged neck veins, and pulmonary rales.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congestive Heart Failure","conceptCode":"C3080","definition":"Failure of the heart to pump a sufficient amount of blood to meet the needs of the body tissues, resulting in tissue congestion and edema. Signs and symptoms include shortness of breath, pitting edema, enlarged tender liver, engorged neck veins, and pulmonary rales.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CEA5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-05-19","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-05-19","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A380-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Cushing Syndrome","valueDescription":"Cushing Syndrome","ValueMeaning":{"publicId":"3210809","version":"1","preferredName":"Cushing Syndrome","longName":"3210809","preferredDefinition":"A syndrome caused by high levels of cortisol in the blood either due to excessive production and secretion of corticosteroids secondary to pituitary or adrenocortical neoplasms, or intake of glucocorticoid drugs. Signs and symptoms include a round face, upper body obesity, fragile and thin skin, purple stretch marks in the skin, fatigue, muscle weakness, hypertension, diabetes mellitus, hypertrichosis and amenorrhea in women, impotence in men, and osteoporosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cushing Syndrome","conceptCode":"C2969","definition":"A syndrome caused by high levels of cortisol in the blood either due to excessive production and secretion of corticosteroids secondary to pituitary or adrenocortical neoplasms, or intake of glucocorticoid drugs. Signs and symptoms include a round face, upper body obesity, fragile and thin skin, purple stretch marks in the skin, fatigue, muscle weakness, hypertension, diabetes mellitus, hypertrichosis and amenorrhea in women, impotence in men, and osteoporosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A38C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A3A2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dementia","valueDescription":"Dementia","ValueMeaning":{"publicId":"3165569","version":"1","preferredName":"Dementia","longName":"3165569","preferredDefinition":"An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dementia","conceptCode":"C4786","definition":"Loss of intellectual abilities interfering with an individual's social and occupational functions. Causes include Alzheimer's disease, brain injuries, brain tumors, and vascular disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96FCF74F-C196-EAB7-E040-BB89AD437850","latestVersionIndicator":"Yes","beginDate":"2010-12-09","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A3AC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Depression","valueDescription":"Depression","ValueMeaning":{"publicId":"2563606","version":"1","preferredName":"Depression","longName":"2563606","preferredDefinition":"A melancholy feeling of sadness and despair.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Depression","conceptCode":"C2982","definition":"A melancholy feeling of sadness and despair.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C583-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A3B6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Dermatitis","valueDescription":"Dermatitis","ValueMeaning":{"publicId":"3210810","version":"1","preferredName":"Dermatitis","longName":"3210810","preferredDefinition":"An inflammatory process affecting the skin. Signs include red rash, itching, and blister formation. Representative examples are contact dermatitis, atopic dermatitis, and seborrheic dermatitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dermatitis","conceptCode":"C2983","definition":"An inflammatory process affecting the skin. Signs include red rash, itching, and blister formation. Representative examples are contact dermatitis, atopic dermatitis, and seborrheic dermatitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A3C2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A3D8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"AIDS-Related Disorder","valueDescription":"AIDS-Related Disorder","ValueMeaning":{"publicId":"3210811","version":"1","preferredName":"AIDS-Related Disorder","longName":"3210811","preferredDefinition":"A non-neoplastic or neoplastic disorder arising as a result of the immunologic defects caused by Autoimmune Deficiency Syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Disorder","conceptCode":"C4991","definition":"A non-neoplastic or neoplastic disorder arising as a result of the immunologic defects caused by Autoimmune Deficiency Syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A3E4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A3FA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Diverticulitis","valueDescription":"Diverticulitis","ValueMeaning":{"publicId":"2577629","version":"1","preferredName":"Diverticulitis","longName":"2577629","preferredDefinition":"An infection that develops in the diverticula of the intestinal tract. Signs and symptoms include abdominal pain, fever, and leukocytosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diverticulitis","conceptCode":"C26752","definition":"An infection that develops in the diverticula of the intestinal tract. Signs and symptoms include abdominal pain, fever, and leukocytosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC4A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-08","modifiedBy":"COOPERM","dateModified":"2020-10-16","changeDescription":"10.16.20 Updated definition with current NCIt. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A404-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Eisenmenger Syndrome","valueDescription":"Eisenmenger Syndrome","ValueMeaning":{"publicId":"3210812","version":"1","preferredName":"Eisenmenger Syndrome","longName":"3210812","preferredDefinition":"A syndrome characterized by the reversal of a septal defect-associated left-to-right shunt due to the resulting secondary pulmonary hypertension. The presence of the pulmonary hypertension causes increased pressure in the right heart chambers resulting in the reversal of the shunt into a right-to-left shunt. Signs and symptoms include cyanosis, pulmonary hypertension, heart failure, and high red blood cell count.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eisenmenger Syndrome","conceptCode":"C84390","definition":"A syndrome characterized by the reversal of a septal defect-associated left-to-right shunt due to the resulting secondary pulmonary hypertension. The presence of the pulmonary hypertension causes increased pressure in the right heart chambers resulting in the reversal of the shunt into a right-to-left shunt. Signs and symptoms include cyanosis, pulmonary hypertension, heart failure, and high red blood cell count.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A410-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A426-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pulmonary Emphysema","valueDescription":"Pulmonary Emphysema","ValueMeaning":{"publicId":"2558715","version":"1","preferredName":"Pulmonary Emphysema","longName":"2558715","preferredDefinition":"A subcategory of chronic obstructive pulmonary disease (COPD). It occurs in people who smoke and suffer from chronic bronchitis. It is characterized by inflation of the alveoli, alveolar wall damage, and reduction in the number of alveoli, resulting in difficulty breathing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Emphysema","conceptCode":"C3348","definition":"A subcategory of chronic obstructive pulmonary disease (COPD). It occurs in people who smoke and suffer from chronic bronchitis. It is characterized by inflation of the alveoli, alveolar wall damage, and reduction in the number of alveoli, resulting in difficulty breathing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B268-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A438-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Endometriosis","valueDescription":"Endometriosis","ValueMeaning":{"publicId":"3210813","version":"1","preferredName":"Endometriosis","longName":"3210813","preferredDefinition":"The growth of functional endometrial tissue in anatomic sites outside the uterine body. It most often occurs in the pelvic organs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometriosis","conceptCode":"C3014","definition":"The growth of functional endometrial tissue in anatomic sites outside the uterine body. It most often occurs in the pelvic organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A444-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A45A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Facial Nerve Paralysis","valueDescription":"Facial Nerve Paralysis","ValueMeaning":{"publicId":"3210814","version":"1","preferredName":"Facial Nerve Paralysis","longName":"3210814","preferredDefinition":"Partial or complete paralysis of the facial muscles of one side of a person's face. It is caused by damage to the seventh cranial nerve. It is usually temporary but it may recur.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cranial Nerve VII Palsy","conceptCode":"C26769","definition":"Partial or complete paralysis of the facial muscles of one side of a person's face. It is caused by damage to the seventh cranial nerve. It is usually temporary but it may recur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A466-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A47C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Glaucoma","valueDescription":"Glaucoma","ValueMeaning":{"publicId":"2746388","version":"1","preferredName":"Glaucoma","longName":"2746388","preferredDefinition":"An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glaucoma","conceptCode":"C26782","definition":"Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C20DB99-730C-0BA9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A486-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Goiter","valueDescription":"Goiter","ValueMeaning":{"publicId":"3210815","version":"1","preferredName":"Goiter","longName":"3210815","preferredDefinition":"Enlargement of the thyroid gland usually caused by lack of iodine in the diet, hyperthyroidism, or thyroid nodules. Symptoms include difficulty in breathing and swallowing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goiter","conceptCode":"C26785","definition":"Enlargement of the thyroid gland usually caused by lack of iodine in the diet, hyperthyroidism, or thyroid nodules. Symptoms include difficulty in breathing and swallowing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A492-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A4A8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hepatitis","valueDescription":"Hepatitis","ValueMeaning":{"publicId":"2567490","version":"1","preferredName":"Hepatitis","longName":"2567490","preferredDefinition":"Inflammation of the liver and liver disease involving degenerative or necrotic alterations of hepatocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis","conceptCode":"C3095","definition":"Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D4AF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-19","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A4B2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hepatitis A Infection","valueDescription":"Hepatitis A","ValueMeaning":{"publicId":"2567486","version":"1","preferredName":"Hepatitis A","longName":"2567486","preferredDefinition":"Hepatitis caused by HEPATOVIRUS. It can be transmitted through fecal contamination of food or water.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis A Infection","conceptCode":"C3096","definition":"Acute inflammation of the liver caused by the hepatitis A virus. It is highly contagious and usually contracted through close contact with an infected individual or their feces, contaminated food or water.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D4AB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-19","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A4C4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hyperplasia","valueDescription":"Hyperplasia","ValueMeaning":{"publicId":"2574092","version":"1","preferredName":"Hyperplasia","longName":"2574092","preferredDefinition":"An abnormal increase in the number of cells in an organ or a tissue with consequent enlargement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperplasia","conceptCode":"C3113","definition":"An abnormal increase in the number of cells in an organ or a tissue with consequent enlargement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EE79-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A4CE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lipoma","valueDescription":"Lipoma","ValueMeaning":{"publicId":"2974460","version":"1","preferredName":"Lipoma","longName":"2974460","preferredDefinition":"A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lipoma","conceptCode":"C3192","definition":"A benign, usually painless, well-circumscribed lipomatous tumor composed of adipose tissue.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BD8A964-F041-8A21-E040-BB89AD436C37","latestVersionIndicator":"Yes","beginDate":"2009-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A4E0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lupus Erythematosus","valueDescription":"Lupus Erythematosus","ValueMeaning":{"publicId":"3210816","version":"1","preferredName":"Lupus Erythematosus","longName":"3210816","preferredDefinition":"An autoimmune, connective tissue chronic inflammatory disorder affecting the skin, joints, kidneys, lungs, heart, and the peripheral blood cells. It is more commonly seen in women than men. Variants include discoid and systemic lupus erythematosus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lupus Erythematosus","conceptCode":"C27153","definition":"An autoimmune, connective tissue chronic inflammatory disorder affecting the skin, joints, kidneys, lungs, heart, and the peripheral blood cells. It is more commonly seen in women than men. Variants include discoid and systemic lupus erythematosus.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A4EC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A502-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Macular Degeneration","valueDescription":"Macular Degeneration","ValueMeaning":{"publicId":"3210817","version":"1","preferredName":"Macular Degeneration","longName":"3210817","preferredDefinition":"Age-related loss of vision in the central portion of the retina (macula), secondary to retinal degeneration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Age-Related Macular Degeneration","conceptCode":"C84391","definition":"Age-related loss of vision in the central portion of the retina (macula), secondary to retinal degeneration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A50E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A524-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mental Retardation","valueDescription":"Mental Retardation","ValueMeaning":{"publicId":"3210818","version":"1","preferredName":"Mental Retardation","longName":"3210818","preferredDefinition":"A developmental disorder characterized by less than average intelligence and significant limitations in adaptive behavior with onset before the age of 18.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mental Retardation","conceptCode":"C84392","definition":"A developmental disorder characterized by less than average intelligence and significant limitations in adaptive behavior with onset before the age of 18.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A530-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A546-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Monoclonal Gammopathy","valueDescription":"Monoclonal Gammopathy","ValueMeaning":{"publicId":"3210819","version":"1","preferredName":"Monoclonal Gammopathy","longName":"3210819","preferredDefinition":"A laboratory test result indicating the presence of an abnormally high level of monoclonal immunoglobulins in the blood or urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Gammopathy","conceptCode":"C35548","definition":"An abnormal laboratory test result indicating the presence of monoclonal immunoglobulins in the blood or urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A552-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A568-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mononeuritis Multiplex","valueDescription":"Mononeuritis Multiplex","ValueMeaning":{"publicId":"2750110","version":"1","preferredName":"Mononeuritis Multiplex","longName":"2750110","preferredDefinition":"A painful asymmetric asynchronous sensory and motor peripheral neuropathy involving isolated damage to at least 2 separate nerve areas; associated with (but not limited to) systemic disorders such as diabetes, vasculitis, amyloidosis, direct tumor involvement, polyarteritis nodosa, rheumatoid arthritis, systemic lupus erythematosus, and paraneoplastic syndromes. It also may be associated with Lyme disease, Wegener's granulomatosis, Sjogren syndrome, cryoglobulinemia, hypereosinophilia, temporal arteritis, scleroderma, sarcoidosis, leprosy, acute viral hepatitis A, and acquired immunodeficiency syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mononeuritis Multiplex","conceptCode":"C70938","definition":"A painful asymmetric asynchronous sensory and motor peripheral neuropathy involving isolated damage to at least 2 separate nerve areas; associated with (but not limited to) systemic disorders such as diabetes, vasculitis, amyloidosis, direct tumor involvement, polyarteritis nodosa, rheumatoid arthritis, systemic lupus erythematosus, and paraneoplastic syndromes. It also may be associated with Lyme disease, Wegener's granulomatosis, Sjogren syndrome, cryoglobulinemia, hypereosinophilia, temporal arteritis, scleroderma, sarcoidosis, leprosy, acute viral hepatitis A, and acquired immunodeficiency syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D5CE735-FC04-136E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A57A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Multiple Sclerosis","valueDescription":"multiple sclerosis","ValueMeaning":{"publicId":"2579888","version":"1","preferredName":"multiple sclerosis","longName":"2579888","preferredDefinition":"A disorder of the central nervous system marked by weakness, numbness, a loss of muscle coordination, and problems with vision, speech, and bladder control. Multiple sclerosis is thought to be an autoimmune disease in which the body's immune system destroys myelin. Myelin is a substance that contains both protein and fat (lipid), serving as a nerve insulator and helping in the transmission of nerve signals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Sclerosis","conceptCode":"C3243","definition":"A progressive autoimmune disorder affecting the central nervous system resulting in demyelination. Patients develop physical and cognitive impairments that correspond with the affected nerve fibers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-051D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A584-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Osteoarthritis","valueDescription":"Osteoarthritis","ValueMeaning":{"publicId":"3158617","version":"1","preferredName":"Osteoarthritis","longName":"3158617","preferredDefinition":"A noninflammatory degenerative joint disease occurring chiefly in older persons, characterised by degeneration of the articular cartilage, hypertrophy of bone at the margins and changes in the synovial membrane. It is accompanied by pain and stiffness, particularly after prolonged activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteoarthritis","conceptCode":"C3293","definition":"A noninflammatory degenerative joint disease occurring chiefly in older persons, characterised by degeneration of the articular cartilage, hypertrophy of bone at the margins and changes in the synovial membrane. It is accompanied by pain and stiffness, particularly after prolonged activity.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94B767EB-75D2-EA97-E040-BB89AD4330C2","latestVersionIndicator":"Yes","beginDate":"2010-11-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A596-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hydatidiform Mole","valueDescription":"Hydatidiform Mole","ValueMeaning":{"publicId":"3211157","version":"1","preferredName":"Hydatidiform Mole","longName":"3211157","preferredDefinition":"A gestational disorder characterized by an abnormal placenta with marked enlargement of the chorionic villi and hyperplasia of the villous trophoblastic cells.  According to the amount of villous involvement, a hydatidiform mole is defined as complete or partial.  Most molar pregnancies are complete and are characterized by generalized hydropic villous changes.  Partial moles are characterized by a mixture of large hydropic villi and normal placenta tissue.  Complete moles are usually diploid and typically present between the eleventh and twenty-fifth week of pregnancy, whereas partial moles are usually triploid and usually present around the nineteenth week of pregnancy.  The incidence of choriocarcinoma is higher in patients with complete hydatidiform mole.  When a hydatidiform mole invades the myometrium and broad ligament, or it is found in distant sites as vagina, vulva, and lung, it is referred as invasive mole.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydatidiform Mole","conceptCode":"C3110","definition":"A gestational trophoblastic disorder characterized by marked enlargement of the chorionic villi, hyperplasia of the villous trophoblastic cells and hydropic changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D5F0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D606-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hydroa Vacciniforme","valueDescription":"Hydroa Vacciniforme","ValueMeaning":{"publicId":"3211158","version":"1","preferredName":"Hydroa Vacciniforme","longName":"3211158","preferredDefinition":"A rare skin disorder of unknown etiology affecting children. It is a photodermatitis, characterized by the formation of vesicles and scarring on sun exposed areas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroa Vacciniforme","conceptCode":"C84766","definition":"A rare skin disorder of unknown etiology affecting children. It is a photodermatitis, characterized by the formation of vesicles and scarring on sun exposed areas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D612-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D628-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hydrocephalus","valueDescription":"Hydrocephalus","ValueMeaning":{"publicId":"2566172","version":"1","preferredName":"Hydrocephalus","longName":"2566172","preferredDefinition":"A disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrocephalus","conceptCode":"C3111","definition":"A disorder characterized by an abnormal increase of cerebrospinal fluid in the ventricles of the brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CF89-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-07-23","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-07-23","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D632-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hydrops Fetalis","valueDescription":"Hydrops Fetalis","ValueMeaning":{"publicId":"3211159","version":"1","preferredName":"Hydrops Fetalis","longName":"3211159","preferredDefinition":"A condition characterized by fluid accumulation in two or more anatomic compartments in the fetus. Causes include Rh incompatibility, congenital heart defects, and chromosomal abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrops Fetalis","conceptCode":"C84767","definition":"A condition characterized by fluid accumulation in two or more anatomic compartments in the fetus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D63E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D654-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hymenolepiasis","valueDescription":"Hymenolepiasis","ValueMeaning":{"publicId":"3211160","version":"1","preferredName":"Hymenolepiasis","longName":"3211160","preferredDefinition":"A parasitic infection caused by tapeworms. Most infected individuals do not have symptoms. When symptoms appear, they include diarrhea, abdominal pain, restlessness, and irritability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hymenolepiasis","conceptCode":"C84768","definition":"A parasitic infection caused by tapeworms. Most infected individuals do not have symptoms. When symptoms appear, they include diarrhea, abdominal pain, restlessness, and irritability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D660-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D676-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hyperargininemia","valueDescription":"Argininemia","ValueMeaning":{"publicId":"3210881","version":"1","preferredName":"Argininemia","longName":"3210881","preferredDefinition":"A rare autosomal recessive metabolic disorder characterized by a deficiency of the enzyme arginase resulting in accumulation of arginine and urea in the blood and cerebrospinal fluid. Signs and symptoms include developmental delays, spasticity, ataxia, seizures and mental retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Argininemia","conceptCode":"C84568","definition":"A rare autosomal recessive metabolic disorder characterized by a deficiency of the enzyme arginase resulting in accumulation of arginine and urea in the blood and cerebrospinal fluid. Signs and symptoms include developmental delays, spasticity, ataxia, seizures and mental retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AEDE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D688-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hyperhomocysteinemia","valueDescription":"Hyperhomocysteinemia","ValueMeaning":{"publicId":"3211161","version":"1","preferredName":"Hyperhomocysteinemia","longName":"3211161","preferredDefinition":"A serious metabolic condition caused by mutations in the MTHFR gene, medications, or nutritional deficiency. It results in increased levels of homocysteine in the blood. Patients with this condition are at an increased risk for recurrent blood clots formation and cardiovascular accidents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperhomocysteinemia","conceptCode":"C84770","definition":"A serious metabolic condition caused by mutations in the MTHFR gene, medications, or nutritional deficiency. It results in increased levels of homocysteine in the blood. Patients with this condition are at an increased risk for recurrent blood clots formation and cardiovascular accidents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D693-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D6A9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hyperlipoproteinemia Type I","valueDescription":"Hyperlipoproteinemia Type I","ValueMeaning":{"publicId":"3211162","version":"1","preferredName":"Hyperlipoproteinemia Type I","longName":"3211162","preferredDefinition":"A genetic disorder of lipoprotein metabolism caused by mutations in the LPL and apolipoprotein (apo) C-II genes. It is characterized by increased levels of chylomicrons and triglycerides in the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperlipoproteinemia, Type I","conceptCode":"C84771","definition":"A genetic disorder of lipoprotein metabolism caused by mutations in the LPL and apolipoprotein (apo) C-II genes. It is characterized by increased levels of chylomicrons and triglycerides in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D6B5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D6CB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hyperostosis Frontalis Interna","valueDescription":"Hyperostosis Frontalis Interna","ValueMeaning":{"publicId":"3211163","version":"1","preferredName":"Hyperostosis Frontalis Interna","longName":"3211163","preferredDefinition":"A condition of unknown etiology characterized by thickening of the inner table of the frontal bone of the skull. It is seen more often in females and is usually bilateral.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperostosis Frontalis Interna","conceptCode":"C84772","definition":"A condition of unknown etiology characterized by thickening of the inner table of the frontal bone of the skull. It is seen more often in females and is usually bilateral.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D6D7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D6ED-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hypertrophic Cardiomyopathy","valueDescription":"Hypertrophic Cardiomyopathy","ValueMeaning":{"publicId":"3211164","version":"1","preferredName":"Hypertrophic Cardiomyopathy","longName":"3211164","preferredDefinition":"A condition in which the myocardium is hypertrophied without an obvious cause. The hypertrophy is generally asymmetric and may be associated with obstruction of the ventricular outflow tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypertrophic Cardiomyopathy","conceptCode":"C34449","definition":"A condition in which the myocardium is hypertrophied without an obvious cause. The hypertrophy is generally asymmetric and may be associated with obstruction of the ventricular outflow tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D6F9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D70F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hypoalphalipoproteinemia","valueDescription":"Hypoalphalipoproteinemia","ValueMeaning":{"publicId":"3211165","version":"1","preferredName":"Hypoalphalipoproteinemia","longName":"3211165","preferredDefinition":"A metabolic disorder characterized by deficiency of high density (alpha) lipoprotein in the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypoalphalipoproteinemia","conceptCode":"C84774","definition":"A metabolic disorder characterized by deficiency of high density (alpha) lipoprotein in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D71B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D731-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hypochromic Anemia","valueDescription":"Hypochromic Anemia","ValueMeaning":{"publicId":"3211166","version":"1","preferredName":"Hypochromic Anemia","longName":"3211166","preferredDefinition":"Anemia caused by the reduction of hemoglobin in relation to the red cell volume. As a result, the red cells have an area of central pallor which is increased in size. The leading cause is iron deficiency.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypochromic Anemia","conceptCode":"C34380","definition":"Anemia caused by the reduction of hemoglobin in relation to the red cell volume. As a result, the red cells have an area of central pallor which is increased in size. The leading cause is iron deficiency.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D73D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D753-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hypokalemic Periodic Paralysis","valueDescription":"Hypokalemic Periodic Paralysis","ValueMeaning":{"publicId":"3211167","version":"1","preferredName":"Hypokalemic Periodic Paralysis","longName":"3211167","preferredDefinition":"An autosomal dominant inherited or genetic disorder characterized by irregular episodes of muscle weakness or paralysis which are always accompanied by low levels of potassium in the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypokalemic Periodic Paralysis","conceptCode":"C84775","definition":"A rare, autosomal dominant inherited disorder characterized by irregular episodes of muscle weakness or paralysis which are always accompanied by low levels of potassium in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D75F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D775-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hypoparathyroidism","valueDescription":"Hypoparathyroidism","ValueMeaning":{"publicId":"2946148","version":"1","preferredName":"Hypoparathyroidism","longName":"2946148","preferredDefinition":"An endocrine disorder characterized by decreased production of parathyroid hormone by the parathyroid glands. It is usually caused by damage of the parathyroid glands during head and neck surgery. Signs and symptoms include muscle cramps, abdominal pain, dry skin, brittle nails, cataracts, tetany, and convulsions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypoparathyroidism","conceptCode":"C78350","definition":"An endocrine disorder characterized by decreased production of parathyroid hormone by the parathyroid glands. It is usually caused by damage of the parathyroid glands during head and neck surgery. Signs and symptoms include muscle cramps, abdominal pain, dry skin, brittle nails, cataracts, tetany, and convulsions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746BC102-05C3-7D5C-E040-BB89AD4332CB","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D77F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hypophosphatasia","valueDescription":"Hypophosphatasia","ValueMeaning":{"publicId":"3211168","version":"1","preferredName":"Hypophosphatasia","longName":"3211168","preferredDefinition":"A rare, serious metabolic disorder caused by mutations in the gene encoding tissue non-specific alkaline phosphatase (TNSALP) activity. It is characterized by low activity of TNSALP in the serum. The signs and symptoms vary significantly and include death in utero, failure to thrive, premature loss of deciduous teeth, early loss of the adult dentition, hypercalcemia, osteomalacia, skeletal defects, renal stones, and movement disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypophosphatasia","conceptCode":"C26798","definition":"A rare, serious metabolic disorder caused by mutations in the gene encoding tissue non-specific alkaline phosphatase (TNSALP) activity. It is characterized by low activity of TNSALP in the serum. The signs and symptoms vary significantly and include death in utero, failure to thrive, premature loss of deciduous teeth, early loss of the adult dentition, hypercalcemia, osteomalacia, skeletal defects, renal stones, and movement disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D78B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D7A1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Hypopituitarism","valueDescription":"Hypopituitarism","ValueMeaning":{"publicId":"3211169","version":"1","preferredName":"Hypopituitarism","longName":"3211169","preferredDefinition":"A condition of diminution or cessation of secretion of one or more hormones from the anterior pituitary gland. This may result from surgical or radiation ablation, non-secretory pituitary neoplasms, metastatic tumors, infarction, pituitary apoplexy, infiltrative or granulomatous processes, and other conditions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypopituitarism","conceptCode":"C62591","definition":"A condition of diminution or cessation of secretion of one or more hormones from the anterior pituitary gland. This may result from surgical or radiation ablation, non-secretory pituitary neoplasms, metastatic tumors, infarction, pituitary apoplexy, infiltrative or granulomatous processes, and other conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D7AD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D7C3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ichthyosis","valueDescription":"Ichthyosis","ValueMeaning":{"publicId":"3211170","version":"1","preferredName":"Ichthyosis","longName":"3211170","preferredDefinition":"A group of inherited or acquired skin disorders characterized by a dry, thickened, and scaly skin. The skin changes range from mild to severe.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ichthyosis","conceptCode":"C84776","definition":"A group of inherited or acquired skin disorders characterized by a dry, thickened, and scaly skin. The skin changes range from mild to severe.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D7CF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D7E5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ichthyosis Bullosa of Siemens","valueDescription":"Ichthyosis Bullosa of Siemens","ValueMeaning":{"publicId":"3211171","version":"1","preferredName":"Ichthyosis Bullosa of Siemens","longName":"3211171","preferredDefinition":"A rare autosomal dominant inherited form of ichthyosis. It is characterized by the presence of an erythematous skin with blisters at birth. The skin subsequently becomes dry, flaky and hyperkeratotic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ichthyosis Bullosa of Siemens","conceptCode":"C84777","definition":"A rare autosomal dominant inherited form of ichthyosis. It is characterized by the presence of an erythematous skin with blisters at birth. The skin subsequently becomes dry, flaky and hyperkeratotic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D7F1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D807-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ichthyosis Vulgaris","valueDescription":"Ichthyosis Vulgaris","ValueMeaning":{"publicId":"3211172","version":"1","preferredName":"Ichthyosis Vulgaris","longName":"3211172","preferredDefinition":"The most common form of ichthyosis. It is an autosomal dominant inherited or acquired disorder characterized by scaling and desquamation of the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ichthyosis Vulgaris","conceptCode":"C84778","definition":"The most common form of ichthyosis. It is an autosomal dominant inherited or acquired disorder characterized by scaling and desquamation of the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D813-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D829-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Idiopathic CD4-Positive T-Lymphocytopenia","valueDescription":"Idiopathic CD4-Positive T-Lymphocytopenia","ValueMeaning":{"publicId":"3211173","version":"1","preferredName":"Idiopathic CD4-Positive T-Lymphocytopenia","longName":"3211173","preferredDefinition":"A rare immunodeficiency syndrome characterized by the decrease of the CD4-positive lymphocytes below 300 per cubic millimeter in the absence of identifiable immunodeficiency causes. Patients with this syndrome are at an increased risk of opportunistic infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idiopathic CD4-Positive T-Lymphocytopenia","conceptCode":"C84780","definition":"A rare immunodeficiency syndrome characterized by the decrease of the CD4-positive lymphocytes below 300 per cubic millimeter in the absence of identifiable immunodeficiency causes. Patients with this syndrome are at an increased risk of opportunistic infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D835-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D84B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Idiopathic Hypersomnolence","valueDescription":"Idiopathic Hypersomnolence","ValueMeaning":{"publicId":"3211174","version":"1","preferredName":"Idiopathic Hypersomnolence","longName":"3211174","preferredDefinition":"A rare sleep disorder characterized by prolonged sleep at night and extreme sleepiness during the day. There are no apparent causes. This disorder affects the ability to function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idiopathic Hypersomnolence","conceptCode":"C84781","definition":"A rare sleep disorder characterized by prolonged sleep at night and extreme sleepiness during the day. There are no apparent causes. This disorder affects the ability to function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D857-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D86D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"IgA Nephropathy","valueDescription":"IgA Nephropathy","ValueMeaning":{"publicId":"3211175","version":"1","preferredName":"IgA Nephropathy","longName":"3211175","preferredDefinition":"A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IgA Nephropathy","conceptCode":"C34643","definition":"A chronic autoimmune glomerulonephritis characterized by the deposition of immunoglobulin A in the mesangium of the glomeruli. It is manifested with hematuria and mild proteinuria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D879-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D88F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ileitis","valueDescription":"Ileitis","ValueMeaning":{"publicId":"3211176","version":"1","preferredName":"Ileitis","longName":"3211176","preferredDefinition":"Inflammation of the ileum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ileitis","conceptCode":"C84782","definition":"Inflammation of the ileum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D89B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D8B1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Immunodeficiency With Hyper-IgM","valueDescription":"Immunodeficiency With Hyper-IgM","ValueMeaning":{"publicId":"3211177","version":"1","preferredName":"Immunodeficiency With Hyper-IgM","longName":"3211177","preferredDefinition":"Immunodeficiency caused by mutations in the gene encoding the CD40 ligand. It is characterized by decreased levels of IgG, IgA, and IgE, and normal or increased levels of IgM. Patients are at an increased risk of infections and development of malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunodeficiency with Hyper-IgM","conceptCode":"C84783","definition":"A genetically heterogenous group of conditions characterized by decreased levels of IgG, IgA, and IgE, and normal or increased levels of IgM. Patients are at an increased risk of infections and development of malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D8BD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D8D3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Imperforate Anus","valueDescription":"Imperforate Anus","ValueMeaning":{"publicId":"3211178","version":"1","preferredName":"Imperforate Anus","longName":"3211178","preferredDefinition":"A congenital birth defect characterized by the absence of a normal anal opening. It may be associated with other congenital abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imperforate Anus","conceptCode":"C84784","definition":"A congenital birth defect characterized by the absence of a normal anal opening. It may be associated with other congenital abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D8DF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D8F5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Inborn Urea Cycle Disorder","valueDescription":"Inborn Urea Cycle Disorder","ValueMeaning":{"publicId":"3211179","version":"1","preferredName":"Inborn Urea Cycle Disorder","longName":"3211179","preferredDefinition":"A genetic inborn error of metabolism characterized by the deficiency of one of the enzymes necessary for the urea cycle. It results in accumulation of ammonia in the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urea Cycle Metabolism Disorder","conceptCode":"C84785","definition":"A genetic inborn error of metabolism characterized by the deficiency of one of the enzymes necessary for the urea cycle. It results in accumulation of ammonia in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D901-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D917-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Inclusion Body Myositis","valueDescription":"Inclusion Body Myositis","ValueMeaning":{"publicId":"3211180","version":"1","preferredName":"Inclusion Body Myositis","longName":"3211180","preferredDefinition":"An acquired or hereditary chronic inflammatory disorder of the muscles characterized by the morphologic finding of vacuoles and filamentous inclusions in the muscle tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Body Myositis","conceptCode":"C84786","definition":"An acquired or hereditary chronic inflammatory disorder of the muscles characterized by the morphologic finding of vacuoles and filamentous inclusions in the muscle tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D923-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D939-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Incontinentia Pigmenti","valueDescription":"Incontinentia Pigmenti","ValueMeaning":{"publicId":"3211181","version":"1","preferredName":"Incontinentia Pigmenti","longName":"3211181","preferredDefinition":"A rare disorder caused by mutations in the IKBKG gene. It is characterized by skin abnormalities, alopecia, dystrophic nails, and abnormal tooth shape. The skin changes evolve from an initial blistering rash, to wart-like lesions, and eventually to hypopigmentation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Incontinentia Pigmenti","conceptCode":"C84787","definition":"A rare disorder caused by mutations in the IKBKG gene. It is characterized by skin abnormalities, alopecia, dystrophic nails, and abnormal tooth shape. The skin changes evolve from an initial blistering rash, to wart-like lesions, and eventually to hypopigmentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D945-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D95B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Infantile Neuroaxonal Dystrophy","valueDescription":"Infantile Neuroaxonal Dystrophy","ValueMeaning":{"publicId":"3211182","version":"1","preferredName":"Infantile Neuroaxonal Dystrophy","longName":"3211182","preferredDefinition":"A rare autosomal recessive neurodegenerative disorder caused by mutations in the PLA2G6 gene. It is characterized by the development of swellings called spehroids along the axons of the central nervous system. Signs and symptoms appear early in life and include movement difficulties, muscle hypotonia and spasticity, and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infantile Neuroaxonal Dystrophy","conceptCode":"C84927","definition":"A rare autosomal recessive neurodegenerative disorder caused by mutations in the PLA2G6 gene. It is characterized by the development of swellings called spehroids along the axons of the central nervous system. Signs and symptoms appear early in life and include movement difficulties, muscle hypotonia and spasticity, and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D967-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D97D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Infantile Refsum Disease","valueDescription":"Infantile Refsum Disease","ValueMeaning":{"publicId":"3211183","version":"1","preferredName":"Infantile Refsum Disease","longName":"3211183","preferredDefinition":"A genetic disorder characterized by abnormalities in the breakdown of phytanic acid. It results in accumulation of phytanic acid in the blood, brain and other tissues. Signs and symptoms include retinitis pigmentosa which may lead to blindness, hearing problems and deafness, hypotonia, ataxia, nystagmus, facial deformities, and mental and growth retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infantile Refsum Disease","conceptCode":"C84789","definition":"A genetic disorder characterized by abnormalities in the breakdown of phytanic acid. It results in accumulation of phytanic acid in the blood, brain and other tissues. Signs and symptoms include retinitis pigmentosa which may lead to blindness, hearing problems and deafness, hypotonia, ataxia, nystagmus, facial deformities, and mental and growth retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D989-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D99F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Inflammatory Breast Carcinoma","valueDescription":"Inflammatory Breast Carcinoma","ValueMeaning":{"publicId":"2593123","version":"1","preferredName":"Inflammatory Breast Carcinoma","longName":"2593123","preferredDefinition":"A type of breast cancer in which the breast looks red and swollen and feels warm. The skin of the breast may also show the pitted appearance called peau d'orange (like the skin of an orange). The redness and warmth occur because the cancer cells block the lymph vessels in the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Inflammatory Carcinoma","conceptCode":"C4001","definition":"An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D4DB6-4D39-242A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D9A9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Intestinal Atresia","valueDescription":"Intestinal Atresia","ValueMeaning":{"publicId":"3211184","version":"1","preferredName":"Intestinal Atresia","longName":"3211184","preferredDefinition":"A malformation characterized by the absence of a normal opening in a part of the intestine. It can occur either in the small or the large intestine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intestinal Atresia","conceptCode":"C84790","definition":"A congenital malformation characterized by the absence of a normal opening in a part of the intestine. It can occur either in the small or the large intestine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D9B5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D9CB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Intracranial Hypertension","valueDescription":"Intracranial Hypertension","ValueMeaning":{"publicId":"3211185","version":"1","preferredName":"Intracranial Hypertension","longName":"3211185","preferredDefinition":"A finding characterized by increased cerebrospinal fluid pressure within the skull.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intracranial Hypertension","conceptCode":"C84791","definition":"A finding characterized by increased cerebrospinal fluid pressure within the skull.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D9D7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-D9ED-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Iridocorneal Endothelial Syndrome","valueDescription":"Iridocorneal Endothelial Syndrome","ValueMeaning":{"publicId":"3211186","version":"1","preferredName":"Iridocorneal Endothelial Syndrome","longName":"3211186","preferredDefinition":"A group of disorders characterized by the presence of an abnormal inner layer of the cornea. This abnormality results in iris distortion, corneal swelling, pupil distortion, and glaucoma. It usually affects only one eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iridocorneal Endothelial Syndrome","conceptCode":"C84792","definition":"A group of disorders characterized by the presence of an abnormal inner layer of the cornea. This abnormality results in iris distortion, corneal swelling, pupil distortion, and glaucoma. It usually affects only one eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-D9F9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DA0F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Islet Cell Adenoma","valueDescription":"Islet Cell Adenoma","ValueMeaning":{"publicId":"3211187","version":"1","preferredName":"Islet Cell Adenoma","longName":"3211187","preferredDefinition":"A benign endocrine neoplasm arising from the pancreas. It is separated from the normal pancreatic tissues by a thin collagenous capsule. It may secrete a hormone (e.g. insulin, gastrin) or it may be non-functional.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Islet Cell Adenoma","conceptCode":"C65184","definition":"A benign endocrine neoplasm arising from the pancreas. It is separated from the normal pancreatic tissues by a thin collagenous capsule. It may secrete a hormone (e.g. insulin, gastrin) or it may be non-functional.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DA1B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DA31-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Jacobsen Syndrome","valueDescription":"Jacobsen Syndrome","ValueMeaning":{"publicId":"3211188","version":"1","preferredName":"Jacobsen Syndrome","longName":"3211188","preferredDefinition":"A very rare genetic syndrome caused by deletion of the terminal band of chromosome 11.  It is characterized by the presence of growth and psychomotor retardation, broad nasal bridge, low set ears, strabismus, trigonocephaly, and thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Jacobsen Syndrome","conceptCode":"C75457","definition":"A very rare genetic syndrome caused by deletion of the terminal band of chromosome 11. It is characterized by the presence of growth and psychomotor retardation, broad nasal bridge, low set ears, strabismus, trigonocephaly, and thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DA4F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DA65-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Japanese B Encephalitis","valueDescription":"Japanese B Encephalitis","ValueMeaning":{"publicId":"3211189","version":"1","preferredName":"Japanese B Encephalitis","longName":"3211189","preferredDefinition":"Viral encephalitis caused by the mosquito-born Japanese encephalitis virus. Signs and symptoms include an initial period of fever, headaches, and malaise, followed by neck rigidity, hemiparesis, and convulsions. It may lead to coma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Japanese B Encephalitis","conceptCode":"C34577","definition":"Viral encephalitis caused by the mosquito-born Japanese encephalitis virus. Signs and symptoms include an initial period of fever, headaches, and malaise, followed by neck rigidity, hemiparesis, and convulsions. It may lead to coma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DA71-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DA87-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Jervell and Lange Nielsen Syndrome","valueDescription":"Jervell and Lange Nielsen Syndrome","ValueMeaning":{"publicId":"3211190","version":"1","preferredName":"Jervell and Lange Nielsen Syndrome","longName":"3211190","preferredDefinition":"An autosomal recessive inherited syndrome caused by mutations in the KCNE1 and KCNQ1 genes. It is characterized by congenital hearing loss and arrhythmia. It is a form of long QT syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Jervell and Lange Nielsen Syndrome","conceptCode":"C84793","definition":"An autosomal recessive inherited syndrome caused by mutations in the KCNE1 and KCNQ1 genes. It is characterized by congenital hearing loss and arrhythmia. It is a form of long QT syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DA93-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DAA9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Jeune Syndrome","valueDescription":"Jeune Syndrome","ValueMeaning":{"publicId":"3211191","version":"1","preferredName":"Jeune Syndrome","longName":"3211191","preferredDefinition":"A rare autosomal recessive inherited syndrome characterized by a narrow thorax, micromelia, and respiratory disturbances which may lead to asphyxiation. It may be associated with bilateral microcystic renal disease which may lead to renal failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Jeune Syndrome","conceptCode":"C84794","definition":"A rare autosomal recessive inherited syndrome characterized by a narrow thorax, micromelia, and respiratory disturbances which may lead to asphyxiation. It may be associated with bilateral microcystic renal disease which may lead to renal failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DAB5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DACB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Joubert Syndrome","valueDescription":"Joubert Syndrome","ValueMeaning":{"publicId":"3211192","version":"1","preferredName":"Joubert Syndrome","longName":"3211192","preferredDefinition":"A rare genetic syndrome characterized by the hypoplasia or absence of the cerebellar vermis.  Signs and symptoms include rapid breathing (hyperpnea), sleep apnea, abnormal eye movements, mental retardation, and ataxia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Joubert Syndrome","conceptCode":"C74996","definition":"A rare genetic syndrome characterized by the hypoplasia or absence of the cerebellar vermis. Signs and symptoms include rapid breathing (hyperpnea), sleep apnea, abnormal eye movements, mental retardation, and ataxia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DAD7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DAED-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Juvenile Myelomonocytic Leukemia","valueDescription":"Juvenile Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2559013","version":"1","preferredName":"Juvenile Myelomonocytic Leukemia","longName":"2559013","preferredDefinition":"A myelodysplastic/myeloproliferative disease of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages.  Myelomonocytic proliferation is seen in the bone marrow and the blood.  The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.  The prognosis is usually poor.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Myelomonocytic Leukemia","conceptCode":"C9233","definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B392-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DAF7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Juvenile Myoclonic Epilepsy","valueDescription":"Juvenile Myoclonic Epilepsy","ValueMeaning":{"publicId":"3211193","version":"1","preferredName":"Juvenile Myoclonic Epilepsy","longName":"3211193","preferredDefinition":"An epilepsy characterized by myoclonic jerks, generalized tonic-clonic seizures, and sometimes absence seizures. It appears during adolescence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Myoclonic Epilepsy","conceptCode":"C84796","definition":"An epilepsy characterized by myoclonic jerks, generalized tonic-clonic seizures, and sometimes absence seizures. It appears during adolescence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DB03-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DB19-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Juvenile Osteochondrosis of Spine","valueDescription":"Juvenile Osteochondrosis of Spine","ValueMeaning":{"publicId":"3211194","version":"1","preferredName":"Juvenile Osteochondrosis of Spine","longName":"3211194","preferredDefinition":"A disorder characterized by osteochondrosis of the vertebral epiphyses in childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Osteochondrosis of Spine","conceptCode":"C34999","definition":"A disorder characterized by osteochondrosis of the vertebral epiphyses in childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DB25-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DB3B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Kala-Azar","valueDescription":"Kala-Azar","ValueMeaning":{"publicId":"3211195","version":"1","preferredName":"Kala-Azar","longName":"3211195","preferredDefinition":"A chronic parasitic infection affecting the viscera and caused by Leishmania donovani. Signs and symptoms include fever, anorexia, fatigue, lymphadenopathy, anemia, and hepatosplenomegaly. If left untreated it may lead to death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kala-Azar","conceptCode":"C34771","definition":"A chronic parasitic infection affecting the viscera and caused by Leishmania donovani. Signs and symptoms include fever, anorexia, fatigue, lymphadenopathy, anemia, and hepatosplenomegaly. If left untreated it may lead to death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DB47-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DB5D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Kallmann Syndrome","valueDescription":"Kallmann Syndrome","ValueMeaning":{"publicId":"3211196","version":"1","preferredName":"Kallmann Syndrome","longName":"3211196","preferredDefinition":"An X-linked or autosomal dominant genetic syndrome characterized by hypogonadotropic hypogonadism and anosmia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypogonadotropic Hypogonadism with Anosmia","conceptCode":"C75479","definition":"An X-linked or autosomal dominant genetic syndrome characterized by hypogonadotropic hypogonadism and anosmia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DB69-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DB7F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Kartagener Syndrome","valueDescription":"Kartagener Syndrome","ValueMeaning":{"publicId":"3211197","version":"1","preferredName":"Kartagener Syndrome","longName":"3211197","preferredDefinition":"A rare autosomal recessive inherited syndrome characterized by situs inversus, bronchiectasis, and chronic sinusitis. There is a defect in the function of the cilia that line the respiratory tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kartagener Syndrome","conceptCode":"C84797","definition":"A rare autosomal recessive inherited syndrome characterized by situs inversus, bronchiectasis, and chronic sinusitis. There is a defect in the function of the cilia that line the respiratory tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DB8B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DBA1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Kearns-Sayre Syndrome","valueDescription":"Kearns-Sayre Syndrome","ValueMeaning":{"publicId":"3211198","version":"1","preferredName":"Kearns-Sayre Syndrome","longName":"3211198","preferredDefinition":"A rare mitochondrial myopathy characterized by a progressive limitation of eye movements, leading to immobility and eye drop. It may be associated with muscle weakness, heart block, hearing loss, ataxia and short stature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kearns-Sayre Syndrome","conceptCode":"C84798","definition":"A rare mitochondrial myopathy characterized by a progressive limitation of eye movements, leading to immobility and eye drop. It may be associated with muscle weakness, heart block, hearing loss, ataxia and short stature.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DBAD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DBC3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Keratoacanthoma","valueDescription":"Keratoacanthoma","ValueMeaning":{"publicId":"3211199","version":"1","preferredName":"Keratoacanthoma","longName":"3211199","preferredDefinition":"A dome-shaped, rapidly growing skin lesion composed of well differentiated squamous cells.  It represents a proliferation of the infundibular epithelium of the hair follicle and its morphologic distinction from a well differentiated carcinoma may be difficult or impossible.  Keratoacanthomas affect males more frequently than females and the majority tend to regress spontaneously.  It has been suggested that keratoacanthoma represents a distinct subtype of squamous cell carcinoma of the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Keratoacanthoma","conceptCode":"C3146","definition":"A dome-shaped, rapidly growing skin lesion composed of well differentiated squamous cells. It usually occurs on sun-exposed areas of the body, most often the head, neck, and limbs. It is considered a variant of well-differentiated squamous cell carcinoma with distinct clinical behavior. Keratoacanthomas affect males more frequently than females and the majority tend to regress spontaneously.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DBCF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DBE5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Keratoconus","valueDescription":"Keratoconus","ValueMeaning":{"publicId":"3211200","version":"1","preferredName":"Keratoconus","longName":"3211200","preferredDefinition":"A degenerative, structural disorder of the eye, characterized by a cone-shaped protrusion of the cornea. It may lead to visual disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Keratoconus","conceptCode":"C26806","definition":"A degenerative, structural disorder of the eye, characterized by a cone-shaped protrusion of the cornea. It may lead to visual disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DBF1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DC07-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Kernicterus","valueDescription":"Kernicterus","ValueMeaning":{"publicId":"3211201","version":"1","preferredName":"Kernicterus","longName":"3211201","preferredDefinition":"A rare neurologic disorder occurring in infants with jaundice. It results from brain damage by existing high levels of unconjugated-indirect bilirubin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kernicterus","conceptCode":"C84799","definition":"A rare neurologic disorder occurring in infants with jaundice. It results from brain damage by existing high levels of unconjugated-indirect bilirubin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DC13-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DC29-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Kleine-Levin Syndrome","valueDescription":"Kleine-Levin Syndrome","ValueMeaning":{"publicId":"3211202","version":"1","preferredName":"Kleine-Levin Syndrome","longName":"3211202","preferredDefinition":"A rare disorder characterized by episodes of excessive sleep and behavioral alterations while awake. It affects predominantly males. The individuals exhibit normal behavior between episodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kleine-Levin Syndrome","conceptCode":"C84800","definition":"A rare disorder characterized by episodes of excessive sleep and behavioral alterations while awake. It affects predominantly males. The individuals exhibit normal behavior between episodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DC35-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DC4B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Osteoporosis","valueDescription":"Osteoporosis","ValueMeaning":{"publicId":"2563635","version":"1","preferredName":"Osteoporosis","longName":"2563635","preferredDefinition":"A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteoporosis","conceptCode":"C3298","definition":"A condition of reduced bone mass, with decreased cortical thickness and a decrease in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis is classified as primary (Type 1, postmenopausal osteoporosis; Type 2, age-associated osteoporosis; and idiopathic, which can affect juveniles, premenopausal women, and middle-aged men) and secondary osteoporosis (which results from an identifiable cause of bone mass loss).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C5A0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-05","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A5A0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pancreatitis","valueDescription":"Pancreatitis","ValueMeaning":{"publicId":"2559694","version":"1","preferredName":"Pancreatitis","longName":"2559694","preferredDefinition":"Inflammation of the pancreas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatitis","conceptCode":"C3306","definition":"Inflammation of the pancreas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B63B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A5AA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Peripheral Sensory Neuropathy","valueDescription":"Peripheral Sensory Neuropathy","ValueMeaning":{"publicId":"2562803","version":"1","preferredName":"Peripheral Sensory Neuropathy","longName":"2562803","preferredDefinition":"Inflammation or degeneration of the sensory nerves.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral Sensory Neuropathy","conceptCode":"C3501","definition":"Inflammation or degeneration of the sensory nerves.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C260-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A5BC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Prostatitis","valueDescription":"Prostatitis","ValueMeaning":{"publicId":"3210820","version":"1","preferredName":"Prostatitis","longName":"3210820","preferredDefinition":"An infectious or non-infectious inflammatory process affecting the prostate gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostatitis","conceptCode":"C26866","definition":"An infectious or non-infectious inflammatory process affecting the prostate gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A5C8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A5DE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Psoriasis","valueDescription":"Psoriasis","ValueMeaning":{"publicId":"2567418","version":"1","preferredName":"Psoriasis","longName":"2567418","preferredDefinition":"A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psoriasis","conceptCode":"C3346","definition":"An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D467-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A5E8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Pulmonary Fibrosis","valueDescription":"Pulmonary Fibrosis","ValueMeaning":{"publicId":"2562761","version":"1","preferredName":"Pulmonary Fibrosis","longName":"2562761","preferredDefinition":"Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Fibrosis","conceptCode":"C26869","definition":"Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C236-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A5FA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Renal Failure","valueDescription":"Renal Failure","ValueMeaning":{"publicId":"2768982","version":"1","preferredName":"Renal Failure","longName":"2768982","preferredDefinition":"Acute or chronic condition, characterized by the inability of the kidneys to adequately filter the blood substances, resulting in uremia and electrolyte imbalances.  Acute renal failure is usually associated with oliguria or anuria, hyperkalemia, and pulmonary edema.  Chronic renal failure is irreversible and requires hemodialysis.--2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Failure","conceptCode":"C4376","definition":"An acute or chronic condition that is characterized by the inability of the kidneys to adequately filter the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53198A5F-968B-1FF8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-07-28","modifiedBy":"COLBERTM","dateModified":"2023-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A60C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Rheumatoid Arthritis","valueDescription":"Rheumatoid Arthritis","ValueMeaning":{"publicId":"2570667","version":"1","preferredName":"Rheumatoid Arthritis","longName":"2570667","preferredDefinition":"A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rheumatoid Arthritis","conceptCode":"C2884","definition":"A chronic, systemic autoimmune disorder characterized by inflammation in the synovial membranes and articular surfaces. It manifests primarily as a symmetric, erosive polyarthritis that spares the axial skeleton and is typically associated with the presence in the serum of rheumatoid factor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E118-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CZECHS","dateModified":"2008-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A616-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Schizophrenia","valueDescription":"Schizophrenia","ValueMeaning":{"publicId":"3165564","version":"1","preferredName":"Schizophrenia","longName":"3165564","preferredDefinition":"A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Schizophrenia","conceptCode":"C3362","definition":"A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96FCF74F-C0A3-EAB7-E040-BB89AD437850","latestVersionIndicator":"Yes","beginDate":"2010-12-09","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A620-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Simultanagnosia","valueDescription":"Simultanagnosia","ValueMeaning":{"publicId":"3210821","version":"1","preferredName":"Simultanagnosia","longName":"3210821","preferredDefinition":"A symptom describing the inability to comprehend more than one element of a visual picture at a given moment, or to integrate the whole visual picture.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Simultanagnosia","conceptCode":"C84395","definition":"A symptom describing the inability to comprehend more than one element of a visual picture at a given moment, or to integrate the whole visual picture.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A62C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A642-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Wound Complication","valueDescription":"Wound Complication","ValueMeaning":{"publicId":"2943832","version":"1","preferredName":"Wound Complication","longName":"2943832","preferredDefinition":"A medical condition that develops at the site of an existing wound. Examples include swelling, draining, bleeding, formation of hematoma, infection, and necrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wound Complication","conceptCode":"C78719","definition":"A medical condition that develops at the site of an existing wound. Examples include swelling, draining, bleeding, formation of hematoma, infection, and necrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7428BBDA-1E9E-B2E3-E040-BB89AD4317E1","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A654-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Abdominal Aortic Aneurysm","valueDescription":"Abdominal Aortic Aneurysm","ValueMeaning":{"publicId":"3210822","version":"1","preferredName":"Abdominal Aortic Aneurysm","longName":"3210822","preferredDefinition":"Enlargement and ballooning of the vessel that supplies arterial blood to the abdomen, pelvis and legs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abdominal Aortic Aneurysm","conceptCode":"C27000","definition":"Enlargement and ballooning of the vessel that supplies arterial blood to the abdomen, pelvis and legs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A660-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A676-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Abducens Nerve Disorder","valueDescription":"Abducens Nerve Disorder","ValueMeaning":{"publicId":"2943956","version":"1","preferredName":"Abducens Nerve Disorder","longName":"2943956","preferredDefinition":"A non-neoplastic or neoplastic disorder affecting the abducens nerve (sixth cranial nerve).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abducens Nerve Disorder","conceptCode":"C27593","definition":"A non-neoplastic or neoplastic disorder affecting the abducens nerve (sixth cranial nerve).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"742CB3BE-B895-F51E-E040-BB89AD432000","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A688-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Abetalipoproteinemia","valueDescription":"Abetalipoproteinemia","ValueMeaning":{"publicId":"3210823","version":"1","preferredName":"Abetalipoproteinemia","longName":"3210823","preferredDefinition":"An autosomal recessive disorder characterized by defective absorption of dietary fat, cholesterol and fat-soluble vitamins. It results in multiple vitamin deficiencies. Signs and symptoms include failure to thrive, diarrhea, steatorrhea, acanthocytosis and ataxia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abetalipoproteinemia","conceptCode":"C84525","definition":"An autosomal recessive disorder characterized by defective absorption of dietary fat, cholesterol and fat-soluble vitamins. It results in multiple vitamin deficiencies. Signs and symptoms include failure to thrive, diarrhea, steatorrhea, acanthocytosis and ataxia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A694-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A6AA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acanthoma","valueDescription":"Acanthoma","ValueMeaning":{"publicId":"3210824","version":"1","preferredName":"Acanthoma","longName":"3210824","preferredDefinition":"A benign skin neoplasm composed of epithelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acanthoma","conceptCode":"C7419","definition":"A benign skin neoplasm composed of epithelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A6B6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A6CC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acanthosis Nigricans","valueDescription":"Acanthosis Nigricans","ValueMeaning":{"publicId":"3210825","version":"1","preferredName":"Acanthosis Nigricans","longName":"3210825","preferredDefinition":"A melanotic cutaneous lesion that develops in the axilla and other body folds. It may be idiopathic, drug-induced, or it may be associated with the presence of an endocrine disorder or malignancy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acanthosis Nigricans","conceptCode":"C26687","definition":"A melanotic cutaneous lesion that develops in the axilla and other body folds. It may be idiopathic, drug-induced, or it may be associated with the presence of an endocrine disorder or malignancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A6D8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A6EE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acatalasemia","valueDescription":"Acatalasemia","ValueMeaning":{"publicId":"3210826","version":"1","preferredName":"Acatalasemia","longName":"3210826","preferredDefinition":"A rare autosomal recessive disorder characterized by deficiency of catalase in the peripheral blood. It is usually manifested with periodontal infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acatalasemia","conceptCode":"C84526","definition":"A rare autosomal recessive disorder characterized by deficiency of catalase in the peripheral blood. It is usually manifested with periodontal infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A6FA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A710-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Achondrogenesis","valueDescription":"Achondrogenesis","ValueMeaning":{"publicId":"3210827","version":"1","preferredName":"Achondrogenesis","longName":"3210827","preferredDefinition":"A rare group of disorders characterized by defective development of bones and cartilage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Achondrogenesis","conceptCode":"C84527","definition":"A rare group of disorders characterized by defective development of bones and cartilage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A71C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A732-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Achondroplasia","valueDescription":"Achondroplasia","ValueMeaning":{"publicId":"3210828","version":"1","preferredName":"Achondroplasia","longName":"3210828","preferredDefinition":"An autosomal dominant disorder that is the most frequent form of short-limb dwarfism. Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, genu varum, and trident hand. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Achondroplasia","conceptCode":"C34345","definition":"An autosomal dominant disorder caused by mutation(s) in the FGFR3 gene, encoding fibroblast growth factor receptor 3. The condition is characterized by inappropriate cartilage growth plate differentiation and deficient endochondral growth, manifest clinically with severe rhizomelic short stature, short limbs, characteristic facies with frontal bossing and midface hypoplasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A73E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A754-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Achromatopsia","valueDescription":"Achromatopsia","ValueMeaning":{"publicId":"3210829","version":"1","preferredName":"Achromatopsia","longName":"3210829","preferredDefinition":"An autosomal recessive genetic disorder affecting the cone cells of the eye. It may be complete, in which the individual can only perceive black, white, or shades or gray, or incomplete, in which the individual has a residual amount of color vision.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Achromatopsia","conceptCode":"C84528","definition":"An autosomal recessive genetic disorder affecting the cone cells of the eye. It may be complete, in which the individual can only perceive black, white, or shades or gray, or incomplete, in which the individual has a residual amount of color vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A760-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A776-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acinar Cell Carcinoma","valueDescription":"Acinar Cell Carcinoma","ValueMeaning":{"publicId":"2558157","version":"1","preferredName":"Acinar Cell Carcinoma","longName":"2558157","preferredDefinition":"A malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. Representative examples include the acinar cell carcinoma of the pancreas and the acinar adenocarcinoma of the prostate gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acinar Cell Carcinoma","conceptCode":"C3768","definition":"A malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. Representative examples include the acinar cell carcinoma of the pancreas and the acinar adenocarcinoma of the prostate gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B03A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A780-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acoustic Schwannoma","valueDescription":"Acoustic Schwannoma","ValueMeaning":{"publicId":"3210830","version":"1","preferredName":"Acoustic Schwannoma","longName":"3210830","preferredDefinition":"A type of benign brain tumor that begins in the Schwann cells, which produce the myelin that protects the acoustic nerve - the nerve of hearing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vestibular Schwannoma","conceptCode":"C3276","definition":"A benign peripheral nerve sheath neoplasm that arises from the vestibular division of the vestibulocochlear nerve (eight cranial nerve) in the auditory canal or within the labyrinth. It is composed almost entirely of differentiated neoplastic Schwann cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A78C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A7A2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acquired Hyperostosis Syndrome","valueDescription":"Acquired Hyperostosis Syndrome","ValueMeaning":{"publicId":"3210831","version":"1","preferredName":"Acquired Hyperostosis Syndrome","longName":"3210831","preferredDefinition":"A chronic inflammatory disorder characterized by hyperostosis, osteitis, synovitis and palmoplantar pustulosis. The most common site of involvement is the anterior chest wall.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acquired Hyperostosis Syndrome","conceptCode":"C84530","definition":"A chronic inflammatory disorder characterized by hyperostosis, osteitis, synovitis and palmoplantar pustulosis. The most common site of involvement is the anterior chest wall.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A7AE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A7C4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acrocallosal Syndrome","valueDescription":"Acrocallosal Syndrome","ValueMeaning":{"publicId":"3210832","version":"1","preferredName":"Acrocallosal Syndrome","longName":"3210832","preferredDefinition":"A rare genetic syndrome characterized by agenesis of the corpus callosum, polydactyly, mental and motor retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acrocallosal Syndrome","conceptCode":"C84531","definition":"A rare genetic syndrome characterized by agenesis of the corpus callosum, polydactyly, mental and motor retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A7D0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A7E6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acrocephalosyndactyly","valueDescription":"Acrocephalosyndactyly","ValueMeaning":{"publicId":"3210833","version":"1","preferredName":"Acrocephalosyndactyly","longName":"3210833","preferredDefinition":"A genetic disorder characterized by craniosynostosis and fusion of the fingers and toes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acrocephalosyndactyly","conceptCode":"C34348","definition":"A genetic disorder characterized by craniosynostosis and fusion of the fingers and toes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A7F2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A808-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acrodermatitis","valueDescription":"Acrodermatitis","ValueMeaning":{"publicId":"3210834","version":"1","preferredName":"Acrodermatitis","longName":"3210834","preferredDefinition":"An inflammatory skin condition affecting children. It is often associated with Epstein-Barr virus infection, hepatitis B infection or cytomegalovirus infection. It is characterized by the presence of cutaneous rashes and patches on the palms and soles. The trunk is not affected.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acrodermatitis","conceptCode":"C84532","definition":"An inflammatory skin condition affecting children. It is often associated with Epstein-Barr virus infection, hepatitis B infection or cytomegalovirus infection. It is characterized by the presence of cutaneous rashes and patches on the palms and soles. The trunk is not affected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A814-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A82A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acromegaly","valueDescription":"Acromegaly","ValueMeaning":{"publicId":"3210835","version":"1","preferredName":"Acromegaly","longName":"3210835","preferredDefinition":"A syndrome characterized by enlargement of the hands, feet, ears, nose, lips, and tongue, skin thickening and swelling of internal organs. It is caused by overproduction of growth hormone in the pituitary gland, usually by a pituitary adenoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acromegaly","conceptCode":"C84533","definition":"A syndrome characterized by enlargement of the hands, feet, ears, nose, lips, and tongue, skin thickening and swelling of internal organs. It is caused by overproduction of growth hormone in the pituitary gland, usually by a pituitary adenoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A836-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A84C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Actinomycetales Infection","valueDescription":"Actinomycetales Infection","ValueMeaning":{"publicId":"3210836","version":"1","preferredName":"Actinomycetales Infection","longName":"3210836","preferredDefinition":"An infectious process caused by actinomycetales which is an order of Actinobacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Actinomycetales Infection","conceptCode":"C84534","definition":"An infectious process caused by actinomycetales which is an order of Actinobacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A858-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A86E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Actinomycosis","valueDescription":"Actinomycosis","ValueMeaning":{"publicId":"3210837","version":"1","preferredName":"Actinomycosis","longName":"3210837","preferredDefinition":"An infectious process caused by bacteria of the Actinomyces species. It is characterized by the formation of purulent and painful abscesses in the mouth, lungs and gastrointestinal tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Actinomycosis","conceptCode":"C34350","definition":"An infectious process caused by bacteria of the Actinomyces species. It is characterized by the formation of purulent and painful abscesses in the mouth, lungs and gastrointestinal tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A87A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A890-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acute Disseminated Encephalomyelitis","valueDescription":"Acute Disseminated Encephalomyelitis","ValueMeaning":{"publicId":"3210838","version":"1","preferredName":"Acute Disseminated Encephalomyelitis","longName":"3210838","preferredDefinition":"An inflammatory process affecting the central nervous system. It is characterized by perivascular demyelination. Symptoms usually follow an acute viral infection or immunization and include fever, confusion, somnolence and involuntary movements. It may lead to coma and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Disseminated Encephalomyelitis","conceptCode":"C34578","definition":"An inflammatory process affecting the central nervous system. It is characterized by perivascular demyelination. Symptoms usually follow an acute viral infection or immunization and include fever, confusion, somnolence and involuntary movements. It may lead to coma and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A89C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A8B2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acute Hemorrhagic Leukoencephalitis","valueDescription":"Acute Hemorrhagic Leukoencephalitis","ValueMeaning":{"publicId":"3210839","version":"1","preferredName":"Acute Hemorrhagic Leukoencephalitis","longName":"3210839","preferredDefinition":"A degenerative brain disorder presenting with acute neurological manifestations. It usually associated with an acute infection or vaccination. It is characterized by brain hemorrhage, vascular necrosis and demyelination. Signs and symptoms include fever, headache, vomiting, convulsions and loss of consciousness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Hemorrhagic Leukoencephalitis","conceptCode":"C84535","definition":"A degenerative brain disorder presenting with acute neurological manifestations. It usually associated with an acute infection or vaccination. It is characterized by brain hemorrhage, vascular necrosis and demyelination. Signs and symptoms include fever, headache, vomiting, convulsions and loss of consciousness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A8BE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A8D4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acute Infective Polyneuritis","valueDescription":"Acute Infective Polyneuritis","ValueMeaning":{"publicId":"3210840","version":"1","preferredName":"Acute Infective Polyneuritis","longName":"3210840","preferredDefinition":"An acute, autoimmune inflammatory process affecting the peripheral nervous system and nerve roots. It results in demyelination. It is often caused by an acute viral or bacterial infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Infective Polyneuritis","conceptCode":"C26790","definition":"An acute inflammatory process affecting the peripheral nervous system and nerve roots. It results in demyelination. It is often caused by an acute viral or bacterial infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A8E0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A8F6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acute Intermittent Porphyria","valueDescription":"Acute Intermittent Porphyria","ValueMeaning":{"publicId":"3210841","version":"1","preferredName":"Acute Intermittent Porphyria","longName":"3210841","preferredDefinition":"A genetic metabolic disorder inherited in an autosomal dominant pattern. It is caused by a deficiency of the enzyme porphobilinogen deaminase, which is involved in heme biosynthesis. Signs and symptoms include nausea, vomiting, severe abdominal pain and distension, urinary retention, port-wine urine discoloration, hypertension, tachycardia, muscle weakness, loss of sensation, anxiety, depression, and arm, leg and back pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Intermittent Porphyria","conceptCode":"C84536","definition":"A genetic metabolic disorder inherited in an autosomal dominant pattern. It is caused by a deficiency of the enzyme porphobilinogen deaminase, which is involved in heme biosynthesis. Signs and symptoms include nausea, vomiting, severe abdominal pain and distension, urinary retention, port-wine urine discoloration, hypertension, tachycardia, muscle weakness, loss of sensation, anxiety, depression, and arm, leg and back pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A902-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A918-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acute Megakaryoblastic Leukemia","valueDescription":"Acute Megakaryoblastic Leukemia","ValueMeaning":{"publicId":"2558163","version":"1","preferredName":"Acute Megakaryoblastic Leukemia","longName":"2558163","preferredDefinition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Megakaryoblastic Leukemia","conceptCode":"C3170","definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B040-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A922-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acyl-CoA Dehydrogenase, Long-Chain Deficiency","valueDescription":"Acyl-CoA Dehydrogenase, Long-Chain Deficiency","ValueMeaning":{"publicId":"3210842","version":"1","preferredName":"Acyl-CoA Dehydrogenase, Long-Chain Deficiency","longName":"3210842","preferredDefinition":"A genetic disorder characterized by deficiency of the enzyme long-chain acyl-coenzyme A dehydrogenase that metabolizes long-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting, illness or exercise. They include hypoglycemia, muscle weakness and lethargy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Long-Chain Acyl-CoA Dehydrogenase Deficiency","conceptCode":"C84537","definition":"A genetic disorder characterized by deficiency of the enzyme long-chain acyl-coenzyme A dehydrogenase that metabolizes long-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting, illness or exercise. They include hypoglycemia, muscle weakness and lethargy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A92E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A944-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acyl-CoA Dehydrogenase, Medium-Chain Deficiency","valueDescription":"Acyl-CoA Dehydrogenase, Medium-Chain Deficiency","ValueMeaning":{"publicId":"3210843","version":"1","preferredName":"Acyl-CoA Dehydrogenase, Medium-Chain Deficiency","longName":"3210843","preferredDefinition":"A genetic disorder characterized by deficiency of the enzyme medium-chain acyl-coenzyme A dehydrogenase that metabolizes medium-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting or illness. They include vomiting, hypoglycemia and lethargy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medium-Chain Acyl-CoA Dehydrogenase Deficiency","conceptCode":"C84538","definition":"A genetic disorder characterized by deficiency of the enzyme medium-chain acyl-coenzyme A dehydrogenase that metabolizes medium-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting or illness. They include vomiting, hypoglycemia and lethargy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A950-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A966-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Acyl-CoA Dehydrogenase, Short-Chain Deficiency","valueDescription":"Acyl-CoA Dehydrogenase, Short-Chain Deficiency","ValueMeaning":{"publicId":"3210844","version":"1","preferredName":"Acyl-CoA Dehydrogenase, Short-Chain Deficiency","longName":"3210844","preferredDefinition":"A genetic disorder characterized by deficiency of the enzyme short-chain acyl-coenzyme A dehydrogenase that metabolizes short-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting or illness. They include vomiting, hypoglycemia, lethargy, hypotonia and failure to thrive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acyl-CoA Dehydrogenase, Short-Chain Deficiency","conceptCode":"C84539","definition":"A genetic disorder characterized by deficiency of the enzyme short-chain acyl-coenzyme A dehydrogenase that metabolizes short-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting or illness. They include vomiting, hypoglycemia, lethargy, hypotonia and failure to thrive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A972-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A988-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Addison's Disease","valueDescription":"Addison's Disease","ValueMeaning":{"publicId":"3210845","version":"1","preferredName":"Addison's Disease","longName":"3210845","preferredDefinition":"A hormonal disorder that occurs when the adrenal glands fail to release adequate amounts of glucocorticoids (cortisol), mineralocorticoids (aldosterone, 11-deoxycorticosterone), and androgens (dehydroepiandrosterone) to meet physiologic needs, despite release of ACTH from the pituitary.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Addison's Disease","conceptCode":"C26689","definition":"A long-standing and persistent diminished production of adrenocortical hormones due to a disorder originating within the adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A994-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A9AA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Adenoid Cystic Carcinoma","valueDescription":"Adenoid cystic carcinoma","ValueMeaning":{"publicId":"2567905","version":"1","preferredName":"Adenoid cystic carcinoma","longName":"2567905","preferredDefinition":"A malignant tumor arising from the epithelial cells. Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma). Adenoid cystic carcinomas mostly occur in the salivary glands. Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs. Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur. Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoid Cystic Carcinoma","conceptCode":"C2970","definition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D64E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-02","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A9BC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Adiposis Dolorosa","valueDescription":"Adiposis Dolorosa","ValueMeaning":{"publicId":"3210846","version":"1","preferredName":"Adiposis Dolorosa","longName":"3210846","preferredDefinition":"A rare genetic disorder characterized by the development of painful lipomas during adulthood, especially in menopausal women. Associated symptoms include fatigue, obesity, confusion and depression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adiposis Dolorosa","conceptCode":"C84540","definition":"A rare genetic disorder characterized by the development of painful lipomas during adulthood, especially in menopausal women. Associated symptoms include fatigue, obesity, confusion and depression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A9C8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-A9DE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Adrenal Gland Hyperplasia","valueDescription":"Adrenal Gland Hyperplasia","ValueMeaning":{"publicId":"3210847","version":"1","preferredName":"Adrenal Gland Hyperplasia","longName":"3210847","preferredDefinition":"A congenital or acquired hyperplasia of the cells of the adrenal cortex or medulla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenal Hyperplasia","conceptCode":"C35408","definition":"A congenital or acquired hyperplasia of the cells of the adrenal cortex or medulla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A9EA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AA00-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Adrenal Gland Neoplasm","valueDescription":"Adrenal Gland Neoplasm","ValueMeaning":{"publicId":"3210848","version":"1","preferredName":"Adrenal Gland Neoplasm","longName":"3210848","preferredDefinition":"A benign or malignant (primary or metastatic) neoplasm affecting the adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenal Gland Neoplasm","conceptCode":"C2859","definition":"A benign or malignant (primary or metastatic) neoplasm affecting the adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AA0C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AA22-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Adrenoleukodystrophy","valueDescription":"Adrenoleukodystrophy","ValueMeaning":{"publicId":"2593452","version":"1","preferredName":"Adrenoleukodystrophy","longName":"2593452","preferredDefinition":"A rare metabolic disorder characterized by damage of the myelin sheaths in the nervous system and degeneration of the adrenal glands. It leads to progressive neurologic disorders, adrenal insufficiency and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenoleukodystrophy","conceptCode":"C61252","definition":"A rare metabolic disorder characterized by damage of the myelin sheaths in the nervous system and degeneration of the adrenal glands. It leads to progressive neurologic disorders, adrenal insufficiency and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAC12-A50B-4B21-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AA2C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"African Trypanosomiasis","valueDescription":"African Trypanosomiasis","ValueMeaning":{"publicId":"3210849","version":"1","preferredName":"African Trypanosomiasis","longName":"3210849","preferredDefinition":"A parasitic disorder caused by protozoa of the Trypanosoma brucei species. It is transmitted by flies and is endemic in various regions of Sub-Saharan Africa. Signs and symptoms include fever, joint pain, headache, and significant swelling of the lymph nodes. If left untreated, the parasitic infection causes anemia, heart, kidney, and endocrine failure, and neurologic damage. Subsequently patients develop confusion, disruption of the sleep cycle, and mental deterioration. The infection may lead to coma and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"African Trypanosomiasis","conceptCode":"C84541","definition":"A parasitic disorder caused by protozoa of the Trypanosoma brucei species. It is transmitted by flies and is endemic in various regions of Sub-Saharan Africa. Signs and symptoms include fever, joint pain, headache, and significant swelling of the lymph nodes. If left untreated, the parasitic infection causes anemia, heart, kidney, and endocrine failure, and neurologic damage. Subsequently patients develop confusion, disruption of the sleep cycle, and mental deterioration. The infection may lead to coma and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AA38-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AA4E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Aganglionic Megacolon","valueDescription":"Aganglionic Megacolon","ValueMeaning":{"publicId":"3210850","version":"1","preferredName":"Aganglionic Megacolon","longName":"3210850","preferredDefinition":"A congenital disorder characterized by the absence of myenteric ganglion cells in the distal colon. It results in a functional stenosis of the distal colon and a massive distention of the proximal colon.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hirschsprung Disease","conceptCode":"C34700","definition":"A congenital disorder characterized by the absence of myenteric ganglion cells in the distal colon. It results in a functional stenosis of the distal colon and a massive distention of the proximal colon.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AA5A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AA70-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Agnosia","valueDescription":"Agnosia","ValueMeaning":{"publicId":"3210851","version":"1","preferredName":"Agnosia","longName":"3210851","preferredDefinition":"A rare disorder characterized by the lack of ability to recognize individuals, objects, shapes, sounds, or smells. There is no loss of memory. It is caused by neurological damage in the brain, specifically in the occipital or parietal lobes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agnosia","conceptCode":"C84542","definition":"A rare disorder characterized by the lack of ability to recognize individuals, objects, shapes, sounds, or smells. There is no loss of memory. It is caused by neurological damage in the brain, specifically in the occipital or parietal lobes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AA7C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AA92-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"AIDS-Related Lymphoma","valueDescription":"AIDS-Related Lymphoma","ValueMeaning":{"publicId":"3210852","version":"1","preferredName":"AIDS-Related Lymphoma","longName":"3210852","preferredDefinition":"An aggressive lymphoma that develops in HIV-positive patients.  There is a significant increase in the incidence of lymphomas associated with the AIDS epidemic in the last two decades.  These lymphomas are usually extranodal, most often express a B-cell phenotype and morphologically are classified as Burkitt, diffuse large B-cell, and Hodgkin lymphomas.  The prognosis is closely related to the severity of immunodeficiency.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Lymphoma","conceptCode":"C3471","definition":"An aggressive lymphoma that develops in HIV-positive patients.  There is a significant increase in the incidence of lymphomas associated with the AIDS epidemic.  These lymphomas are usually extranodal, most often express a B-cell phenotype and morphologically are classified as Burkitt, diffuse large B-cell, and Hodgkin lymphomas.  The prognosis is closely related to the severity of immunodeficiency.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AA9E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AAB4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ainhum","valueDescription":"Ainhum","ValueMeaning":{"publicId":"3210853","version":"1","preferredName":"Ainhum","longName":"3210853","preferredDefinition":"Spontaneous autoamputation of a digit, usually the fifth toe. It results from the formation of a fibrotic band which constricts the full radius of the digit and eventually causes the spontaneous autoamputation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ainhum","conceptCode":"C84544","definition":"Spontaneous autoamputation of a digit, usually the fifth toe. It results from the formation of a fibrotic band which constricts the full radius of the digit and eventually causes the spontaneous autoamputation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AAC0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AAD6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Klinefelter Syndrome","valueDescription":"Klinefelter Syndrome","ValueMeaning":{"publicId":"3211203","version":"1","preferredName":"Klinefelter Syndrome","longName":"3211203","preferredDefinition":"A sex chromosome disorder caused by the presence of an extra X chromosome in the male karyotype. Affected individuals are infertile and have a small penis and testes. They tend to have tall stature and long legs and may have difficulties with speech and language development. Gynecomastia may be present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Klinefelter Syndrome","conceptCode":"C34752","definition":"A sex chromosome disorder caused by the presence of an extra X chromosome in the male karyotype. Affected individuals are infertile and have a small penis and testes. They tend to have tall stature and long legs and may have difficulties with speech and language development. Gynecomastia may be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DC57-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DC6D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Klippel-Trenaunay-Weber Syndrome","valueDescription":"Klippel-Trenaunay-Weber Syndrome","ValueMeaning":{"publicId":"3211204","version":"1","preferredName":"Klippel-Trenaunay-Weber Syndrome","longName":"3211204","preferredDefinition":"A rare syndrome characterized by the presence of port-wine stain (a vascular malformation), varicose veins, and hypertrophy of the soft tissues and bones in an extremity. It usually affects one extremity, most commonly a leg.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Klippel-Trenaunay-Weber Syndrome","conceptCode":"C84801","definition":"A rare syndrome characterized by the presence of port-wine stain (a vascular malformation), varicose veins, and hypertrophy of the soft tissues and bones in an extremity. It usually affects one extremity, most commonly a leg.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DC79-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DC8F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Kluver-Bucy Syndrome","valueDescription":"Kluver-Bucy Syndrome","ValueMeaning":{"publicId":"3211205","version":"1","preferredName":"Kluver-Bucy Syndrome","longName":"3211205","preferredDefinition":"A rare syndrome resulting from damage to both temporal lobes of the brain. Signs and symptoms include oral exploratory behavior, docility, altered sexuality, dietary changes, and visual agnosia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kluver-Bucy Syndrome","conceptCode":"C84802","definition":"A rare syndrome resulting from damage to both temporal lobes of the brain. Signs and symptoms include oral exploratory behavior, docility, altered sexuality, dietary changes, and visual agnosia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DC9B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DCB1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Korsakoff Syndrome","valueDescription":"Korsakoff Syndrome","ValueMeaning":{"publicId":"3211206","version":"1","preferredName":"Korsakoff Syndrome","longName":"3211206","preferredDefinition":"A psychotic syndrome caused by damage to the brain by lack of thiamine (vitamin B1). Signs and symptoms include anterograde and retrograde amnesia, confabulation, apathy, ataxia, and coma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Korsakoff Syndrome","conceptCode":"C84803","definition":"A psychotic syndrome caused by damage to the brain by lack of thiamine (vitamin B1). Signs and symptoms include anterograde and retrograde amnesia, confabulation, apathy, ataxia, and coma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DCBD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DCD3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Krabbe Disease","valueDescription":"Krabbe Disease","ValueMeaning":{"publicId":"2593454","version":"1","preferredName":"Krabbe Disease","longName":"2593454","preferredDefinition":"A rare inherited neurodegenerative disorder that belongs to the group of leukodystrophies. It is characterized by myelin destruction, gliosis in the brain, and the presence of multinucleated globoid cells. Signs and symptoms include irritability, mental and motor developmental disturbances, muscle weakness, seizures, blindness, and deafness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Krabbe Disease","conceptCode":"C61254","definition":"A rare inherited neurodegenerative disorder that belongs to the group of leukodystrophies. It is characterized by myelin destruction, gliosis in the brain, and the presence of multinucleated globoid cells. Signs and symptoms include irritability, mental and motor developmental disturbances, muscle weakness, seizures, blindness, and deafness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAC79-C5A9-4B39-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DCDD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Krukenberg Tumor","valueDescription":"Krukenberg Tumor","ValueMeaning":{"publicId":"3211207","version":"1","preferredName":"Krukenberg Tumor","longName":"3211207","preferredDefinition":"Metastatic signet-ring cell carcinoma to the ovary from a gastrointestinal tract or breast primary tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Krukenberg Tumor","conceptCode":"C3153","definition":"Metastatic signet-ring cell carcinoma in the ovary. The primary site is the gastrointestinal tract or breast.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DCE9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DCFF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lafora Disease","valueDescription":"Lafora Disease","ValueMeaning":{"publicId":"3211208","version":"1","preferredName":"Lafora Disease","longName":"3211208","preferredDefinition":"A rare, fatal autosomal recessive inherited disorder caused by mutations in the genes EPM2A and EPM2b. It is characterized by the presence of cytoplasmic inclusion bodies called Lafora bodies in many cells of the body including neurons, muscle cells, and liver cells. The Lafora bodies contain mucopolysaccharides. Signs and symptoms include seizures, myoclonus, ataxia, and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lafora Disease","conceptCode":"C84804","definition":"A rare, fatal autosomal recessive inherited disorder caused by mutations in the genes EPM2A and EPM2b. It is characterized by the presence of cytoplasmic inclusion bodies called Lafora bodies in many cells of the body including neurons, muscle cells, and liver cells. The Lafora bodies contain mucopolysaccharides. Signs and symptoms include seizures, myoclonus, ataxia, and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DD0B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DD21-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lambert Eaton Myasthenic Syndrome","valueDescription":"Lambert Eaton Myasthenic Syndrome","ValueMeaning":{"publicId":"3211209","version":"1","preferredName":"Lambert Eaton Myasthenic Syndrome","longName":"3211209","preferredDefinition":"A rare autoimmune presynaptic disorder characterized by impairment of the impulse transmission at the neuromuscular junction. It affects predominantly the proximal muscles of the lower extremities, resulting in muscle weakness and fatigability. It has been associated with small cell lung carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lambert Eaton Myasthenic Syndrome","conceptCode":"C3155","definition":"A rare autoimmune presynaptic disorder characterized by impairment of the impulse transmission at the neuromuscular junction. It affects predominantly the proximal muscles of the lower extremities, resulting in muscle weakness and fatigability. It has been associated with small cell lung carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DD2D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DD43-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lamellar Ichthyosis","valueDescription":"Lamellar Ichthyosis","ValueMeaning":{"publicId":"3211210","version":"1","preferredName":"Lamellar Ichthyosis","longName":"3211210","preferredDefinition":"A very rare, autosomal recessive inherited skin disorder present at birth. It is characterized by the presence of a transparent membrane encasing the newborn. This membrane sheds in about two weeks after birth to reveal generalized scaling and skin erythema.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamellar Ichthyosis","conceptCode":"C84805","definition":"A very rare, autosomal recessive inherited skin disorder present at birth. It is characterized by the presence of a transparent membrane encasing the newborn. This membrane sheds in about two weeks after birth to reveal generalized scaling and skin erythema.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DD4F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DD65-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Landau-Kleffner Syndrome","valueDescription":"Landau-Kleffner Syndrome","ValueMeaning":{"publicId":"3211211","version":"1","preferredName":"Landau-Kleffner Syndrome","longName":"3211211","preferredDefinition":"A rare childhood syndrome characterized by the progressive or sudden inability to understand and use spoken language (aphasia) and paroxysmal electrical brain waves. Patients develop epileptic seizures and behavioral changes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Landau-Kleffner Syndrome","conceptCode":"C84806","definition":"A rare childhood syndrome characterized by the progressive or sudden inability to understand and use spoken language (aphasia) and paroxysmal electrical brain waves. Patients develop epileptic seizures and behavioral changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DD71-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DD87-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Langerhans Cell Histiocytosis","valueDescription":"Langerhans Cell Histiocytosis","ValueMeaning":{"publicId":"2559022","version":"1","preferredName":"Langerhans Cell Histiocytosis","longName":"2559022","preferredDefinition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination.  Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease.  The clinical course is generally related to the number of organs affected at presentation.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Langerhans Cell Histiocytosis","conceptCode":"C3107","definition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B39B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DD91-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Latent Syphilis","valueDescription":"Latent Syphilis","ValueMeaning":{"publicId":"3211212","version":"1","preferredName":"Latent Syphilis","longName":"3211212","preferredDefinition":"A stage of syphilis characterized by the serologic evidence of infection by Treponema pallidum without evidence of accompanying signs or symptoms related to the disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Latent Syphilis","conceptCode":"C35056","definition":"A stage of syphilis characterized by the serologic evidence of infection by Treponema pallidum without evidence of accompanying signs or symptoms related to the disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DD9D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DDB3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lateral Medullary Syndrome","valueDescription":"Lateral Medullary Syndrome","ValueMeaning":{"publicId":"3211213","version":"1","preferredName":"Lateral Medullary Syndrome","longName":"3211213","preferredDefinition":"A syndrome caused by an infarct in the vertebral or posterior inferior cerebellar artery. It is characterized by sensory defects affecting the same side of the face as the infarct and the opposite side of the trunk as the infarct. Patients experience difficulty swallowing and/or speaking.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lateral Medullary Syndrome","conceptCode":"C84807","definition":"A syndrome caused by an infarct in the vertebral or posterior inferior cerebellar artery. It is characterized by sensory defects affecting the same side of the face as the infarct and the opposite side of the trunk as the infarct. Patients experience difficulty swallowing and/or speaking.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DDBF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DDD5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Leber Hereditary Optic Atrophy","valueDescription":"Leber Hereditary Optic Atrophy","ValueMeaning":{"publicId":"3211214","version":"1","preferredName":"Leber Hereditary Optic Atrophy","longName":"3211214","preferredDefinition":"A hereditary disorder caused by mitochondrial mutations, resulting in the degeneration of the retinal ganglion cells and optic atrophy. It is characterized by an acute or subacute loss of central vision. It may initially affect one eye only, but eventually the central loss of vision becomes bilateral.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leber Hereditary Optic Atrophy","conceptCode":"C84808","definition":"A hereditary disorder caused by mitochondrial mutations, resulting in the degeneration of the retinal ganglion cells and optic atrophy. It is characterized by an acute or subacute loss of central vision. It may initially affect one eye only, but eventually the central loss of vision becomes bilateral.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DDE1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DDF7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lecithin Acyltransferase Deficiency","valueDescription":"Lecithin Acyltransferase Deficiency","ValueMeaning":{"publicId":"3211215","version":"1","preferredName":"Lecithin Acyltransferase Deficiency","longName":"3211215","preferredDefinition":"A disorder of lipoprotein metabolism caused by mutations in the LCAT gene. It is characterized by deficiency of the enzyme lecithin cholesterol acyltransferase. It is manifested with corneal opacity, hemolytic anemia, and proteinuria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lecithin Acyltransferase Deficiency","conceptCode":"C84813","definition":"A disorder of lipoprotein metabolism caused by mutations in the LCAT gene. It is characterized by deficiency of the enzyme lecithin cholesterol acyltransferase. It is manifested with corneal opacity, hemolytic anemia, and proteinuria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DE03-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DE19-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Leigh Disease","valueDescription":"Leigh Disease","ValueMeaning":{"publicId":"3211216","version":"1","preferredName":"Leigh Disease","longName":"3211216","preferredDefinition":"An inherited disorder affecting the nervous system, caused by genetic mutations in the mitochondrial DNA or deficiency of pyruvate dehydrogenase. Signs and symptoms appear in infancy and include loss of the motor abilities, poor sucking abilities, irritability, lack of muscle tone, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leigh Disease","conceptCode":"C84814","definition":"An inherited disorder affecting the nervous system, caused by genetic mutations in the mitochondrial DNA or deficiency of pyruvate dehydrogenase. Signs and symptoms appear in infancy and include loss of the motor abilities, poor sucking abilities, irritability, lack of muscle tone, and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DE25-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DE3B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Leiomyosarcoma","valueDescription":"Leiomyosarcoma","ValueMeaning":{"publicId":"2562491","version":"1","preferredName":"Leiomyosarcoma","longName":"2562491","preferredDefinition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women. It is characterized by a proliferation of neoplastic spindle cells. Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leiomyosarcoma","conceptCode":"C3158","definition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C128-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-09-27","endDate":null,"createdBy":"PWEST","dateCreated":"2002-09-27","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DE45-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Leishmaniasis","valueDescription":"Leishmaniasis","ValueMeaning":{"publicId":"3211217","version":"1","preferredName":"Leishmaniasis","longName":"3211217","preferredDefinition":"A parasitic infection caused by protozoa of the genus Leishmania. It is transmitted to humans via the bite of sandflies. There are three main forms of the disease: cutaneous, mucocutaneous, and visceral leishmaniasis. Cutaneous leishmaniasis causes skin ulcers; mucocutaneous leishmaniasis causes destructive lesions of the mucous membranes of the nose, mouth, and throat; visceral leishmaniasis is the most severe form of the disease and is manifested with anemia, weight loss, hepatomegaly and splenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leishmaniasis","conceptCode":"C34767","definition":"A parasitic infection caused by protozoa of the genus Leishmania. It is transmitted to humans via the bite of sandflies. There are three main forms of the disease: cutaneous, mucocutaneous, and visceral leishmaniasis. Cutaneous leishmaniasis causes skin ulcers; mucocutaneous leishmaniasis causes destructive lesions of the mucous membranes of the nose, mouth, and throat; visceral leishmaniasis is the most severe form of the disease and is manifested with anemia, weight loss, hepatomegaly and splenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DE51-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DE67-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lennox-Gastaut Syndrome","valueDescription":"Lennox-Gastaut Syndrome","ValueMeaning":{"publicId":"3211218","version":"1","preferredName":"Lennox-Gastaut Syndrome","longName":"3211218","preferredDefinition":"A syndrome characterized by frequent episodes of epilepsy during childhood. The epileptic episodes may be tonic, atonic, myoclonic, or absence seizures. It may be accompanied by mental retardation and behavioral problems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lennox-Gastaut Syndrome","conceptCode":"C84816","definition":"A syndrome characterized by frequent episodes of epilepsy during childhood. The epileptic episodes may be tonic, atonic, myoclonic, or absence seizures. It may be accompanied by mental retardation and behavioral problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DE73-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DE89-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"LEOPARD Syndrome","valueDescription":"LEOPARD Syndrome","ValueMeaning":{"publicId":"3211219","version":"1","preferredName":"LEOPARD Syndrome","longName":"3211219","preferredDefinition":"A genetic syndrome caused by mutations in the PTPN11 and RAF1 genes. It is characterized by the following abnormalities: multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormalities in genitalia, growth retardation, and deafness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"LEOPARD Syndrome","conceptCode":"C84820","definition":"A genetic syndrome caused by mutations in the PTPN11 and RAF1 genes. It is characterized by the following abnormalities: multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormalities in genitalia, growth retardation, and deafness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DE95-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DEAB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Leprosy","valueDescription":"Leprosy","ValueMeaning":{"publicId":"3211220","version":"1","preferredName":"Leprosy","longName":"3211220","preferredDefinition":"A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leprosy","conceptCode":"C84824","definition":"A bacterial granulomatous infection caused by Mycobacterium leprae. It is a progressive disease affecting the skin, peripheral nerves, and limbs. If untreated, it causes permanent tissue damage leading to autoamputations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DEB7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DECD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Leptospirosis","valueDescription":"Leptospirosis","ValueMeaning":{"publicId":"3211221","version":"1","preferredName":"Leptospirosis","longName":"3211221","preferredDefinition":"A contagious bacterial infection caused by spirochetes of the genus Leptospira. Humans are infected by contact with water and soil which have been contaminated with animal waste products. The signs and symptoms include an initial flu-like phase, followed by a second phase in which patients may develop meningitis, liver failure and renal failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leptospirosis","conceptCode":"C84825","definition":"A contagious bacterial infection caused by spirochetes of the genus Leptospira. Humans are infected by contact with water and soil which have been contaminated with animal waste products. The signs and symptoms include an initial flu-like phase, followed by a second phase in which patients may develop meningitis, liver failure and renal failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DED9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DEEF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lewy Body Dementia","valueDescription":"Lewy Body Dementia","ValueMeaning":{"publicId":"3211222","version":"1","preferredName":"Lewy Body Dementia","longName":"3211222","preferredDefinition":"A progressive form of dementia characterized by the presence of protein deposits called Lewy bodies in the midbrain and cerebral cortex, and loss of cholinergic and dopaminergic neurons. The signs and symptoms overlap with Alzheimer and Parkinson disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lewy Body Dementia","conceptCode":"C84826","definition":"A progressive form of dementia characterized by the presence of protein deposits called Lewy bodies in the midbrain and cerebral cortex, and loss of cholinergic and dopaminergic neurons. The signs and symptoms overlap with Alzheimer and Parkinson disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DF05-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DF1B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lichen Sclerosus et Atrophicus","valueDescription":"Lichen Sclerosus et Atrophicus","ValueMeaning":{"publicId":"3211223","version":"1","preferredName":"Lichen Sclerosus et Atrophicus","longName":"3211223","preferredDefinition":"A chronic inflammatory process affecting the skin. It is characterized by the presence of white, indurated plaques, epidermal atrophy, and fibrosis of the upper dermis. It usually appears in the vulva and penis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lichen Sclerosus et Atrophicus","conceptCode":"C26817","definition":"A chronic inflammatory process affecting the skin. It is characterized by the presence of white, indurated plaques, epidermal atrophy, and fibrosis of the upper dermis. It usually appears in the vulva and penis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DF27-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DF3D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Liddle Syndrome","valueDescription":"Liddle Syndrome","ValueMeaning":{"publicId":"3211224","version":"1","preferredName":"Liddle Syndrome","longName":"3211224","preferredDefinition":"An autosomal dominant inherited syndrome caused by dysregulation of the amiloride-sensitive sodium channel. It is characterized by early onset hypertension, hypokalemia, metabolic alkalosis, low plasma renin and hypoaldosteronism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liddle Syndrome","conceptCode":"C84827","definition":"An autosomal dominant inherited syndrome caused by dysregulation of the amiloride-sensitive sodium channel. It is characterized by early onset hypertension, hypokalemia, metabolic alkalosis, low plasma renin and hypoaldosteronism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DF49-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DF5F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Li-Fraumeni Syndrome","valueDescription":"Li-Fraumeni Syndrome","ValueMeaning":{"publicId":"3211225","version":"1","preferredName":"Li-Fraumeni Syndrome","longName":"3211225","preferredDefinition":"An autosomal dominant hereditary neoplastic syndrome caused by an alteration in the p53 tumor suppressor gene.  It is characterized by the development of malignant neoplasms at various anatomic sites.  The malignant neoplasms associated with Li-Fraumeni syndrome include adrenal cortex carcinoma, astrocytic tumors, colorectal carcinoma, gastric carcinoma, malignant breast neoplasms, medulloblastoma, osteosarcoma, and soft tissue sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Li-Fraumeni Syndrome","conceptCode":"C3476","definition":"An autosomal dominant cancer predisposition syndrome caused by germline mutations of the TP53 gene. It is associated with breast carcinoma, choroid plexus carcinoma, adrenal cortex carcinoma, astrocytic tumors, medulloblastoma, soft tissue sarcoma, osteosarcoma, and leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DF6B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DF81-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Limb-Girdle Muscular Dystrophy","valueDescription":"Limb-Girdle Muscular Dystrophy","ValueMeaning":{"publicId":"3211226","version":"1","preferredName":"Limb-Girdle Muscular Dystrophy","longName":"3211226","preferredDefinition":"A group of autosomal recessive and less frequently autosomal dominant muscular dystrophies affecting the muscles of the hips and shoulders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Limb-Girdle Muscular Dystrophy","conceptCode":"C84828","definition":"A group of autosomal recessive and less frequently autosomal dominant muscular dystrophies affecting the muscles of the hips and shoulders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DF8D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DFA3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Limbic Encephalitis","valueDescription":"Limbic Encephalitis","ValueMeaning":{"publicId":"3211227","version":"1","preferredName":"Limbic Encephalitis","longName":"3211227","preferredDefinition":"A rare disorder characterized by degenerative changes in the limbic area of the brain. Causes include infections and autoimmune conditions; it may also manifest as a paraneoplastic syndrome, most often caused by small cell lung carcinoma. Signs and symptoms include behavioral changes, hallucinations and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Limbic Encephalitis","conceptCode":"C4350","definition":"A rare disorder characterized by degenerative changes in the limbic area of the brain. Causes include infections and autoimmune conditions; it may also manifest as a paraneoplastic syndrome, most often caused by small cell lung carcinoma. Signs and symptoms include behavioral changes, hallucinations and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DFAF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DFC5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lipoid Proteinosis of Urbach and Wiethe","valueDescription":"Lipoid Proteinosis of Urbach and Wiethe","ValueMeaning":{"publicId":"3211228","version":"1","preferredName":"Lipoid Proteinosis of Urbach and Wiethe","longName":"3211228","preferredDefinition":"A rare, autosomal recessive metabolic disorder characterized by hoarseness of voice, eyelid beading, skin lesions, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lipoid Proteinosis of Urbach and Wiethe","conceptCode":"C84829","definition":"A rare, autosomal recessive metabolic disorder characterized by hoarseness of voice, eyelid beading, skin lesions, and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DFD1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-DFE7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Localized Scleroderma","valueDescription":"Localized Scleroderma","ValueMeaning":{"publicId":"3211229","version":"1","preferredName":"Localized Scleroderma","longName":"3211229","preferredDefinition":"A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. Localized scleroderma typically affects the skin, with formation of patches or lines of thick and unyielding tissue; there can be muscle and underlying tissue involvement as well as occasional joint complications. The affected areas of skin can be restrictive and disfiguring. The shape, depth and location of the affected area is used to classify one of the four types of local scleroderma. An individual can have a combination of localized scleroderma types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Localized Scleroderma","conceptCode":"C72069","definition":"A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. Localized scleroderma typically affects the skin, with formation of patches or lines of thick and unyielding tissue; there can be muscle and underlying tissue involvement as well as occasional joint complications. The affected areas of skin can be restrictive and disfiguring. The shape, depth and location of the affected area is used to classify one of the four types of local scleroderma. An individual can have a combination of localized scleroderma types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DFF3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E009-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Loss of Chromosome 8","valueDescription":"Loss of Chromosome 8","ValueMeaning":{"publicId":"3211230","version":"1","preferredName":"Loss of Chromosome 8","longName":"3211230","preferredDefinition":"A structural cytogenetic abnormality characterized by partial or complete loss of chromosome 8.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Loss of Chromosome 8","conceptCode":"C36535","definition":"A cytogenetic abnormality that refers to loss of all or part of chromosome 8.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E015-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E02B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lymphangioma","valueDescription":"Lymphangioma","ValueMeaning":{"publicId":"3211231","version":"1","preferredName":"Lymphangioma","longName":"3211231","preferredDefinition":"A benign neoplasm arising from the lymphatics. The tumor is composed of dilated lymphatic channels. Painless swelling is the usual clinical manifestation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphangioma","conceptCode":"C8965","definition":"A benign lesion composed of dilated lymphatic channels. Painless swelling is the usual clinical manifestation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E037-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E04D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lymphangioleiomyomatosis","valueDescription":"Lymphangioleiomyomatosis","ValueMeaning":{"publicId":"3211232","version":"1","preferredName":"Lymphangioleiomyomatosis","longName":"3211232","preferredDefinition":"A multifocal neoplasm with perivascular epithelioid cell differentiation affecting almost exclusively females of child-bearing age. It is characterized by the presence of smooth muscle and epithelioid cells and by the proliferation of lymphatic vessels. Sites of involvement include the lungs, mediastinum, and the retroperitoneum. It usually presents with chylous pleural effusion or ascites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphangioleiomyomatosis","conceptCode":"C3725","definition":"A multifocal neoplasm with perivascular epithelioid cell differentiation affecting almost exclusively females of child-bearing age. It is characterized by the presence of smooth muscle and epithelioid cells and by the proliferation of lymphatic vessels. Sites of involvement include the lungs, mediastinum, and the retroperitoneum. It usually presents with chylous pleural effusion or ascites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E059-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E06F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Lymphedema","valueDescription":"Lymphedema","ValueMeaning":{"publicId":"2857226","version":"1","preferredName":"Lymphedema","longName":"2857226","preferredDefinition":"Edema due to obstruction of lymph vessels or disorders of the lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphedema","conceptCode":"C3207","definition":"Excess fluid collection in tissues, causing swelling. It is the result of obstruction of lymphatic vessels or lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"661EB49B-B562-7D2B-E040-BB89AD4340DC","latestVersionIndicator":"Yes","beginDate":"2009-03-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E079-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Machado-Joseph Disease","valueDescription":"Machado-Joseph Disease","ValueMeaning":{"publicId":"3211233","version":"1","preferredName":"Machado-Joseph Disease","longName":"3211233","preferredDefinition":"A very rare, autosomal dominant inherited neurodegenerative disorder. Signs and symptoms include ataxia, spasticity, and abnormalities in the ocular movements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spinocerebellar Ataxia Type 3","conceptCode":"C84830","definition":"A very rare, autosomal dominant inherited neurodegenerative disorder. Signs and symptoms include ataxia, spasticity, and abnormalities in the ocular movements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E085-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E09B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Macroglossia","valueDescription":"Macroglossia","ValueMeaning":{"publicId":"3211234","version":"1","preferredName":"Macroglossia","longName":"3211234","preferredDefinition":"A finding indicating enlargement of the tongue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Macroglossia","conceptCode":"C84832","definition":"A finding indicating enlargement of the tongue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E0A7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E0BD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malakoplakia","valueDescription":"Malakoplakia","ValueMeaning":{"publicId":"3211235","version":"1","preferredName":"Malakoplakia","longName":"3211235","preferredDefinition":"An inflammatory reaction characterized by the presence of papules or nodules usually in the genitourinary tract. It is usually a reaction to an infection. Morphologically, it consists of foamy histiocytes and characteristic basophilic inclusion bodies called Michaelis-Gutmann bodies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malakoplakia","conceptCode":"C84833","definition":"An inflammatory reaction characterized by the presence of papules or nodules usually in the genitourinary tract. It is usually a reaction to an infection. Morphologically, it consists of foamy histiocytes and characteristic basophilic inclusion bodies called Michaelis-Gutmann bodies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E0C9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E0DF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malaria","valueDescription":"Malaria (Plasmodium)","ValueMeaning":{"publicId":"3211236","version":"1","preferredName":"Malaria (Plasmodium)","longName":"3211236","preferredDefinition":"A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malaria","conceptCode":"C34797","definition":"A protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E0EB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E101-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malformations of Cortical Development","valueDescription":"Malformations of Cortical Development","ValueMeaning":{"publicId":"3211237","version":"1","preferredName":"Malformations of Cortical Development","longName":"3211237","preferredDefinition":"A group of neural cortical developmental malformations of diverse genetic causes. Clinical manifestations include epilepsy and developmental delays.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malformations of Cortical Development","conceptCode":"C84834","definition":"A group of neural cortical developmental malformations of diverse genetic causes. Clinical manifestations include epilepsy and developmental delays.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E10D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E123-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Atrophic Papulosis","valueDescription":"Malignant Atrophic Papulosis","ValueMeaning":{"publicId":"3211238","version":"1","preferredName":"Malignant Atrophic Papulosis","longName":"3211238","preferredDefinition":"A rare disorder of unknown etiology. It may present as a cutaneous disorder with a benign clinical course or a systemic disorder with a grim prognosis. Both the cutaneous and systemic variants are characterized by the presence of papular skin lesions. The systemic variant, in addition to the skin papules, is characterized by gastrointestinal manifestations including abdominal pain and distention, nausea, vomiting, diarrhea, intestinal infarction, and intestinal perforation. The central and peripheral nervous systems may also be involved in the systemic variant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Atrophic Papulosis","conceptCode":"C84835","definition":"A rare disorder of unknown etiology. It may present as a cutaneous disorder with a benign clinical course or a systemic disorder with a grim prognosis. Both the cutaneous and systemic variants are characterized by the presence of papular skin lesions. The systemic variant, in addition to the skin papules, is characterized by gastrointestinal manifestations including abdominal pain and distention, nausea, vomiting, diarrhea, intestinal infarction, and intestinal perforation. The central and peripheral nervous systems may also be involved in the systemic variant.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E12F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E145-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Fibrous Histiocytoma","valueDescription":"Malignant Fibrous Histiocytoma","ValueMeaning":{"publicId":"3211239","version":"1","preferredName":"Malignant Fibrous Histiocytoma","longName":"3211239","preferredDefinition":"A pleomorphic sarcoma characterized by the presence of fibrohistiocytic cells and spindle cells arranged in a storiform pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Pleomorphic Sarcoma","conceptCode":"C4247","definition":"An undifferentiated soft tissue sarcoma characterized by the presence of a pleomorphic malignant cellular infiltrate.  It is also known as malignant fibrous histiocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E151-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E167-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Hyperthermia Syndrome","valueDescription":"Malignant Hyperthermia Syndrome","ValueMeaning":{"publicId":"3211240","version":"1","preferredName":"Malignant Hyperthermia Syndrome","longName":"3211240","preferredDefinition":"A rare disorder characterized by rapid rise of the body temperature, accompanied by rhabdomyolysis and, if untreated, by collapse and death. It occurs in susceptible individuals who receive certain drugs for general anesthesia, gas anesthetics, or succinylcholine. It may be inherited in an autosomal dominant pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Hyperthermia Syndrome","conceptCode":"C84869","definition":"A rare disorder characterized by rapid rise of the body temperature, accompanied by rhabdomyolysis and, if untreated, by collapse and death. It occurs in susceptible individuals who receive certain drugs for general anesthesia, gas anesthetics, or succinylcholine. It may be inherited in an autosomal dominant pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E173-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E189-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Malignant Peripheral Nerve Sheath Tumor","valueDescription":"Malignant Peripheral Nerve Sheath Tumor","ValueMeaning":{"publicId":"2838605","version":"1","preferredName":"Malignant Peripheral Nerve Sheath Tumor","longName":"2838605","preferredDefinition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Peripheral Nerve Sheath Tumor","conceptCode":"C3798","definition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE88-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E19B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mallory-Weiss Syndrome","valueDescription":"Mallory-Weiss Syndrome","ValueMeaning":{"publicId":"3211241","version":"1","preferredName":"Mallory-Weiss Syndrome","longName":"3211241","preferredDefinition":"A disorder characterized by upper gastrointestinal tract bleeding caused by longitudinal mucosal tears in the gastroesophageal junction. The tears result from retching or forceful coughing. It was initially described in alcoholics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mallory-Weiss Syndrome","conceptCode":"C84881","definition":"A disorder characterized by upper gastrointestinal tract bleeding caused by longitudinal mucosal tears in the gastroesophageal junction. The tears result from retching or forceful coughing. It was initially described in alcoholics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E1A7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E1BD-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mansonelliasis","valueDescription":"Mansonelliasis","ValueMeaning":{"publicId":"3211242","version":"1","preferredName":"Mansonelliasis","longName":"3211242","preferredDefinition":"A parasitic infection caused by the nematode Mansonella. Signs and symptoms include pruritus, headache, fever, arthralgias, and eosinophilia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mansonelliasis","conceptCode":"C84882","definition":"A parasitic infection caused by the nematode Mansonella. Signs and symptoms include pruritus, headache, fever, arthralgias, and eosinophilia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E1C9-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E1DF-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Maple Syrup Urine Disease","valueDescription":"Maple Syrup Urine Disease","ValueMeaning":{"publicId":"3211243","version":"1","preferredName":"Maple Syrup Urine Disease","longName":"3211243","preferredDefinition":"An autosomal recessive inherited disorder caused by mutations in the BCKDHA, BCKDHB, DBT, and DLD genes. It is characterized by a deficiency of branched-chain alpha-keto acid dehydrogenase complex, leading to accumulation of metabolites in the body fluids. The name of the disease derives from the sweet odor of the urine in infants, reminiscent of maple syrup. Signs and symptoms usually appear in infancy and include lethargy and developmental delays. If untreated, it may lead to seizures, coma, and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maple Syrup Urine Disease","conceptCode":"C34806","definition":"An autosomal recessive inherited disorder caused by mutations in the BCKDHA, BCKDHB, DBT, and DLD genes. It is characterized by a deficiency of branched-chain alpha-keto acid dehydrogenase complex, leading to accumulation of metabolites in the body fluids. The name of the disease derives from the sweet odor of the urine in infants, reminiscent of maple syrup. Signs and symptoms usually appear in infancy and include lethargy and developmental delays. If untreated, it may lead to seizures, coma, and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E1EB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E201-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Marburg Virus Disease","valueDescription":"Marburg Virus Disease","ValueMeaning":{"publicId":"3211244","version":"1","preferredName":"Marburg Virus Disease","longName":"3211244","preferredDefinition":"A viral infectious disorder caused by Marburg virus. Signs and symptoms include fever, headache, myalgias, chest and abdominal pain, jaundice, liver failure, massive hemorrhaging, and multiple organ failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marburg Virus Disease","conceptCode":"C84883","definition":"A viral infectious disorder caused by Marburg virus. Signs and symptoms include fever, headache, myalgias, chest and abdominal pain, jaundice, liver failure, massive hemorrhaging, and multiple organ failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E20D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E223-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mast Cell Leukemia","valueDescription":"Mast Cell Leukemia","ValueMeaning":{"publicId":"2590857","version":"1","preferredName":"Mast Cell Leukemia","longName":"2590857","preferredDefinition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mast Cell Leukemia","conceptCode":"C3169","definition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28446C9F-B55A-188F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E237-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Medullary Sponge Kidney","valueDescription":"Medullary Sponge Kidney","ValueMeaning":{"publicId":"3211245","version":"1","preferredName":"Medullary Sponge Kidney","longName":"3211245","preferredDefinition":"A developmental disorder of the kidney characterized by cystic dilatation of the medullary collecting ducts, resulting in a spongy gross appearance of the kidney. It may be asymptomatic or complicated by hematuria, infections, or renal stones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medullary Sponge Kidney","conceptCode":"C34751","definition":"A developmental disorder of the kidney characterized by cystic dilatation of the medullary collecting ducts, resulting in a spongy gross appearance of the kidney. It may be asymptomatic or complicated by hematuria, infections, or renal stones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E243-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E259-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Medulloblastoma","valueDescription":"Medulloblastoma","ValueMeaning":{"publicId":"2578699","version":"1","preferredName":"Medulloblastoma","longName":"2578699","preferredDefinition":"A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma","conceptCode":"C3222","definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum or posterior fossa. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0078-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E263-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Albinism","valueDescription":"Albinism","ValueMeaning":{"publicId":"3210854","version":"1","preferredName":"Albinism","longName":"3210854","preferredDefinition":"A congenital disorder characterized by partial or complete absence of melanin pigment in the eyes, hair and skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Albinism","conceptCode":"C84543","definition":"A congenital disorder characterized by partial or complete absence of melanin pigment in the eyes, hair and skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AAE2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AAF8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alexander Disease","valueDescription":"Alexander Disease","ValueMeaning":{"publicId":"3210855","version":"1","preferredName":"Alexander Disease","longName":"3210855","preferredDefinition":"A rare genetic neurodegenerative disorder which belongs to the group of leukodystrophies. It has a slow and progressive clinical course and is characterized by developmental delay, macrocephaly, seizures, dementia and spasticity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alexander Disease","conceptCode":"C84545","definition":"A rare genetic neurodegenerative disorder which belongs to the group of leukodystrophies. It has a slow and progressive clinical course and is characterized by developmental delay, macrocephaly, seizures, dementia and spasticity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AB04-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AB1A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alkaptonuria","valueDescription":"Alkaptonuria","ValueMeaning":{"publicId":"3210856","version":"1","preferredName":"Alkaptonuria","longName":"3210856","preferredDefinition":"A rare autosomal recessive disorder characterized by abnormalities in the metabolism of phenylalanine and tyrosine. It results in the accumulation in the blood of homogentisic acid which is excreted in the urine. The presence of homogentisic acid in the urine causes its color to turn black. The excessive amount of homogentisic acid in the blood may cause damage to cartilage and heart valves, and may result in the formation of kidney stones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alkaptonuria","conceptCode":"C84546","definition":"A rare autosomal recessive disorder characterized by abnormalities in the metabolism of phenylalanine and tyrosine. It results in the accumulation in the blood of homogentisic acid which is excreted in the urine. The presence of homogentisic acid in the urine causes its color to turn black. The excessive amount of homogentisic acid in the blood may cause damage to cartilage and heart valves, and may result in the formation of kidney stones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AB26-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AB3C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Allergic Bronchopulmonary Aspergillosis","valueDescription":"Allergic Bronchopulmonary Aspergillosis","ValueMeaning":{"publicId":"3210857","version":"1","preferredName":"Allergic Bronchopulmonary Aspergillosis","longName":"3210857","preferredDefinition":"An immune reaction to aspergillus in patients usually suffering from asthma or cystic fibrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allergic Bronchopulmonary Aspergillosis","conceptCode":"C84547","definition":"An immune reaction to aspergillus in patients usually suffering from asthma or cystic fibrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AB48-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AB5E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alpha Thalassemia","valueDescription":"Alpha Thalassemia","ValueMeaning":{"publicId":"3210858","version":"1","preferredName":"Alpha Thalassemia","longName":"3210858","preferredDefinition":"A genetic hematologic disorder characterized by partial or complete absence of the alpha globin chains of the heme molecule.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha Thalassemia","conceptCode":"C34368","definition":"A genetic hematologic disorder characterized by partial or complete absence of the alpha globin chains of the heme molecule.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AB6A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AB80-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alpha-Mannosidosis","valueDescription":"Alpha-Mannosidosis","ValueMeaning":{"publicId":"3028413","version":"1","preferredName":"Alpha-Mannosidosis","longName":"3028413","preferredDefinition":"An autosomal recessive lysosomal storage disease characterized by deficient activity of the enzyme alpha-D-mannosidase. There is a wide range of signs and symptoms including hepatomegaly, splenomegaly, hearing loss, respiratory infections, mental retardation, skeletal abnomalities, leveled nasal bridge and protuding forehead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-Mannosidosis","conceptCode":"C84548","definition":"An autosomal recessive lysosomal storage disease characterized by deficient activity of the enzyme alpha-D-mannosidase. There is a wide range of signs and symptoms including hepatomegaly, splenomegaly, hearing loss, respiratory infections, mental retardation, skeletal abnormalities, leveled nasal bridge and protruding forehead.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC2C-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AB92-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alport Syndrome","valueDescription":"Alport Syndrome","ValueMeaning":{"publicId":"3210859","version":"1","preferredName":"Alport Syndrome","longName":"3210859","preferredDefinition":"A genetic syndrome usually inherited as an X-link trait.  It is caused by abnormalities in the COL4A5 gene.  It affects males more often than females and is characterized by hematuria, progressive renal insufficiency, hearing loss, and ocular abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alport Syndrome","conceptCode":"C34842","definition":"A genetic syndrome usually inherited as an X-link trait. It is caused by abnormalities in the COL4A5 gene. It affects males more often than females and is characterized by hematuria, progressive renal insufficiency, hearing loss, and ocular abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AB9E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ABB4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alstrom Syndrome","valueDescription":"Alstrom Syndrome","ValueMeaning":{"publicId":"3210860","version":"1","preferredName":"Alstrom Syndrome","longName":"3210860","preferredDefinition":"A rare autosomal recessive syndrome caused by mutations in the gene ALMS1. Signs and symptoms include blindness, obesity, hearing loss, endocrine abnormalities, cardiomyopathy and congestive heart failure, hepatic and renal failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alstrom Syndrome","conceptCode":"C84549","definition":"A rare autosomal recessive syndrome caused by mutations in the gene ALMS1. Signs and symptoms include blindness, obesity, hearing loss, endocrine abnormalities, cardiomyopathy and congestive heart failure, hepatic and renal failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ABC0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ABD6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alveolar Rhabdomyosarcoma","valueDescription":"Alveolar Rhabdomyosarcoma","ValueMeaning":{"publicId":"3179233","version":"1","preferredName":"Alveolar Rhabdomyosarcoma","longName":"3179233","preferredDefinition":"A rapidly growing malignant mesenchymal neoplasm. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma resembling an alveolar growth pattern. The tumor usually presents in the extremities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alveolar Rhabdomyosarcoma","conceptCode":"C3749","definition":"A rapidly growing malignant mesenchymal neoplasm. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma resembling an alveolar growth pattern. The tumor usually presents in the extremities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CD32-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"ONEDATA","dateModified":"2010-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ABE8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alveolar Soft Part Sarcoma","valueDescription":"Alveolar Soft Part Sarcoma","ValueMeaning":{"publicId":"3179234","version":"1","preferredName":"Alveolar Soft Part Sarcoma","longName":"3179234","preferredDefinition":"A rare malignant neoplasm characterized by the presence of large epithelioid cells with abundant cytoplasm forming nests and pseudoalveolar structures. The groups of the epithelioid cells are separated by thin-walled sinusoidal spaces. It occurs most often in adolescents and young adults. In adults the most common sites of involvement are the extremities, and in infants and children, the head and neck. It usually presents as a slowly growing mass and it frequently metastasizes to other anatomic sites. The most common sites of metastasis are the lungs, bone, and brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alveolar Soft Part Sarcoma","conceptCode":"C3750","definition":"A rare malignant neoplasm characterized by the presence of large epithelioid cells with abundant cytoplasm forming nests and pseudoalveolar structures. The groups of the epithelioid cells are separated by thin-walled sinusoidal spaces. It occurs most often in adolescents and young adults. In adults the most common sites of involvement are the extremities, and in infants and children, the head and neck. It usually presents as a slowly growing mass and it frequently metastasizes to other anatomic sites. The most common sites of metastasis are the lungs, bone, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CD57-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"ONEDATA","dateModified":"2010-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ABFA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Alzheimer's Disease","valueDescription":"Alzheimer's Disease","ValueMeaning":{"publicId":"3165575","version":"1","preferredName":"Alzheimer's Disease","longName":"3165575","preferredDefinition":"A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alzheimer's Disease","conceptCode":"C2866","definition":"A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96FCF74F-C22C-EAB7-E040-BB89AD437850","latestVersionIndicator":"Yes","beginDate":"2010-12-09","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AC04-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Amaurosis Fugax","valueDescription":"Amaurosis Fugax","ValueMeaning":{"publicId":"3210861","version":"1","preferredName":"Amaurosis Fugax","longName":"3210861","preferredDefinition":"Transient loss of vision in one eye due to retinal ischemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amaurosis Fugax","conceptCode":"C84550","definition":"Transient, monocular loss of vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AC10-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AC26-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Amebiasis","valueDescription":"Amebiasis","ValueMeaning":{"publicId":"3210862","version":"1","preferredName":"Amebiasis","longName":"3210862","preferredDefinition":"A parasitic infectious disorder caused by amoebas. The parasite may cause colitis which is manifested with bloody diarrheas, abdominal pain, nausea and fever. In rare cases it may spread to the liver, brain and lungs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amebiasis","conceptCode":"C84551","definition":"A parasitic infectious disorder caused by amoebas. The parasite may cause colitis which is manifested with bloody diarrhea, abdominal pain, nausea and fever. In rare cases it may spread to the liver, brain and lungs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AC32-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AC48-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ameloblastoma","valueDescription":"Ameloblastoma","ValueMeaning":{"publicId":"3210863","version":"1","preferredName":"Ameloblastoma","longName":"3210863","preferredDefinition":"The most common odontogenic tumor, arising from the epithelial component of the embryonic tooth and usually affecting the molar-ramus region of the mandible or maxilla.  Although most ameloblastomas are morphologically and clinically benign, they may cause extensive local destruction, recur, or metastasize.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ameloblastoma","conceptCode":"C4313","definition":"The most common odontogenic tumor, arising from the epithelial component of the embryonic tooth and usually affecting the molar-ramus region of the mandible or maxilla.  Although most ameloblastomas are morphologically and clinically benign, they may cause extensive local destruction, recur, or metastasize.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AC54-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AC6A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Amniotic Band Syndrome","valueDescription":"Amniotic Band Syndrome","ValueMeaning":{"publicId":"3210864","version":"1","preferredName":"Amniotic Band Syndrome","longName":"3210864","preferredDefinition":"A rare congenital disorder which is caused by entrapment of anatomic parts of the fetus in fibrous amniotic bands during pregnancy. It may result in the formation of constriction rings around the digits and upper and lower extremities, swelling of the extremities and congenital amputations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amniotic Band Syndrome","conceptCode":"C84552","definition":"A rare congenital disorder which is caused by entrapment of anatomic parts of the fetus in fibrous amniotic bands during pregnancy. It may result in the formation of constriction rings around the digits and upper and lower extremities, swelling of the extremities and congenital amputations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AC76-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AC8C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Amyloid Neuropathy","valueDescription":"Amyloid Neuropathy","ValueMeaning":{"publicId":"3210865","version":"1","preferredName":"Amyloid Neuropathy","longName":"3210865","preferredDefinition":"Neuropathy caused by amyloid deposition in the peripheral nerves.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloid Neuropathy","conceptCode":"C84553","definition":"Neuropathy caused by amyloid deposition in the peripheral nerves.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AC98-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ACAE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Amyloidosis","valueDescription":"Amyloidosis","ValueMeaning":{"publicId":"3210866","version":"1","preferredName":"Amyloidosis","longName":"3210866","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ACBA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ACD0-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Amyotrophic Lateral Sclerosis","valueDescription":"Amyotrophic Lateral Sclerosis","ValueMeaning":{"publicId":"3165574","version":"1","preferredName":"Amyotrophic Lateral Sclerosis","longName":"3165574","preferredDefinition":"A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyotrophic Lateral Sclerosis","conceptCode":"C34373","definition":"A neurodegenerative disorder characterized by progressive degeneration of the motor neurons of the central nervous system. It results in weakness and atrophy of the muscles which leads to an inability to initiate and control voluntary movements.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96FCF74F-C1FD-EAB7-E040-BB89AD437850","latestVersionIndicator":"Yes","beginDate":"2010-12-09","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ACDA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Anal Neoplasm","valueDescription":"Anal Neoplasm","ValueMeaning":{"publicId":"3210867","version":"1","preferredName":"Anal Neoplasm","longName":"3210867","preferredDefinition":"A benign or malignant neoplasm involving the anus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anal Neoplasm","conceptCode":"C2877","definition":"A benign or malignant neoplasm that affects the anal canal or anal margin.  Representative examples of benign neoplasms include squamous papilloma and papillary hidradenoma.  Representative examples of malignant neoplasms include carcinoma, lymphoma, and melanoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ACE6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ACFC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Anaplastic Large Cell Lymphoma","valueDescription":"Anaplastic Large Cell Lymphoma","ValueMeaning":{"publicId":"2558222","version":"1","preferredName":"Anaplastic Large Cell Lymphoma","longName":"2558222","preferredDefinition":"A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells.  Majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein.  The most frequently seen genetic alteration is a t(2;5) translocation.  Majority of patients present with advanced disease.  The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Large Cell Lymphoma","conceptCode":"C3720","definition":"A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B07B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AD0E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Andersen Syndrome","valueDescription":"Andersen Syndrome","ValueMeaning":{"publicId":"3210868","version":"1","preferredName":"Andersen Syndrome","longName":"3210868","preferredDefinition":"A form of long QT syndrome characterized by ventricular arrhythmia, muscle weakness, and developmental abnormalities which include micrognathia, low-set ears and deformities of the fingers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Long QT Syndrome 7","conceptCode":"C84559","definition":"A subtype of long QT syndrome caused by mutation(s) in the KCNJ2 gene, encoding inward rectifier potassium channel 2. It is characterized by ventricular arrhythmia, muscle weakness, and developmental abnormalities which include micrognathia, low-set ears and deformities of the fingers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AD1A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AD30-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ovarian Sertoli-Leydig Cell Tumor","valueDescription":"Ovarian Sertoli-Leydig Cell Tumor","ValueMeaning":{"publicId":"3210869","version":"1","preferredName":"Ovarian Sertoli-Leydig Cell Tumor","longName":"3210869","preferredDefinition":"A benign or malignant sex cord-stromal tumor arising from the ovary. It is characterized by the presence of neoplastic Leydig cells. Signs and symptoms include hirsutism, menorrhagia and metrorrhagia. It may be associated with trisomy 8.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Sertoli-Leydig Cell Tumor","conceptCode":"C2880","definition":"A benign or malignant sex cord-stromal tumor arising from the ovary. It is characterized by the presence of neoplastic Leydig cells. Signs and symptoms include hirsutism, menorrhagia and metrorrhagia. It may be associated with trisomy 8.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AD3C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AD52-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Anencephaly","valueDescription":"Anencephaly","ValueMeaning":{"publicId":"3210870","version":"1","preferredName":"Anencephaly","longName":"3210870","preferredDefinition":"A rare neural tube defect during pregnancy, resulting in the absence of a large portion of the brain and skull in the fetus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anencephaly","conceptCode":"C84560","definition":"A rare neural tube defect during pregnancy, resulting in the absence of a large portion of the brain and skull in the fetus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AD5E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AD74-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Angelman Syndrome","valueDescription":"Angelman Syndrome","ValueMeaning":{"publicId":"3210871","version":"1","preferredName":"Angelman Syndrome","longName":"3210871","preferredDefinition":"A genetic syndrome characterized by mental retardation, speech impairment, microcephaly, ataxia, and seizures.  The majority of cases result from deletions on the long arm of chromosome 15.  A minority of cases result from mutations in the UBE3A gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Angelman Syndrome","conceptCode":"C75462","definition":"A genetic syndrome characterized by mental retardation, speech impairment, microcephaly, ataxia, and seizures. The majority of cases result from deletions on the long arm of chromosome 15. A minority of cases result from mutations in the UBE3A gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AD80-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AD96-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Angiofollicular Lymphoid Hyperplasia","valueDescription":"Angiofollicular Lymphoid Hyperplasia","ValueMeaning":{"publicId":"3210872","version":"1","preferredName":"Angiofollicular Lymphoid Hyperplasia","longName":"3210872","preferredDefinition":"A disorder characterized by lymphoid hyperplasia in the lymph nodes. There are two histologic variants recognized: the hyaline-vascular type and the plasma cell type. In the hyaline vascular type there are hyalinized vessels present in the lymphoid follicles. In the plasma cell type there is pronounced plasma cell proliferation. Clinically, the disease may be localized; manifested with localized lymphadenopathy, or multicentric; manifested with generalized lymphadenopathy, fever, organomegaly, and sometimes POEMS syndrome. In contrast to patients with localized disease who are usually cured following resection of the lesion, patients with the multicentric form of the disease may follow a progressive clinical course, complicated by infection, Kaposi sarcoma or lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Castleman Disease","conceptCode":"C3056","definition":"A disorder characterized by lymphoid hyperplasia in the lymph nodes. There are two histologic variants recognized: the hyaline-vascular type and the plasma cell type. In the hyaline vascular type there are hyalinized vessels present in the lymphoid follicles. In the plasma cell type there is pronounced plasma cell proliferation. Clinically, the disease may be localized; manifested with localized lymphadenopathy, or multicentric; manifested with generalized lymphadenopathy, fever, organomegaly, and sometimes POEMS syndrome. In contrast to patients with localized disease who are usually cured following resection of the lesion, patients with the multicentric form of the disease may follow a progressive clinical course, complicated by infection, Kaposi sarcoma or lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ADA2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ADB8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Anhidrotic Ectodermal Dysplasia 1","valueDescription":"Anhidrotic Ectodermal Dysplasia 1","ValueMeaning":{"publicId":"3210873","version":"1","preferredName":"Anhidrotic Ectodermal Dysplasia 1","longName":"3210873","preferredDefinition":"A rare genetic disorder characterized by mutations in the gene encoding ectodysplasin A. It results in abnormalities in the morphogenesis of the structures originating from the ectoderm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anhidrotic Ectodermal Dysplasia 1","conceptCode":"C84562","definition":"A rare genetic disorder characterized by mutations in the gene encoding ectodysplasin A. It results in abnormalities in the morphogenesis of the structures originating from the ectoderm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ADC4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ADDA-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Aniridia","valueDescription":"Aniridia","ValueMeaning":{"publicId":"3210874","version":"1","preferredName":"Aniridia","longName":"3210874","preferredDefinition":"A rare genetic inherited abnormality characterized by the partial or complete absence of the iris of the eye.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aniridia","conceptCode":"C84563","definition":"A rare genetic inherited abnormality characterized by the partial or complete absence of the iris of the eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ADE6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-ADFC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ankylosing Spondylitis","valueDescription":"Ankylosing Spondylitis","ValueMeaning":{"publicId":"3210875","version":"1","preferredName":"Ankylosing Spondylitis","longName":"3210875","preferredDefinition":"An autoimmune chronic inflammatory disorder characterized by inflammation in the vertebral joints of the spine and sacroiliac joints. It predominantly affects young males. Patients present with stiffness and pain in the spine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ankylosing Spondylitis","conceptCode":"C84564","definition":"An autoimmune chronic inflammatory disorder characterized by inflammation in the vertebral joints of the spine and sacroiliac joints. It predominantly affects young males. Patients present with stiffness and pain in the spine.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AE08-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AE1E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Anthrax","valueDescription":"Anthrax","ValueMeaning":{"publicId":"3210876","version":"1","preferredName":"Anthrax","longName":"3210876","preferredDefinition":"An infection caused by Bacillus anthracis bacteria. It may affect the lungs, gastrointestinal tract, or skin. Patients with lung infection present with fever, headaches, cough, chest pain and shortness of breath. Patients with gastrointestinal infection present with nausea, vomiting and bloody diarrhea. Patients with skin infection develop blisters and ulcers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anthrax","conceptCode":"C84565","definition":"An infection caused by Bacillus anthracis bacteria. It may affect the lungs, gastrointestinal tract, or skin. Patients with lung infection present with fever, headaches, cough, chest pain and shortness of breath. Patients with gastrointestinal infection present with nausea, vomiting and bloody diarrhea. Patients with skin infection develop blisters and ulcers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AE2A-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AE40-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Anti-Glomerular Basement Membrane Disease","valueDescription":"Anti-Glomerular Basement Membrane Disease","ValueMeaning":{"publicId":"3210877","version":"1","preferredName":"Anti-Glomerular Basement Membrane Disease","longName":"3210877","preferredDefinition":"An autoimmune disorder characterized by the production of autoantibodies against type IV collagen of the glomerular basement membrane of the kidney. In the majority of patients the immune reaction also extends to the alveolar capillary membrane of the lungs. The latter cases are referred to as Goodpasture Syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Glomerular Basement Membrane Disease","conceptCode":"C84566","definition":"An autoimmune disorder characterized by the production of autoantibodies against type IV collagen of the glomerular basement membrane of the kidney. In the majority of patients the immune reaction also extends to the alveolar capillary membrane of the lungs. The latter cases are referred to as Goodpasture Syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AE4C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AE62-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Aortic Arch Syndrome","valueDescription":"Aortic Arch Syndrome","ValueMeaning":{"publicId":"3210878","version":"1","preferredName":"Aortic Arch Syndrome","longName":"3210878","preferredDefinition":"A syndrome resulting from structural defects of the arteries that arise from the aortic arch. Signs and symptoms include weakness, dizziness, arm numbness, blurred vision and transient ischemic attacks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aortic Arch Syndrome","conceptCode":"C34391","definition":"A syndrome resulting from structural defects of the arteries that arise from the aortic arch. Signs and symptoms include weakness, dizziness, arm numbness, blurred vision and transient ischemic attacks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AE6E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AE84-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Aortic Coarctation","valueDescription":"Aortic Coarctation","ValueMeaning":{"publicId":"3210879","version":"1","preferredName":"Aortic Coarctation","longName":"3210879","preferredDefinition":"Congenital narrowing of a segment of the aorta. Signs and symptoms include hypertension, muscle weakness, shortness of breath, headaches and leg cramps.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aortic Coarctation","conceptCode":"C84567","definition":"Congenital narrowing of a segment of the aorta. Signs and symptoms include hypertension, muscle weakness, shortness of breath, headaches and leg cramps.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AE90-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AEA6-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Arachnoid Cyst","valueDescription":"Arachnoid Cyst","ValueMeaning":{"publicId":"3210880","version":"1","preferredName":"Arachnoid Cyst","longName":"3210880","preferredDefinition":"An intracranial or spinal cyst which contains fluid and is composed of arachnoid cells. Intracranial arachnoid cysts may present with headaches, seizures and hydrocephalus. Spinal arachnoid cysts may present with symptoms of radiculopathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arachnoid Cyst","conceptCode":"C3455","definition":"An intracranial or spinal cyst which contains fluid and is composed of arachnoid cells. Intracranial arachnoid cysts may present with headaches, seizures and hydrocephalus. Spinal arachnoid cysts may present with symptoms of radiculopathy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AEB2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AEC8-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Arachnoiditis","valueDescription":"Arachnoiditis","ValueMeaning":{"publicId":"2562623","version":"1","preferredName":"Arachnoiditis","longName":"2562623","preferredDefinition":"Inflammation of the arachnoid membrane and adjacent subarachnoid space.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arachnoiditis","conceptCode":"C37913","definition":"Inflammation of the arachnoid membrane and adjacent subarachnoid space.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C1AC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AED2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Argininemia","valueDescription":"Argininemia","ValueMeaning":{"publicId":"3210881","version":"1","preferredName":"Argininemia","longName":"3210881","preferredDefinition":"A rare autosomal recessive metabolic disorder characterized by a deficiency of the enzyme arginase resulting in accumulation of arginine and urea in the blood and cerebrospinal fluid. Signs and symptoms include developmental delays, spasticity, ataxia, seizures and mental retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Argininemia","conceptCode":"C84568","definition":"A rare autosomal recessive metabolic disorder characterized by a deficiency of the enzyme arginase resulting in accumulation of arginine and urea in the blood and cerebrospinal fluid. Signs and symptoms include developmental delays, spasticity, ataxia, seizures and mental retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AEDE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AEF4-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Argininosuccinic Aciduria","valueDescription":"Argininosuccinic Aciduria","ValueMeaning":{"publicId":"3210882","version":"1","preferredName":"Argininosuccinic Aciduria","longName":"3210882","preferredDefinition":"A genetic inherited disorder caused by mutations in the ASL gene. It is characterized by accumulation of ammonia in the blood. It presents with lethargy in the first few days of life, accompanied by developmental delay and mental retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Argininosuccinic Aciduria","conceptCode":"C84569","definition":"A genetic inherited disorder caused by mutations in the ASL gene. It is characterized by accumulation of ammonia in the blood. It presents with lethargy in the first few days of life, accompanied by developmental delay and mental retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AF00-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AF16-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Arnold-Chiari Malformation","valueDescription":"Arnold-Chiari Malformation","ValueMeaning":{"publicId":"3210883","version":"1","preferredName":"Arnold-Chiari Malformation","longName":"3210883","preferredDefinition":"A rare genetic brain malformation characterized by displacement of the brain stem and cerebellum through the foramen magnum. It may result in hydrocephalus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arnold-Chiari Malformation","conceptCode":"C84570","definition":"A rare genetic brain malformation characterized by displacement of the brain stem and cerebellum through the foramen magnum. It may result in hydrocephalus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AF22-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AF38-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Arrhythmogenic Right Ventricular Dysplasia","valueDescription":"Arrhythmogenic Right Ventricular Dysplasia","ValueMeaning":{"publicId":"3210884","version":"1","preferredName":"Arrhythmogenic Right Ventricular Dysplasia","longName":"3210884","preferredDefinition":"A rare genetic disorder characterized by cardiomyopathy affecting the right ventricle. The heart tissue is replaced by fibrous and adipose tissues. Patients often have arrhythmias. It is a cause of sudden death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arrhythmogenic Right Ventricular Dysplasia","conceptCode":"C84571","definition":"A rare genetic disorder characterized by cardiomyopathy affecting the right ventricle. The heart tissue is replaced by fibrous and adipose tissues. It is characterized by ventricular arrhythmia and right ventricular dysfunction. It is a cause of sudden death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AF44-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AF5A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Arthrogryposis","valueDescription":"Arthrogryposis","ValueMeaning":{"publicId":"3210885","version":"1","preferredName":"Arthrogryposis","longName":"3210885","preferredDefinition":"A rare, non-progressive congenital disorder characterized by multiple joint contractures which are present at birth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arthrogryposis","conceptCode":"C84572","definition":"A rare, non-progressive congenital disorder characterized by multiple joint contractures which are present at birth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AF66-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AF7C-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Asbestosis","valueDescription":"Asbestosis","ValueMeaning":{"publicId":"3210886","version":"1","preferredName":"Asbestosis","longName":"3210886","preferredDefinition":"A lung disorder caused by inhalation of asbestos fibers. It results in fibrosis of the lung parenchyma. Signs and symptoms include coughing, shortness of breath and chest pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asbestosis","conceptCode":"C84573","definition":"A lung disorder caused by inhalation of asbestos fibers. It results in fibrosis of the lung parenchyma. Signs and symptoms include coughing, shortness of breath and chest pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AF88-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AF9E-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Astrocytoma","valueDescription":"Astrocytoma, NOS","ValueMeaning":{"publicId":"2837827","version":"1","preferredName":"Astrocytoma, NOS","longName":"2837827","preferredDefinition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"628169CF-83A0-F4D3-E040-BB89AD433D78","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"REEVESD","dateModified":"2014-07-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AFB2-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Ataxia Telangiectasia Syndrome","valueDescription":"Ataxia Telangiectasia Syndrome","ValueMeaning":{"publicId":"2593388","version":"1","preferredName":"Ataxia Telangiectasia Syndrome","longName":"2593388","preferredDefinition":"Rare hereditary disease characterized by extreme sensitivity to ionizing radiation or radiomimetic drugs because of a defect in DNA repair. AT heterozygosity is estimated to occur in more than 2% of the U.S. population; heterozygotes exhibit increased radiation sensitivity and are at increased risk for several types of cancer. The normal version of the gene that is defective in AT appears to activate the p53-dependent response to DNA damage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ataxia Telangiectasia Syndrome","conceptCode":"C2887","definition":"Rare hereditary disease characterized by extreme sensitivity to ionizing radiation or radiomimetic drugs because of a defect in DNA repair. AT heterozygosity is estimated to occur in more than 2% of the U.S. population; heterozygotes exhibit increased radiation sensitivity and are at increased risk for several types of cancer. The normal version of the gene that is defective in AT appears to activate the p53-dependent response to DNA damage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2883B655-AF9E-439B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AFBC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Atrophic Muscular Disorder","valueDescription":"Atrophic Muscular Disorder","ValueMeaning":{"publicId":"3210887","version":"1","preferredName":"Atrophic Muscular Disorder","longName":"3210887","preferredDefinition":"A group of primary or secondary disorders affecting the muscles. It is characterized by an abnormal reduction in the muscle volume and atrophy. The atrophy may be caused by diseases of the muscle tissues or diseases of the peripheral nerves.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atrophic Muscular Disorder","conceptCode":"C84574","definition":"A group of primary or secondary disorders affecting the muscles. It is characterized by an abnormal reduction in the muscle volume and atrophy. The atrophy may be caused by diseases of the muscle tissues or diseases of the peripheral nerves.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AFC8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-AFDE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Auditory Perceptual Disorder","valueDescription":"Auditory Perceptual Disorder","ValueMeaning":{"publicId":"3210888","version":"1","preferredName":"Auditory Perceptual Disorder","longName":"3210888","preferredDefinition":"A disorder characterized by the inability of the brain to properly interpret or process the auditory signals it receives from the anatomic structures of the ear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Auditory Perceptual Disorder","conceptCode":"C84575","definition":"A disorder characterized by the inability of the brain to properly interpret or process the auditory signals it receives from the anatomic structures of the ear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AFEA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B000-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Autoimmune Hemolytic Anemia","valueDescription":"Autoimmune Hemolytic Anemia","ValueMeaning":{"publicId":"3131205","version":"1","preferredName":"Autoimmune Hemolytic Anemia","longName":"3131205","preferredDefinition":"An acquired anemia caused by destruction of the red blood cells by autoantibodies. Causes include autoimmune disorders, lymphoproliferative disorders, infections and drugs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Hemolytic Anemia","conceptCode":"C34378","definition":"An acquired anemia caused by destruction of the red blood cells by autoantibodies. Causes include autoimmune disorders, lymphoproliferative disorders, and infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E463458-E315-7F10-E040-BB89AD433128","latestVersionIndicator":"Yes","beginDate":"2010-08-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2010-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B012-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Autoimmune Hepatitis","valueDescription":"Autoimmune Hepatitis","ValueMeaning":{"publicId":"3210889","version":"1","preferredName":"Autoimmune Hepatitis","longName":"3210889","preferredDefinition":"Hepatitis caused by autoantibodies. Drugs, infections, and toxins may trigger the production of the autoantibodies against the liver parenchyma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Hepatitis","conceptCode":"C27029","definition":"Hepatitis caused by autoantibodies. Drugs, infections, and toxins may trigger the production of the autoantibodies against the liver parenchyma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B01E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B034-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Autoimmune Lymphoproliferative Syndrome","valueDescription":"Autoimmune Lymphoproliferative Syndrome","ValueMeaning":{"publicId":"3210890","version":"1","preferredName":"Autoimmune Lymphoproliferative Syndrome","longName":"3210890","preferredDefinition":"An autoimmune hematologic disorder characterized by autoimmune hemolytic anemia, thrombocytopenia, lymphadenopathy, hepatomegaly and splenomegaly. Patients are at an increased risk of developing Hodgkin and non-Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Lymphoproliferative Syndrome","conceptCode":"C37864","definition":"An autoimmune hematologic disorder characterized by autoimmune hemolytic anemia, thrombocytopenia, lymphadenopathy, hepatomegaly and splenomegaly. Patients are at an increased risk of developing Hodgkin and non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B040-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B056-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Autoimmune Polyendocrinopathy Syndrome","valueDescription":"Autoimmune Polyendocrinopathy Syndrome","ValueMeaning":{"publicId":"3210891","version":"1","preferredName":"Autoimmune Polyendocrinopathy Syndrome","longName":"3210891","preferredDefinition":"A rare genetic syndrome characterized by autoantibodies production against more than one endocrine organ. The range of endocrinopathies includes hypoparathyroidism, adrenal insufficiency, hypogonadism, type 1 diabetes mellitus and hypothyroidism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Polyendocrinopathy Syndrome","conceptCode":"C84576","definition":"A rare genetic syndrome characterized by autoantibodies production against more than one endocrine organ. The range of endocrinopathies includes hypoparathyroidism, adrenal insufficiency, hypogonadism, type 1 diabetes mellitus and hypothyroidism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B062-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B078-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Autosomal Dominant Optic Atrophy","valueDescription":"Autosomal Dominant Optic Atrophy","ValueMeaning":{"publicId":"3210892","version":"1","preferredName":"Autosomal Dominant Optic Atrophy","longName":"3210892","preferredDefinition":"An autosomal dominant hereditary condition characterized by optic atrophy and progressive visual loss.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autosomal Dominant Optic Atrophy","conceptCode":"C84577","definition":"An autosomal dominant hereditary condition characterized by optic atrophy and progressive visual loss.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B084-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B09A-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Autosomal Dominant Polycystic Kidney Disease","valueDescription":"Autosomal Dominant Polycystic Kidney Disease","ValueMeaning":{"publicId":"3210893","version":"1","preferredName":"Autosomal Dominant Polycystic Kidney Disease","longName":"3210893","preferredDefinition":"Polycystic kidney disease inherited in an autosomal dominant pattern. Symptoms usually appear at middle age and include abdominal pain, hematuria and high blood pressure. Patients may develop brain aneurysms and liver cysts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autosomal Dominant Polycystic Kidney Disease","conceptCode":"C84578","definition":"Polycystic kidney disease inherited in an autosomal dominant pattern. Symptoms usually appear at middle age and include abdominal pain, hematuria and high blood pressure. Patients may develop brain aneurysms and liver cysts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B0A6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B0BC-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Autosomal Recessive Hypohidrotic Ectodermal Dysplasia","valueDescription":"Autosomal Recessive Hypohidrotic Ectodermal Dysplasia","ValueMeaning":{"publicId":"3210894","version":"1","preferredName":"Autosomal Recessive Hypohidrotic Ectodermal Dysplasia","longName":"3210894","preferredDefinition":"A rare autosomal recessive disorder characterized by developmental abnormalities of the skin, sweat glands, hair and nails. Patients have a reduced ability to sweat. Other signs and symptoms include hypotrichosis and teeth malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autosomal Recessive Hypohidrotic Ectodermal Dysplasia","conceptCode":"C84580","definition":"A rare autosomal recessive disorder characterized by developmental abnormalities of the skin, sweat glands, hair and nails. Patients have a reduced ability to sweat. Other signs and symptoms include hypotrichosis and teeth malformations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B0C8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-B0DE-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Meesmann Corneal Dystrophy","valueDescription":"Meesmann Corneal Dystrophy","ValueMeaning":{"publicId":"3211246","version":"1","preferredName":"Meesmann Corneal Dystrophy","longName":"3211246","preferredDefinition":"An autosomal dominant inherited corneal disorder caused by mutations in the KRT3 and KRT12 genes. It is characterized by the formation of multiple tiny cysts in the epithelial layer of the cornea. The cysts may rupture, causing pain, redness and light sensitivity. Vision usually is not affected.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meesmann Corneal Dystrophy","conceptCode":"C84795","definition":"An autosomal dominant inherited corneal disorder caused by mutations in the KRT3 and KRT12 genes. It is characterized by the formation of multiple tiny cysts in the epithelial layer of the cornea. The cysts may rupture, causing pain, redness and light sensitivity. Vision usually is not affected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E26F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E285-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Megaloblastic Anemia","valueDescription":"Megaloblastic Anemia","ValueMeaning":{"publicId":"3211247","version":"1","preferredName":"Megaloblastic Anemia","longName":"3211247","preferredDefinition":"Anemia characterized by the presence of unusually large erythroblasts in the bone marrow called megaloblasts. It is usually caused by vitamin B12 or folic acid deficiency. Other causes include toxins and drugs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Megaloblastic Anemia","conceptCode":"C34382","definition":"Anemia characterized by the presence of unusually large erythroblasts in the bone marrow called megaloblasts. It is usually caused by vitamin B12 or folic acid deficiency. Other causes include toxins and drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E291-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E2A7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"MELAS Syndrome","valueDescription":"MELAS Syndrome","ValueMeaning":{"publicId":"3211248","version":"1","preferredName":"MELAS Syndrome","longName":"3211248","preferredDefinition":"A rare progressive neurodegenerative disorder characterized by mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MELAS Syndrome","conceptCode":"C84885","definition":"A rare progressive neurodegenerative disorder characterized by mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E2B3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E2C9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Melkersson-Rosenthal Syndrome","valueDescription":"Melkersson-Rosenthal Syndrome","ValueMeaning":{"publicId":"3211249","version":"1","preferredName":"Melkersson-Rosenthal Syndrome","longName":"3211249","preferredDefinition":"A rare syndrome characterized by recurrent facial nerve paralysis, edema of the lips and face, and furrowed tongue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melkersson-Rosenthal Syndrome","conceptCode":"C84886","definition":"A rare syndrome characterized by recurrent facial nerve paralysis, edema of the lips and face, and furrowed tongue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E2D5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E2EB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Melorheostosis","valueDescription":"Melorheostosis","ValueMeaning":{"publicId":"3211250","version":"1","preferredName":"Melorheostosis","longName":"3211250","preferredDefinition":"A very rare bone disorder characterized by thickening of the cortex in a linear pattern. Signs and symptoms include joint pain, joint swelling, limb deformity, and changes in the skin covering the bone lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melorheostosis","conceptCode":"C84887","definition":"A very rare bone disorder characterized by thickening of the cortex in a linear pattern. Signs and symptoms include joint pain, joint swelling, limb deformity, and changes in the skin covering the bone lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E2F7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E30D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Meningeal Tuberculosis","valueDescription":"Meningeal Tuberculosis","ValueMeaning":{"publicId":"3211251","version":"1","preferredName":"Meningeal Tuberculosis","longName":"3211251","preferredDefinition":"A bacterial infection of the membranes covering the brain and the spinal cord caused by Mycobacterium tuberculosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningeal Tuberculosis","conceptCode":"C84888","definition":"A bacterial infection of the membranes covering the brain and the spinal cord caused by Mycobacterium tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E319-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E32F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Menkes Disease","valueDescription":"Menkes Disease","ValueMeaning":{"publicId":"3211252","version":"1","preferredName":"Menkes Disease","longName":"3211252","preferredDefinition":"An X-linked disorder caused by mutations in the ATP7A gene resulting in the abnormal transport and metabolism of copper.  It affects primarily male infants.  It is characterized by hypotonia, seizures, failure to thrive, and peculiar colorless or steel-colored brittle hair.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Menkes Disease","conceptCode":"C75486","definition":"An X-linked disorder caused by mutations in the ATP7A gene resulting in the abnormal transport and metabolism of copper. It affects primarily male infants. It is characterized by hypotonia, seizures, failure to thrive, and peculiar colorless or steel-colored brittle hair.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E33B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E351-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"MERRF Syndrome","valueDescription":"MERRF Syndrome","ValueMeaning":{"publicId":"3211253","version":"1","preferredName":"MERRF Syndrome","longName":"3211253","preferredDefinition":"A very rare mitochondrial abnormality characterized by myoclonic epilepsy and the microscopic finding of ragged-red fibers in muscle tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myoclonic Epilepsy Associated with Ragged-Red Fibers","conceptCode":"C84889","definition":"A condition that can be caused by mutation(s) in more than one mitochondrial gene. It is characterized by myoclonic epilepsy and ragged-red fibers present on muscle biopsy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E35D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E373-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Metachromatic Leukodystrophy","valueDescription":"Metachromatic Leukodystrophy","ValueMeaning":{"publicId":"2593450","version":"1","preferredName":"Metachromatic Leukodystrophy","longName":"2593450","preferredDefinition":"An autosomal recessive inherited disorder characterized by abnormalities in the development of the myelin sheaths. It is caused by a deficiency of the enzyme arylsulfatase A. There are three forms of this disease: late infantile, juvenile, and adult. In the late infantile form symptoms include muscle weakness and rigidity, gait disturbances, developmental delays, and seizures. In the juvenile form symptoms include gait disturbances, mental deterioration and seizures. The adult form is characterized by psychotic symptoms and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metachromatic Leukodystrophy","conceptCode":"C61251","definition":"An autosomal recessive inherited disorder characterized by abnormalities in the development of the myelin sheaths. It is caused by a deficiency of the enzyme arylsulfatase A. There are three forms of this disease: late infantile, juvenile, and adult. In the late infantile form symptoms include muscle weakness and rigidity, gait disturbances, developmental delays, and seizures. In the juvenile form symptoms include gait disturbances, mental deterioration and seizures. The adult form is characterized by psychotic symptoms and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBABB0-0B0C-4B1B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E37D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"5' 10' Methylenetetrahydrofolate Reductase Deficiency","valueDescription":"5' 10' Methylenetetrahydrofolate Reductase Deficiency","ValueMeaning":{"publicId":"3211254","version":"1","preferredName":"5' 10' Methylenetetrahydrofolate Reductase Deficiency","longName":"3211254","preferredDefinition":"A rare disorder associated with mental retardation, spasticity, and early death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"5' 10' Methylenetetrahydrofolate Reductase Deficiency","conceptCode":"C84524","definition":"A rare disorder associated with mental retardation, spasticity, and early death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E389-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E39F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mevalonate Kinase Deficiency","valueDescription":"Mevalonate Kinase Deficiency","ValueMeaning":{"publicId":"3211255","version":"1","preferredName":"Mevalonate Kinase Deficiency","longName":"3211255","preferredDefinition":"A very rare autosomal recessive disorder of cholesterol biosynthesis. It is caused by a deficiency of the enzyme mevalonate kinase, resulting in the accumulation of mevalonic acid in the urine. Signs and symptoms include psychomotor retardation, ataxia, recurrent fevers, skin rash, hepatosplenomegaly, and lymphadenopathy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mevalonate Kinase Deficiency","conceptCode":"C84890","definition":"A very rare autosomal recessive disorder of cholesterol biosynthesis. It is caused by a deficiency of the enzyme mevalonate kinase, resulting in the accumulation of mevalonic acid in the urine. Signs and symptoms include psychomotor retardation, ataxia, recurrent fevers, skin rash, hepatosplenomegaly, and lymphadenopathy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E3AB-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E3C1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Microscopic Polyarteritis","valueDescription":"Microscopic Polyarteritis","ValueMeaning":{"publicId":"2757467","version":"1","preferredName":"Microscopic Polyarteritis","longName":"2757467","preferredDefinition":"A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener's granulomatosis than to classic polyarteritis nodosa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Microscopic Polyarteritis","conceptCode":"C70549","definition":"A systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. In some cases, however, microscopic vessels are also affected (e.g., in the kidneys), a condition that has been called microscopic polyarteritis or polyangiitis; this disorder is felt to be more closely associated with Wegener granulomatosis than to classic polyarteritis nodosa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F19E9E5-642C-39EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-06-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E3D3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Microsporidiosis","valueDescription":"Microsporidiosis","ValueMeaning":{"publicId":"3211256","version":"1","preferredName":"Microsporidiosis","longName":"3211256","preferredDefinition":"A protozoal parasitic infection caused by Microsporidia. It occurs in immunocompromised patients, causing diarrhea and wasting.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Microsporidiosis","conceptCode":"C84891","definition":"A fungal infection caused by Microsporidia. It occurs in immunocompromised patients, causing diarrhea and wasting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E3DF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E3F5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Minimal Change Glomerulonephritis","valueDescription":"Minimal Change Glomerulonephritis","ValueMeaning":{"publicId":"3211257","version":"1","preferredName":"Minimal Change Glomerulonephritis","longName":"3211257","preferredDefinition":"A glomerular disorder characterized by the electron microscopic finding of loss of podocyte foot processes. Light microscopic examination does not show glomerular changes. Patients present with proteinuria and nephrotic syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimal Change Glomerulonephritis","conceptCode":"C34844","definition":"A glomerular disorder characterized by the electron microscopic finding of loss of podocyte foot processes. Light microscopic examination does not show glomerular changes. Patients present with proteinuria and nephrotic syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E401-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E417-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mixed Connective Tissue Disease","valueDescription":"Mixed Connective Tissue Disease","ValueMeaning":{"publicId":"3211258","version":"1","preferredName":"Mixed Connective Tissue Disease","longName":"3211258","preferredDefinition":"An autoimmune overlap syndrome characterized by the presence of symptoms of systemic lupus erythematosus, systemic scleroderma, and polymyositis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Connective Tissue Disease","conceptCode":"C84892","definition":"An autoimmune overlap syndrome characterized by the presence of symptoms of systemic lupus erythematosus, systemic scleroderma, and polymyositis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E423-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E439-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mobius Syndrome","valueDescription":"Mobius Syndrome","ValueMeaning":{"publicId":"3211259","version":"1","preferredName":"Mobius Syndrome","longName":"3211259","preferredDefinition":"A very rare congenital syndrome affecting the sixth and seventh cranial nerves. It is characterized by facial paralysis leading to lack of facial expression and the inability to move the eyes laterally.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mobius Syndrome","conceptCode":"C84893","definition":"A very rare congenital syndrome affecting the sixth and seventh cranial nerves. It is characterized by facial paralysis leading to lack of facial expression and the inability to move the eyes laterally.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E445-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E45B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Monilethrix","valueDescription":"Monilethrix","ValueMeaning":{"publicId":"3211260","version":"1","preferredName":"Monilethrix","longName":"3211260","preferredDefinition":"A rare autosomal dominant inherited hair shaft disorder caused by mutations in the type II keratin gene. It is characterized by the presence of thin, fragile hairs that appear beaded.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monilethrix","conceptCode":"C84894","definition":"A rare autosomal dominant inherited hair shaft disorder caused by mutations in certain cuticular type II keratin genes. It is characterized by the presence of thin, fragile hairs that appear beaded.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E467-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E47D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Morquio Syndrome","valueDescription":"Morquio Syndrome","ValueMeaning":{"publicId":"2593471","version":"1","preferredName":"Morquio Syndrome","longName":"2593471","preferredDefinition":"A rare autosomal recessive lysosomal storage disease characterized by abnormal skeletal developments, dwarfism, heart disorders, and central nervous system deficits.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morquio Syndrome","conceptCode":"C61263","definition":"A rare autosomal recessive lysosomal storage disease characterized by abnormal skeletal developments, dwarfism, heart disorders, and central nervous system deficits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBEE5A-A52B-56E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E487-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Moyamoya Disease","valueDescription":"Moyamoya Disease","ValueMeaning":{"publicId":"3211261","version":"1","preferredName":"Moyamoya Disease","longName":"3211261","preferredDefinition":"A rare inherited vascular disorder characterized by constriction of arteries at the base of the brain, resulting in the formation of collateral circulation in order to compensate for the constriction. The name \"moyamoya\" in Japanese means \"puff of smoke\" and derives from the characteristic radiographic appearance of the collateral vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Moyamoya Disease","conceptCode":"C84895","definition":"A rare inherited vascular disorder characterized by constriction of arteries at the base of the brain, resulting in the formation of collateral circulation in order to compensate for the constriction. The name \"moyamoya\" in Japanese means \"puff of smoke\" and derives from the characteristic radiographic appearance of the collateral vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E493-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E4A9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mucolipidosis Type IV","valueDescription":"Mucolipidosis Type IV","ValueMeaning":{"publicId":"3211262","version":"1","preferredName":"Mucolipidosis Type IV","longName":"3211262","preferredDefinition":"An autosomal recessive lysosomal storage disease caused by mutations in the MCOLN1 gene. It is characterized by psychomotor developmental delays and ophthalmologic abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucolipidosis Type IV","conceptCode":"C84896","definition":"An autosomal recessive lysosomal storage disease caused by mutations in the MCOLN1 gene. It is characterized by psychomotor developmental delays and ophthalmologic abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E4BF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E4D5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis Type I","valueDescription":"Mucopolysaccharidosis Type I","ValueMeaning":{"publicId":"3211263","version":"1","preferredName":"Mucopolysaccharidosis Type I","longName":"3211263","preferredDefinition":"The most common type of mucopolysaccharidosis. It is inherited in an autosomal recessive pattern. It comprises a group of lysosomal storage diseases which includes the most severe form (Hurler syndrome) and the mildest form (Scheie syndrome).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type I","conceptCode":"C85053","definition":"The most common type of mucopolysaccharidosis. It is inherited in an autosomal recessive pattern. It comprises a group of lysosomal storage diseases which includes the most severe form (Hurler syndrome) and the mildest form (Scheie syndrome).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E4E1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E4F7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis Type IIIA","valueDescription":"Mucopolysaccharidosis Type IIIA","ValueMeaning":{"publicId":"3005737","version":"1","preferredName":"Mucopolysaccharidosis Type IIIA","longName":"3005737","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme heparan sulfate sulfatase. It is characterized by behavioral changes, sleep disturbances, mental developmental delays and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IIIA","conceptCode":"C84897","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme heparan sulfate sulfatase. It is characterized by behavioral changes, sleep disturbances, mental developmental delays and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB83E85-E76F-D623-E040-BB89AD434EBC","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E509-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis Type IIIB","valueDescription":"Mucopolysaccharidosis Type IIIB","ValueMeaning":{"publicId":"3005736","version":"1","preferredName":"Mucopolysaccharidosis Type IIIB","longName":"3005736","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetyl-alpha-D-glucosaminidase. It is characterized by behavioral changes, sleep disturbances, and mental developmental delays.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IIIB","conceptCode":"C84898","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetyl-alpha-D-glucosaminidase. It is characterized by behavioral changes, sleep disturbances, and mental developmental delays.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB83E85-E74A-D623-E040-BB89AD434EBC","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E51B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis Type IIIC","valueDescription":"Mucopolysaccharidosis Type IIIC","ValueMeaning":{"publicId":"3005735","version":"1","preferredName":"Mucopolysaccharidosis Type IIIC","longName":"3005735","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme acetyl-CoA:alpha-glucosaminide acetyltransferase. It is characterized by behavioral changes, sleep disturbances, and mental developmental delays.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IIIC","conceptCode":"C84899","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme acetyl-CoA:alpha-glucosaminide acetyltransferase. It is characterized by behavioral changes, sleep disturbances, and mental developmental delays.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB83E85-E725-D623-E040-BB89AD434EBC","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E52D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis Type IIID","valueDescription":"Mucopolysaccharidosis Type IIID","ValueMeaning":{"publicId":"3005734","version":"1","preferredName":"Mucopolysaccharidosis Type IIID","longName":"3005734","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylglucosamine-6-sulfatase. It is characterized by behavioral changes, sleep disturbances and mental developmental delays.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IIID","conceptCode":"C84900","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylglucosamine-6-sulfatase. It is characterized by behavioral changes, sleep disturbances and mental developmental delays.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB83E85-E700-D623-E040-BB89AD434EBC","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E53F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis Type IVA","valueDescription":"Mucopolysaccharidosis Type IVA","ValueMeaning":{"publicId":"3005743","version":"1","preferredName":"Mucopolysaccharidosis Type IVA","longName":"3005743","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme galactosamine-6-sulfatase. It is characterized by skeletal and central nervous system deficits.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IVA","conceptCode":"C84901","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme galactosamine-6-sulfatase. It is characterized by skeletal and central nervous system deficits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB86C79-20F4-52DA-E040-BB89AD436057","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E551-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis Type IVB","valueDescription":"Mucopolysaccharidosis Type IVB","ValueMeaning":{"publicId":"3005742","version":"1","preferredName":"Mucopolysaccharidosis Type IVB","longName":"3005742","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta galactosidase. It is characterized by skeletal dysplasia and short stature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IVB","conceptCode":"C84902","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta galactosidase. It is characterized by skeletal dysplasia and short stature.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB86C79-20CF-52DA-E040-BB89AD436057","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E563-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Muenke Syndrome","valueDescription":"Muenke Syndrome","ValueMeaning":{"publicId":"3211264","version":"1","preferredName":"Muenke Syndrome","longName":"3211264","preferredDefinition":"A rare autosomal dominant inherited disorder caused by mutations in the FGFR3 gene. It is characterized by premature fusion of cranial bones, resulting in head shape abnormalities, flattened cheekbones, and wide-set eyes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Muenke Syndrome","conceptCode":"C84904","definition":"A rare autosomal dominant inherited disorder caused by mutations in the FGFR3 gene. It is characterized by premature fusion of cranial bones, resulting in head shape abnormalities, flattened cheekbones, and wide-set eyes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E56F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E585-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Muir-Torre Syndrome","valueDescription":"Muir-Torre Syndrome","ValueMeaning":{"publicId":"3211265","version":"1","preferredName":"Muir-Torre Syndrome","longName":"3211265","preferredDefinition":"A usually autosomal dominant inherited neoplastic syndrome caused by mutations in the hMSH-2 and hMLH-1 genes. It is characterized by the presence of sebaceous skin tumors (adenoma or carcinoma), and internal organ malignant tumors, usually of the gastrointestinal or genitourinary tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Muir-Torre Syndrome","conceptCode":"C84905","definition":"A usually autosomal dominant inherited neoplastic syndrome caused by mutations in the hMSH-2 and hMLH-1 genes. It is characterized by the presence of sebaceous skin tumors (adenoma or carcinoma), and internal organ malignant tumors, usually of the gastrointestinal or genitourinary tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E591-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E5A7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mulibrey Nanism","valueDescription":"Mulibrey Nanism","ValueMeaning":{"publicId":"3211266","version":"1","preferredName":"Mulibrey Nanism","longName":"3211266","preferredDefinition":"An autosomal recessive inherited disorder caused by mutations in the TRIM37 gene. It is characterized by marked growth retardation and abnormalities in multiple organs including heart, liver, muscle, eyes, and brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mulibrey Nanism","conceptCode":"C84906","definition":"An autosomal recessive inherited disorder caused by mutations in the TRIM37 gene. It is characterized by marked growth retardation and abnormalities in multiple organs including heart, liver, muscle, eyes, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E5B3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E5C9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Multi-Infarct Dementia","valueDescription":"Multi-Infarct Dementia","ValueMeaning":{"publicId":"3211267","version":"1","preferredName":"Multi-Infarct Dementia","longName":"3211267","preferredDefinition":"A common form of dementia caused by multiple cortical or subcortical cerebral infarctions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multi-Infarct Dementia","conceptCode":"C34522","definition":"A common form of dementia caused by multiple cortical or subcortical cerebral infarctions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E5D5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E5EB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Multiple Acyl-CoA Dehydrogenase Deficiency","valueDescription":"Multiple Acyl-CoA Dehydrogenase Deficiency","ValueMeaning":{"publicId":"3211268","version":"1","preferredName":"Multiple Acyl-CoA Dehydrogenase Deficiency","longName":"3211268","preferredDefinition":"A rare autosomal recessive inherited metabolic disorder caused by mutations in the ETFA, ETFB, and ETFDH genes. It is characterized by defects of the electron transfer flavoprotein or electron transfer flavoprotein dehydrogenase. Clinical presentations include congenital abnormalities, hepatomegaly, metabolic acidosis, and hypotonia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Acyl-CoA Dehydrogenase Deficiency","conceptCode":"C84907","definition":"A rare autosomal recessive inherited metabolic disorder caused by mutations in the ETFA, ETFB, or ETFDH genes. It is characterized by deficiency of either electron transfer flavoprotein (ETF) or electron transfer flavoprotein dehydrogenase (ETFDH). Clinical presentations include congenital abnormalities (brain and facial malformations), hypotonia, dilated cardiomyopathy, hepatomegaly, metabolic acidosis, hypoglycemia, and behavioral changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E5F7-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E60D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Multiple Endocrine Neoplasia","valueDescription":"Multiple Endocrine Neoplasia","ValueMeaning":{"publicId":"3211269","version":"1","preferredName":"Multiple Endocrine Neoplasia","longName":"3211269","preferredDefinition":"An autosomal dominant inherited neoplastic syndrome characterized by the development of various endocrine neoplasms and abnormalities in various anatomic sites. There are three types recognized: type 1 (MEN 1), caused by inactivation of the tumor suppressor gene MEN-1, type 2A (MEN 2A), caused by mutation of the RET gene, and type 2B (MEN 2B) also caused by mutation of the RET gene. Patients with MEN 1 may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors. Patients with MEN 2A develop medullary thyroid carcinomas, and may also develop pheochromocytomas and parathyroid gland hyperplasia. Patients with MEN 2B develop medullary thyroid carcinomas and numerous neural defects including neuromas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Endocrine Neoplasia","conceptCode":"C6432","definition":"An autosomal dominant inherited neoplastic syndrome characterized by the development of various endocrine neoplasms and abnormalities in various anatomic sites. There are four types recognized: type 1 (MEN 1), caused by inactivation of the tumor suppressor gene MEN-1, type 2A (MEN 2A), caused by mutation of the RET gene, type 2B (MEN 2B) also caused by mutation of the RET gene, and type 4 (MEN 4) caused by mutation of the CDKN1B gene. Patients with MEN 1 may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors. Patients with MEN 2A develop medullary thyroid carcinomas and may also develop pheochromocytomas and parathyroid gland hyperplasia. Patients with MEN 2B develop medullary thyroid carcinomas and numerous neural defects including neuromas. Patients with MEN 4 develop endocrine neoplasms, particularly in the parathyroid glands, pituitary, and pancreas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E619-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E62F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Multiple Endocrine Neoplasia Type 1","valueDescription":"Multiple Endocrine Neoplasia Type 1","ValueMeaning":{"publicId":"3211270","version":"1","preferredName":"Multiple Endocrine Neoplasia Type 1","longName":"3211270","preferredDefinition":"Multiple endocrine neoplasia caused by inactivation of the tumor suppressor gene MEN-1. Patients may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Endocrine Neoplasia Type 1","conceptCode":"C3225","definition":"Multiple endocrine neoplasia caused by inactivation of the tumor suppressor gene MEN-1. Patients may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E63B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E651-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Multiple Endocrine Neoplasia Type 2A","valueDescription":"Multiple Endocrine Neoplasia Type 2A","ValueMeaning":{"publicId":"3211271","version":"1","preferredName":"Multiple Endocrine Neoplasia Type 2A","longName":"3211271","preferredDefinition":"Multiple endocrine neoplasia caused by mutation of the RET gene. Patients develop medullary thyroid carcinomas, and may also develop pheochromocytomas and parathyroid gland hyperplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Endocrine Neoplasia Type 2A","conceptCode":"C3226","definition":"Multiple endocrine neoplasia caused by mutation of the RET gene. Patients develop medullary thyroid carcinomas, and may also develop pheochromocytomas and parathyroid gland hyperplasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E65D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E673-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Multiple Endocrine Neoplasia Type 2B","valueDescription":"Multiple Endocrine Neoplasia Type 2B","ValueMeaning":{"publicId":"3211272","version":"1","preferredName":"Multiple Endocrine Neoplasia Type 2B","longName":"3211272","preferredDefinition":"Multiple endocrine neoplasia caused by mutation of the RET gene. Patients develop medullary thyroid carcinomas and numerous neural defects including neuromas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Endocrine Neoplasia Type 2B","conceptCode":"C3227","definition":"Multiple endocrine neoplasia caused by mutation of the RET gene. Patients develop medullary thyroid carcinomas and numerous neural defects including neuromas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E67F-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E695-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Multiple Osteochondromas","valueDescription":"Multiple Osteochondromas","ValueMeaning":{"publicId":"3211273","version":"1","preferredName":"Multiple Osteochondromas","longName":"3211273","preferredDefinition":"A neoplastic chondrogenic process affecting multiple sites. Grossly and microscopically it resembles an osteochondroma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Osteochondromas","conceptCode":"C53457","definition":"An autosomal dominant neoplastic chondrogenic process affecting multiple sites. It is caused by mutations in the EXT1 or EXT2 genes.  Grossly and microscopically, the lesions resemble an osteochondroma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E6A1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E6B7-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Multiple Sulfatase Deficiency Disease","valueDescription":"Multiple Sulfatase Deficiency Disease","ValueMeaning":{"publicId":"3211274","version":"1","preferredName":"Multiple Sulfatase Deficiency Disease","longName":"3211274","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by mutations in SUMF1 gene. It is characterized by deficiency of all sulfatase enzymes. Signs and symptoms include neurologic damage, mental retardation, skeletal abnormalities, hepatosplenomegaly, and ichthyosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Sulfatase Deficiency Disease","conceptCode":"C84908","definition":"A rare autosomal recessive lysosomal storage disease caused by mutations in SUMF1 gene. It is characterized by deficiency of all sulfatase enzymes. Signs and symptoms include neurologic damage, mental retardation, skeletal abnormalities, hepatosplenomegaly, and ichthyosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E6C3-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E6D9-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Multiple System Atrophy","valueDescription":"Multiple System Atrophy","ValueMeaning":{"publicId":"3211275","version":"1","preferredName":"Multiple System Atrophy","longName":"3211275","preferredDefinition":"A rare neurodegenerative disorder characterized by loss of autonomic nervous system functions and disturbances of motor, balance and muscle coordination.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple System Atrophy","conceptCode":"C84909","definition":"A rare neurodegenerative disorder characterized by loss of autonomic nervous system functions and disturbances of motor, balance and muscle coordination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E6E5-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E6FB-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Muscular Dystrophy","valueDescription":"Muscular Dystrophy","ValueMeaning":{"publicId":"3211276","version":"1","preferredName":"Muscular Dystrophy","longName":"3211276","preferredDefinition":"A group of inherited progressive muscle disorders characterized by muscle weakness and eventual death of the muscle tissues. Examples include Duchenne muscular dystrophy, Becker's muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and limb-girdle muscular dystrophy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Muscular Dystrophy","conceptCode":"C84910","definition":"A group of inherited progressive muscle disorders characterized by muscle weakness and eventual death of the muscle tissues. Examples include Duchenne muscular dystrophy, Becker's muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and limb-girdle muscular dystrophy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E707-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E71D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Mycosis Fungoides","valueDescription":"Mycosis Fungoides","ValueMeaning":{"publicId":"2559297","version":"1","preferredName":"Mycosis Fungoides","longName":"2559297","preferredDefinition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides","conceptCode":"C3246","definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B4AE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E727-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Myeloid Sarcoma","valueDescription":"Myeloid Sarcoma","ValueMeaning":{"publicId":"2559301","version":"1","preferredName":"Myeloid Sarcoma","longName":"2559301","preferredDefinition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid Sarcoma","conceptCode":"C3520","definition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B4B2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E731-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Myokymia","valueDescription":"Myokymia","ValueMeaning":{"publicId":"3211277","version":"1","preferredName":"Myokymia","longName":"3211277","preferredDefinition":"A disorder characterized by involuntary and irregular muscle contractions not associated with muscle weakness or atrophy. It most often affects facial muscles. It may be localized or generalized.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myokymia","conceptCode":"C84911","definition":"A disorder characterized by involuntary and irregular muscle contractions not associated with muscle weakness or atrophy. It most often affects facial muscles. It may be localized or generalized.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E73D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E753-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Myositis","valueDescription":"Myositis","ValueMeaning":{"publicId":"2562650","version":"1","preferredName":"Myositis","longName":"2562650","preferredDefinition":"An inflammatory process affecting the skeletal muscles. Causes include infections, injuries, and autoimmune disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myositis","conceptCode":"C27578","definition":"An inflammatory process affecting the skeletal muscles. Causes include infections, injuries, and autoimmune disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C1C7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-11","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-11","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E75D-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Myositis Ossificans","valueDescription":"Myositis Ossificans","ValueMeaning":{"publicId":"3211278","version":"1","preferredName":"Myositis Ossificans","longName":"3211278","preferredDefinition":"A disorder characterized by non-neoplastic bone formation in soft tissues. It usually follows blunt trauma and bleeding in the deep soft tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myositis Ossificans","conceptCode":"C3253","definition":"A self-limited benign neoplasm characterized by a zonal architecture. It is composed of spindle cells oriented randomly or in short intersecting fascicles. Peripherally, the spindle cells merge with osteoblasts that rim and populate ill-defined trabeculae and sheets of unmineralized woven bone, which is surrounded by well-formed trabecular and cortical-type bone that remodels into lamellar bone. Treatment is usually simple excision. Prognosis is excellent; recurrence is uncommon. (WHO 2020)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E769-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E77F-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Myotonia Congenita","valueDescription":"Myotonia Congenita","ValueMeaning":{"publicId":"3211279","version":"1","preferredName":"Myotonia Congenita","longName":"3211279","preferredDefinition":"A genetic congenital neuromuscular disorder affecting the skeletal muscles. It is caused by mutations in the chloride channel gene (CLCN1 gene). It is characterized by muscle stiffness, hypertrophy, pain, and cramping.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myotonia Congenita","conceptCode":"C84912","definition":"A genetic congenital neuromuscular disorder affecting the skeletal muscles. It is caused by mutations in the chloride channel gene (CLCN1 gene). It is characterized by muscle stiffness, hypertrophy, pain, and cramping.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E78B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E7A1-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Myotonic Disorder","valueDescription":"Myotonic Disorder","ValueMeaning":{"publicId":"3211280","version":"1","preferredName":"Myotonic Disorder","longName":"3211280","preferredDefinition":"An inherited or acquired, localized or generalized disorder affecting the muscles. It may be associated with abnormalities in the chloride or sodium channels of the muscles. It is characterized by delayed muscle relaxation following stimulation or contraction. Representative examples include myotonia congenita and myotonic dystrophy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myotonic Disorder","conceptCode":"C84913","definition":"An inherited or acquired, localized or generalized disorder affecting the muscles. It may be associated with abnormalities in the chloride or sodium channels of the muscles. It is characterized by delayed muscle relaxation following stimulation or contraction. Representative examples include myotonia congenita and myotonic dystrophy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E7AD-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E7C3-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Myotonic Dystrophy","valueDescription":"Myotonic Dystrophy","ValueMeaning":{"publicId":"3211281","version":"1","preferredName":"Myotonic Dystrophy","longName":"3211281","preferredDefinition":"An inherited progressive disorder affecting the muscles. It is characterized by muscle wasting and hypotonia, cataracts, heart conduction defects and endocrinopathies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myotonic Dystrophy","conceptCode":"C84914","definition":"An inherited progressive disorder affecting the muscles. It is characterized by muscle wasting and hypotonia, cataracts, heart conduction defects and endocrinopathies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E7CF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E7E5-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nail-Patella Syndrome","valueDescription":"Nail-Patella Syndrome","ValueMeaning":{"publicId":"3211282","version":"1","preferredName":"Nail-Patella Syndrome","longName":"3211282","preferredDefinition":"A rare autosomal dominant syndrome caused by mutations in the LMX1B gene.  It is characterized by fingernail deformities, absence or hypoplasia of the patellae, iliac horns, deformities of the radial heads, nephropathy, and glaucoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nail-Patella Syndrome","conceptCode":"C75120","definition":"A rare autosomal dominant syndrome caused by mutations in the LMX1B gene. It is characterized by fingernail deformities, absence or hypoplasia of the patellae, iliac horns, deformities of the radial heads, nephropathy, and glaucoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E7F1-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E807-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nasal Cavity and Paranasal Sinus Lethal Midline Granuloma","valueDescription":"Nasal Cavity and Paranasal Sinus Lethal Midline Granuloma","ValueMeaning":{"publicId":"3211283","version":"1","preferredName":"Nasal Cavity and Paranasal Sinus Lethal Midline Granuloma","longName":"3211283","preferredDefinition":"An aggressive, progressive, and destructive lesion affecting the nasal cavities, paranasal sinuses, and the palate.  The vast majority of cases are malignant lymphoproliferations affecting the midline of the face in patients with nasal type extranodal NK/T-cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasal Cavity and Paranasal Sinus Lethal Midline Granuloma","conceptCode":"C8196","definition":"An aggressive, progressive, and destructive lesion affecting the nasal cavities, paranasal sinuses, and the palate.  The vast majority of cases are malignant lymphoproliferations affecting the midline of the face in patients with nasal type extranodal NK/T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E813-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E829-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Nasopharyngeal Neoplasm","valueDescription":"Nasopharyngeal Neoplasm","ValueMeaning":{"publicId":"3211284","version":"1","preferredName":"Nasopharyngeal Neoplasm","longName":"3211284","preferredDefinition":"A benign or malignant neoplasm affecting the nasopharynx. Representative examples of benign neoplasms include angiofibroma and squamous papilloma. Representative examples of malignant neoplasms include keratinizing squamous cell carcinoma and nonkeratinizing carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasopharyngeal Neoplasm","conceptCode":"C3257","definition":"A benign or malignant neoplasm affecting the nasopharynx. Representative examples of benign neoplasms include angiofibroma and squamous papilloma. Representative examples of malignant neoplasms include keratinizing squamous cell carcinoma and nonkeratinizing carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-E835-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9F52E161-E84B-C614-E040-BB89AD4377D5","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"ONEDATA","dateModified":"2011-03-25","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B1447E3-C35B-63D1-E050-BB89AD432A13","beginDate":"2015-07-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-07-17","modifiedBy":"ONEDATA","dateModified":"2015-07-17","deletedIndicator":"No"},{"value":"Primary Hepatic Sarcoma","valueDescription":"Primary Liver Sarcoma","ValueMeaning":{"publicId":"4903573","version":"1","preferredName":"Primary Liver Sarcoma","longName":"4903573","preferredDefinition":"Occurring first in time or sequence; original; of greatest rank or importance or value.: A malignant soft tissue neoplasm that arises from the liver.  Representative examples include angiosarcoma, undifferentiated (embryonal) sarcoma, rhabdomyosarcoma, and leiomyosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Liver Sarcoma","conceptCode":"C4437","definition":"A malignant soft tissue neoplasm that arises from the liver.  Representative examples include angiosarcoma, undifferentiated (embryonal) sarcoma, rhabdomyosarcoma, and leiomyosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B1447E3-C36A-63D1-E050-BB89AD432A13","latestVersionIndicator":"Yes","beginDate":"2015-07-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B1447E3-C383-63D1-E050-BB89AD432A13","beginDate":"2015-07-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-07-17","modifiedBy":"ONEDATA","dateModified":"2015-07-17","deletedIndicator":"No"},{"value":"Celiac disease","valueDescription":"Celiac Disease","ValueMeaning":{"publicId":"3249580","version":"1","preferredName":"Celiac Disease","longName":"3249580","preferredDefinition":"A digestive disease that is caused by an immune response to a protein called gluten, which is found in wheat, rye, barley, and oats. Celiac disease damages the lining of the small intestine and interferes with the absorption of nutrients from food. A person with celiac disease may become malnourished no matter how much food is consumed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Celiac Disease","conceptCode":"C26714","definition":"An autoimmune genetic disorder with an unknown pattern of inheritance that primarily affects the digestive tract. It is caused by intolerance to dietary gluten. Consumption of gluten protein triggers an immune response which damages small intestinal villi and prevents adequate absorption of nutrients. Clinical signs include abdominal cramping, diarrhea or constipation and weight loss. If untreated, the clinical course may progress to malnutrition, anemia, osteoporosis and an increased risk of intestinal malignancies. However, the prognosis is favorable with successful avoidance of gluten in the diet.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D99025-BE2B-DBB4-E040-BB89AD434418","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F89D91E-7085-211C-E053-F662850AA3DB","beginDate":"2017-12-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-12-04","modifiedBy":"ONEDATA","dateModified":"2017-12-04","deletedIndicator":"No"},{"value":"Hepatoblastoma/HCC mix","valueDescription":"Hepatoblastoma Hepatocellular Carcinoma Mix","ValueMeaning":{"publicId":"5983684","version":"1","preferredName":"Hepatoblastoma Hepatocellular Carcinoma Mix","longName":"5983684","preferredDefinition":"A malignant liver neoplasm that occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Grossly, hepatoblastoma is solid, well circumscribed, and more often solitary than multiple. Microscopically, most of the tumors are composed exclusively of immature hepatocytic elements. About a fourth of hepatoblastomas contain a stromal component that may be undifferentiated or develop into bone or cartilage. The treatment of choice for hepatoblastoma is surgical excision with adjuvant therapy. Liver transplantation is being increasingly used as well.: A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.: To bring or combine together or with something else; add as an additional element or part.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatoblastoma","conceptCode":"C3728","definition":"A malignant embryonal neoplasm that arises from the liver. It occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Microscopically,  it consists of either epithelial or epithelial and mesenchymal components.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mix","conceptCode":"C64925","definition":"To bring or combine together or with something else; add as an additional element or part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A19685A-9692-7E6A-E053-F662850ABA25","latestVersionIndicator":"Yes","beginDate":"2017-09-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-09-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A19685A-96AB-7E6A-E053-F662850ABA25","beginDate":"2017-09-26","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-09-26","modifiedBy":"ONEDATA","dateModified":"2017-09-26","deletedIndicator":"No"},{"value":"Desmoid tumor","valueDescription":"Fibromatosis Desmoid Tumor","ValueMeaning":{"publicId":"3249546","version":"1","preferredName":"Fibromatosis Desmoid Tumor","longName":"3249546","preferredDefinition":"An insidious poorly circumscribed neoplasm arising from the deep soft tissues. It is characterized by the presence of elongated spindle-shaped fibroblasts, collagenous stroma formation, and an infiltrative growth pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desmoid Fibromatosis","conceptCode":"C9182","definition":"An insidious, locally aggressive, poorly circumscribed neoplasm arising from the deep soft tissues. It is characterized by the presence of elongated spindle-shaped fibroblasts, collagenous stroma formation, and an infiltrative growth pattern. It lacks metastatic potential.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D8A436-0883-647C-E040-BB89AD435D86","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A1A17E4-FEA5-7986-E053-F662850A30EB","beginDate":"2019-05-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-30","modifiedBy":"ONEDATA","dateModified":"2019-05-30","deletedIndicator":"No"},{"value":"Meningioma","valueDescription":"Meningioma","ValueMeaning":{"publicId":"4265263","version":"1","preferredName":"Meningioma","longName":"4265263","preferredDefinition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade I tumors, and some are WHO grade II or III tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningioma","conceptCode":"C3230","definition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4D52-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A1A17E4-FEB0-7986-E053-F662850A30EB","beginDate":"2019-05-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-30","modifiedBy":"ONEDATA","dateModified":"2019-05-30","deletedIndicator":"No"},{"value":"Pancreatic adenoma","valueDescription":"Pancreatic adenoma","ValueMeaning":{"publicId":"6771235","version":"1","preferredName":"Pancreatic adenoma","longName":"6771235","preferredDefinition":"Of or pertaining to the pancreas.: A neoplasm arising from the epithelium.  It may be encapsulated or non-encapsulated but non-invasive.  The neoplastic epithelial cells may or may not display cellular atypia or dysplasia.  In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ.  Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic","conceptCode":"C25726","definition":"Of or pertaining to the pancreas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenoma","conceptCode":"C2855","definition":"A neoplasm arising from the epithelium.  It may be encapsulated or non-encapsulated but non-invasive.  The neoplastic epithelial cells may or may not display cellular atypia or dysplasia.  In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ.  Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A1A17E4-FEBB-7986-E053-F662850A30EB","latestVersionIndicator":"Yes","beginDate":"2019-05-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-30","modifiedBy":"COOPERM","dateModified":"2019-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A1A17E4-FED4-7986-E053-F662850A30EB","beginDate":"2019-05-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-30","modifiedBy":"ONEDATA","dateModified":"2019-05-30","deletedIndicator":"No"},{"value":"Colorectal adenoma","valueDescription":"Colorectal Adenoma","ValueMeaning":{"publicId":"6771237","version":"1","preferredName":"Colorectal Adenoma","longName":"6771237","preferredDefinition":"An adenoma that arises from the colon or rectum.  The group of colorectal adenomas includes tubular, villous, and tubulovillous adenomas, traditional serrated adenomas, sessile serrated adenomas/polyps, and familial adenomatous polyposis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colorectal Adenoma","conceptCode":"C5673","definition":"An adenoma that arises from the colon or rectum.  The group of colorectal adenomas includes tubular, villous, and tubulovillous adenomas, traditional serrated adenomas, sessile serrated adenomas/polyps, and familial adenomatous polyposis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A1A17E4-FEE1-7986-E053-F662850A30EB","latestVersionIndicator":"Yes","beginDate":"2019-05-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-30","modifiedBy":"ONEDATA","dateModified":"2019-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8A1A17E4-FEFA-7986-E053-F662850A30EB","beginDate":"2019-05-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-05-30","modifiedBy":"ONEDATA","dateModified":"2019-05-30","deletedIndicator":"No"},{"value":"B Lymphoblastic Leukemia/Lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2593075","version":"1","preferredName":"Precursor B-Lymphoblastic Lymphoma/Leukemia","longName":"2593075","preferredDefinition":"A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called precursor B lymphoblastic leukemia (B-cell acute lymphoblastic leukemia).  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma","conceptCode":"C8936","definition":"A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called B acute lymphoblastic leukemia.  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-19BC-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDC4AAFB-E814-5ADB-E053-731AD00A5034","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"T Lymphoblastic Leukemia/Lymphoma","valueDescription":null,"ValueMeaning":{"publicId":"2568286","version":"1","preferredName":"Precursor T-lymphoblastic lymphoma/leukemia","longName":"2568286v1.00","preferredDefinition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Lymphoblastic Leukemia/Lymphoma","conceptCode":"C8694","definition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7CB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDC4AAFB-E815-5ADB-E053-731AD00A5034","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"Mixed Phenotype Acute Leukemia","valueDescription":null,"ValueMeaning":{"publicId":"7000422","version":"1","preferredName":"Mixed Phenotype Acute Leukemia","longName":"7000422","preferredDefinition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia","conceptCode":"C82179","definition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"950E57BC-8DF0-20B0-E053-F662850A4478","latestVersionIndicator":"Yes","beginDate":"2019-10-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-10-16","modifiedBy":"KUMMEROA","dateModified":"2023-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDC4AAFB-E816-5ADB-E053-731AD00A5034","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"Actinic Keratosis","valueDescription":null,"ValueMeaning":{"publicId":"4263935","version":"1","preferredName":"Actinic (Solar) Keratosis","longName":"4263935","preferredDefinition":"A precancerous lesion of the skin composed of atypical keratinocytes.  It is characterized by the presence of thick, scaly patches of skin.  Several histologic variants have been described, including atrophic, acantholytic, and hyperkeratotic variants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Actinic Keratosis","conceptCode":"C3148","definition":"A precancerous lesion of the skin composed of atypical keratinocytes. It is characterized by the presence of thick, scaly patches of skin. Several histologic variants have been described, including atrophic, acantholytic, and hyperkeratotic variants.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63D55FF-3461-F699-E040-BB89AD433A6C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019273BC-25B5-6F37-E063-731AD00A9066","beginDate":"2023-07-28","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2023-07-28","modifiedBy":"RAGUNATHANU","dateModified":"2023-07-28","deletedIndicator":"No"},{"value":"Normal Skin","valueDescription":null,"ValueMeaning":{"publicId":"6995294","version":"1","preferredName":"Normal Skin","longName":"6995294","preferredDefinition":"The pores are visible but not large. The skin texture is neither fine or thick and it neither feels dry or oily to the touch.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Normal Skin","conceptCode":"C74593","definition":"The pores are visible but not large. The skin texture is neither fine or thick and it neither feels dry or oily to the touch.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E79011-EF4F-1BD6-E053-F662850A5E79","latestVersionIndicator":"Yes","beginDate":"2019-10-14","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-14","modifiedBy":"ONEDATA","dateModified":"2019-10-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019273BC-25B6-6F37-E063-731AD00A9066","beginDate":"2023-07-28","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2023-07-28","modifiedBy":"RAGUNATHANU","dateModified":"2023-07-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2513925","version":"1","preferredName":"Activity","preferredDefinition":"An action taken in pursuit of an objective; the state of being active.","longName":"C43431","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B8A8A1E-77BA-4685-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"CURTIST","dateCreated":"2006-08-21","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433877","version":"1","preferredName":"Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4D2F-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8E66-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"RAGUNATHANU","dateModified":"2023-07-28","changeDescription":"5/05/14 VD released per Ian Fore as part of Draft Model content review. jc 5.30.18 Added max length and PVs for HCMI request. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3204728","version":"1","longName":"Common Biorepository Model","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3204729","version":"1","longName":"gov.nih.nci.cbm.domain.LogicalModel","context":"NCIP"}]},{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"7589448","version":"1","longName":"Pediatric Liver Cancer","context":"OCG"},{"publicId":"10000192","version":"1","longName":"Colorectal","context":"OCG"}]}],"AlternateNames":[{"name":"Diagnosis:diagnosisType","type":"UML Class:UML Attr","context":"NCIP"},{"name":"gov.nih.nci.cbm.domain.LogicalModel.Diagnosis.diagnosisType","type":"UML Qualified Attr","context":"NCIP"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"DxTp","type":"COG GDE Short Name","context":"COG"},{"name":"gastrointestinal_disorder","type":"HCMI Name","context":"OCG"},{"name":"OCG","type":"USED_BY","context":"OCG"},{"name":"diagnosis","type":"HCMI Name","context":"OCG"}],"ReferenceDocuments":[{"name":"Data Element Diagnosis Type does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Diagnosis Type does not have Preferred Question Text","url":null,"context":"NCIP"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Diagnosis/Histology","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Disease:","url":null,"context":"COG"},{"name":"HCMI Question Text","type":"Alternate Question Text","description":"diagnosis","url":null,"context":"OCG"},{"name":"HCMI Alternate Question Text","type":"Alternate Question Text","description":"Gastrointestinal disorder diagnosed","url":null,"context":"OCG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Clinical diagnosis:","url":null,"context":"COG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Diagnosis type:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F533297-1E20-B02E-E040-BB89AD436F86","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":"5/05/14 CDE released per Ian Fore as part of Draft Model content review. jc Released for OCG reuse. mc 9.13.18","administrativeNotes":"2022.11.18 AQT added for ticket request CADSR0001705. ak","unresolvedIssues":null,"deletedIndicator":"No"}}